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ABSTRACT OF THESIS
This study investigated three possible new approaches to the treatment of human
insulin-dependent diabetes mellitus (IDDM ) using the insulin-dependent BB/E rat as
an animal model of spontaneous diabetes.
Islets encapsulated in alginate-poly-L-lysine-alginate microcapsules and transplanted
into animal models of IDDM may be protected from autoimmune rejection and
destruction. Conflicting results have been reported upon testing the capacity of
microencapsulated islets to secrete insulin in response to glucose challenge in vitro.
The glucose-induced insulin secretory responses of (1) freshly isolated free islets and
(2) free (i.e. non-encapsulated ) and encapsulated islets cultured for different periods
of time, in a multichannel perifusion system were therefore compared. Optimal insulin
secretion of freshly isolated free islets was found to be significantly higher than that
of free cultured and encapsulated cultured islets. A slight delay in response to glucose
stimulus was observed in the encapsulated islet group. Insulin secretion by free
cultured and encapsulated cultured islets was optimal after six and seven days culture
respectively, and diminished thereafter. A recovery period appears critical for optimal
function of encapsulated islet grafts.
In the second study, metabolic control and feeding patterns in spontaneously diabetic
BB/E and streptozotocin-diabetic rats treated either conventionally with daily
injections of insulin or using novel sustained release insulin implants were compared.
Food consumption and plasma glucose concentration over a 24 hour period were
measured and glycosylated haemoglobin determined in diabetic rats initially treated
with daily injections of insulin and one month later following treatment with sustained
release insulin implants, and compared with non-diabetic rats. Diabetic animals
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maintained on conventional insulin treatment exhibited unstable plasma glucose
profiles, and both random plasma glucose concentrations and glycated haemoglobin
levels were inaccurate indices of overall metabolic control. In contrast, sustained
release insulin implants achieved a relatively stable plasma glucose profile which was
accurately reflected by these parameters. However, tissue concentrations of the
principal metabolites of the polyol pathway, although decreased by both methods of
insulin treatment, were not significantly different. Finally, non-diabetic rats consumed
significantly more food during the twelve hour dark cycle than the light cycle, whereas
diabetic rats ate continuously throughout the 24 hour period, and consumed
significantly more than non-diabetic rats, irrespective of type and treatment of
diabetes.
In the final study, the effect of a short course ( 14 days ) of treatment with
non-depleting and depleting monoclonal antibodies specific for T lymphocyte subsets
on preventing rejection and autoimmune destruction of intraportal islet allografts was
investigated in BB/E rats with established, insulin-dependent diabetes. Treatment
with a depleting monoclonal antibody specific for helper/inducer ( CD4+ ) T
lymphocytes either alone or in combination with a depleting antibody directed against
cytotoxic/suppressor ( CD8+ ) T cells was most effective in prolonging graft function.
Treated animals with early graft failure were compared with animals whose grafts
functioned for a shorter or longer time in respect of changes in (1) T lymphocyte
subsets in the circulation, peripheral and mesenteric lymph nodes, peritoneal exudate,
spleen and thymus, (2) the proliferative ability of their peripheral blood lymphocytes
( mitogen stimulation assay ) and (3) hepatic, pancreatic and islet graft infiltration.
Rats with a long-term functioning graft ( 64 - 91 ) days received a second
donor-specific islet graft under the kidney capsule without further antibody treatment.
Approximately 30 days later animals were killed and tissues, including the
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islet-bearing kidney, were assessed as described above. FACS analysis of
lymphocytes and lymphocyte subsets demonstrated that 0X38 moAb exerted its
immunosuppressive effect without significant depletion of CD4+ cell numbers.
Furthermore, there was no significant difference between the lymphocyte and
lymphocyte subset numbers in the peripheral blood or lymphoid tissues of
moAb-treated BB/E rats maintaining short- or long-term functioning islet grafts.
Stimulation indices as a measure of the proliferative ability of PBL to Con A were
decreased following moAb injection but no consistent finding to explain the prolonged
survival of certain islet grafts over others was observed. However, analysis of
lymphocytes and their subsets from peripheral blood and lymphoid tissues may not
accurately reflect events within the islet allograft. All BB/E rats receiving a 2° islet
graft under the kidney capsule remained normoglycaemic until death with the
exception of a single animal which was borderline hyperglycaemic prior to 2° islet
transplantation. Histologically, a chronic inflammatory cell infiltrate was observed
within short-term functioning intraportal islet grafts and islets were weakly positive or
negative for insulin, whereas a mild infiltrate was observed around islets that
maintained long-term normoglycaemia which were strongly positive for insulin. In
contrast to the long-term unresponsiveness to 1° islet grafts in moAb-treated BB/E
rats, secondary islet grafts were not afforded the same protection.
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11 HUMAN AUTOIMMUNE INSULIN-DEPENDENT DIABETES
MELLITUS
1.1.1. INTRODUCTION
The discovery of insulin, isolated from dog pancreas, by Banting and Best was initially
announced to the Medical Faculty of the University of Toronto on the 11th
November, 1921. Their findings were reported in the Journal of Laboratory and
Clinical Medicine in February 1922 ( 1 ). Clinical trials using insulin in the treatment
of human insulin-dependent diabetes mellitus ( IDDM ) began early in the same year,
and the results published later in 1922 (2).
Subsequently pure crystalline insulin was commercially produced, and insulin therapy
as a treatment for human diabetes was thought to have " cured " an otherwise fatal
disease. Treatment with one or more injections of insulin per day, given into the
subcutaneous tissue, controlled the symptoms of diabetes produced by acute elevation
of blood glucose, including unassuageable thirst, protuse urination, lethargy and
rapidly progressive body wasting, terminating in stupor, coma and death. Death from
ketoacidosis was also greatly reduced.
It was almost 30 years before it was discovered that subjects thought to be " cured "
of their diabetes by daily injections of insulin developed serious micro- and
macroangiopathic complications of the disease ( 3 ). Neuropathy, nephropathy,
retinopathy and vascular disease were particularly prevalent. After 20 years of
diabetes, 80% of subjects had retinopathy and of these, approximately 50% were
destined to die of kidney failure within another 10-15 years. This substantial
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morbidity and mortality necessitated the need for an alternative " cure " for diabetes
mellitus.
A " cure " for diabetes can be approached in two ways : primary prevention or a
better method of treatment that allows the patient to lead a truly normal lifestyle and
prevents the development of long term complications.
112 AETIOLOGY OF HUMAN 11)DM
It is now generally recognised that genetic susceptibility plays a major role in the
aetiology of IDDM. However, genetic studies have been hindered by several major
obstacles, including variable age at onset of IDDM, the potential interaction of genetic
and environmental factors, the lack of knowledge of the basic defect and the existence
of genetic heterogeneity, i.e. separating IDDM from other forms of diabetes and the
possibility ofmultiple forms of the disease.
1.1.2.1. HLA ANTIGENS
In man, genes of the major histocompatibility complex ( MHC ) called the HLA
region are located on the short arm of chromosome 6, and encode for the three major
classes of proteins : HLA-A, B and C encode class I molecules which act as cell
surface recognition molecules; HLA-D contains genes for class II proteins which are
involved in cooperation and interaction between cells of the immune system, and the
region between HLA-D and B encodes class III proteins which are components of the
complement system, including C2, factor B and C4a and C4b ( 4,5 ). These genes are
located close to one another on chromosome 6 and thus are linked.
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In man essentially all nucleated cells carry HLA-A, B and C class I proteins in
varying amounts. Class I proteins consist of two polypeptides, the larger of which is
encoded by the MHC and non-covalently associated with the polypeptide 02"
microglobulin, which is encoded outside the MHC. In contrast, the class II molecules
encoded by HLA-D have a restricted distribution, and consist of two non-covalently
associated peptides, the a- and (3-chains, both ofwhich are encoded by the MHC.
1.1.2.2. PATHOGENESIS
Three non-immunosuppressed diabetic twins receiving a segmental pancreas
transplant from their non-diabetic co-twins, who were themselves unlikely to develop
IDDM since they had been discordant for diabetes for more than 17 years, were
temporarily cured of their diabetes. However, within a few weeks disease recurrence
was observed as donor pancretic islets became infiltrated ( insulitis ) and graft
functioning ceased ( 6 ). A fourth patient received a similar transplant under cover of
the immunosuppressant azathioprine. No insulitis was observed and diabetes did not
recur. Histolological examination of the failed pancreatic grafts demonstrated that, in
contrast to a graft rejection response, only the islet insulin-producing (3-cells were
destroyed. This destructive process could not be inherited since the donor pancreas
came from a non-diabetic co-twin, and the rapid destruction of apparently
normal P-cells when transplanted from the non-diabetic to the diabetic twin indicated
that the destructive process was recurrent recipient-mediated P-cell specific
cytotoxicity. Furthermore, this cytotoxic memory was retained for at least 17 years.
The most characteristic pathological finding in the pancreases of IDDM patients at the
onset of disease is the mononuclear cellular infiltration within the pancreatic islets,
referred to as "insulitis" by Von Meyenburg in 1940 ( 7 ). Insulitis is accompanied by
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the specific destruction of islet (3-cells ( 8 ), and after approximately 90% of the (3-cell
mass has been destroyed the clinical manifestations of IDDM present themselves ( 9 ).
However, the extent of insulitis within individual patients is very variable, affecting
13-75% of islets ( 10 ). MacLaren ( 11 ) pointed out that the pace of these events
may well relate to age of onset and the underlying genetic heterogeneity of the
individual. As in other endocrine tissues undergoing active autoimmune destruction,
Gepts ( 9 ) reported the presence of lymphocytes, macrophages and plasma cells in
pancreatic sections from IDDM patients who died soon after diagnosis. Furthermore,
areas of pancreas containing islets devoid of P-cells and insulitis were often observed
adjacent to pancreatic lobules containing many islets, predominantly composed of
hyperactive P-cells ( 9 ). Some of these islets were free of insulitis, whilst others were
infiltrated by a few lymphocytes or heavily infiltrated. Thus, biopsies taken from a
" diabetic " pancreas showing patchy insulitis may give rise to inconsistent findings,
and may explain why Doniach and Morgan failed to observe insulitis in any of
13 recent onset diabetic patients studied (12 ).
Conventional histological examination of fixed pancreatic tissues does not allow the
precise characterisation of the various lymphocyte subpopulations infiltrating the
islets. In 1985, Bottazzo et al ( 13 ) examined frozen blocks of a fresh pancreas
obtained at post-mortem from a type I diabetic child who died shortly after diagnosis.
Using various monoclonal antibodies ( moAb ) with single or double fluorochrome
techniques, it was shown that most of the mononuclear cells in the inflammatory
infiltrate were T lymphocytes. Cytotoxic/suppressor ( CD8+ ) lymphocytes formed
the majority of T cells, but helper/inducer ( CD4+ ) T lymphocytes were also present.
A large proportion of these CD4+ T lymphocytes expressed HLA class II molecules,
and a lesser number were positive for interleukin-2 receptors ( IL-2R ), demonstrating
that infiltrating T cells were activated, and suggesting a specific immune response
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directed against islet autoantigens. Many B lymphocytes were also present around
individual islets, as were immunoglobulin G ( IgG ) deposits, thus demonstrating
antibody penetration following injury to the islet cell membrane. The presence of
macrophages in the inflammatory infiltrate, capable of engulfing P-cells, has also been
reported in human diabetic pancreases ( 14 ). However, Foulis and Farquharson
(15) noted a scarcity of macrophages in the islets of diabetic patients at the time of
diagnosis, and hence could not attribute a myeloid/lymphoid phenotype for the class
II positive cells observed in these islets. This was further substantiated using
anti-class II and anti-macrophage antisera which identified macrophages primarily in
the exocrine portion of the pancreas, and their appearance and distribution resembled
that of tissue resident macrophages, having no apparent aggression towards islets.
1.1.2.3. IMMUNOPATHOGENESIS
1.1.2.3.1. Cellular immunity
Evidence accumulated over the last several decades strongly supports the hypothesis
that IDDM has an autoimmune pathogenesis ( 16,17 ). Evidence includes an
immunogenetic susceptibility, cell-mediated immune abnormalities detected in the
peripheral blood, lymphocytic infiltration in islets of diabetic patients and
autoantibodies to islet cells.
Extensive research has been carried out on the cell-mediated processes involved in the
autoimmune destruction of islet P-cells. The leucocyte migration inhibition test using
homogenate prepared from pooled porcine pancreas, has shown that peripheral blood
leucocytes from newly diagnosed IDDM patients are sensitised to pancreatic antigens
( 18,19 ) and it is likely that these immunocytes recognise different pancreatic P-cell
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antigens from those reacting with islet cell antibodies ( ICA ). In addition
lymphocytes from IDDM patients have been shown to produce cytotoxicity to various
islet cell targets in vitro ( 20 ), and Boitard et al ( 21 ) reported that mononuclear
cells from 80-90% of IDDM patients specifically inhibited glucose-stimulated, but not
arginine-stimulated, insulin release from mouse islets in vitro ( 22 ).
Conflicting results for total numbers of peripheral T and B lymphocytes have been
reported in IDDM patients. These discrepancies may be partially explained by
differences in the metabolic control of patients ( 23 ), including hyperglycaemia and
ketoacidosis ( 24,25 ), and the analytical technique employed ( 26 ). However, both
normal T and B lymphocyte numbers ( 27,28 ) and decreased numbers of circulating
T lymphocytes ( 29 ) have been reported in IDDM patients irrespective of glycaemic
control.
The use of moAb specific for lymphocyte subsets has failed to resolve this
discrepancy, since both increased ( 30 ) and decreased (31 ) ratios of
helper/suppressor cells have been reported in IDDM patients. With respect to
lymphocyte subsets, most studies report that the frequency of helper/inducer cells are
normal at onset of IDDM ( 31-33 ). Cytotoxic/suppressor T lymphocytes have been
reported as normal ( 32,34 ), increased ( 27,31 ) and decreased ( 28,33 ). A reduction
in cytotoxic/suppressor T cells would be consistent with one of the classic theories of
the pathogenesis of autoimmune disease, namely that a defect in the suppressor
mechanism allows latent autoimmunity to become frank autoaggression. Jackson et al
( 32 ) initially reported an increase in the number of activated T cells in the
circulation of newly diagnosed IDDM patients. Approximately 10% of circulating T
lymphocytes were MHC class II-positive in 9 of 11 diabetic patients, compared with
1% class II-positive T cells in controls. Several studies have since confirmed these
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findings ( 27,31,34-36 ). De Berardinis et al ( 36 ) further described the presence of
IL-2R-bearing, i.e. activated, T cells in approximately 50% of recently diagnosed
IDDM patients, and most of these activated T cells were of the helper/inducer
(CD4+) subset.
Diminished activity and functional abnormalities of suppressor T cells have been
reported in IDDM. Using antigen non-specific assays, several reports have described
an impairment of suppressor T lymphocyte function in diabetic patients at, or close to,
the time of diagnosis ( 26 ). However, interpretation of these results is difficult since
T cell functions are generally grossly altered in diabetic individuals, primarily due to
abnormal metabolic status ( 23 ). This conclusion is supported by the reversibility of
the defect in most cases upon the restoration ofmetabolic control by administration of
insulin ( 37 ). However, abnormal suppressor T cell function has also been
demonstrated in non-diabetic HLA-DR3 individuals ( 38 ) and in approximately
20% of healthy first degree relatives of IDDM patients ( 39 ), suggesting that
abnormal suppressor T cell function may alternatively be related to genetic
background. A decrease in the number of natural killer ( NK ) cells circulating in
newly-diagnosed IDDM patients has also been reported, but this appears to be a
genetically determined abnormality which may be compensated by the observed
increase in NK activity per cell, although diminished activity has also been reported
( 40 ). K cell activity is increased ( 41 ).
The role of two isoforms of the cell surface marker CD45, which divide
T lymphocytes into " naive " and " memory " populations, has recently been reviewed
( 42 ). Naive or virgin lymphocytes bear the CD45RA isoform ofCD45, are relatively
unresponsive to antigen stimulation, have a suppressive influence on other lymphocyte
functions, and form the vast majority of lymphocytes in the foetal circulation. In
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contrast, memory or primed cells bear the CD45RO isoform, proliferate in response
to antigen, promote a range of functions in other lymphocytes and are increasingly
represented in peripheral blood from birth onwards. The balance of these two
populations is interpreted as having an overall influence on immune functions, with
imbalances resulting in either predominantly suppressive or promotive activity.
Interest in the naive and memory populations in IDDM patients stems from three
seperate studies which have produced a clear and consistent picture in which there is a
preponderance ofCD45RA+CD4+ lymphocytes at diagnosis of disease. Later studies
extended these findings, demonstrating that CD45RA+CD8+ lymphocytes were also
overexpressed. In addition, using a technique to label naive and memory markers
simultaneously, it was demonstrated that the increase in naive lymphocytes at
diagnosis of IDDM is a result of an increased number of CD4 and CD8 lymphocytes
simultaneously co-expressing both CD45RA and CD45RO. These double-positive
lymphocytes are in transition between the two functional states, but as yet the reason
for an expansion in these cells in association with the development of IDDM remains
unclear.
The studies described here strongly support a role for cell-mediated immunity in the
pathogenesis of IDDM. However, as the transfer of diabetes using peripheral blood
lymphocytes from an IDDM patient is unsuccessful, the requirement of an initial
triggering stimulus prior to activation of autoreactive lymphocytes appears necessary.
As discussed earlier, genetic influences are important in the development of IDDM
but the disease must be, at least in part, determined by non-genetic factors, including




Many familial studies on IDDM have been published, more recently by Tillil and
Kobberling ( 43 ), and all studies show that diabetes occurs more frequently in
families with a history of diabetes than would be expected by chance alone. A risk of
IDDM among first-degree relatives of approximately 5% has consistently been
reported, corresponding to a risk 10-20 times higher than that in the general
population, although IDDM is more likely in the progeny of diabetic fathers than
diabetic mothers ( 44,45 ). The risk of diabetes in the sibling of a diabetic child is
related to the number of haplotypes the sibling shares with the diabetic proband ( 46 )
unless the shared haplotype is the heterozygous HLA-DR3/4, when the absolute risk
of IDDM is 25% ( 47 ). In addition, second-degree relatives show an increased risk,
but this risk is considerably less than that of first-degree relatives.
Twin studies provide a unique tool in genetic research, and by comparing the
frequency of concordance ( both members of the twin pair affected ) ofmonozygotic
( identical ) twins with that of dizygotic ( fraternal ) twins, an estimate of the
heritability may be obtained. Monozygotic twins share all genes and in theory should
be concordant for those disorders with pure genetic aetiology. Dizygotic twins share
only half their genes and thus are no more alike genetically than a pair of siblings.
Barnett et al ( 48 ) demonstrated that the estimated concordance rate, i.e. the risk of
developing IDDM in monozygotic co-twins was 30-50%, and the heterozygous
HLA-DR3/4 phenotype was more prevalent in concordant pairs ( 59% ) than with
discordant pairs ( 28% ) (49 ). Olmos et al ( 50 ) reported a concordance estimate of
approximately 36%, which is probably a more accurate estimate. Taken together,
twin and familial studies provide strong evidence that genetic factors play an
10
important role in the susceptibility of individuals to IDDM, and indicate the
requirement of other factors to elicit the disease in genetically susceptible individuals.
Following the initial detection of the association between markers for the class I
HLA-B locus, namely HLA-B8 and B15, and IDDM in the early 1970's (51 ), a large
number of association studies have been reported ( 52 ). However, with the
development of cellular typing for class II molecules and the isolation of class II
antisera, it became clear that HLA-B markers appeared to be secondary to stronger
population associations of IDDM with class II HLA-DR markers ( 53,54 ),
particularly DR3 and DR4 which have consistently been positively associated with
diabetes. This implies that the associations of class I antigens are probably due to
linkage disequilibrium between class I and class II genes, resulting in high frequencies
of certain combinations of alleles or haplotypes in the population. Indeed, over 95%
of Caucasians with IDDM have the DR3 or DR4 antigens ( allelic products of the
class II HLA-DR(3l and DRa loci respectively ) or both, compared with
approximately 50% of controls ( 52 ) demonstrating the increased risk for
HLA-DR3/4 heterozygotes ( 55,56 ). This risk is greater than the sum of the risks for
HLA-DR3 and DR4 homozygotes. These findings have led to the hypothesis that two
different genes, one linked to HLA-DR3 and one linked to HLA-DR4, may each
confer susceptibility ( 49 ). The DR4 haplotype is more common in younger diabetic
individuals and is associated with a more rapid loss of P-cell mass and a short
" honeymoon " period. In contrast, diabetic patients expressing DR3 usually show a
slower disease course, with a prolonged " honeymoon " phase. HLA-DR2 is
negatively associated with IDDM in Caucasian populations ( 57 ), and is only
observed in 2% of patients with IDDM compared with a frequency of 30% in the
normal population ( 58 ). The relative risk of IDDM in HLA-DR2 individuals is
approximately 75 times less than that of the HLA-DR3/4 heterozygotes ( 59 ).
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The class II gene products are encoded by loci in the HLA-D region of the MHC and
consist of an a-chain ( 32 kD ) and a P-chain ( 29 kJD ) which form a heterodimer on
the surface of cell subsets including macrophages, B and activated T lymphocytes and
dendritic cells ( 60 ). Three related and highly polymorphic class II antigens have
been identified, designated HLA-DR, DQ and DP, and the polymorphic residues have
been postulated to interact with the T cell receptor and/or foreign antigen ( 61,62 ).
The recognition of foreign antigen peptide fragments associated with an MHC class II
molecule leads to T cell activation. The haplotypes defined by class II serologic
typing, i.e. the HLA-DR and DQ serotypes, are genetically heterogeneous and were
initially subdivided using serological and cellular typing analysis. Using these
techniques, the HLA-DR4 locus could be subdivided into five different subtypes
( 63 ), two of which, namely DwlO and Dw4, are increased in HLA-DR4+ IDDM
patients over HLA-DR4+ controls ( 64,65 ). Evidence suggests that variation in the
DQP region may be more strongly associated with risk for IDDM than variation in the
DR region, at least regarding the HLA-DR4 associated susceptibility. Several groups
have reported a variation in the DQP region in linkage disequilibrium with DR4,
which occurs with increased frequency in IDDM patients. This variant, formerly
called the DQw3.2 allele and now called DQw8, occurs in as many as 90-95% of
those IDDM patients who carry the HLA-DR4 allele ( 66 ) and in approximately
60-75% ofDR4-carrying non-diabetic controls ( 52 ). In contrast, the DQw3.1 allele
in the DQP region, now called DQw7, is decreased.
Restriction fragment length polymorphism ( RFLP ) analysis studies have
demonstrated that linkage disequilibrium is very strong between the HLA-DR and
DQ subregions. Owerbach et al ( 67 ) were the first to discover a HLA-DQP1 DNA
polymorphism using a HLA-DQP gene probe and the restriction enzyme Bam HI.
This group found a 3.7 kB DQP gene related fragment that was present in 2% of
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Danish IDDM patients but as many as 37% of racially matched controls. These
findings have consequently been extended by many groups, and the overall conclusion
confirms that the diabetogenic gene(s) may lie very close to the HLA-DQ locus
( 68-71 ). Other DQP chain RFLP have been identified, and these DQP associations
overlap other HLA-DR specificities, such as HLA-DR1, which are associated with
IDDM.
Class II A and B chain sequence data utilising the polymerase chain reaction method
showed that, disappointingly, the first domain of the DQw8 sequence did not differ
between IDDM patients and non-diabetic individuals ( 72,73 ). Sequencing the
polymorphic first domain of DRP, DQa and DQP revealed no unique class II
sequence found exclusively in IDDM patients, indicating that HLA-conferred
susceptibility to IDDM is not mediated by structurally distinct HLA class II molecules
( 72 ). This group ( 72 ) further suggested that the genetic susceptibility of IDDM
associated with genes of the HLA-DQ locus may be explained by amino acid variation
within the DQP molecule. Comparison of the amino acid sequence of the positively
and negatively IDDM associated HLA-DQw8 and DQw7 alleles respectively revealed
only six amino acid differences between the two alleles, four of which were in the
N-terminal polymorphic domain at residues 13, 26, 45 and 57. Coding sequences of
DQw8 and DQw7 were identical between controls and patients. Accordingly, these
four amino acids might be responsible for the associations of these two haplotypes
with IDDM. Todd et al ( 72 ) cloned and sequenced HLA-DQP genes in HLA-DR
homozygous typing cells possessing susceptibility haplotypes, i.e. DR4-DQw8,
DR3-DQw2, DRl-DQwl.l and DR3-DQwl.AZH, and haplotypes protective or
neutral to the disease, i.e. DR4-DQw7, DR5-DQw7, DR2-DQwl.l2 and
DR2-DQwl .2. In the latter group an aspartate was found at position 57 of the DQP
molecule in all haplotypes whereas in all haplotypes associated with IDDM
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susceptibility, a different amino acid was found, often serine, valine or alanine. No
other polymorphic residues within the sequenced domains of either DR(5, DQa and
DQP showed a similar association. According to this hypothesis, IDDM develops in
individuals carrying two non-Asp-57 DQP alleles, as is the case for DR3/4 IDDM
patients. However, this is not only observed in DQP chains associated with DR3 and
DR4, as the IDDM-protective DR2-associated DQP chains contain DQP Asp-57,
whereas 77% of IDDM patients with DR2 carry the DQwl.AZH allele with serine at
position 57 ( 72 ).
A possible mechanism by which this observation might be of importance has come
from the recent understanding of the three-dimensional structure of the HLA
molecule. The presence of a charged amino acid, e.g. aspartic acid, at residue 57 of
the DQp chain may allow the formation of a salt bridge with a conserved arginine at
residue 79 in the DQa chain ( 74 ). This salt bridge would be situated in one end of
the foreign antigen binding cleft and may therefore affect antigen binding capacity or
T cell interaction of the HLA-DQ molecule. In contrast, a non-charged residue, e.g.
serine, valine or alanine, at position 57 would prevent the formation of the salt bridge.
However, the concept of this single HLA-DQ residue at position 57 as being totally
responsible for HLA-linked IDDM is incompatible with currently available data, and
there are a number of exceptions to this association ( 75 ). Firstly, many more normal
individuals have been shown to possess this same characteristic, thus decreasing the
disease specificity of this finding. Indeed, calculations of the absolute risk for IDDM
suggest that this molecular observation increases the specificity only modestly, i.e. at
most two-fold. Secondly, aspartic acid in position 57 is not always associated with
resistance to IDDM, particularly in Japanese type I diabetics where as many as 24%
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of the IDDM patients appear to be homozygous for aspartate at position 57 of the
DQp chain ( 76,77 ).
Owerbach et al ( 78 ) found that other amino acid residues ( other than residue 57 of
the DQP chain ) are important for IDDM susceptibility in Caucasians, and the DQa
gene also has a role in diabetes susceptibility. In support of the concept of additional
HLA-D locus determinants, Sheehy et al ( 65 ) have provided data that implicate both
DR and DQ simultaneously.
In conclusion, the mode of inheritance for IDDM remains unknown but is clearly
polygenic ( 72 ). The weight of evidence indicates that the DQal and DQP1 loci
both exert an influence on predisposition to IDDM. Combined analyses of twin and
family data suggest that there are at least two HLA-linked susceptibility loci : the
HLA-DR4-associated determinant in the absence of HLA-DR3 is the most
diabetogenic and is inherited in a dominant/intermediate fashion ( 56,79 ).
Conversely, DR3-associated susceptibility in the absence ofHLA-DR4 appears to be
recessive ( 56 ). However, mere possession of these haplotypes is not sufficient for
the development of IDDM, and no abnormalities present exclusively in class II genes
of IDDM patients have been identified. Furthermore, the increased risk of the DR3/4
heterozygote is clearly not explained solely by the DQP non-Asp hypothesis.
Therefore, the more specific diabetes-predisposing genes or combination of genes that
are carried on HLA haplotypes within IDDM families still need to be identified.
1.1.2.5. NON-MHC GENES
At least four non-MHC loci have been associated with susceptibility to IDDM,
namely the Kidd blood group on chromosome 18 ( 80,81 ), immunoglobulin heavy
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chain haplotypes on chromosome 14 ( 79 ), the T cell receptor P-chain on
chromosome 7 ( 82,83 ) and small inserts of the DNA variable region proximal to the
insulin gene on the short arm of chromosome 11 ( 84 ). The involvement of the
insulin gene is further supported by studies of the extended haplotype of this region
( 85 ), and by the observation that this gene provides susceptibility to IDDM
regardless ofHLA type ( 86 ). However, the effect of this locus is much smaller than
that of HLA, which provides the major genetic susceptibility to IDDM.
1.1.2.6. ENVIRONMENTAL FACTORS
Environmental factors might function as initiating factors which begin or continue the
aetiologic processes that eventually lead to IDDM, or as precipitating factors which
convert pre-clinical diabetes into clinical disease. Evidence of the aetiological
importance of environmental factors include the increase in IDDM incidence with time
( 87 ), the geographical variation in IDDM within and between countries ( 88 ) and
the well-documented seasonal variation of the clinical onset of IDDM, with relatively
more cases diagnosed during the autumn and winter months ( 89,90 ). However, no
individual environmental determinants of IDDM have been detected with certainty,
although viruses ( 91,92 ), dietary factors ( 93,94 ), socio-economic standard ( 95 )
and stressful life events ( 96 ) have been implicated.
1.1.2.6.1. Viral infection
The most likely candidates for exogenous agents contributing to IDDM appear to be
viruses. Several studies have suggested that viruses play an important role in the
pathogenesis of diabetes on the basis of ( a ) the presence of viral-specific antigens in
the pancreatic islets and destruction of P-cells of diabetic patients ( 97 ), ( b ) the
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presence of viral antibodies with rising titres in paired sera from newly diagnosed
IDDM patients ( 97,98 ), ( c ) a high frequency of Coxsackie B virus-specific IgM
antibody in newly identified diabetic children ( 99 ), ( d ) P-cell damage in children
who died of well-documented overwhelming viral infections ( 101 ), ( e ) the isolation
of viruses from patients with acute-onset diabetes and the demonstration that these
isolated viruses could induce diabetes in mice ( 97,98 ), and ( f) the association of
autoantibody production with certain viral infections, including congenital rubella and
persistent cytomegalovirus infection ( 101,102 ). Diabetes is frequently found in
patients with congenital rubella syndrome, although disease may take 5-20 years to
develop ( 103 ), and these individuals have a significantly increased frequency of
HLA-DR3 and a significantly decreased frequency of HLA-DR2 ( 97 ). The
seasonality of the onset of diabetes ( 104 ) and the increased viral antibody titres at
this time ( 99 ) provide further evidence that a viral infection may precipitate disease.
It has been hypothesised that viruses may be responsible for the inappropriate class II
expression observed on the surface of islet P-cells of diabetic patients that are
undergoing autoimmune attack ( 105 ). In these islets, glucagon-secreting a-cells,
somatostatin-secreting 5-cells and exocrine cells do not express class II antigens,
which is consistent with the sparing of these cells in the killing process. Once P-cells
become positive for class II molecules, they themselves could act as antigen
presenting cells ( APC ) of its own surface autoantigens to T cells ( 106 ), thus
by-passing the requirement for conventional APC such as macrophages and dendritic
cells. If this phenomenon occurs in genetically susceptible individuals, i.e. those with
the predisposing HLA-DR3 and/or DR4 haplotype, but not HLA-DR2-positive
individuals, autoantigens normally expressed on the surface of P-cells can be
presented to helper T lymphocytes, leading to their activation. Subsequently, effector
B and cytotoxic T cells are stimulated. The outcome of the induction of autoimmune
T cells may depend upon the activity of regulatory mechanisms, such as suppressor T
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cell activity, which normally downregulates self-responsiveness ( 107 ), and
production of anti-idiotypic antibodies, i.e. antibodies directed against particular
clones of autoreactive lymphocytes ( 108 ). Interferon-y ( IFN-y ) and tumour
necrosis factor ( TNF-a ) produced by invading lymphocytes and macrophages are
likely to have a role in perpetuating the class II hyperexpression ( 109 ), although a
more direct cytopathic role for interleukin-1 ( IL-1 ) has been suggested due to its
cytotoxicity to P-cells in vitro ( 110).
Enhanced HLA class I expression is another phenomenon observed in the islets of
IDDM patients, which may explain the abundant presence of cytotoxic T cells among
infiltrating lymphocytes at the time of diagnosis of diabetes ( 111 ). These T cells
appear to be the main effectors in the final selective destruction of P-cells. However,
this hypotheses is only one of several proposed over the years to explain how the
autoimmune attack against pancreatic P-cells is initiated in the IDDM patient.
Hopefully, amalgamation of individual theories will elucidate the pathogenesis of
diabetes.
1.1.2.6.2. Diet
The autoimmune process leading to IDDM could be precipitated by a factor present in
the diet during infancy ( 112 ). Cow's milk in particular has been proposed as a
possible trigger ( 113 ). Animal studies have suggested bovine serum albumin
( BSA ) is the milk protein responsible and an albumin peptide containing 17 amino
acids ( ABBOS ) may be the reactive epitope. Antibodies to this peptide react with
p69 which is a P-cell surface protein that may represent the target antigen for
milk-induced P-cell-specific immunity. All diabetic patients had increased serum
concentrations of IgG anti-BSA antibodies ( but not of antibodies to other milk
18
proteins ), the bulk ofwhich were specific for ABBOS. IgA antibody levels were also
elevated. Concentrations of these antibodies decreased after diagnosis and reached
normal levels in most patients within 1-2 years. Savilahti et al ( 114) investigated the
humoral response to cow's milk and (3-lactoglobulin in paediatric patients with newly
diagnosed IDDM by enzyme-linked immunosorbent assay ( ELISA ). Patients <3
years of age had a markedly higher median level of IgG and IgA antibodies to cow's
milk and IgG antibodies to P-lactoglobulin compared with control subjects. Older
diabetic patients (3-15 years of age ) also showed higher levels of IgA antibodies to
cow's milk and P-lactoglobulin than age-matched controls or non-diabetic siblings,
although levels were lower than those found in the younger group. These results
suggest that the proteins of cow's milk may trigger the autoimmune process of IDDM.
1.1.3. CONCLUSION
IDDM is a group of disorders that are the result of destruction of the
insulin-producing P-cells of the pancreas, principally by autoimmune-mediated
mechanisms. It is possible that some cases are due to direct viral destruction of
the P-cells but, if so, these would appear to be only a small fraction of the total. In
the majority of cases, this autoimmune destruction of the P-cells proceeds over
months and years. The major defined risk factor for IDDM is genetic susceptibility,
and at least two major genes have been localised to the HLA complex on
chromosome 6, one associated with DR3, the other principally with DR4. When
occurring together, these two genes dramatically increase the susceptibility to IDDM.
There is tentative evidence for a smaller contribution by other genes, such as the DNA
polymorphic region proximal to the insulin gene on chromosome 11. Since human
IDDM has a long natural prediabetic period, if both the detailed immunologic
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processes and the exact genetic susceptibility could be identified, primary disease
prevention might become possible.
12 PRIMARY PREVENTION OF IDDM
Primary prevention not only depends on elucidating the mechanism of p-cell
destruction but also the ability to accurately predict individuals who will develop
clinical IDDM, as distinct from identifying subjects with increased susceptibility to
disease or with insulitis who never progress to metabolic decompensation. Current
predictive markers used to determine individuals at high risk of developing type I
diabetes include HLA-screening and autoantibodies directed against components of
the islet cell, which are observed in the circulation well before the clinical onset of
diabetes.
1.2.1. HLA-SCREENING
As mentioned earlier, it has been estimated that 60% or more of the overall genetic
susceptibility to IDDM is contributed by HLA-region genes. Thus, an accurate
marker for the HLA-linked genetic susceptibility would identify the majority of those
individuals in the population who are genetically at increased risk of developing
IDDM. However, even the identical co-twin of a diabetic individual, who is
genetically at the highest risk for diabetes, has only a 30-40% chance of developing
diabetes.
There are two ways in which HLA genes might be used in screening : ( a ) to test for
" high-risk " HLA types randomly in the population, and ( b ) to test for genetic risk in
siblings, offspring and other relatives of IDDM patients. Approximately 50% of the
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non-diabetic population have the same DR types as patients with IDDM. Thus, at
least 98% of the people with HLA-DR3 or DR4 will never develop IDDM. For every
1000 persons with HLA-DR3 or DR4 in the population, only 2-4 will develop IDDM
in their lifetime. HLA typing will therefore result in many more false positives than
true positives in terms ofgenetic risk.
After identical twins, the individuals at highest risk of developing IDDM are the
siblings of type I diabetic patients, who have an overall 5-10% risk for developing
IDDM. HLA testing can be used to define these risks within families ( 56,115,116 ).
A sibling who shares all HLA types with his or her diabetic sibling has a 12-24% risk
of developing IDDM, a sibling with one haplotype in common has a 4-7% risk, and a
sibling who shares no HLA types has a 1-2% risk.
HLA typing is probably best used as a research tool to elucidate the development of
diabetes, whereas autoantibodies to islet cell components might be used to screen for
preclinical IDDM in HLA-susceptible individuals, either within families or in the
general population ( 11,16).
1.2.2 AUTOANTIBODIES
Evidence accumulated over the past two decades describing the detection of
autoantibodies directed towards pancreatic islets in the sera of diabetic patients has
further supported the view that IDDM is an autoimmune disease. Only those
autoantibodies showing sufficient diabetes specificity to be used as markers of an
ongoing autoimmune process against pancreatic P-cells will be discussed further.
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1.2.2.1. Islet cell cytoplasmic antibodies
Islet cell cytoplasmic antibodies ( ICCA ) were first described in type I diabetic
patients who had other co-existent autoimmune polyendocrine disorders ( 117 ) and
subsequently in 60-80% of IDDM patients shortly after diagnosis (118). In contrast,
only 2-4% of healthy first degree relatives of patients with IDDM and 0.2% of the
general population are positive for ICCA ( 119). ICCA decreased both in frequency
and titre in the circulation of diabetic patients after disease onset, falling to 20%, 2-5
years after diagnosis ( 120,121 ). This decrease may reflect a gradual loss of antigenic
stimulus as islets are destroyed, leading to an absolute absence of P-cells ( 122 ).
ICCA reacting with islet cytoplasmic cell antigens were detected by indirect
immunofluorescence in thin cryostat sections of human pancreas, using tissue from
blood group " O " donors, thus preventing interference with isoagglutinins ( 123 ).
The autoantibody was shown to be exclusively of the IgG subclass, and predominantly
IgGl ( 124 ). However, despite 20 years of research the target antigen of ICCA has
still to be fully characterised, although studies strongly suggest a ganglioside as target
( 125 ).
ICCA lack specificity for the P-cell since they can also react with the cytoplasm of the
other islet cell types, namely a- and 5- cells, suggesting that these endocrine cells
share a common autoantigen ( 126 ). Some ICCA, in particular those of high titre,
are able to fix complement ( 127 ), the major effector of damage in humoral immunity,
and later studies have shown a definite correlation between titre and complement-
fixing ability of ICCA ( 124,128 ). Complement-fixing ICCA are present in fewer
patients than conventional ICCA, though these autoantibodies are more strongly
predictive of IDDM ( 129 ).
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Islet cell specific autoantibodies are thought to mediate islet cell injury by two
mechanisms. The first involves complement-dependent antibody-mediated cell
mediated cytotoxicity ( CAMC ), where antibodies bound to a cell surface antigen link
to and activate the complement pathway leading to increased vascular permeability,
chemotaxis for phagocytes and eventual cell lysis. These events lead to the activation
of the second mechanism, i.e. antibody-dependent cellular cytotoxicity ( ADCC ).
Cross-linking of Fc antibody receptors on the surface of macrophages induces
phagocytosis and islet cell damage, probably due to the secretion of lymphokines.
Although detectable several years prior to the onset of IDDM, ICCA are unlikely to
mediate CAMC or ADCC, and thereby p-cell cytotoxicity in IDDM patients, since
they are directed to cytoplasmic components and lack P-cell specificity. Also,
transfusion of ICCA-positive sera does not transfer diabetes to animals, and no infant
born to an IDDM mother has been reported to have aquired the disease in utero, even
though maternal antibodies readily pass through the placenta to the foetus ( 130 ).
1.2.2.2. Islet cell surface antibodies
Islet cell surface antibodies (ICSA) are by definition autoantibodies which react with
surface antigens on viable islet cells, and were initially discovered in 1975 by
MacLaren and co-workers who found antibodies reactive with the surface of cultured
human insulinoma cells in approximately 87% of diabetic patients ( 131 ).
Subsequently, indirect immunofluorescence was used to detect the presence of ICSA
in the sera of newly diagnosed IDDM patients ( 132,133 ). 125j_iabenecj second
antibodies ( 134 ) and ^5i_iabene(i protein A ( 135 ) have also been used for
determining ICSA.
23
The prevalence of ICSA has been shown to vary widely among studies. When
dispersed rat or mouse islet cells are used, frequencies of 30-60% have been reported
among IDDM patients ( 132,133 ). It should be noted that human sera should be
preabsorbed with rodent tissues to diminish non-islet-specific cross-reactions between
human antibodies and the rat islet cells under these conditions. Since ICSA is not
species specific, the sensitivity of ICSA detection may be higher when human islet
cells are used instead of rodent islets. Indeed, 82% of newly diagnosed IDDM
patients were positive for ICSA in a study using cultured neonatal human islets
(136).
In contrast to ICCA, ICSA appear to be exclusively 3-cell specific, particularly in
patients aged under 30 years ( 133,137-139 ). However, in older diabetic patients,
ICSA were occasionally preferentially bound to a- and polypeptide cells. In addition,
ICSA have also been detected in patients with non-insulin-dependent diabetes mellitus
( NIDDM ) ( 139 ), in 30% of non-diabetic patients suffering with thyroid disease
( 140 ), and in animal models of spontaneous diabetes, namely the BB rat ( 141 ) and
non-obese diabetic ( NOD ) mouse ( 142 ). Again, as for ICCA, the prevalence of
ICSA decreases with an increasing duration of IDDM ( 132 ).
An important feature of ICSA is its ability to lyse cultured islets in the presence of
complement ( 133,137,138,143 ), and this ICSA-complement-dependent cytotoxicity
was preferentially directed against P-cells ( 133,137 ), although approximately 10% of
non-P-cells were also lysed ( 137 ). ICSA are thought to mediate their cytotoxicity
via ADCC in which ICSA bind to Fc receptors on cells such as macrophages and NK
cells.
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ICSA are more likely to mediate CAMC or ADCC than ICCA, as they react with
antigens on the surface of islet cells. Indeed, ICSA-positive sera have been reported
to mediate CAMC using rat and hamster islet cells and rat insulinoma cells as target
( 133,143,144 ). However, both ICCA and ICSA are present in healthy subjects
without causing disease, and neither positively segregates with the diabetogenic
haplotype in families ( 144 ). These autoantibodies must therefore be considered of
limited value as predictive markers of IDDM.
1.2.2.3. Insulin autoantibodies
Spontaneous autoantibodies to insulin (IAA ) were initially described in 1970 in the
hypoglycaemic syndrome, which was later termed the insulin autoimmune syndrome
( 145 ). IAA were subsequently identified in untreated newly diagnosed diabetic
patients ( 146 ), their first degree relatives ( 147,148 ) and patients with other
unrelated autoimmune disorders ( 149 ). More recently, circulating IAA have been
found to be particularly prevalent in young diabetics at diagnosis, although
frequencies reported vary between different groups. This variation is most likely due
to the use of different assay systems, i.e. radioimmunoassay ( RIA ) versus ELISA,
and the use of different insulin species as substrate, i.e. human versus bovine or
porcine insulin. Palmer ( 150 ), using a liquid phase RIA and a porcine insulin tracer,
detected IAA in 18% of children at diagnosis of diabetes, but siblings of the diabetic
probands appeared negative for IAA. Other studies have described a frequency of
IAA closer to 40% ( 151 ), whereas a frequency of only 3.8% was detected in a study
of 26 adults at diagnosis of IDDM ( 152 ). Controvesy also exists between the
correlation of IAA with ICCA, with some groups reporting an association ( 147,153 )
and others not ( 152,154 ). Despite assay differences, IAA can be detected as early as
ICCA and ICSA in the prediabetic period, but carry minimal pathogenic potential.
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IAA assays also detect antibodies reacting with proinsulin as well as insulin, although
autoantibodies reacting specifically with proinsulin have been detected in 14% of
IAA-negative patients ( 155 ).
1.2.2.4. Glutamic acid decarboxylase autoantibodies
Autoantibodies to a 64 kD protein were first discovered in the early 1980's by
Baekkeskov et al ( 156 ). Crude detergent lysates of 35s methionine-labelled human
islets were immunoprecipitated using sera from newly diagnosed diabetic children and
sera from healthy control individuals. Eight of ten children immunoprecipitated a
64 kD protein, whereas none of the control sera did. This 64 kD protein is found
exclusively in the plasma membrane of P-cells, comprising at most 0.01% of total
trichloracetic acid precipitable counts in 35s methionine-labelled human islets. The
high affinity and specificity of autoantibodies to the 64 kD protein, recently identified
as glutamic acid decarboxylase ( GAD ), are demonstrated by their ability to bind to
and specifically precipitate this protein in the presence of a huge excess of islet
proteins ( 157 ).
The prevalence ofGAD autoantibodies at clinical onset of diabetes is high, with 81%
of 134 newly diagnosed IDDM patients being positive compared with 2% of 111
healthy controls ( 156,158 ). Additionally, these autoantibodies were not detected in
the sera of patients suffering from Hashimoto's thyroiditis, Graves' disease and
systemic lupus erythrematosus, demonstrating their specificity for the (3-cell.
In the first familial study of 14 prediabetic individuals, followed from 4-91 months
prior to IDDM onset, GAD autoantibodies were detected up to 8 years before clinical
onset in 11 patients ( 159 ). These findings have been verified by Atkinson et al
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( 158 ), who detected GAD autoantibodies in the first serum sample in 23 of 28
individuals, 2-75 months prior to IDDM onset. Interestingly, of the 23 GAD
antibody-positive patients, ten and five were negative for IAA and ICCA respectively.
However, it should be noted that as the majority of (3-cells disappear prior to the
clinical onset of diabetes, the prevalence of GAD autoantibodies, ICCA and ICSA
may decrease also. Thus GAD antibody-negative individuals at onset may have had
circulating antibodies during the prediabetic period. For these reasons MacLaren
(11) suggested that the incidence of autoantibodies may even be higher if the sera of
patients is analysed regularly. The progress of GAD autoantibodies in positive
patients after the onset of IDDM suggest that GAD antibody immunoreactivity
declines slowly and may take several years, despite a very low concentration of the
protein.
More recently, cloning and sequencing studies revealed the existence of two GAD
isoforms, GADg5 and GADg7, which share 67% sequence homology and are
encoded by seperate genes on different chromosomes ( 160 ). GADg5 has been
shown to be identical to the 64 kD autoantigen, and is the main target for GAD
autoantibodies in sera from recent onset IDDM patients ( 161 ).
The autoantibody directed against GAD may be the most promising potential marker
for prediabetes. It is P-cell specific and appears before ICSA and IAA, i.e. many
years beore the clinical onset of IDDM. The observation that autoantibodies against
the 64 kD protein appear before insulitis and other immune abnormalities in both the
BB rat ( 162 ) and NOD mouse ( 163 ) suggests that the antibodies may be primary
rather than secondary to P-cell destruction. Furthermore, Petersen et al ( 164 ) have
recently developed a simple, reproducible and quantitative immunoprecipitation
radioligand assay that allows large numbers of serum samples to be tested for GADg5
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antibodies in a relatively short time, thus allowing screening of individuals with or
without a family history of IDDM for the presence of this marker. However, it should
be noted that none of the autoantibodies are absolute predictive markers.
More recently, the risk of progression to IDDM has been assessed using " decision
tree " analysis ( 165 ) which can be applied to individuals with or without a family
history of IDDM. Indeed, it is possible to predict IDDM with a high degree of
specificity in a small subset of first-degree relatives of IDDM patients. However, as
approximately 90% of future cases of IDDM will come from individuals who have no
close relative with EDDM, prediction within the general population must be a main
priority for the future.
1.2.3. CONCLUSION
Predicting the development of IDDM in an individual subject is difficult and not
wholly accurate, therefore population screening for IDDM at this time is unrealistic.
However, screening of first degree relatives might be justified if an effective and safe
method of preventing type I diabetes was available. As mentioned, primary
prevention depends on the elucidation of the precise sequence of events leading to
mass destruction of islet P-cells, which, because of the inaccessibility of the human
pancreas as target organ, depends in turn on the availability of an appropriate animal
model of diabetes. These models can also be used to investigate the role of
environmental factors in the clinical expression of diabetes and assess intervention
studies.
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13 ANIMAL MODELS OF IDDM
Many models of either spontaneous or chemically-induced insulin-dependent diabetes
mellitus ( IDDM ) have been described ( 166 ). In this thesis, studies performed on
one particular animal model will be reported : the spontaneously diabetic BB rat. In
addition, references will be made to two other commonly used animal models of
IDDM, namely the NOD mouse and the streptozotocin ( STZ )-induced diabetic
mouse.
1.3.1. THE SPONTANEOUSLY DIABETIC. INSULIN-DEPENDENT BB RAT
1.3 .1.1. INTRODUCTION
The BB rat was discovered in 1974 by the Chappel brothers in a commercial colony
of albino Wistar derived rats at the Bio-Breeding laboratories ( hence the designation
BB ) in Ottawa, Canada ( 167 ). Its appearance in the colony is thought to have been
the result of a spontaneous mutation. Initially the cumulative incidence of diabetes in
the colony was approximately 10% ( 165 ), but selective breeding has increased this
figure substantially ( 168-171 ).
In 1977, a breeding colony of BB rats was established at the Animal Resources
Division of Health and Welfare in Canada, which subsequently supplied the animals
used to establish other breeding colonies, including our own in Edinburgh. In
accordance with the recommended nomenclature, the original Ottawa colony, from
which all BB rats descend, is designated BB, the colony at Worcester BB/W, that at
Edinburgh BB/E, and so on ( 172 ). Prins et al ( 173 ) recently investigated the extent
of the heterogeneity among 26 distinct lines of BB rat and reported considerable
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variability, suggesting that the genetics of each line should be considered when
comparing results obtained using animals from different colonies. The incidence of
diabetes in diabetes prone ( DP ) BB rats not only varies widely from one colony to
another, but also within colonies maintained under apparently constant conditions.
This may be due to inadvertent changes in the environment. Environmental factors
identified as affecting the incidence of diabetes include infection ( 174 ), diet ( 175 )
and stress ( 176 ). Undoubtedly other contributing factors have yet to be identified.
Particularly attractive features of this animal as a research tool for work in IDDM
include a prediabetic period of approximately 2-3 months, involvement of both
genetic and immune factors in aetiology, the fact that not all animals in litters with a
high susceptibility to diabetes develop clinically overt IDDM, the absence of obesity,
and the occurrence of functional and structural changes in the nerves, retina and
kidneys of established diabetic animals. In addition, genetic manipulation and
long-term selective breeding have led to an inbred line of diabetes-resistant ( DR ) BB
rats which can serve as experimental controls, in order to determine whether
experimental differences are diabetes or strain-related. Fewer than 1% of DR-BB in
the Worcester colony have become diabetic through >32 generations of inbreeding
( 177,178 ). However, it should be emphasised that it is inappropriate to use
non-diabetic littermates of animals with IDDM as controls, as many of these animals
have impaired glucose tolerance, and are metabolically abnormal in other respects,




The onset of IDDM in the DP-BB rat is abrupt and acute, and has a peak incidence
around the age of sexual maturation, i.e. between 60 and 120 days ( 170,171 ). The
disease affects both sexes equally ( 169 ) and shows all the clinical features
characteristic of the human disorder including polyuria, polydipsia, severe weight loss
despite hyperphagia, and lethargy. Metabolically, BB rat and human diabetes are also
analogous in many ways ( 179 ). At onset of IDDM, hyperglycaemia is associated
with hypoinsulinaemia, hyperglucagonaemia, hyperketonaemia, hyperlipidaemia
( including free fatty acids, glycerol, triglycerides and cholesterol ) and uraemia.
Blood levels of branched-chain amino acids and taurine, glycine, tyrosine,
phenylalanine, ornithine and lysine are all elevated, whilst alanine and lactate are low
( 180 ). Increased urinary levels of nitrogen and 3-methylhistidine, together with
enhanced ammoniagenesis, reflect a generalised catabolic state. Insulin responses to
feeding and intravenous (i.v. ) glucose challenge may be normal up to 10 days before
disease onset ( 181 ). Death invariably ensues in the absence of exogenous insulin
treatment.
1.3.1.2.2. Complications
Secondary systemic changes suggestive of human diabetic complications are found in
long term insulin-treated diabetic BB rats. The abnormalities include alterations in
nerve conduction and morphology, renal physiology and biochemistry, retina, hepatic
metabolism, including accelerated gluconeogenesis and impaired glucose utilisation
( 182,183 ), gonadal dysfunction related to low circulating testosterone levels ( 184 ),
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and cardiac dysfunction, associated with abnormalities in cardiac contractile proteins
( 185,186 ). Lymphocytic infiltration of the thyroid has been described in human
IDDM and in both both diabetic and non-diabetic DP-BB rats. However, in the BB
rat, thyroiditis is mild and the lesion does not progress to frank hypothyroidism
( 187 ), although the incidence of thyroiditis can be increased by the administration of
dietary iodide ( 188 ). Atherosclerosis and severe microangiopathy, both ofwhich are
common in human IDDM, have not been reported in the diabetic BB rat ( 189 ).
Thus, many of the features of diabetes observed in the BB rat make it clinically
analogous to human IDDM. Indeed, if human diabetes is closely related to diabetes in
the BB rat, then much of the evidence obtained from studies involving this animal
model will further substantiate and propagate the involvement of autoimmunity in the
aetiology of IDDM. The most important of the secondary complications observed in
the diabetic BB rat will be further discussed here.
1.3.1.2.2.1. Neuropathy
Diabetic neuropathy is the most common complication of diabetes. The BB rat
develops reproducible structural changes in somatic peripheral and autonomic nerves
which are characteristic of human IDDM, making this an ideal animal model in which
to study the pathogenesis of neuropathy ( 190 ).
The first characteristic morphological change in the somatic nerves of the BB rat is
observed within three weeks of diabetes onset, and consists of localised swellings of
large axons at the nodes of Ranvier. This is associated with, and probably caused by,
a 4-5-fold increase in intra-axonal sodium content resulting from a
/wyo-inositol-related decrease in sodium/potassium ATPase activity. This intracellular
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sodium accumulation also leads to the inactivation of sodium ion channels in the
diabetic rat nerve, resulting in a decrease in maximum available sodium permeability
( 191 ). These metabolic abnormalities underly the functional neuronal changes
observed, including decreased amplitude of evoked muscle potentials indicating loss
of functioning motor units, and reduction in nerve conduction velocity, as confirmed
by Russell et al ( 192 ) in the saphenous nerve. At this stage both structural and
functional abnormalities can be completely reversed by the attainment of good
glycaemic control with intensive insulin treatment, and partly reversed by acarbose
treatment in conjunction with low dose insulin treatment. In both cases the protective
effect diminished with age ( 193 ). Aldose reductase, a rate limiting enzyme in the
polyol pathway associated with the conversion of glucose to sorbitol, is thought to
contribute to the long-term complications of IDDM ( 194,195 ). The enzyme is
located in the eye, kidney, and myelin sheath, and is activated only when hexokinase is
saturated, i.e. during hyperglycaemia. The accumulation of sorbitol in these tissues
and the resulting diabetic complications have been linked to depletion of /Myoinositol
content, resulting in a derangement of sodium/potassium ATPase activity. Yorek et al
( 196 ) recently demonstrated that reduced motor nerve conduction velocity and
sodium/potassium ATPase activity in rats maintained on L-fucose ( a potent
competitive inhibitor of /Myoinositol transport ) could be reversed by /Myoinositol
supplementation, further demonstrating that myo-inositol deficiency may be a major
factor in the development of neural defects associated with acute diabetic neuropathy.
Administration of aldose reductase inhibitors was shown to completely prevent the
characteristic nerve conduction slowing and structural abnormalities of the nodes of
Ranvier, despite only partial preservation of axonal integrity. After six months of
diabetes, treatment only resulted in a partial prevention of neuropathy, demonstrating
the importance of additional mechanisms besides polyol pathway activation in the
pathogenesis of neuropathy ( 197 ).
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Without specific treatment, nerve conduction velocity falls to 85% and then 60% of
normal values after 4 and 11 months of diabetes respectively. This deterioration in
function is accompanied by subtle structural changes heralding the irreversible stage
of neuropathy. These changes include the disappearance of paranodal axoglial
junctional complexes, which anchor the terminal myelin loops to the axolemma. Loss
of myelin attachment to the paranodal region leads to paranodal myelin retraction,
demyelination and eventual remyelination of the nodal area in the form of
" intercalated " nodes. Marked axonal atrophy and loss of myelinated fibres is
observed, followed by distal Wallerian degeneration and fibre loss. Changes identical
to those described in sympathetic nerves were also found in sensory ganglion cells,
proximal extramedullary axons and in proximal and distal myelinated axons of the
spinal dorsal columns ( 198 ). However, sequential morphometric studies have shown
that the structural changes occur earlier in sensory nerves and there is a clear
proximal-distal gradient of severity. After eleven months of conventionally
insulin-treated diabetes, approximately 30% of animals develop vascular features with
endoneurial infarcation and focal loss of myelinated fibres. Endothelial cell
degeneration and capillary occlusion by platelets and fibrin are prominent features.
Thus, a good correlation has been demonstrated between metabolic, morphological,
and functional abnormalities but the mechanisms responsible for these changes are still
unclear.
The long-term diabetic rat also shows clinical signs of autonomic neuropathy
including recurrent diarrhoea, colonic dilatation, bladder dysfunction with urinary
retention, and male infertility. Impaired autonomic function has been shown to fall to
72% and 51% of normal values after two and six months of diabetes respectively.
Structural changes only occur after eight months and consist primarily of axonal
atrophy of both myelinated and unmyelinated nerves and loss of synaptic contacts.
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Thus, the hallmark of both somatic and autonomic neuropathy, is extensive axonal
degeneration and this structural pathology is preceded by functional abnormalities
which are reversible with treatment in the earlier stages of diabetes.
1.3.1.2.2.2. . Retinopathy
Little information is available on the effect of diabetes on the eye in the diabetic BB
rat. The classical clinical features of retinopathy are not seen on ophthalmoscopy in
this animal but the retinopathology has been described ( 199,200 ).
One of the earliest signs of diabetic retinopathy in the BB rat is the selective loss of
pericytes and a degeneration of endothelial cells from retinal capillaries. Capillary
occlusions by fibrin and platelet thrombi were also frequently observed. Light and
ultrastructural morphometric techniques have demonstrated the characteristic capillary
basement thickening in both the superficial and deep capillary beds of the retina.
Functional damage was suggested by the demonstration of increased permeability
across the retinal pigment epithelium (201 ).
A chronic high tissue concentration of glucose is thought to be the underlying factor
that triggers retinopathy. Indeed, basement membrane thickening of retinal capillaries
can be completely prevented by vigorous blood glucose control, as achieved by
intensive insulin therapy (201 ). Again, acarbose, which led to a substantial reduction
in postprandial hyperglycaemia, gave similar results. Hyperglycaemia also leads to
increased metabolism ofglucose through the polyol pathway which is thought to play
a role in the pathogenesis of diabetic retinopathy ( 194,195 ). Immunohistochemistry
studies have indeed revealed an increase in the aldose reductase content of retinal
pigment epithelium and in the pericytes and endothelial cells of retinal capillaries in the
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diabetic BB rat ( 202 ). Treatment with an aldose reductase inhibitor only achieved a
complete prevention of basement membrane thickening in the deep, but not
superficial, capillary bed of the diabetic retina (201 ).
Many other factors, including formation of advanced glycosylation end products are
considered to have important roles in the development of diabetic retinopathy.
1.3.1.2.2.3. Nephropathy
The use of STZ- and alloxan-induced diabetic animal models in the study of
nephropathy is limited due to the significant nephrotoxic effects of both drugs.
Changes observed in renal function and morphology cannot be confidently attributed
to the effects of diabetes alone. Despite this, there are few reports concerning the
kidney in the diabetic BB rat ( 203-205 ). As was found with retinopathy, the
pathological and clinical features of severe nephropathy found in human IDDM are
not observed in the BB rat. Within a few months proteinuria, though not albuminuria,
and glomerular basement membrane thickening were evident, and there was an
increase in renal blood flow and glomerular filtration rate. Urinary protein excretion
correlated significantly with the glomerular basement membrane width in diabetic rats
indicating that poor glycaemic control contributed to both clinical features. Indeed,
treatment with insulin decreased proteinuria and slowed the progression of glomerular
basement membrane thickening. No glomerulopathy was observed, even in
established diabetic animals which may be related to the lesser degree of
intraglomerular hyperfiision, hyperfiltration, hypertension and PGE2 synthesis
observed in the BB rat ( 206 ). This finding was contradicted by Woehrle et al
( 207 ), who more recently reported several clearly detectable glomerular
morphological changes in the diabetic BB rat, including enlargement of mesangial
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space, mesangial cell proliferation, increased expression of glomerular IgG and C3
deposits, and occurence of Armanni cells. The differences observed may be due to
the different insulin regimes used in these studies. Woehrle gave irregular insulin
injections to his BB rats which led to a more severe form of diabetes, whereas insulin
was given daily in the earlier study.
The main disadvantage of the BB rat as an animal model of diabetes relates to its
increased susceptibility to pulmonary infections : sterile granulomas in lymph nodes,
kidney and pancreas, and prostatic atrophy ( 189 ). The most significant lesions
involve the lymph nodes, and in young BB rats, lymph nodes show variable degrees of
paracortical and medullary replacement by plasmacytoid lymphocytes ( 208 ). These
findings may be related to the lymphopenia commonly, but not invariably, seen in
these animals. Initially it was proposed that lymphopenia was mandatory for the
development of IDDM ( 209,210 ), and as this is not a feature of human IDDM,
seemed to represent a major difference between IDDM in man and the BB rat.
However, it is now known that not only is lymphopenia frequently present without
diabetes, but also that IDDM can develop in the absence of lymphopenia ( 211,212 ).
In addition, difficulty in animal care and breeding have been reported.
1.3.1.2.3. Pancreatic insulitis
Intense mononuclear cell infiltration within and around the pancreatic islets of
Langerhans, i.e. insulitis, is the characteristic histopathological lesion observed at the
onset of spontaneous diabetes in DP-BB rats ( 168 ). The degree of insulitis varies
widely between animals and corresponds to the severity of their diabetic symptoms.
Thus, mild patchy insulitis commonly exists without any detectable impairment of
either glucose tolerance or insulin secretion, whilst more severe and extensive insulitis
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is associated with impaired glucose tolerance and reduced glucose-induced, but not
arginine-induced, insulin secretion ( 213 ). The first phase of insulin secretion is
particularly affected ( 214 ). At diabetes onset there is an absolute deficiency in
circulating insulin, massive insulitis and a decrease in the number and size of
pancreatic islets observed ( 215 ). However, progression through these phases is not
inevitable ( 216 ), and whilst IDDM never occurs without insulitis, animals with
insulitis do not necessarily go on to develop IDDM.
Many methods have been developed to isolate and characterise islet inflammatory
cells from diabetic and prediabetic BB rats in situ. These include use of serial
pancreatic biopsy ( 217 ), semiquantitative methods such as immunohistochemistry in
conjunction with moAb, and more recently, specific combinations of double moAb
staining for candidate effector cells ( 218 ). The semiquantitative approaches do not
permit concomitant population-based in situ islet mononuclear cell functional studies,
and are difficult to interpret quantitatively because of cross-reactivity of moAb to
multiple mononuclear subsets. Double staining antibody avoids such cross-reactivity.
Despite the different methodologies used, most studies find that the in situ infiltration
of specific cell types is time dependent ( 219-221 ). Lesions are observed as early as
2-3 weeks before overt diabetes onset and are initially focal, with most islets in one
pancreatic lobule showing some degree of peri-islet infiltration, whereas islets in
adjacent lobules might be unaffected, i.e. islets behave as independent organs ( 222 ).
Progressive spreading of the insulitis process ultimately leads to the complete
destruction of islet P-cells ( 217,222,223 ) and the onset of overt diabetes in the
DP-BB rat. In chronically diabetic animals, only end stage islets remain with few or
no inflammatory cells present. In such animals, islet a-, 8- and pancreatic polypeptide
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cells appear to be well preserved, highlighting the striking P-cell specificity of the
destructive process within infiltrated islets ( 217,224 ).
1.3.1.2.4. T cell and non-T cell involvement
Both T and non-T cell mechanisms are known to be involved in the destruction of
pancreatic P-cells in the DP-BB rat, and subpopulations of lymphoid cells present at
different stages of insulitis have been extensively characterised.
Marked recruitment ofEDI+ macrophages from the circulation and their subsequent
accumulation at periductal and perivascular locations adjacent to non-infiltrated islets
is the earliest, possibly the first, abnormal cellular event observed ( 220,221 ).
Approximately 10-14 days before the onset of diabetes, these activated cells, which
are quite distinct from the resident ED2+ tissue macrophages, further infiltrate
adjacent islets. Substantial numbers of T lymphocytes, including helper/inducer
( CD4+ ) and cytotoxic/suppressor ( CD8+ ) T cells, and NK cells are also observed.
B lymphocytes are found to a lesser degree ( 219,225-227 ).
Semiquantitative analyses suggest that just prior to, or after, the onset of diabetes, the
relative percentages of in situ mononuclear cells follows the hierarchy of dendritic
cells and macrophages, CD4+ T cells, similar or lesser numbers of CD8+ T cells and
finally NK cells ( 219,221,227-229 ). Some infiltrating T cells show class II
expression indicating that they are active ( 218-221,228,229 ). Furthermore, Signore
et al ( 230 ) injected 1231-labelled interleukin-2 ( IL-2 ) into DP-BB rats to show it
specifically bound to IL-2R-bearing lymphocytes infiltrating the pancreatic islets,
again indicative of a state of activation.
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Recently, more quantitative and specific methods have been used to structurally
analyse islet infiltrating mononuclear cells, thereby allowing comparisons to be made
to numbers observed in other lymphoid organs such as spleen and blood ( 218,231 ).
In the lymphopenic DP-BB rat spleen, both before and after diabetes onset, the
following hierarchy of cell composition exists : B lymphocytes ( 40% ), macrophages
( 30% ), T cells ( 20% ) and NK cells ( 10% ). This composition for all cell types,
except B lymphocytes, is strikingly different from normal Wistar Furth ( WF ) or
non-lymphopenic DR-BB rats. Furthermore, analyses of splenic T cell subsets
indicate that percentages of double-negative ( CD8"CD4" ) and activated T cells
represent major cell populations. However, the in situ islet infiltrate mononuclear
composition is distinctly different and should be more directly related to diabetes
onset. NK cells were the major cell population ( 70% ) of immune cells present
during prediabetes. At diabetes onset the NK population remained high ( 47% ), but
an increased population of T cells ( 40% ) was observed. CD4+ T cells were the
predominant subset ( 50-55% of total T cells ) before and after disease onset,
although double-negative CD4"CD8" T cell ( 25-30% ) and CD8+ T cells ( 15-20% )
were also present. Only a minority of activated T cells were reported ( <3% ). The
role of double-negative T cells is unclear, and has been described as providing B cell
help in generating pathogenic glomerular basement membrane antibodies in murine
and human lupus ( 232,233 ).
Although macrophages are amongst the first immune cells to infiltrate islets, it has not
been proven that they are the first cells to mediate P-cell damage. Nagy et al ( 234 )
determined the macrophage-mediated cytotoxicity in DP-BB rats of different ages
compared with age-matched DR-BB controls. No enhanced islet cell killing was
observed until onset of IDDM, when macrophage-mediated killing was increased in
all diabetic animals. Disease onset was accompanied by insulitis ( 82% ) and
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increased cytotoxicity ( 55% ) which is similar to the number of DP-BB rats that
progressed to diabetes. These studies indicate that macrophages are involved in cell
mediated islet destruction and may indeed be the first cellular effectors to result in
islet killing.
Several studies ( 231,235 ) have found significantly higher percentages of splenic and
peripheral blood cell macrophages in the DP-BB rat compared with those in the
DR-BB and normal Wistar rat. The quantity of MHC class II molecules on
circulating macrophages was shown to be unrelated to the pathogenesis of IDDM in
this animal.
Alternatively, the appearance of dendritic cells has been proposed as the earliest
infiltrative event in the development of diabetes ( 229 ). These cells, like
macrophages, are APC, and are capable of initiating T cell mediated immune
responses ( 236,237 ), suggesting an association with autoimmunity in the BB rat.
Tarufi et al ( 238 ) demonstrated that splenic dendritic cells isolated from DP-BB,
DR-BB and WF rats were morphologically and phenotypically indistinguishable.
However, quantitative functional assays revealed that BB rat dendritic cells were
more active than those isolated from WF rats in stimulating in vitro T cell proliferative
responses. Dendritic cells also show a higher stimulatory activity upon interaction
with macrophages and their derived factors, i.e. cytokines.
The presence ofNK cells as the major mononuclear cell population, both before and
at onset of diabetes, implicates their involvement in the pathogenesis of diabetes in the
BB rat. Additionally, Like et al ( 239 ) demonstrated that in vivo injection of
anti-CD8 moAb prevents diabetes in DP-BB rats, and since NK cells account for the
majority of peripheral blood lymphocytes expressing the CD8 antigen in the DP-BB
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rat, their involvement in IDDM is further implicated ( 239-241 ). However, treatment
also depleted cytotoxic T lymphocytes which also express the CD8 marker. The
direct role ofNK cells is suggested by prevention of autoimmune diabetes in BB rats
directly treated with the antiserum anti-asialo GM1 which is cytolytic ( although not
specifically ) to NK cells ( 242,243 ). In contrast, depletion ofNK cells by injection
of the NK-specific moAb, 3.2.3, decreased intra-islet accumulation without
preventing or delaying diabetes onset. This result suggests that NK cells are
unnecessary for autoimmune islet destruction in the spontaneously diabetic BB rat and
supports the role of cytotoxic T lymphocytes.
The proportion of cytotoxic CD8+ T cells in the lymphopenic DP-BB rat is markedly
reduced compared with non-lymphopenic controls, and the few remaining CD8+ cells
are widely thought to be NK cells. Bellgrau et al ( 244 ) reported that approximately
30% of thoracic duct CD8+ lymphocytes express T cell receptors for antigen, thus
identifying these cells as part of the T cell lineage. However, the expression of cell
surface CD8 is greatly reduced, possibly explaining their consistent failure to lyse
target cells susceptible to T cell mediated cytotoxicity. In contrast, normal cytotoxic
activity of these cells could be demonstrated against target cell lines expressing higher
than normal levels of class I MHC antigen.
Activated CD4+8~ and CD4"8+ T cells were isolated from diabetic DP-BB rats and
injected into young ( 30 day old ) large granular lymphocyte ( LGL )/NK cell depleted
DP-BB rats. The incidence of diabetes was not significantly altered compared with
untreated recipients ( 40% vs 57% respectively ). Thus the diabetic syndrome can be
adoptively transferred in the absence of LGL/NK cells, suggesting that CD8+ T cells
are involved in the diabetogenic process in the BB rat. The incidence of IDDM was
significantly increased when CD4+8" and CD4~8+ T cells from diabetic DP-BB
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donors were injected into LGL/NK cell depleted DP-BB recipients, compared with
recipients depleted of CD4~8+ T cells or treated with an anti-CD8 moAb ( p<0.05 ).
These studies demonstrated that donor CD4~8+ T cells are required for adoptive
transfer of the BB rat diabetic syndrome.
Rabinovitch et al ( 245 ) reported upon the ability of prediabetic and newly diabetic
DP-BB rat spleen lymphoid cells to kill DR-BB, WF ( MHC-compatible ) and Lewis
( MHC-incompatible ) rat islet P-cells. Both the proportion and the islet-directed
cytotoxicity of NK cells was found to be significantly greater in prediabetic and
diabetic DP-BB rats than in non-diabetic DR-BB rats. The cytotoxic effect was also
shown to be p-cell specific but not MHC-restricted. More recently functional studies
of a quantitative nature confirmed these findings ( 226 ).
Interestingly, 80-95% of DP-BB animals that fail to develop diabetes also show
inflammation of pancreatic islets, confirming the earlier observation that insulitis can
be present without the subsequent onset of diabetes. Qualatitively, there was no
difference between long-term normoglycaemic and prediabetic BB rats with respect to
the phenotypes of infiltrating cells, but quantitatively, an enhanced amount of
activated T cells expressing class II antigens and IL-2R were observed in prediabetic
animals ( 226 ).
1.3.1.2.5. Involvement ofMHC class II expression
The involvement of class II gene products in determining susceptibility to other
autoimmune diseases has been determined, as evidenced in studies showing disease
prevention using class Il-specific moAb ( 246 ). Studies of the thymus in both DP-BB
and DR-BB rats revealed defective expression ofMHC class II on cortical epithelial
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cells ( 247 ). This lesion may lead to a failure of the normal process by which
autoreactive T cells are clonally deleted during ontogeny ( 248 ). Class II molecules
aberrantly expressed on P-cells that become targets of autoimmunity ( 249 ) may
additionally present both foreign ( 250 ) and self antigens (251 ). Inappropriate
expression of these class II molecules could theoretically lead to the immunogenic
presentation of autoantigens to helper T cells by P-cells. Indeed, transgenic mice that
constitutively express class II molecules specifically on the surface of their P-cells
develop islet atrophy and hyperglycaemia, but without insulitis ( 252,253 ).
However, hyperexpression of MHC class II antigens on islet p-cells has not been
reported by all groups ( 254,255 ). Preliminary studies using the BB/E rat only
showed occassional expression of class II molecules on p-cells 2-3 weeks prior to
IDDM onset, although this phenomenon was not observed in more detailed pancreatic
biopsy studies ( 249 ). At onset, expression of MHC class II molecules is
occasionally observed in association with the few remaining insulin-secreting P-cells.
It has been proposed that this phenomenon represents the phagocytic uptake of
fragments of damaged insulin containing islets by cells such as macrophages, which
express class II antigens. Seemayer et al ( 225 ) used ultrastructural studies to show
the presence of macrophages containing ingested P-cell debris within the islets of
diabetic BB rats. Hyperexpression of class I antigens on islets and exocrine cells has
also been observed prior to the onset of diabetes in the BB rat and possibly before
cellular infiltration of the pancreas ( 227,256,257 ).
1.3.1.2.6. Adoptive transfer studies
T cells are involved in the pathogenesis of the autoimmune destruction of pancreatic
cells in DP-BB rats. Neonatal thymectomy prevents development of spontaneous
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diabetes ( 258 ) and peripheral depletion of T cells with anti-CD5 moAb also protects
weaning animals from diabetes ( 238,259 ). Other evidence for the involvement of
T cells in IDDM comes from studies examining the adoptive transfer of diabetes to
normal recipients.
Diabetes can also be induced in normal recipients using serum or lymphoid cells from
a newly diagnosed diabetic BB rat. However, early attempts to transfer diabetes gave
conflicting results. Nakhooda et al ( 260 ) reported that lymphocytes from newly
detected diabetic BB rats caused the appearance of insulitis in 37% of athymic
recipients. The incidence was increased to 58% if several lymphocyte injections were
given, although no hyperglycaemia was reported, probably due to the small number of
islets affected by insulitis ( 13% and 17% respectively ).
Rossini ( 261 ) failed to transfer insulitis, hyperglycaemia or glucose intolerance to
athymic mice and rats after injection of acutely diabetic BB rat lymphocytes, despite
using a wide variety of dose regimens and pretreatments.
Koevary et al ( 262,263 ) found that pretreatment of spleen cells isolated from
diabetic BB rats with the T cell mitogen concanavalin A ( Con A ) produced severe
diabetes, insulitis and hyperglycaemia within two weeks of transfer to young ( 30-40
day old) DP-BB recipients, i.e. before the age at which spontaneous diabetes appears.
Lymph node or spleen cells from acutely diabetic donors that had not been
preincubated with Con A failed to transfer diabetes, as did administration of Con A
activated lymphocytes to DR-BB or MHC-incompatible WF rats. Transfer of
diabetes to these rats was only possible if recipients were immunosuppressed with a
single injection of cyclophosphamide ( a compound which selectively depresses
cytotoxic/suppressor T cells ), 24-48 hours before administration of Con A stimulated
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spleen cells from acutely diabetic BB rats. However, the incidence of disease was low
( 15% ), although no control animals became diabetic. Interestingly, prophylactic
insulin treatment has also been reported to prevent the transfer of diabetes by Con A
activated diabetic BB spleen cells in the recipient BB rat and completely prevent the
incidence of diabetes ( 264 ).
Like et al ( 265 ) also reported that immunosuppression of DR-BB recipients with
cyclophosphamide or anti-lymphocyte serum ( ALS ), or neonatal thymectomy was
necessary for adoptive transfer of diabetes. This same adoptive transfer procedure
could also induce disease in Fj hybrid offspring ofBB x Lewis ( RTl^), BB x Brown
Norway ( RTln ), BB x Yashida ( RT1U ) and BB x NEDH ( RT18 ) matings.
The possible role of soluble factors in the transfer of diabetes has also been examined
by injecting young ( 30-35 day old ) DP-BB rats with culture supernatants from Con
A-treated spleen cells of acutely diabetic BB rats. Diabetes developed in 25% of
recipients ( 266 ). The nature of the diabetogenic factor is uncertain but cytokines
such as IL-1, TNF-a, and IFN-y are likely candidates ( 245 ).
It has been shown that Con A activation of T lymphocytes requires the presence of
macrophages ( 267 ). Other mitogens, namely phorbol myrisate acetate ( PMA; a
direct activator of protein kinase C ) and ionomycin ( I; a Ca^+ ionophore ) can
reportedly activate lymphocytes in the absence of accessory cells ( 268 ), and when
used in conjunction were shown to improve in vitro proliferation of diabetic BB
splenocyte subsets in comparison to Con A.
The incidence of adoptive transfer was similar when DP-BB splenocytes were injected
into 30 day old DP-BB rats after activation with either PMA + I + IL-2 or Con A
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( 57% vs 50% respectively ). However, injection of a purified splenocyte subset
containing T lymphocytes and LGL, but depleted of macrophages, isolated from
DP-BB animals after PMA + I + IL-2 activation resulted in a significantly higher
incidence of adoptive transfer (90%, p<0.05 ), even when cells were injected in small
numbers. Such autoreactive cells were found in the young DP-BB rat and further
studies determined that preactivated and enriched CD4+ T lymphocytes, but not
B lymphocytes, induced the adoptive transfer of diabetes in recipients, demonstrating
that p-cell destruction can be induced by this T cell subset ( 269 ).
IDDM can be induced in sublethally irradiated NOD mice receiving high doses of
cyclophosphamide after transfer of diabetic spleen cells. Short-term treatment with a
non-depleting CD4 moAb prevented transfer of diabetes ( 270 ) and
cyclophosphamide-induced diabetes ( 262 ) long after cessation of moAb treatment.
However, cyclophosphamide can abrogate this induced tolerance without the
requirement for newly generated T cells by the thymus.
Several groups have shown that the adoptive transfer of diabetes can be prevented.
Barlow and Like ( 271 ) reported anti-CD2 moAb treatment of the DP-BB recipient
prevented the transfer of diabetes with Con A-treated splenocytes from diabetic
BB donors. This treatment depleted the recipients of CD4+ T lymphocytes without
the depletion of NK cells or CD8+ T lymphocytes providing further evidence for
CD4+ T lymphocyte involvement in the transfer of diabetes.
Adoptive transfer is known to be facilitated by prior in vivo depletion of RT6+
T lymphocytes using an RT6-specific cytotoxic moAb. Diabetes can be induced in
approximately 50% of DR-BB rats treated from 30 days of age ( 273 ), and
RT6-depleted DR-BB splenocytes can transfer diabetes to athymic nude rats with no
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prior in vitro mitogen activation ( 274 ), strongly suggesting that both DP-BB and
DR-BB rats circulate autoreactive cells that have escaped clonal deletion.
Conversely, transfusion ofRT6+ T lymphocytes from DR-BB to DP-BB rats prevents
diabetes. It has also been reported that a single transfusion of lymphocytes from
long-term normoglycaemic DP-BB rats into prediabetic DP-BB recipients decreased
the incidence of diabetes ( 275 ). These results taken together provide evidence for
suppression of autoreactive T cells in BB rat diabetes, and suggest two defects in
these animals : one causing autoreactive cells to appear in the peripheral tissues, and
another at the level of stem cells causing lymphopenia ( 276,277 ). Depletion of
RT6+ T cells in the DR-BB in essence makes these animals the functional equivalent
of the DP-BB rat.
1.3.1.3. IMMUNOPATHOGENESIS
1.3.1.3.1. Humoral immunity
The identity of the putative P-cell antigen that is the target for autoimmune attack has
still to be determined. The presence of abnormal surface antigen(s) in the diabetic
pancreas, either congenital or induced e.g. by viral infection, has been suggested but
no evidence to support this theory has been reported.
As in human IDDM, indirect evidence that the humoral arm of the immune system
contributes to the pathogenesis of autoimmune diabetes in the BB rat is suggested by
the appearance of autoantibodies reacting against various tissues and proteins, both in
the prediabetic stage and at diabetes onset. These include antibodies to gastric
parietal, smooth muscle and thyroid cells and lymphocytes ( 162,278-280 ). ICSA
have been detected 4-8 weeks before diabetes onset ( 281-283 ) and IAA have been
48
reported ( 256,282,284 ). A 64 kD protein, now recogmised as GAD, has been
proposed as a potential autoantigen in humans and animal models of diabetes ( 285 ).
However, the 64 kD protein present in the BB rat remains to be proven to be GAD
( 162 ). Antibodies to pituitary, adrenal, testis and ovary cells and islet cell
cytoplasmic components ( 278,279 ) have not been reported in the BB rat and no
mononuclear cell infiltration is observed in these non-pancreatic tissues.
ICSA were first reported in approximately 85% of newly diagnosed diabetic BB rats
by Dyrberg et al ( 286 ) using an 125i_protejn \ radioligand assay with dispersed
Wistar rat islet cells. Subsequently, using the rat insulinoma cell line RINm5F ( 287 ),
ICSA were also shown to be present in the prediabetic period and in some animals at
weaning, long before the presence of any morphological and metabolic disturbances
associated with IDDM. However, the use of this autoantibody as a predictive marker
for the onset of diabetes is limited because of conflicting findings between groups.
Pollard et al ( 288 ) detected ICSA in 100% of prediabetic and diabetic animals using
an indirect immunofluorescence assay on pancreatic islet cell suspensions, whereas
Pipeleers et al ( 281 ) only reported ICSA in the diabetic, but not the prediabetic, rat.
The majority of ICSA are capable of complement-mediated cytolytic activity against
pancreatic islets in vitro ( 289,290 ), but no direct pathogenic role of these
autoantibodies has been demonstrated in vivo. Thus, ICSA may represent a
secondary phenomenon resulting from the destruction of islet cells.
The presence of IAA has been reported in the BB rat but the finding is disputed. Diaz
et al ( 291 ) followed the time course of IAA in the DP-BB rat by ELISA using
purified rat insulin, and found increased IAA frequency and titre with time. No
DP-BB rats were IAA positive at 45 days of age, whereas 89% were positive at day
90 and 100% were positive thereafter. This pattern was similar for the DR-BB rat
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with 100% IAA positive at day 90. Wistar controls were IAA negative at 105 days,
with only an occassional positive sera at 120 days of age. IAA therefore appeared
early in the majority of both DP-BB and DR-BB rats and much later, if at all, in
controls, suggesting that IAA is a strain-related phenomenon rather than a marker for
either insulitis or the development of IDDM in the BB rat. Markholst et al ( 292 )
attempted to resolve this controversy by measuring IAA in well-characterised inbred
BB rats using a radioligand assay with 125j_iabene(i rat insulin and an ELISA method
using rat insulin as antigen. DP-BB rats were studied from 15 weeks of age to the
last week before onset, and at onset of diabetes. Age-matched non-diabetic DP-BB
and DR-BB animals were used as controls. Levels of antibody binding increased
slightly with increasing age in all groups. In contrast to previous studies, a low
frequency of IAA was only detected at diabetes onset and was undetectable in the
prediabteic period. Markholst et al proposed that differences in analytical method,
animal age and inappropriate comparison of sera from BB and Wistar rats may
account for the variable results from different studies.
Dean et al ( 282 ) determined the presence of ICSA and IAA in DP- and DR-BB/E
rats. A higher prevalence for ICSA than IAA was reported and a higher incidence of
both autoantibodies was demonstrated in DP-BB than in DR-BB rats. There was
however no correlation between ICSA and IAA in individual animals and whereas a
highly significant association was observed between ICSA and the development of
diabetes ( p<0.005 ), IAA was only weakly associated with diabetes ( p<0.03 ).
There was no significant association of IAA with DP- in comparison to DR-BB rats,
although positive IAA values were significantly elevated in the former compared with
the latter (p<0.01).
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The 64 kD islet cell protein is expressed at high levels in brain, and at lower levels in
islets, kidney, liver, testis, ovary and pituitary, thyroid and adrenal glands in the
diabetic BB rat ( 293 ). 64 kD protein expression in rat pancreatic islets was recently
shown to increase upon high glucose stimulation, mediated via an increase of 64 kD
protein mRNA expression ( 294 ). The rate of 64 kD protein expression therefore
followed the pattern of insulin release suggesting that the regulation of 64 kD protein
expression in the P-cell co-varies with the expression of the insulin gene.
Rat islets have recently been shown to contain autoantibodies to 64 and 67 kD
proteins which are encoded by different genes in the rat ( 295 ), and are P-cell specific
in their expression. Autoantibodies against the 64 kD were initially detected in rat
islet cell fractions using an immunoprecipitation technique ( 296 ). All diabetic and
92% ofprediabetic DP-BB rats were positive for 64 kD protein antibodies. However,
a lower frequency was observed in the DR-BB rats, and WF rats were negative for
64 lcD protein antibodies. More recently, ELISA using GAD-enriched rat brain
extract has been used for the detection of this autoantibody in the BB/OK rat, and
similar results have been reported ( 297 ). Sera of non-diabetic and diabetic DP-BB
rats showed a 97% and 88% antibody prevalence respectively at 120 days of age
compared with none of the age-matched Lewis control group. Antibodies to 64 kD
protein could be detected approximately 50 days before diabetic manifestation in both
diabetic ( 84.6% ) and non-diabetic ( 71.4% ) DP-BB groups, indicating a close
association of autoantibody with genetic susceptibility to diabetes. However it is not
of predictive value with respect to the onset of diabetes in BB/OK rats.
Autoantibody to a rat islet cell-protein of 38 kD has been detected in sera of
30-day-old DP-BB rats using immunoprecipitation and Western blotting methods
( 298 ). Over 90% of DP-BB rats in which the antibody was detected eventually
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developed IDDM and the antibody disappeared within two weeks of onset. The
anti-38 kD islet cell autoantibody was not observed in the sera of 5-20 day old
DP-BB or WF rats, and appeared to be P-cell dependent, since the autoantibody
disappeared after almost complete depletion of P-cells, and was consistently present
as long as P-cells remained. Identification of the autoantibody will be invaluable for
study of the molecular nature of target islet cell autoantigen(s) associated with the
induction of autoimmunity in the DP-BB rat.
Recently, a new quantitative method to measure autoantibodies directed against
T lymphocytes based on two-colour fluorescence labelling of mononuclear cells and
two-colour flow cytometry has been developed ( 299 ). As mentioned earlier,
lymphocyte antibodies are present before insulitis and diabetes onset in the BB rat,
and show a positive correlation with ICSA. Lymphocyte autoantibodies bound both
CD4+ and CD8+ T cells and were present in 90% of BB rats at diabetes onset
compared with only 11% of Wistar rats. At 75 days of age, 83% of BB rats which
later became diabetic were positive for lymphocyte antibodies, compared with 15% of
their littermates maintaining normal glucose tolerance. Using this novel method, the
presence of lymphocyte autoantibodies could predict the development of diabetes
with a sensitivity of 83% and a specificity of 85% in BB rats.
1.3.1.3.2. Cellular immunity
The severe lymphopenia associated with the diabetic state in the BB rat is well
established ( 299,300 ) and is present in affected animals from the preweaning period
( 301 ). Until recently, it was thought that lymphopenia was obligatory for the
development of IDDM ( 209,210 ). However, it is now clear that lymphopenia is
frequently present without diabetes, and conversely IDDM can develop in the absence
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of the lymphopenic trait, although not necessarily of a high frequency ( 211,212 ).
Indeed a newly derived diabetes-susceptible rat strain, designated Long Evans
Tokushima Lean and developed from the RTlu-bearing Long Evans stock, appears
not to be lymphopenic ( 302 ). However the development of diabetes is greatly
favoured by the presence of lymphopenia ( 210,303 ).
The lymphopenia affects both the T and B lymphocyte subsets and both populations
are depressed, with T cells being affected to a greater degree. The proportion of
B cells are reported to be normal ( 300 ) or slightly increased ( 304 ) but in terms of
absolute numbers a decrease in the population is apparent ( 305 ).
The T cell lymphopenia is largely accounted for by a total or very near total absence
of mature CD5+ T cells in peripheral blood, spleen and lymph nodes expressing the
T cell differentiation alloantigen RT6 ( 306,307 ). Concomitantly, there is also a
markedly reduced level ofCD4+ helper/inducer T cells and a total ( 209,308 ) or near
total absence ( 309 ) of the CD8+ cytotoxic/suppressor T cell subset. A greatly
diminished density ofCD8 antigen on the few remaining CD8+ cells is observed.
The gene encoding RT6 is on chromosome 1 in the rat ( 310 ) and its RT6 allogeneic
system comprises of at least two alleles, a and b. The RT6a gene encodes the RT6.1
alloantigen and RT6b encodes RT6.2. Biochemical analysis of the RT6.2 antigen
from normal rats indicates that it is a polypeptide anchored to the cell membrane
through a phosphatidyl inositol linkage (311 ). Evidence of an intact phosphatidyl
inositol linkage of the RT6 molecule was demonstrated by immunoprecipitation of the
phosphatidyl inositol protein ( 306 ) or treatment with a phosphatidyl inositol specific
phospholipase C ( 311 ). Both treatments led to a markedly reduced RT6 density on
T cells indicating that the RT6.1 antigen is correctly processed and folded in diabetic
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BB rat lymph node cells. This data demonstrates that the near total absence ofRT6+
T cells in the BB rat is unlikely to be caused by a defect in the RT6 gene expression
per se. Defects in gene regulation or other cellular defects leading to premature cell
death in the T cell lineage alone or in combination may instead be responsible.
The RT6 alloantigen is expressed on approximately 60% of the peripheral T cells in
the normal or DR-BB rat, including approximately 50% of CD4+ and 70-80% of
CD8+ T cells ( 306 ). RT6 is a maturational antigen found on B lymphocytes, brain,
thymocytes or bone marrow cells, but not on neonatal peripheral T cells, and adult
levels of expression are not achieved until approximately 60 days of age ( 312 ).
Bone marrow adoptive transfer studies using DP-BB and WF rats have traced the
inability ofDP-BB rats to generate RT6+ cells to developmental defects of their bone
marrow-derived stem cells ( 313-315 ). These defects appear not to be expressed at
the pre-thymic developmental stage of T cell precursors ( 316 ), therefore RT6
represents a marker for post-thymic T lymphocyte maturation.
Given the exclusive expression of RT6 antigen on mature lymphocytes, it has been
suggested that the peripheral T cell pool ofDP-BB rats consists almost exclusively of
immature lymphocytes. This hypothesis is supported by the defective expression of
the CD45R marker on DP-BB rat T lymphocytes (317). CD45R is a surface antigen
found on both T and B lymphocytes ( 318 ) and 33% ofRT6+ T cells in the DR-BB
rat ( 319 ), which subdivides the mature CD4+ T cell subset into suppressor/inducer
( CD4+/CD45R+ ) and memory helper/inducer ( CD4+/CD45R" ) populations.
Interestingly, athymic rats transfused with CD45R+ T cells develop autoimmune
symptoms that do not occur ifCD45R" cells are present ( 320 ).
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T lymphocytes expressing RT6 are important regulators of the autoimmune process in
the BB rat. The regulatory function of RT6+ T cells was first suggested by the
observation that spleen cell transfusions from normal rats prevents diabetes in the
DP-BB rat if the treatment led to engraftment of the RT6+ donor T cells ( 321,322 ).
Conversely, treatment of non-lymphopenic DR-BB rats circulating normal RT6 cells
with anti-RT6 moAb from 30 days of age led to the destruction ofRT6+ T cells and
increased the frequency of diabetes from <1% to >50% within 2-3 weeks. None of
the controls developed IDDM ( 273,319 ). If anti-RT6 moAb treatment was delayed
to 60 days of age, diabetes did not occur suggesting the existence of a critical period
during which the autoimmune process is initiated and afterwhich the regulatory
population ofRT6+ cells cannot reverse.
Angelillo et al ( 315 ) used genetic complementation studies to show that the DP-BB
rat T lymphocytes contain an intact RT6 gene but failed to express the RT6.1
alloantigen. Southern blot analysis of DP-BB genomic DNA showed that this gene
was not grossly altered ( 323 ). Possible reasons for this lack of expression include
functional absence of an accessory factor provided by RT6+ T cells, lack of
appropriate induction signals, or a failure to generate T cells which can be induced to
express RT6 during post-thymic differentiation ( 324 ). T lymphocytes released from
the DP-BB thymus suffer from a maturational block which does not allow induction
ofRT6. As these animals are lymphopenic, despite a normal number of T cells being
released from their thymus as judged by the number of Thyl+ lymph node cells
( 323 ), it may be concluded that in the DP-BB rat most thymic emigrants die before
RT6 can be expressed.
Recently, several studies have questioned the reported absence of RT6+ cells in the
DP-BB rat. Lang and Kastern ( 325 ) reported that the RT6 subset is present in the
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diabetic BB rat in normal proportions, when based upon total lymphocyte number,
and suggest that the widely reported decrease in RT6 cell numbers results from,
rather than causes, the lymphopenia. Kastern took advantage of the close linkage
between RT6 and the albino genes on rat chromosome 1 to verify the exact role of the
RT6 gene in the inheritance of lymphopenia. The F2 generation of outcrosses
between diabetic BB and Long Evans Hooded (LEH) rats required both homologues
of chromosome 1 from the diabetic BB grandparent in order to be albino. Although
most of the albino F2 rats should also have been homozygous for the BB RT6 gene,
no increase in the incidence of IDDM ( 3.7% ) and lymphopenia ( 22.2% ) was
observed. Furthermore, the RT6 gene was fully functional and was expressed
normally on the surface of T cells of peripheral blood lymphocytes within the F2
population. This suggested that neither a defective RT6 gene nor an altered
expression of RT6 antigen could account for diabetes or lymphopenia in the DP-BB
rat.
Crisa et al ( 326 ) used molecular and biochemical procedures to investigate the
absence of the RT6+ T cell subset in the diabetic BB rat. A mRNA encoding RT6
protein was present in the DP-BB spleen cells, and nucleotide sequencing of this
transcript revealed an intact coding sequence for the RT6.1 alloantigen. Sensitive
chemiluminescent assay of lymph node cell detergent extracts showed that the RT6
mRNA was translated in vivo, and quantitatively these cells expressed <10% of the
RT6.1 protein found on DR-BB rat lymph node cells.
Further evidence demonstrating that the DP-BB rat possesses a functional RT6 gene
came from analysis of the isolated intestinal intraepithelium lymphocytes ( IEL ), using
an immunofluorescence method ( 324 ). The normal rat is known to express a very
high density ofRT6 molecules on the IEL. The population of IEL in the diabetic rat
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was found to be reduced by 50% and consisted predominantly of CD4+ T cells, the
majority of which clearly expressed RT6. However, the RT6 cell surface expression
was still only approximately 10% of that observed in normal rats. These observations
may be explained when considering that IEL may be a thymus independent T cell
population (310). It is possible that RT6+ IEL are therefore derived from a different
precursor population and mature along a different developmental pathway. If RT6
expression is an early differentiation step in the maturation of IEL, then EEL of
DP-BB rats may reach the stage of RT6 expression before the maturational block
becomes effective. Thymus-dependent peripheral T cells of the same rat have an
unusually short life span in comparison and may not live long enough to reach the
stage of complete maturity characterised by surface expression of T cell differentation
markers such as RT6 and CD45R ( 327 ). This theory is supported by McKeever
et al ( 274 ) who reported that the level of CD5+ T cells in DP-BB rat lymph nodes
falls from approximately 29% to 2%, 25 days after thymectomy at 4-6 weeks of age.
This data further suggests that CD5+ T cells in diabetic rats have a very short lifespan,
and because cells committed to the RT6 lineage do not express the RT6 antigen on
their surface until 4-14 days after release into the circulation ( 306,327 ), this may be
another explanation for the lack ofRT6+ T cells in the diabetic BB rat. Particularly
relevant to this finding is the recent report of Jacob et al ( 328 ), who described the
chromosomal localization of a DP-BB rat gene, designated Lyp, which may be
responsible for lymphopenia. This gene and the RT6 gene are thought to be different
( 325,328 ). In order to ascertain whether the shortened life span of diabetic T cells is
attributable to under- or overexpression of the Lyp gene product, further studies
involving the cloning and characterization of the Lyp gene are necessary.
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1.3.1.4. GENETICS
Inheritance of IDDM in BB rats appears to be polygenic involving at least two
independent recessive genes ( 329 ). One of these genes is associated with the rat
major histocompatibility complex ( MHC ) which is designated RT1. The RT1
complex encodes three types of class I molecules located at the RT1.A, RT1.E and
RT1.C loci, and two types of class II molecules at the RT1.B and RT1.D loci.
Studies have shown that expression of diabetes is independent of class I haplotype,
but requires the presence of at least one class II RT1U allele ( 330,331 ). However,
intercross studies indicate that the u allele of the BB rat is not a unique diabetogenic
variant allele, since u alleles derived from normal rat strains also confer susceptibility
( 332,333 ). Diabetic male BB rats crossed with inbred female Lewis ( RTl' ) or
Buffalo ( RTlb ) rat strains demonstrated that all diabetic animals were either
homozygous ( RT1U^U ) or heterozygous ( RTW or RT1U//^ ) for the u haplotype.
There was no apparent difference between BB rats that were homozygous or
heterozygous for the u haplotype in relation to age of diabetes onset or sex related
incidence of diabetes, although IDDM occurs more frequently in homozygous RT1 u/u
animals ( 334 ). This observation is similar to the human situation, where only one
copy of the permissive class II allele is sufficient to confer susceptibility. Thus, as in
diabetic sibships where affected siblings have one, and in many cases both, haplotypes
in common with the propositus irrespective of the HLA determinants that make up the
haplotype, so within BB rat litters where MHC haplotypes are segregating, diabetes
occurs in animals with the same genotype. If the first animal to develop diabetes is
RTiu/u then subsequent diabetic animals will also be RT1U/U. Conversely if the first
diabetic is RT 1 u^x then subsequent litter mates are also RT1U^X.
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Several genetic studies indicate that the class II region of the BB rat RT1 complex is
involved with the development of disease ( 332,335 ). Boitard et al ( 336 )
demonstrated that treatment of BB rats in vivo with anti-RTl.D but not RT1.B
monoclonal antibody reduced the frequency of diabetes and thyroiditis, emphasising
the importance ofMHC class II gene products in these animals.
The possible association of variant or unique class II MHC molecules with IDDM
susceptibility has been investigated by comparing the RT1U allele carried by BB rats
with that of other strains using various biochemical techniques. These techniques
show that the gene product of the BB rat RT1U haplotype is indistinguishable from
the RT1U gene products of normal WF rats ( 337 ). The nucleotide sequences of
class II ( RT1.B and RT1.D ) rnRNA's from DP-BB, DR-BB and normal WF rats
have also been determined ( 338 ). The first external domains of the P-chains of
RT1.B and RT1.D molecules were shown to be identical for the u haplotype in the
BB rats, but differed from the WF class II genes. These findings establish that the
class II gene sequences of the BB rat may be unique and that these class II molecules
of the u haplotype support the autoimmune response in the BB rat.
Speculation about mechanisms of class II involvement with diabetes susceptibility
include the concept that abberant expression of class II genes and/or structural
differences in class II molecules provide the basis for disease susceptibility by allowing
the presentation of environmental antigen and/or self antigen to the immune system.
This hypothesis is strengthened by the elevated steady-state mRNA levels of the
RTI.D, but not RT1.B, genes in the lymphocytes of DP-BB rats alone, indicating
differences in their class II regulation.
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The amino acid serine at position 57 in both class II RT1.B and RT1.D p-chains of
both DP-BB and DR-BB rats appears to be positively associated with IDDM,
whereas the presence of aspartate at this location is neutral or negatively associated
with diabetes. This phenomenon is also found in the human HLA-DQ P-chain.
Interestingly, non-diabetic Lewis ( RTl') and Buffalo ( RTl^ ) rats possess a serine
residue rather than an aspartate residue at this position ( 337 ). This suggests that the
allelic amino acid at position 57 of class II P-chain sequences does not serve as an
autoimmune disease susceptibility marker in the BB rat. However, the absence of
differences in the class II p-chain sequences of DP-BB and DR-BB rats does not
mean that these genes are not involved in IDDM susceptibility. Other unidentified
class II allelic differences or factors may be involved, and due to the polygenic nature
of spontaneous diabetes in the BB rat, these genes or factors may lie outside the MHC
region.
The RT1-linked diabetogenic gene of the BB rat was further defined by studying
RFLP in order to determine any MHC differences between DP-BB and DR-BB rats at
the genomic level. Both class I and II MHC probes were used. Using the restriction
endonucleases BamHl and EcoRl in conjunction with an I-Aa ( class II mouse
MHC ) gene probe, Buse et al ( 339 ) distinguished four polymorphic chromosome
types (la, lb, Ha and lib ) in the DR-BB population, only one ofwhich is found in the
DP-BB rat ( all homozygous for the type Ha chromosome ). From this finding, the
RT1-linked diabetogenic gene of the BB rat is linked to a defined gene of the type Ha
chromosome. The same pattern of polymorphisms, though of different molecular
weights, was found using a HLA-DCp probe ( human class II light chain ). In
contrast, Kastern et al ( 340 ) reported no detection of polymorphisms using this
probe.
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Recent evidence has suggested the possibility of a uniquely important role for faulty
class I expression in diabetes pathogenesis in humans and NOD mice (341 ). Class I
molecules are important restrictive elements for T cell selection of targets and play a
key role in antigen presentation. Indeed, hyperexpression of class I antigens appears
to occur on islet and exocrine cells in diabetic animals, and hyperexpression on
vascular endothelial cells may be the earliest abnormality in the development of
diabetes in BB rats ( 256 ). Enhanced levels ofMHC class I heavy-chain mRNA in
pancreatic islets has also been demonstrated in DP-BB rats before overt inflammation
and onset of diabetes ( 257 ). Immunohistochemistry revealed enhanced class I
antigen expression in all pancreatic islets of newly diabetic animals without induction
of class II.
Polymorphisms that further subdivided the DP-BB and DR-BB rat were found and
characterised using a mouse class I gene as probe ( 340 ). Specifically, a 2 kB
BamHl fragment was present in all non-diabetic, but not diabetic, BB rats. Similar
polymorphisms were observed with various other restriction enzymes, paticularly
Xbal, Hind II and Sac I, further demonstrating that the BB rat diabetic syndrome may
be linked to differences in class I MHC genes.
A gene or gene cluster determining T cell lymphopenia is also strongly associated with
the development of autoimmune diabetes in DP-BB rats. Lymphopenia behaves as an
autosomal recessive trait and segregates independently of the RT1 haplotype
( 303,342 ). However, lymphopenia is only permissive and not obligatory for diabetes
development, as indicated by the sporadic cases of diabetes in non-lymphopenic
DR-BB sublines. Furthermore, in neonatally thymectomised DP-BB rats, i.e. rats
lacking T cells, diabetes did not occur ( 258 ).
61
The role of the thymus was therefore investigated with respect to the lymphopenic
state and the pathogenesis of autoimmune diabetes ( 343 ). Neonatal BB rats were
inoculated with MHC-compatible, T cell deficient WF bone marrow cells, thus
rendering the host unresponsive to WF antigens. The animals were then given a
thymus allograft from a normal non-lymphopenic WF donor during early adulthood.
There was no prevention of diabetes and no significant alteration in the recipient
lymphopenic profile, suggesting neither (3-cell destruction, nor lymphopenia were
consequences of a defective thymus and/or a result of impaired intrathymic
maturation. A stem cell or prothymocyte defect within the central lymphoid
compartment of the BB rat may explain both the lymphopenia and the defective
immunoregulation that ultimately permits the expression of diabetes in the BB rat.
Guberski et al ( 342 ) and Markholst et al ( 303 ) used classical genetic studies to
confirm the permissive relationship between lymphopenia and diabetes and the
recessive nature ofboth. Furthermore, it was suggested that the combination of genes
responsible for diabetes among lymphopenic and non-lymphopenic BB rats may be
distinct.
In summary, genetic studies have shown that the inheritance of IDDM in the
spontaneously diabetic BB rat is polygenic, and at least two genes are necessary for
its development. One gene is linked to the rat MHC, specifically the class II region,
and the presence of at least one u haplotype appears to be a necessary prerequisite for
IDDM development. The MHC development of diabetes in the BB rat can be further
mapped to the class II RT1.D locus, although there is no evidence to indicate an
abnormal class II RT1.D gene product. The other implicated diabetogenic gene is
autosomal recessive and determines the profound T lymphopenia observed in this
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animal. Other non-MHC genes also modify disease penetrance and the time of onset
of diabetes (261 ).
1.3.1.5. INVOLVEMENT OF CYTOKINES
As noted earlier, macrophages are amongst the first infiltrating cells in the DP-BB rat
islet and may therefore be involved in islet cell injury. Administration of silica, which
is selectively toxic to macrophages, prevented insulitis and diabetes in young BB rats
( 344-346 ). Furthermore, DP-BB neonates injected with Con-A-activated
splenocytes from silica treated, but not untreated, diabetic rats were also protected
from IDDM and insulitis. Similar protection was observed for both DP-BB and
RT6-depleted DR-BB rats fed a diet deficient in essential fatty acids, which is known
to affect macrophage number and function ( 347 ).
Macrophage-mediated injury could be caused by cytokine release. IL-1 is a cytokine
produced in an antigen non-specific, non-MHC-restricted way, primarily by activated
macrophages and monocytes, but also by several other cell types ( 348 ). Novel
studies by Mandrup-Poulsen et al ( 349 ) showed that cytokines from human
mononuclear cells caused both functional and structural damage to isolated rat
islet (3-cells. It was later demonstrated that the cytotoxic action of cytokines was
exerted through IL-1 activity specifically. IL-ip is known to have complex dual
effects on islet P-cell function : at low concentrations (0.5 U/ml ) and/or short
exposures ( 60-90 minutes ), IL-lp stimulates insulin synthesis and secretion.
Conversely, at high concentrations ( 5 U/ml ) and/or long exposures ( >24 hours ),
this cytokine caused an inhibition of biosynthesis and insulin secretion ( 350,351 ).
The P-cell response to IL-ip was also affected by ambient glucose concentration.
High IL-ip and glucose concentrations caused an earlier and more pronounced
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inhibition of insulin secretion. In contrast, low IL-ip and non-stimulatory glucose
concentrations delayed the shift from stimulation to inhibition. This glucose effect,
which is also observed with leucine, suggests that the fL-ip effect may depend upon
the degree of p-cell activity, i.e. increasing IL-ip concentration, exposure time
and P-cell activity resulted in increased islet disintegration. Thus, the resting P-cell is
more resistant to IL-ip-mediated impairment than the working P-cell. Jobe et al
( 352 ) confirmed these findings by demonstrating that daily low dose injections of
IL-lp decreased the frequency of IDDM in the DP-BB rat. Conversely, high doses of
IL-ip induced an earlier than normal onset of diabetes, and this was associated with
increased lymphocyte and neutrophil numbers.
TNF-a is also secreted by activated macrophages and monocytes. Although TNF-a
has virtually no effect on islet P-cell function alone, low concentrations of TNF-a
potentiate the cytotoxic effect of IL-ip on pancreatic islets ( 353,354 ). In contrast to
the normal IL-1 production by activated macrophages in DP-BB rats, TNF-a
production is probably upregulated ( 355 ). Rothe et al ( 355 ) further reported that
activated peritoneal macrophages secrete strikingly higher amounts of TNF-a than
DR-BB or Wistar rat macrophages. Enhanced TNF-a was detected prior to
occurrence of insulitis, and precursor cell-derived macrophages from the diabetic
DP-BB rat bone marrow also showed upregulated TNF-a secretion upon challenge
with IFN-y. This reported TNF-a hypersecretion may affect thymic and post-thymic
T cell maturation and promote pancreatic islet inflammation, thus contributing to the
autoimmune diabetes. In contrast, prevention of diabetes and insulitis after treatment
of BB rats with TNF-a suggests that deficient TNF-a production may be involved in
the immunopathologies of autoimmune diabetes ( 356 ). TNF-a production by
peritoneal macrophages from DP-BB rats was significantly decreased, both in the
basal state and after stimulation, with either IFN-y or lipopolysaccharide in vivo and
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in vitro, as compared with control rats. Deficient macrophage production of TNF-a
may therefore be casually related to development of IDDM in the DP-BB rat ( 357 ).
The mechanism of this cytokine-mediated P-cell cytotoxic effect is uncertain. It has
been suggested that induction of intracellular free oxygen ( 02*" ), hydroxide ( OH* ),
and nitric oxide ( NO* ) radicals may be involved ( 59, 358 ), since IL-1 has been
shown to produce free radicals in other cells ( 359,360 ). NO is synthesised from
L-arginine by the enzyme NO synthase ( NOS ). Two different types ofNO synthase
exist both of which depend upon the cofactor NADPH for activity. Small
physiological amounts of NO are produced by the calcium-dependent isoform,
whereas large cytotoxic doses are generated by the calcium-independent,
cytokine-inducible isoform (361 ). These cytotoxic effects are thought to be caused
by NO-mediated destruction of iron-sulphur centres of iron containing enzymes and
result in an impairment of mitochondrial function and DNA synthesis ( 362 ).
Recently, Fehsel et al ( 363 ) reported that NO-induced islet cell lysis was preceded by
DNA damage. Since DNA damage is a mechanism of cytokine-induced cell death in
certain cell types, Rabinovitch et al ( 364 ) measured DNA fragmentation in rat islets
to determine the cytotoxic effects of cytokines at the nuclear level. Although the
individual cytokines IL-1, TNF and IFN-y inhibited insulin release from rat islets, no
DNA fragmentation or islet destruction was observed unless the three cytokines were
used in combination. The cytokine-induced DNA fragmentation was found to
precede cell lysis in islet P-cell lines. These findings identify DNA as an early target
of cytokine action in islet P-cells and implicates DNA fragmentation as a mechanism
of cytokine-induced P-cell destruction. Administration of the free-radical scavenger
nicotinamide prevented both DNA fragmentation and IL-1-mediated P-cell damage in
isolated rat islets. Nicotinamide also prevented islet graft destruction in the NOD
65
mouse ( 365 ). In addition, antioxidants have been shown to prevent ( 366 ) or
reduce the incidence of ( 367 ) diabetes in NOD mice.
1.3.1.6. THE B-CELL AND IDDM
Since normal rat islets transplanted into DP-BB rats are destroyed by recurrent
autoimmunity, islets from diabetic BB rats do not appear to be antigenically unique
( 368,369 ). As discussed earlier, the functional state of the P-cell may determine its
susceptibility to autoimmune destruction. Indeed, chronic insulin administration to
young DP-BB rats significantly decreased the incidence of diabetes and insulitis
( 370,371 ). Furthermore, Gotfredsen et al ( 371 ) noted that despite the
discontinuation of insulin administration at 140 days of age, the majority of treated
DP-BB rats remained normoglycaemic until 230 days of age. Diazoxide, an insulin
secretion inhibitor, also decreased the incidence of overt diabetes by approximately
50%, demonstrating that the protective effect of insulin was not simply a
hypoglycaemic effect ( 372 ). However, the mechanisms by which a decrease in the
insulin secretory activity protects against the autoimmune process has yet to be
determined.
Other studies have demonstrated a selective survival of neonatal pancreatic islets as
compared with adult islets transplanted in acutely diabetic DP-BB rats ( 373 ),
suggesting that the putative P-cell target antigen might be absent in neonatal
BB rat p-cells. Additionally, neonatal metabolic stimulation of 3-cells has been
reported to prevent the development of diabetes in BB rats ( 374 ). Taken together,
these studies may suggest that an aberration in the temporal expression of
potential P-cell autoantigens early in life, at a time when tolerance to self antigens is
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established, may lead to islet autoimmunity. Expression of this putative autoantigen
appears to be related to the functional maturity of the p-cells.
In summary, in vitro studies have demonstrated the cytotoxicity of the cytokines
IL-ip, TNF-a and IFN-y either alone or in combination, to the P-cell, possibly
involving the generation of free radicals. These cytokines are synthesised by activated
macrophages which are present in the initial pancreatic islet infiltrate in the
pre-diabetic BB rat. The factor initiating the insulitis and subsequent autoimmune
destruction of the islet P-cell is unknown. Cytokines, if present at high local
concentrations in the islet, may cause p-cell cytolysis, resulting in the release of
sequestered antigen(s) from the cell. Macrophages and dendritic cells bearing MHC
class II molecules can act as antigen presenting cells and may initiate autoimmune
processes by presenting the putative P-cell antigen(s) to autoreactive helper T cells
also present in the insulitis. This recognition results in the activation of helper T cells,
involving both the growth of antigen-specific T lymphocyte clones and their
differentiation to an effector function, which may involve secretion of bioactive
substances or the development of a specific capacity such as cytotoxicity or
phagocytosis. The damaged P-cells hyperexpress class I molecules and thereby elicit
an increased attack by cytotoxic T cells. Activated macrophages in the infiltrate
produce free radicals and P-cells are further damaged. Proteins normally sequestered
within the P-cell are released, and as they are unfamiliar to the immune system, they
are perceived as foreign and autoantibodies are produced against them. This scenario
may represent the sequence of events leading to the autoimmune destruction of
islet p-cells. As more and more insulin-producing cells are destroyed, the remaining
healthy P-cells become more overworked. This hyperactivity stresses the cells and
perhaps leads to an increased susceptibility to autoimmune attack. Once an
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insufficient number of (3-cells remain, the clinical expression of IDDM in the BB rat is
observed.
1.3.1.7. ENVIRONMENTAL FACTORS
One of the many unsolved problems associated with the inheritance of human IDDM
is the observation that approximately 50% of all pairs of monozygotic twins are
discordant for diabetes ( 375 ). A similar situation pertains to the BB rat where even
in long established inbred colonies the frequency of diabetes is still only 50-80%. This
suggests that environmental factors may play a possible role in the expression and
incidence of diabetes.
1.3.1.7.1. Viral infection
An early study ( 376 ) into the influence of infectious agents on the incidence of
diabetes in the spontaneously diabetic BB rat reported that the expected percentage of
animals became diabetic, despite the fact that animals were raised in a sterile
environment, which excluded viral and bacterial pathogens. This initially suggested
that the BB rat diabetic syndrome is not influenced by infection. However this study
was incomplete, as it did not exclude vertically transmitted or slow viruses.
Two subsequent studies ( 377,378 ) both showed that inoculation of 30 day old
DP-BB rats with lymphocytic choriomeningitis virus could significantly reduce the
incidence of diabetes over a prolonged period of time. These rats were
normoglycaemic, had normal levels of pancreatic insulin and little or no mononuclear
cell infiltration in their pancreatic islets. The infection was primarily lymphotrophic,
and pan T cells and cytotoxic/suppressor T lymphocyte subsets were markedly
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reduced for 4-7 days after infection. This selective immunosuppression induced by
the virus appeared to be enough to suppress the autoimmune response that would
have otherwise caused IDDM.
More recently, an outbreak of spontaneous diabetes among DR-BB rats coincided
with the serological evidence of the onset of a viral infection ( 379 ). The incidence of
spontaneous diabetes in the DR-BB rat is normally <1%. This apparent link between
viral infection and the expression of diabetes was further investigated using
polyionosonic-polycytidic acid ( poly I:C; an inducer of interferon known to
accelerate diabetic onset in DP-BB rats ), and a cytotoxic anti-RT6 moAb, also
known to induce diabetes and thyroiditis in DR-BB rats. Neither were effective at
inducing diabetes in seronegative DR-BB rats unless used together, whereas either
reagent alone was successful when given to seropositive DR-BB rats. Poly I:C also
accelerated the onset of DP-BB diabetes to a greater extent in seropositive, as
opposed to seronegative, rats. Neither agent was successful when given to non-BB
rats. It was therefore suggested that expression of the genetic predisposition to
diabetes present in all BB rats depended on cellular factors, including modulatory
environmental factors such as viral exposure to pathogens.
Like et al ( 178 ) reported that elimination of environmental viruses by caesarean
derivation increased the frequency and accelerated the tempo of spontaneous diabetes
among DP-BB rats. This effect was not accompanied by any changes in the
lymphocyte subsets. The viral-antibody free environment did not alter the resistance
ofDR-BB rats to diabetes, suggesting that environmental viral pathogens may act to
inhibit effector cell function in lymphopenic DP-BB rats, while enhancing effector cell
activity in non-lymphopenic DR-BB rats.
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Thus, viral infection may affect the expression of diabetes in DP-BB and DR-BB rats
in opposite ways, in that the absence of viral pathogens is associated with enhanced
susceptibility of DP-BB rats to spontaneous diabetes, but reduced susceptibility of
DR-BB rats to induced diabetes. Environmental viruses may protect DP-BB rats by
directly infecting and downregulating a subset of peripheral helper T cells, as was
observed with the lymphocytic choriomeningitis virus. In contrast, infection of
suppressor cells may result in the upregulation of effector cells in DR-BB rats leading
to a decreased susceptibility to IDDM. Thus, the different degrees of
immunocompetence of DP-BB and DR-BB rats, resulting in different clearance
capacities of viral pathogens, may contribute to the differential expression of
autoimmune diabetes in virally-infected BB rats.
In addition, chronic viral infection is a common stimulus for the release of interferons
from epithelial cells which have been shown to enhance expression of MHC class I
molecules by pancreatic endocrine cells in vitro. Hyperexpression of MHC class I
molecules on pancreatic p-cells is an early and striking feature in prediabetic BB rats,
thus indicating that the role of viruses in the pathogenesis of IDDM deserves further
attention.
1.3.1.7.2. Non-viral infection
As mentioned earlier, BB rats are also very susceptible to mycoplasmic infections.
Mycoplasma are known to be strong mitogens which activate both T and B
lymphocytes. It has been reported that such infection resulted in a reduced incidence
of IDDM in a BB colony on two seperate occasions ( 380 ). Rederivation of the
colony led to an increase in the diabetic incidence again, almost to 100%.
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1.3.1.7.3. Diet
Early studies demonstrated that the expression of diabetes in the BB rat was not
influenced by diet (381 ). Weanling BB rats placed on either a high carbohydrate,
protein or fat diet did not show any significant difference in their incidence of diabetes
when followed for 120 days. However, Elliot et al ( 382 ) demonstrated that the
incidence of IDDM in DP-BB rats fell from a normal 50% down to 15% when the
standard chow diet was replaced by a semi-synthetic diet from weaning, in which
L-amino acids were substituted for natural intact proteins. When this basic
semi-synthetic diet was supplemented with glucose or milk, the incidence of diabetes
again rose to 35% and 52% respectively. The presence of intact proteins in the diet
therefore appears necessary for the full expression of the genetic susceptibility to
develop diabetes in the BB rat. More recently certain plant protein sources found in a
cereal-based rodent diet were shown to have an influence on the spontaneous
development of diabetes in the BB rat ( 383 ). Other studies have also tried to
identify dietary components that may have an effect on the incidence of diabetes
( summarised by Scott et al, 384 ). Milk proteins and cereal-based diets were found
to have the strongest diabetogenic effect and have been designated " initiators " of
disease, and are capable of triggering the events that lead to the eventual destruction
of p-cells. Hydrolysed caesin-based purified diets were reported to be the weakest
diabetogenic agents ( 384 ). Additionally, circulating antibodies to dietary antigens
such as bovine serum albumin and crude wheat gliadin may be elevated in the DP-BB
rat. The mechanisms by which nutrients in diets protect from diabetes remain
unknown ( 385 ). No correction of T cell lymphopenia, improvement of T cell
proliferative response to mitogens or significant alterations of T cell subset
distribution have been observed ( 386 ). It should be noted that chemicals or
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microbial agents associated with the protein source rather than the protein itself could
mediate the observed effects.
Dietary lipids and lard are potent immune system modulators, and the preventive
effects of a diet deficient in essential fatty acids in both DP-BB and RT6-depleted
DR-BB rats have been demonstrated ( 387 ). This effect could be overcome if the
animals were given dietary supplements of linoleate beginning at 70 days of age, but
not after the peak incidence of diabetes at 120 days of age. Again the mechanisms
underlying the protective effect of a fatty acid-free diet are unknown, but it has been
suggested that this diet interferes with the generation of lipid mediators such as
leukotriene B4 and platelet activating factor ( 388 ), both ofwhich may act to attract
leukocytes to a focal inflammatory site. Alternatively, the preventive effect may be
mediated through an effect on macrophages, as essential fatty acid deficiency prevents
the influx ofmacrophages to injured tissue in glomerulonephritis ( 389 ).
Dietary components clearly influence the expression of the diabetic syndrome in the
BB rat. It is therefore important to identify the chemical nature of such components
before their preventive mode of action can be understood, and perhaps used in a
clinical situation.
1.3.1.7.4. Stress
A preliminary study suggested that environmental stress may modify both the age of
onset and, less certainly, the incidence of overt diabetes in DP-BB rats ( 390 ). Stress
applied to animals in this experiment included overcrowding, periods of restraint, slow
rotation and resocialisation. However, stress in the form of ultrasound on a short but
daily basis from an early age had no effect on the age or onset of diabetes in the BB
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rat ( 391 ). More recently, Lehman et al ( 392 ) subjected 25-day-old DP-BB rats to
a triad of stressors, designed to model chronic-to-moderate stress over a 14-week
period. Animals were weighed and tested for glycosuria twice weekly and blood
glucose measurements performed weekly to 130 days of age. Chronic stress was
found to significantly increase the incidence of IDDM : 80% and 70% of the male and
female stress animals developed diabetes respectively, compared with 50% in both
control groups. Interestingly, stressed males developed manifest diabetes at the same
time as their matched controls, whereas stressed females had significantly delayed
onset in relation to controls.
Other hormonal and environmental factors, including castration, vagotomy,
hypophysectomy, 3-methyl-O-D-glucose ( an agent that protects against certain P-cell
toxins ), and nicotinamide did not affect the cumulative incidence of diabetes (261 ).
1.3.1.8. PREVENTION OF SPONTANEOUS DIABETES IN THE BB RAT
It has been reported that cyclosporin A ( CsA ) when given in the prediabetic period
prevented the development of IDDM in DP-BB rats to a variable extent. No DP-BB
rats receiving oral CsA from 40-150 days of age developed diabetes by an age of 150
days, nor after stopping CsA treatment ( 393 ). In a longer-term study using the
BB/E rat, CsA administered from 30-100 days of age completely prevented the
development of diabetes up to an age of 150 days, and reduced the incidence to 50%
compared with controls at 452 days of age ( 256 ). Thus, treatment with CsA in the
prediabetic period both postponed the onset and reduced the overall incidence of
diabetes in DP-BB rats. The appearance of circulating ICSA closely correlated with
the development of diabetes, and were not found in any CsA-treated rat up to 150
days of age, but subsequently occured in 79% of CsA-treated and 80% of control rats
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developing diabetes by 450 days of age. In contrast, circulating IAA were detected in
16% of CsA-treated rats during treatment and in 15% of diabetic and non-diabetic
rats regardless of treatment regimen. Although CsA is thought to exert its
immunosuppressive effect specifically by inhibiting the production of messenger RNA
for lymphokine production by primed T lymphocytes, in this study the most striking
result of CsA treatment was the reduced accumulation of ED1+ macrophages at
perivascular or periductal sites adjacent to islets free of infiltration, an early event in
the pancreas of the prediabetic BB/E rat. The subsequent recruitment of immune
effector cells was also markedly inhibited. The findings that CsA directly inhibited
ED1+ macrophage recruitment suggests they may play a key role in the development
of insulitis in the DP-BB rat. As anticipated, CsA treatment at diagnosis of IDDM did
not ameliorate the disease in the BB/E rat since by this time, the central core of
insulin-containing cells has completely disappeared from virtually all the islets
throughout the pancreas, leaving only end stage islets consisting of rings or clumps of
glucagon-containing cells.
FK506 is another potent immunosuppressive agent that suppresses T lymphocyte
activation by inhibiting the transcription of mRNA's for early phase lymphokines,
although it is chemically unrelated to CsA . The central action of CsA and FK506 is
thought to involve the inhibition of the enzyme peptidylpropyl isomerase, which is the
principal constituent of their cytosolic binding site. FK506, when given
intragastrically in doses of 1 or 2 mg/kg/day to prediabetic DP-BB rats from
30-120 days of age, reduced the incidence of diabetes from 75% in water-dosed
controls to 15% and 0% respectively ( 394 ). Animals protected from diabetes by
low or high-dose FK506 had normal intraperitoneal ( i.p. ) glucose tolerance tests,
virtual absence histopathologically of autoimmune insulitis, normal liver and kidney
function tests and normal pancreatic insulin content.
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DP-BB rats receiving weekly i.p. injections of 0.2 mg of OK-432, a
non-immunosuppressive streptococcal preparation, starting from 5-6 weeks of age
and continuing through to 20-30 weeks of age had a significantly lower cumulative
index of IDDM than that found in non-treated DP-BB rats ( 395 ). Additionally, the
pancreas of OK-432-treated rats retained a greater number of non-infiltrated, intact
islets, and the populations of pan, CD4+ and CD8+ peripheral blood lymphocytes
were unchanged.
Finally, treatment of DP-BB rats with tetradine, a novel anti-inflammatory plant
alkaloid, at a dose of 20mg/kg/day from 35 to 120 days of age also reduced the
cumulative index of IDDM from 75.5% to 10.9% ( 396 ). The reduction of the
incidence of diabetes was not as marked if tetradine treatment was delayed until
70 days of age. Histologically, pancreases from tetradine-treated rats showed a lesser
degree of insulitis than controls, and drug toxicity was not observed. Thus,
non-immunosuppressive drugs such as OK-432 and tetradine may be of value in
preventing diabetes, either alone or in combination with potent immunosuppressive
drugs, such as CsA or FK-506, thereby enabling the intermittent use or lowering in
dosage of the latter, thus decreasing toxicity without loss of efficacy.
1.3.1.9. CONCLUSION
The diabetic syndrome of the BB rat shares many characteristics of human IDDM.
There is a genetic predisposition to diabetes development, and the long prediabetic
period is followed by the abrupt onset of symptoms at puberty. Symptoms include
weight loss, glycosuria, hyperglycaemia, and hypoinsulinaemia with subsequent
ketoacidosis which often proves fatal unless exogenous insulin is administered. The
onset of diabetes is accompanied by pancreatic insulitis, similar to that described in
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human IDDM, with macrophages, T lymphocytes ( both helper and
cytotoxic/suppressor subsets ), NK cells and B lymphocytes present at the onset of
diabetes.
The inheritance of diabetes in the BB rat remains unclear. Development of disease
requires the presence of one MHC complex-associated gene, and at least two
additional genes located outside the MHC region. Both cellular and humoral
immunity is involved in the pathogenesis of diabetes in the BB rat as evidenced by
adoptive transfer experiments, autoantibodies to islet cell components, the presence of
pancreatic insulitis, and successful immune intervention studies.
However, differences in characteristics between human and BB rat IDDM have been
reported, particularly the absence of ICCA and the presence of lymphopenia and T
cell defects in diabetic BB rats. It should be noted that BB rats can develop diabetes
in the absence of lymphopenia and/or depressed T cell responses, suggesting that
neither abnormality is essential for the development of diabetes in this animal model.
1.3.2. THE NON-OBESE DIABETIC MOUSE
1.3.2.1. INTRODUCTION
In 1974, a female mouse in the normoglycaemic subline of Jcl-ICR mice was found to
be overtly diabetic, and the non-obese diabetic ( NOD ) mouse strain was
subsequently established by Makino and co-workers of the Shionogi Research
Laboratories in Aburahi, Japan ( 397,398 ). The mice were found to have many
characteristics similar to human autoimmune diabetes and have increasingly been used
as an animal model in the study of IDDM ( 397 ). The incidence of spontaneous
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diabetes is relatively constant after many generations of selective breeding, and is
influenced by gonadal sex hormones. By 30 weeks of age, 70-80% of female and
approximately 20% of male NOD mice become overtly diabetic ( 399 ), characterised
by polydipsia, polyuria, hyperglycaemia, glycosuria and, in some mice, ketonuria.
Female NOD mice castrated at 5 weeks of age showed an incidence of diabetes as low
as that of untreated males, whereas castration of males increased the incidence of
overt disease to that of non-operated female mice ( 400 ). A similar experiment
showed that the removal of sex organs at 10 weeks of age did not affect the incidence
of diabetes in either sex. However, no NOD mice of either sex developed diabetes
upon testosterone administration, whereas oestradiol administration caused the
appearance of overt diabetes in both sexes of mice, directly demonstrating that sex
hormones regulate the development of diabetes in NOD mice.
1.3.2.2. PATHOGENESIS
Diabetes development in NOD mice is histologically characterised by a leukocytic
infiltration of the pancreatic islets. A pervasive insulitis emanating from the pancreatic
vasculature and secretory ducts is first observed at a time when the islets are free of
lesions. Consequently, leukocytes aggregate at the periphery of islets ( peri-insulitis )
prior to penetrating the islet core. This widespread insulitis is evident between 4 and
7 weeks of age (401 ), and is virtually complete at the clinical onset of diabetic
symptoms ( approximately 12-15 weeks of age ). At this time marked decreases in
pancreatic insulin content are observed ( 402 ). Onset of diabetes is marked by the
appearance of moderate glycosuria and non-fasting plasma glucose higher than
13.9 mmol/1. Both glycosuria and hyperglycaemia become progressively more severe
over the following 3-4 weeks, during which weight loss, polydipsia and polyuria are
observed. In contrast to the destruction of insulin producing P-cells leading to
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hypoinsulinaemia and the onset of clinically overt diabetes ( 403 ), other islet
endocrine cells are untouched by the immune response. Without exogenous insulin
treatment, NOD mice become severely hyperglycaemic and ketonaemic, but not
ketoacidotic (404).
1.3.2.3. IMMUNOPATHOGENESIS
The subsets of mononuclear cells infiltrating the pancreatic islets in the prediabetic
NOD autoimmune process have been determined by immunohistochemical analysis.
The predominant cell type was found to be activated T lymphocytes, including
helper/inducer L3T4+ and cytotoxic/suppressor Lyt-1+. Lyt-2+ T cells were less
frequently encountered ( 405 ). These observations suggest that diabetogenesis is a
T lymphocyte dependent process. B lymphocytes and macrophages are also present
in the early islet infiltrate ( 406,407 ), whereas NK cells are functionally defective
( 408 ). Additional evidence for an autoimmune aetiology in the NOD mouse came
from Wicker et al ( 409 ) who developed an adoptive transfer protocol that used
splenocytes from overtly diabetic NOD mice to effectively transfer diabetes to
>95% irradiated NOD mice that were >6 weeks of age, within 12-22 days, i.e. at a
higher frequency and at a younger age. Transfers were unsuccessful in recipient NOD
mice <6 weeks of age. Furthermore, even though male NOD mice display a lower
incidence of spontaneous diabetes than the female, transfers into males and females
were equally successful.
Hanafiisa et al ( 410 ) further identified the T lymphocyte subset responsible for the
transfer of insulitis or diabetes in T cell depleted NOD mice which rarely develop
insulitis. Spleen and lymph node cells isolated from diabetic mice treated with
cyclophosphamide ( a compound known to significantly increase the incidence of
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diabetes at an age when spontaneous diabetes rarely occurs in untreated NOD mice )
were separated into various T lymphocyte subsets using moAb against various surface
antigens in conjunction with complement. These subsets were then adoptively
transferred to NOD mice recipients. Transfer of either the Thy-1+, Lyt-1+ or L3T4+
cell-depleted fraction ofT cells caused no increase in the incidence of insulitis in T cell
depleted NOD mice. In contrast, donor cells depleted of the Lyt-2+ fraction
successfully induced insulitis in T cell depleted recipient mice. These data were
consistent with immunohistochemical studies which showed that 2 weeks after cell
transfer, L3T4+ helper T cells were the predominant phenotype of cells infiltrating the
islets, again indicating the importance of the L3T4+Lyt-2~ T lymphocyte subset in the
pathogenesis of insulitis in NOD mice.
More recently, Christianson et al ( 411 ) performed transfer studies in NOD mice
homozygous for the severe combined immune deficiency ( scid ) mutation, which fail
to develop functional T and B lymphocytes and are consequently insulitis- and
diabetes-free. Purified splenic L3T4+, but not Lyt-1+, T cells from diabetic NOD
donors already primed to P-cell antigens adoptively transferred insulitis and diabetes
into unirradiated NOD-scid/scid recipients. However, purified splenic L3T4+ T cells
from prediabetic NOD mice were incapable of transferring disease in the absence of
Lyt-1+ T lymphocytes, confirming that these T cells are required for the initiation
of P-cell destruction during the natural course of the disease in euthymic NOD mice
(411).
These findings are in agreement with Koike et al ( 412 ) who reported that NOD
neonatal mice treated with injections of the anti-L3T4 moAb GK1.5 for 12 weeks
prevented the insulitis and diabetes associated with NOD mice. At the same time,
Wang et al ( 413 ) also reported success with this moAb in the prolonged survival of
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cultured BALB/c mice islets allografted into GK1.5-treated diabetic NOD mice.
Treatment reduced the level of L3T4+ T lymphocytes from an initial 43% of the
peripheral blood lymphocytes to <4%, and levels remained low for approximately two
weeks after cessation of GK1.5 treatment. The gradual return to hyperglycaemia
roughly correlated with the reappearance of L3T4+ T lymphocytes in the peripheral
circulation.
Thus, it is widely agreed that class II-restricted L3T4+ T cells play an essential role in
the development of diabetes in the NOD mouse. However, two studies have reported
that for the successful transfer of diabetes to NOD neonatal mice using spleen cells
from diabetic NOD mice donors, both L3T4+ and Lyt-2+ T cells are necessary
( 414,415 ). This finding suggests that disease transfer probably involves cooperation
between these T cell subsets in the effector phase of P-cell destruction. Neither
insulitis nor diabetes was induced in young irradiated recipients by transfer of either
T cell subset alone, and it is likely that L3T4+ cells act as helper cells cooperating
with activated Lyt-2+ cytotoxic cells, possibly by providing expansion signals such as
secretion of the cytokine, IL-2. Miller et al ( 414 ) further demonstrated that both
T cell populations had to be obtained from diabetic NOD mice rather than from young
non-diabetic donors, in order to successfully transfer diabetes and/or insulitis to the
NOD recipient.
Most recently, Wicker et al ( 416 ) in an attempt to assess the contribution of
cytotoxic/suppressor Lyt-2+ T cells to diabetes developed a class ofNOD mouse that
lacks expression of P2-microglobulin ( NOD-B2mnull). These mice do not express
cell surface MHC class I molecules or produce detectable levels of Lyt-2+ T cells in
the periphery, and fail to develop insulitis and diabetes. The observation that
NOD-B2mnull mice do not develop L3T4+ T cell mediated insulitis suggests that at
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least one role of Lyt-2+ T cells is at the initiation of the autoimmune response
to P-cells in the NOD mouse. Serreze et al ( 417 ) confirmed these findings in the
MHC class I deficient NOD-B2mnull mouse, and also reported that the presence of a
disrupted B2m locus did not negatively affect plasma insulin levels in these mice.
It has been demonstrated by a number of groups that cells can process and present
peptide antigens derived from intracellular sources in the context of their own MHC
class I molecules ( 418 ). CD8+ T cell lines from NOD mice which recognise
antigens in the context of MHC class I molecules are able to kill islet cells in an
MHC-restricted manner ( 419 ). 70% of lymphocytes derived from the culture of
cells isolated from the insulitis lesions of the diabetic NOD pancreas in the presence of
IL-2 were Lyt-2+, and were capable of killing islets, but not thyroid cells, in a manner
restricted by the MHC haplotype of target islet cells. These results suggest that islet
cells are able to present islet-specific peptide antigen to autoreactive T cells that
mediate specific killing. In contrast, MHC class II antigens are not normally
expressed on islet P-cells, and the ability of P-cells to present antigens to CD4+ T
cells in the context ofMHC class II has not been demonstrated. L3T4+ helper T cells
in NOD mice are stimulated by P-cell antigen(s) expressed on, or presented by, class
II bearing cells, such as macrophages and dendritic cells, to produce lymphokines.
Recently, a L3T4+ T cell line cloned from a NOD mouse was shown to proliferate
and produce lymphokines in response to islet cell antigen and NOD mice APC ( 420 ).
This cell line was shown to destroy grafted islet cells in a tissue-specific manner. The
secreted lymphokines activate class I restricted Lyt-2+ T cells specific for the
same P-cell antigen, and proceed to mediate P-cell destruction. Lyt-2+ T
lymphocytes were shown to inhibit insulin release from normal islet cells in response
to theophylline/arginine stimulation (421 ).
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Support for a class I restricted effector mechanism came from transplantation studies
in the NOD mouse ( H-2K^ , D^ ) ( 422 ). In these studies pancreases from newborn
histoincompatible CBA ( H-2^ ) mice were accepted by CsA-treated diabetic NOD
mice. However, islets within the donated pancreases were rejected, suggesting that
CsA treatment at 40mg/kg/day could not prevent the pre-existing anti-P-cell
autoimmunity. Islets isolated from BALB/c and B.10 mice, both of which share class
I antigen with the NOD mouse ( and D^ respectively ), showed a significant
increase in lymphocytic infiltration compared with CBA islets. This suggests that
effector cells utilise class I antigen as restricting elements for the autoimmune
response, and anti-islet autoimmunity in NOD mice appears to exert its effect in an
H-2 restricted manner. In contrast, Prowse et al ( 423 ) cultured CBA islets in order
to remove APC that may cause allograft rejection before transplanting them into NOD
mice. These CBA grafts were still rejected despite the acceptance of CBA cultured
pituitary tissue transplanted to the same NOD mice. This group hypothesised that an
MHC-unrestricted mechanism was responsible for the P-cell destruction seen in the
NOD mouse. However, these results may not have been due to the effect ofMHC
antigens alone, as diverse minor alloantigens are also present in these donor mice.
Immune responses to minor alloantigens also involve MHC antigens and may
influence islet allograft destruction. Recently, this group repeated their previous
studies in the absence ofminor alloantigenic differences between donor mouse strains
( 424 ). The pancreata from three B.10 congenic lines were transplanted under the
kidney capsule of NOD mice immunosuppressed with a dose of CsA that prevents
allorejection, but not autoimmune destruction, within one month of diabetes onset.
All grafts were harvested ten days after transplantation and examined
immunohistologically. Pancreatic allografts from B.10 congenic mice sharing H-2K^
with NOD mice showed the strongest infiltration, and no islets or P-cells were
evident. Pancreases from mice sharing the same H-2Db also showed severe
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lymphocytic infiltration and only a few P-cells were present as single cells. In
contrast, grafts completely incompatible at the H-2 locus showed the least infiltration,
and normal islets containing many P-cells were found in the majority of grafts. These
results confirm the previous findings of this group, i.e. islet allograft destruction in
diabetic NOD mice is MHC-restricted and not controlled by CsA therapy. In a
seperate study, Matsuo et al ( 425 ) reported the presence of non-MHC-restricted
islet allograft damage which was milder in its anti-islet response and easily controlled
by CsA.
These results demonstrate the involvement of other mechanisms in P-cell destruction,
such as macrophage-mediated production of oxygen free radicals which can damage
islet P-cells ( 426 ). The contribution of oxygen free radicals to the development of
insulitis in NOD mice was examined by administration of the scavengers superoxide
dismutase and catalase. Treatment with superoxide dismutase reduced the number of
islets with insulitis compared with the control group, and catalase treatment gave
similar, although non-significant results. The content of reactive oxygen intermediates
in islet cells in a culture system were measured by flow cytometry and the effect of
peritoneal exudate cells and T cells on their production were examined. Peritoneal
exudate cells, but not T cells, from NOD mice increased the content of reactive
oxygen intermediates in islet cells of NOD mice. The addition of superoxide
dismutase to the culture medium suppressed this increase, thereby supporting the
concept that production of oxygen free radicals mediated by macrophages can damage
islet P-cells, directly resulting in autoimmune diabetes in NOD mice.
As mentioned earlier, macrophages also play an important role in the initiation of
insulitis in the NOD mouse and are required to recruit or activate diabetogenic
T lymphocytes ( 427,428 ). Silica is selectively toxic to macrophages and i.p.
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injections completely prevented the development of insulitis and diabetes in NOD
mice, either treated with cyclophosphamide or untreated. These findings were
confirmed by Charlton et al ( 429 ), who additionally reported that administration of
anti-Lyt-2+ moAb into cyclophosphamide-treated NOD mice prevented the
occurrence of diabetes, demonstrating that both Lyt-2+ T lymphocytes and
macrophages were necessary, but not sufficient, for (3-cell destruction in the NOD
mouse. This group therefore proposed that macrophages present P-cell antigen to
L3T4+ T cells which induce cytotoxic Lyt-2+ T lymphocytes to specifically
destroy P-cells.
Yasunami and Bach ( 430 ) also used cyclophosphamide-induced diabetic NOD mice
for their studies. Spleen T cells from these mice were shown to be capable of
transferring diabetes into irradiated non-diabetic syngeneic recipients, indicating that
the diabetogenic effect of cyclophosphamide is not mediated by direct toxicity on
pancreatic P-cells, but by abrogation of a suppressor mechanism which may prevent
activation of T cells responsible for the development of diabetes in the NOD mouse.
The importance of abnormal suppressor function has also been reported by Serreze
and Leiter ( 408 ) who found a defect in suppressor cell activation rather than the
absence of this immunoregulatory cell population in NOD mice after reporting a T cell
response to self-MHC class II antigens in a syngeneic mixed lymphocyte reaction
(MLR).
Several groups have suggested the presence of haematopoietic stem cells in the bone
marrow of NOD mice, which may be the site of origin of these immunological
abnormalities. Ikehera et al ( 431 ) reported that when 6 month old NOD mice were
irradiated and reconstituted with bone marrow cells from young ( <2 month
old ) BALB/c nu/nu mice, the NOD mouse developed neither insulitis nor overt
84
diabetes and had normal T and B cell functions. In addition, the newly developed
T cells were tolerant to cells with both donor and host-type MHC determinants. A
similar result was reported by Wicker et al ( 432 ) who constructed radiation bone
marrow chimeras in which ( NOD x B.10 ) Fj irradiated recipients were reconstituted
with NOD bone marrow cells. Insulitis was observed in the majority of Fj chimeras
and 31% developed diabetes. In contrast, unmanipulated ( NOD x B. 10 ) Fj mice or
irradiated F] mice reconstituted with Fj or B.10 bone marrow did not develop
insulitis or diabetes. These data further demonstrate that expression of the diabetic
phenotype in the NOD mouse is dependent on NOD-derived haematopoietic stem
cells. Furthermore, since F ] chimeras reject P-cells within pancreas transplants from
newborn B.10 mice, the P-cells of the NOD mouse do not appear to express a unique
antigenic determinant that is the target of autoimmune response. Finally, Serreze et al
( 433 ) observed autoimmune P-cell destruction in lethally irradiated diabetes-resistant
Fj mice from an outcross between NOD and non-obese normal inbred strains after
adoptive transfer of haematopoietic stem cells from NOD donors. These defects have
been attributed to APC, such as macrophages and dendritic cells that develop from
myelocytic precursors in the bone marrow. In contrast, F j mice reconstituted with
either non-obese normal or F \ bone marrow did not develop hyperglycaemia.
1.3.2.3.1. Humoral immunity
The presence of various autoantibodies in the sera ofNOD mice has been reported by
several groups. Reddy et al ( 434 ) examined the ontogeny of insulitis, ICA, and IAA
cross-sectionally at days 15, 25, 40 and 90 in young female NOD mice. ICA and IAA
were studied longitudinally from day 35 or day 144-168, until day 250. Insulitis was
first observed at day 40 ( 50% ) and subsequently at day 90 ( 70% ). ICA and IAA
were present at day 15 in 46% and 54% of the animals respectively. The incidence of
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ICA was slightly higher at day 25 ( 60% ) than at day 40 ( 40% ) and day 90 ( 54% ),
whereas IAA were present in all samples from days 25-90. At day 40 and 90, insulitis
and IAA were present together in 42% and 70% of the animals respectively, whereas
insulitis and ICA had a lower rate of concordance : 17% and 42% respectively. The
concordance rates for ICA and IAA were 42% at day 40 and 54% at day 90.
Concordance for all three markers was first observed at day 40 ( 17% ) which
increased to 38% at day 90. In longitudinal studies, ICA and IAA were often present
together whether diabetes supervened or not. The three markers investigated are
expressed early after birth and well before clinical symptoms appear in NOD mice, but
their early expression alone is not predictive of diabetes. Using an ELISA assay,
Pontesilli et al ( 435 ) detected IAA in all NOD mice throughout the entire period of
study. Autoantibodies reacting with the cytoplasm of islet cells in Bouins fixed
pancreas sections were found in 47%-58% of the samples from NOD mice aged
75-150 days. The percentage of circulating T lymphocytes and their L3T4+ and
Lyt-2+ subsets were also found to be higher in NOD mice for all ages and both sexes
than in controls. However, neither the autoantibodies or lymphocyte abnormalities
are predictive of the appearance of overt diabetes.
Yokono et al ( 436 ) demonstrated the presence of circulating autoantibodies to ICSA
in some NOD mice by a protein-A ligand assay after establishing the moAb to ICSA
from NOD splenocytes.
Atkinson and MacLaren ( 437 ) reported that the sera from newly diagnosed NOD
mice contained an autoantibody to the 64 kD p-cell protein, GAD. The autoantibody
was detectable at weaning but disappeared within weeks of diabetes onset, and was
absent from older non-diabetic NOD mice as well as several non-diabetic control mice
strains.
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The T cell reactivity to an antigen cross-reactive with a mycobacterial 64 kD heat
shock protein is also thought to be associated with the pathogenesis of diabetes in the
NOD mouse ( 438 ). The specificities of the helper T cell clones capable of causing
hyperglycaemia and diabetes were studied in order to identify the critical peptide
epitopes. A peptide within the sequence of the human variant of the 65 kD heat
shock protein was discovered. T cell clones recognising this functionally important
peptide mediate insulitis and hyperglycaemia and administration of the peptide itself to
NOD mice was found to downregulate immunity to the 65 kD heat shock protein and
prevent the development of diabetes.
Recently, Gelber et al ( 439 ) attempted to identify the earliest T cell autoantigen in
the NOD mouse, reasoning that this antigen could be casually involved in the
initiation of the disease. To this end the spontaneous T cell proliferative response of
peripheral lymphatic tissue from young prediabetic NOD mice to extracts of a
pancreatic insulinoma cell line were determined. T cell proliferative responses to
whole cell extracts and subcellular fractions of the insulinoma were seen in NOD mice
>8 days old, demonstrating that T cells responsive to J3-cell antigens exist in the
peripheral lymphoid tissue of these mice before manifestation of histologically
detectable insulitis. T cell clones derived from young, prediabetic NOD mice also
responded to whole cell extracts and the subcellular fractions of the insulinoma as did
peripheral lymphocytes. However, the clones did not respond to purified
autoantigens, including GAD 65 or 67, ICA69, carboxypeptidase-H, peripherin,
insulin or 65 kD heat shock protein, suggesting that these responses were specific for
novel P-cell autoantigens. Finally, NOD T cell proliferative responses were also
observed to an extract of human islets, suggesting potential shared antigenic
determinants between human and mouse P-cells. If the human and
murine P-cell-specific antigens are conserved, the identification of these murine
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autoantigens may lead to the discovery of the human homologue, thus leading to
possible immunotherapy and/or early diagnosis of IDDM.
Other autoantibodies have also been reported in NOD mice ( 440 ), e.g. antibodies
reacting with the apical border of the thyroid follicular cells or with the duct cells of
submandibular glands. Older NOD mice have anti-nuclear antibodies. However, sera
from NOD mice do not contain antibodies against adrenal glands or gastric parietal
cells regardless of age.
1.3.2.4. GENETICS
The susceptibility of NOD mice to autoimmune IDDM is under complex polygenic
control, with environmental factors exerting strong effects on gene penetrances.
Genetic analyses ( 398,441,442 ) have shown that at least 3 recessive genes are
involved, the most important of which is tightly linked to the MHC genes on
chromosome 17, i.e. H-2g^. Sequence analysis of the MHC genes and their
corresponding molecules by Acha-Orbea and McDevitt ( 443 ) has shown that unique
genetic abnormalities in the class II MHC region contribute to the propensity of the
NOD mouse to develop diabetes. Mouse MHC genes encode two types of class II
proteins : I-A and I-E. The I-A molecule is involved in the recognition of antigens by
T cells, whereas the I-E protein plays an important role in normal suppressor activity.
The nucleotide sequence of I-A molecules in the NOD mouse is different from any
known I-A(3 gene, resulting in the expression of a unique class II I-A(3 molecule.
Furthermore, although the class II I-Ea gene is present, mRNA for this gene is
absent, resulting in a complete lack of expression of I-Ea molecules. These genes
may therefore be directly responsible for the development of insulitis and/or diabetes
in NOD mice.
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Nishimoto et al ( 444 ) used backcross studies to further investigate the contribution
of the I-Ea defect to insulitis occurrence in the NOD mouse. The F \ mice of a cross
between I-Ea deficient mice and C57BL mice expressing the I-Ea molecule were
crossed with NOD mice. Offspring expressed I-Ea molecules, and the development
of autoimmune insulitis was prevented. This group also reported that the I-E gene
directly injected into NOD mice induced the expression of I-E molecules in recipients,
and again insulitis failed to develop. These data highlight the important contributory
role that the I-Ea defect plays in the occurrence of insulitis. However, although the
diabetogenic H-2g? haplotype is permissive for insulitis development, insulitis
sufficiently widespread to produce the clinical phenotype of diabetes is rarely
observed in segregants that are not homozygous for the diabetogenic class II MHC
alleles.
The mechanism leading to the prevention of insulitis in I-E bearing NOD mice is
unknown. Possible mechanisms include the induction of suppressor T cells as a result
of I-E expression, which prevent the generation of autoreactive P-cell-specific helper
T cells. Alternatively, I-E molecules may crossreact with an epitope formed by
interaction of the (3-cell antigen and MHC molecules. Thus, the expression of I-E in
the early neonatal stage can make T cells tolerant to autologous P-cells. However,
the lack of the I-Ea gene is not the sole cause of diabetes, since many otherwise
normal strains ofmice not expressing I-E proteins do not develop insulitis or diabetes.
As observed in the human and spontaneously diabetic BB rat, an aspartic acid residue
at position 57 of the NOD mouse I-AP chain ( homologous to human HLA-DQP
chain ) contributes to the protection of islet P-cells against an autoimmune response.
The substitution of aspartate at this position with serine, as found in the NOD mouse,
may alter the 3-D configuration of the I-AP molecules resulting in the aberrant
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recognition of the P-cell autoantigen by T lymphocytes, which finally leads to the
development of an autoimmune reaction against the islet P-cell.
Taken together, these results suggest that either the lack of I-Ea expression or the
unique amino acid sequence of the I-AP chain could be responsible for the
development of diabetes in the NOD mouse. Roles for 2 out of the 3 recessive
diabetogenic genes have also been proposed. The second diabetogenic gene, which
is located close to the gene for the T cell surface antigen Thy-1 on chromosome
9 ( 445,446 ), may play a primary role in the development of insulitis. Subsequently,
the first MHC-linked diabetogenic gene might contribute to the progression from
insulitis to overt diabetes. No information is presently available on the third
diabetogenic gene.
Although immunogenetic analyses has concentrated on the diabetogenic contributions
of the MHC class II region of the H-2g^ haplotype, current evidence suggests that the
haplotype as a whole should be considered as contributing to diabetes susceptibility.
Strong evidence comes from the congenic transfer of the haplotype of a NOD
mouse-related strain, cataract Shionogi, which contains the same class II alleles but
distinct class I loci, onto the NOD inbred background, resulting in a lower incidence
of diabetes and insulitis in the mice homozygous for the cataract Shionogi MHC
( 398,447 ). Intra-MHC regions both proximal and distal to the H-2g^ class II region
therefore contain alleles that may contribute to diabetes susceptibility, including a
unique heat-shock protein 70 allele ( 448 ) and alleles at Tap-1 and Tap-2 ( 449 ).
The products of the Tap-1 and Tap-2 loci are members of ATP-dependent transport
proteins, and may function to transport processed antigenic peptide fragments
generated in endosomal compartments into the lumen of the endoplasmic reticulum
for association with MHC class I molecules ( 450 ). Defective 7iap-gene transcription
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in NOD mice spleens has recently been reported (451 ), but not in cultured peritoneal
macrophages ( 452 ).
Non-MHC genes also control diabetes development, and analysis ofMHC congenic
stocks has shown that the NOD strain diabetogenic H-2g^ haplotype requires
interaction with non-MHC linked susceptibility to mediate IDDM ( 453 ).
1.3.2.5 ENVIRONMENTAL FACTORS
Diabetes in the NOD mouse has been categorised as an autoimmune disease based on
the involvement of various effector systems, including macrophages, T lymphocytes,
( particularly class Il-restricted L3T4+ and class I-restricted Lyt-2+ T lymphocytes ),
and humoral mediators. Environmental factors are also important modulators of
genetic susceptibility to IDDM, and account for a major component of the variation
observed in the incidence of diabetes in NOD mice among different colonies
(441).
1.3.2.5.1. Viral infection
The initial events that trigger the autoimmune response in NOD mice remain largely
unknown. It has been suggested that diabetes could result from an immune response
to viral antigens in the host cells, or to host cell-specific antigens that are exposed as a
result of viral infection. Indeed, Suenaga and Yoon ( 454 ) frequently found clusters
of endogenous retrovirus like particles in the (3-cells of male NOD mice receiving
silica for the preservation of islets, and subsequently cyclophosphamide to produce
overt diabetes. In contrast, retrovirus-like particles were rarely found in the P-cells of
male NOD mice receiving silica alone. Other endocrine cells, including a- and 8-cells,
91
pancreatic polypeptide-producing cells, and exocrine acinar cells, did not contain such
virus-like particles. The clear correlation between the presence of retrovirus-like
particles in P-cells and insulitis lesions in the cyclophosphamide-treated mice led to
the conclusion that (3-cell-specific expression of endogenous retrovirus-like particles is
associated with the development of insulitis and diabetes in NOD mice.
However, viral infections are more frequently reported to reduce rather than
exacerbate the incidence of diabetes in the NOD mouse. Transfer of male NOD mice
from a conventional mouse room into germfree conditions increased the diabetic
incidence from 6% to 70% ( 455 ). Certain peripheral immunoregulatory functions
appear to be defective in NOD mice maintained in specific pathogen-free
environments, including defective T-suppressor cell functions in vitro, and defects in
the differentiation and maturation of APC developing from bone marrow progenitors
( 456 ). These defects appear to perturb presentation of self antigens in the course of
tolerance induction and are associated with defective secretion of endogenous
cytokines, including IL-1, IL-2 and interleukin-4 ( 457,458 ). It has been proposed
that exposure to viral pathogens counterbalance these defects via elevation of
inflammatory cytokine levels. Indeed, exposure of newborn or adult NOD mice to a
variety of exogenous murine viruses, e.g. encephalomyocarditis, lymphocytic
choriomeningitis and murine hepatitis virus, have been reported to reduce the
incidence of diabetes ( 459,460 ). Treatment of prediabetic NOD mice with various
types of exogenous immunomodulators, including complete Freunds adjuvant ( 461 )
also circumvent the development of diabetes (441 ). Finally, lymphocytes from
virus-infected donors failed to transfer diabetes, providing further evidence that these
infectious agents protect by providing general immunostimulation. Alternatively,
infection may modulate pre-existing autoimmune responses to (3-cells, thereby
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decreasing the immunological attack against the islet cells and ameliorating the
development of diabetes.
1.3.2.5.2. Diet
Elliot et al ( 462 ) fed female NOD mice diets containing different proteins from just
before weaning. Only mice receiving meat meal or casein as the protein source
developed diabetes at the rate expected from this colony. Lactalbumin and gluten did
not precipitate diabetes except in a small number of animals. Casein hydrolysate in
lieu of protein protects NOD mice against overt diabetes, but only if introduced at an
early age. The animals which did not show overt diabetes nevertheless had
intermittent trace glycosuria and the majority showed mild degrees of peri-insular
lymphocyte infiltration. Both cows milk casein and some unidentified substance in
commercial mouse chow therefore appear to be dietary triggers of diabetes in the
NOD mouse when introduced at weaning. Coleman et al ( 463 ) also reported
diabetogenic catalysts present in natural ingredient diets, which contain lipoidal
moieties that are absent or present in low concentration in semi-purified diets.
1.3.2.6. PREVENTION OF SPONTANEOUS DIABETES IN THE NOD MOUSE
Many therapeutic interventions can successfully alter the incidence of insulitis and
diabetes in the NOD mouse, and these strategies have recently been reviewed by
Bowman et al ( 464 ). Ogawa et al ( 465 ) initially demonstrated that neonatal
thymectomy prevented the occurrence of diabetes in NOD mice, further supporting
the involvement of T lymphocytes in disease development. Many studies have
examined the ability ofCsA to suppress and/or ameliorate IDDM in NOD mice. Kida
et al ( 466 ) reported that oral administration of 20 or 40 mg/kg/day of CsA for 5
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weeks from an age of 4 weeks reduced the incidence of insulitis in NOD mice. This
was more marked in male rather than female mice. Mori et al ( 467 ) treated NOD
mice aged 30-60 days with oral doses of 2.5, 15 and 25 mg/kg CsA on alternate days
until 160 days of age. This regimen prevented the development of insulitis and
diabetes in NOD mice, and histologically the islets of the mice whose diabetes had
been prevented with CsA had an almost normal appearance. However, CsA appeared
to have little therapeutic effect on diabetes after development ofglucose intolerance in
NOD mice, even at the higher dose.
Wang et al ( 468 ) reported similar findings, and reasoned that since CsA did not
inhibit the synthesis of lymphokine once the message is present in the cell, it might be
expected that CsA was relatively inefficient as an agent for the regulation of disease
recurrence following administration to established diabetic recipients. Furthermore,
disease recurrence in cultured islet grafts was found to be a CD4+ T cell-dependent
process as determined by the in vivo administration of anti-CD4 and anti-CD8 moAb
prior to the grafting of islet tissue. However, CD4+ T cell depleted NOD mice
transplanted with islet tissue, prior to administration of low-dose CsA therapy still
failed to maintain their grafts.
The preventive and therapeutic effects of large-dose nicotinamide administration on
diabetes in young female NOD mice has also been studied ( 469 ). After 40 days of
treatment, all mice showed almost normal glucose tolerance and only mild insulitis
upon histological examination. Of the NOD mice given nicotinamide from the day of
the first appearance of glycosuria, 66% showed an improvement in glucose tolerance
and a disappearance of glycosuria. However, if nicotinamide treatment was withheld
until 1-2 weeks after the onset of marked glycosuria, the majority of treated NOD
mice did not become negative for urinary glucose, suggesting that nicotinamide
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administration only reverses P-cell damage in the early stages of diabetes. It should
be noted that nicotinamide may increase intracellular NAD content not only by
serving as a precursor in NAD synthesis, but also by possibly reducing poly- and/or
mono-ADP ribosylation.
Nomikos et al ( 365 ) prevented the autoimmune destruction of allogeneic islet tissue
transplanted to NOD mice by treating recipients with combined desferrioxamine and
nicotinamide, an iron chelator and inhibitor of hydroxy radical formation.
Transplanted animals became normoglycaemic and remained so for the duration of the
treatment, suggesting that oxygen-derived free-radicals produced by activated
inflammatory cells may be involved in islet damage in the NOD mouse. This group
( 470 ) further demonstrated that in vivo treatment of NOD mice with the enzyme
superoxide dismutase and catalase protected islet tissue from disease recurrence
following transplantation into diabetic mice. Similar results were obtained when
animals were treated with either enzyme alone. This effect was dose-dependent and
little protection was observed when lower doses of enzyme were used. These results
indicate that oxygen metabolites, especially superoxide and hydrogen peroxide, are
directly involved in the pathogenesis of EDDM in the NOD mouse. Free-radical
damage may account for the specificity of P-cell destruction in autoimmune diabetes
resulting from superoxide production, as the P-cell is particularly sensitive to
free-radical damage.
The mechanism of nicotinamide action has been postulated by Nakajima et al ( 471 ).
Firstly, nicotinamide was shown to inhibit ADCC activity and thus may modulate
immune responses. Secondly, nicotinamide might be utilised to produce NAD, which
is reduced in islets ofNOD mice. Alternatively, nicotinamide may act as an inhibitor
of poly ( ADP-ribose ) synthetase ( 472 ), thus preventing the reduction ofNAD and
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the breakdown ofDNA at the same time. Nicotinamide was also found to prevent the
earlier and increased induction of diabetes in NOD mice after cyclophosphamide
treatment ( 473 ), and ADCC might play a role in the insulitis process. ADCC of
splenic mononuclear cells was measured in female NOD mice and age-matched
non-diabetes-prone controls. No significant difference in activities was observed
between the two groups of prediabetic mice. However, ADCC activities in the
diabetic NOD mouse were significantly higher than those in control mice, suggesting
that nicotinamide strongly inhibits ADCC of mononuclear cells isolated from diabetic
NOD mice.
1.3.2.7. CONCLUSION
Many key features of human IDDM are reflected in the NOD mouse, including the
development of insulitis, the inheritance of particular MHC class II alleles
representing the major component of genetic susceptibility, the transfer of IDDM by
haematopoietic cells in bone marrow and the T cell dependence of disease
pathogenesis. However, there are also several important differences between human
and mouse disease. The presence of a high percentage of T cells ( both CD4+ and
CD8+ subsets ) in NOD lymphoid tissues and peripheral blood distinguishes NOD
mice from human diabetes and also from the severely T lymphopenic BB rat. NOD
mice do not display the severe diabetic ketoacidosis characteristic of untreated human
IDDM patients, perhaps due to an enhanced ability of mice to metabolise blood
ketones to lactate. NOD mice also show a pronounced female gender bias for disease
susceptibility that is not observed in humans or BB rats. In addition, the pathogenesis
of IDDM in NOD mice is associated with expression of endogenous defective
retroviruses in P-cells, a feature that has not been previously described in the P-cells
of insulitic islets from BB rats or humans. Finally, many studies use
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cyclophosphamide to induce and increase the early onset of diabetes in the NOD
mouse. This, in theory, is a chemically-induced animal model of IDDM, rather than a
spontaneously autoimmune diabetic model.
1.3.3. THE STREPTOZOTOCIN-INDUCEP DIABETIC MOUSE
Streptozotocin is a naturally occurring antibiotic produced by Streptomyces
achromogenes ( 474 ), which was originally screened for use in cancer chemotherapy
or as an antibiotic in 1960. During preclinical screening three years later, STZ was
found to be diabetogenic in rats and dogs ( 475 ), and subsequently in a variety of
laboratory animals. Its structure has been determined to be the nitrosamide
methylnitrosurea linked to D-glucose. The glucose moiety appears to be the essential
component in STZ that specifically directs it to the P-cell, as methylnitrosurea alone is
much less toxic to islet insulin-secreting cells ( 476 ). Once inside the cell, STZ
spontaneously decomposes to form an isocyanate compound and a
methyldiazohydroxide ( 477 ), which further decomposes to form a carbonium ion.
This highly reactive ion is able to alkylate various cellular components, including
DNA, leading to lesions which are removed by excision repair. Part of this repair
process involves the activation of the enzyme poly ( ADP-ribose ) synthetase to form
poly ( ADP-ribose ) using NAD as a substrate ( 476,478 ). In the P-cell, this enzyme
is overactivated and NAD is critically depleted, resulting in a cessation of cellular
function and ultimately cell death ( 479 ). Indeed, treatment of islets with
nicotinamide prevents depletion ofNAD and protects against the diabetogenic effect
of STZ ( 480 ). Although this hypothesis is widely accepted, more recent studies
suggest that the mode of action of STZ may involve a more complex mechanism than
the overactivation of a single enzyme ( 476,478 ).
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Various forms of diabetes can be induced by STZ depending upon the administration
protocol employed. IDDM occurred following injection of STZ either as a single high
dose ( >50-60 mg/kg/body weight) or as five consecutive subdiabetogenic injections
( 40 mg/kg ), with the latter leading to a gradual development of permanent, stable
hyperglycaemia (481 ).
1.3.3.1. MULTIPLE LOW-DOSE STZ-DIABETES
Prior to the discovery of the BB rat and NOD mouse, the multiple low-dose STZ
diabetic mouse, as developed by Like and Rossini (481 ), provided researchers with
an animal model of diabetes in which P-cell pathogenesis could be observed.
Progressively severe glucose intolerance was noted within a few days of the last
injection of STZ, and by day 11, heavy insulitis and disruption of islet architecture
was observed, eventually leading to permanent, severe diabetes. Interestingly, only
males appeared susceptible to diabetes induction ( 482 ). Castration of males blunted
the level of multiple low-dose STZ-diabetic hyperglycaemia, whereas testosterone
treatment restored full sensitivity. Additionally, testosterone treatment of both
castrated and non-castrated female mice increased diabetes to levels comparable with
those observed in male mice.
IDDM pathogenesis in the low-dose STZ-diabetic model is assumed to involve
thymus-dependent immunity against P-cells, possibly mediated by cytotoxic T
lymphocytes. Indeed, lethal irradiation eliminated sensitivity of athymic male mice to
STZ, whereas sensitivity was restored by reconstitution of T cell enriched splenocytes
( 483 ), demonstrating the diabetogenic potential ofT lymphocytes in this model.
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Diabetes in this multiple low-dose model is not solely due to the direct toxicity of
STZ, since microscopic studies revealed mononuclear cells in and around the
pancreatic islets, i.e. insulitis. Injection of 3-O-methyl glucose, nicotinamide or ALS
in low-dose STZ-treated mice retarded development of hyperglycaemia during the
course of treatment. However, diabetes developed shortly after treatment ceased
( 484 ), demonstrating the requirement of a cell-mediated response elicited by direct
STZ-mediated (3-cell injury.
Infiltrating cells comprise macrophages as well as T and B cells. However, despite
the detection of autoantibodies following subdiabetogenic doses of STZ ( 485 ),
mice exhibiting B lymphocyte deficiency responded to multiple low-dose
STZ-diabetogenesis. This data does not support a primary role for humoral immunity
in this animal model ( 486 ). Macrophages and neutrophils are probably the earliest
infiltrating cells. Macrophages develop spontaneous cytotoxicity against islet cells
in vitro ( 487 ), and the cytokines IL-1(3 and TNF secreted by activated macrophages
are extremely cytotoxic to cultured islet cells, particularly in combination with
IFN-y ( 488 ). In addition, high concentrations of IFN-y and TNF have been shown
to act synergistically to induce MHC class II antigens on islets in vitro ( 489 ). The
expression of class II antigens on islet p-cells may play a role in the pathogenesis
of IDDM ( 490, 105 ). Anti-inflammatory steroids were found to be strongly
immunoprotective in multiple low-dose STZ mice diabetogenesis (491 ).
Kolb ( 492 ), in a review of the literature describing the effects of immunomodulatory
compounds on low-dose STZ-diabetes in the mouse, reported that nearly all
compounds suppressing T lymphocyte or macrophage function, including antibodies
against MHC class II I-A and I-E, Thy-1, Lyt-2, whole body UV irradiation,
anti-inflammatory steroids, agents inhibiting serotonin-enhanced vascular
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permeability, and silica, partially suppress development of diabetes. Only
administration of CsA failed to suppress diabetes ( 493 ). On the contrary, CsA
enhanced the development of low-dose STZ-diabetes, probably as a result of the
combined toxicity ofCsA and STZ on mice islet P-cells ( 494 ).
The contribution of the immune system to the destruction of the P-cell mass is clearly
demonstrated in this animal model. However, multiple low-dose STZ-diabetes is not
truly autoimmune in nature, and only one report has claimed to successfully transfer
overt diabetes to naive recipients using splenocytes from low-dose STZ-diabetic mice
( 495 ). In this study, recipients were only monitored over a short period of time and
the level of hyperglycaemia reported was modest. More typical is the report of Kim
and Steinberg ( 496 ) who failed to adoptively transfer diabetes into normal male mice
receiving splenocytes from low-dose STZ-diabetic syngeneic donors.
Further evidence demonstrating lack of autoimmunity in these mice came from islet
transplantation studies. Transplantation of syngeneic islets into diabetic recipients in
numbers sufficient to reverse hyperglycaemia did not result in autoimmune destruction
of the islet graft at a time when insulitis was present in the recipients native pancreas
( 497 ). If cell-mediated immunity is involved in low-dose STZ-induction of diabetes,
an explanation as to why islets were not rejected involves their modification by STZ,
implying that P-cells must be altered to render them antigenically distinct from normal
P-cells. Indeed, recipients of an intrasplenic syngeneic islet graft treated following
transplantation with STZ became hyperglycaemic ( 498 ), confirming that P-cells had
to be altered for an immune reaction to ensue.
In summary, the multiple low-dose STZ-diabetic mouse represents a useful model in
which to study the consequences of insulitis and IDDM. However, the diabetic
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condition is primarily produced by an environmental toxin, and not by a loss of
tolerance to p-cell specific antigens in a genetically susceptible individual. In this
respect, pathogenesis in this animal model is distinct from autoimmune diabetes of
humans, BB rats and NOD mice.
1.3.4. CONCLUSIONS
Studies involving animal models of diabetes have greatly contributed to the
elucidation of the sequence of events in the pathogenesis of IDDM. The resemblance
of these models, particularly the BB rat and NOD mouse, to human autoimmune
IDDM allows us to tentatively extrapolate this information and use it in the
unravelling of events leading to the onset of the human diabetic condition. However,
initiation factor(s) resulting in the onset of this disease have still to be determined in
both animal models and human IDDM. Until then, primary prevention of human
IDDM will remain elusive and, in addition, the very real problem of accurately
predicting individuals susceptible to diabetes still exists. For these reasons, major
efforts concentrating on improving methods of insulin treatment and delivery appear
more worthwhile at the present time.
1.4. IMPROVED METHODS OF INSULIN DELIVERY
1.4.1. INSULIN THERAPY
The introduction of insulin remains the single most important milestone in the history
of diabetes, and over the seven decades since subcutaneous insulin injections were
first given, no other therapy has displaced insulin as the principal treatment for
diabetes. Insulin treatment reverses the diabetic state and restores an anabolic
101
condition where fuel is stored and released roughly in keeping with need. To achieve
this balance, insulin must be provided to approximate the variations occurring in
non-diabetic individuals, with increases at meal-times and subsequent decreases to
appropriate basal amounts in the post-absorptive periods of the day.
In the therapeutic sense, short-acting insulins are ideally suited to the requirements of
primary meals ( breakfast and dinner ) , while admixed intermediate-acting insulins
can accommodate the secondary meals ( lunch and supper ) as well as provide the
extended basal requirements overnight ( 499,500 ). All currently available
intermediate-acting insulins have a duration of less than 24 hours ( 501 ) and therefore
if the patient releases no endogenous insulin, twice-daily injection is required ( 502 ).
It has been noted that the actual metabolic control achieved with daily insulin
injections and monthly interventions for dosage adjustments is inferior to that
occurring naturally in the non-diabetic population, and close-to-normal blood glucose
values were not achieved. The recently released findings of the Diabetes Control and
Complications Trial ( 503 ) clearly indicate that intensively managed IDDM patients
maintain lower blood glucose than fairly well controlled conventionally-treated
patients. More importantly, intensification of insulin therapy led to a substantial
reduction in the development or progression of retinopathy, nephropathy and
neuropathy, as well as a likely reduction in macrovascular complications. However, it
should be noted that the long-term complications of IDDM are reduced rather than
prevented. In addition, a three-fold increase in risk of severe hypoglycaemia and
modest excess weight gain are observed in intensively managed patients ( 504 ), and a
considerable increase in patient effort will be required to reproduce the results of the
Diabetes Control and Complications Trial in practice, and at a substantial cost.
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Entry of insulin into the body primarily determines insulin levels and action and
constitutes the principal problem with current therapy since the disappearance of
insulin from the bloodstream is fast ( half-life of approximately 3-5 minutes in
non-diabetic subjects ). A discussion of these difficulties is therefore helpful in
understanding the need for alternative approaches to insulin delivery.
1.4.1.1. POOR COMPLIANCE
Poor compliance is a general problem of injection therapy which has recently been
exacerbated by the need to inject insulin more frequently with optimised regimens
than with previous treatments employing once or twice-daily injections. The
introduction of the insulin pen containing a pre-filled cartridge of short-acting,
intermediate-acting or pre-mixed insulin, has greatly improved compliance since it is
convenient, portable, and less painful on injection compared with syringes and needles
( 505 ).
1.4.1.2. ADVERSE INSULIN PHARMACOKINETICS
The non-physiological delivery of subcutaneous insulin is thought to lead to
hyperinsulinaemia in many patients, probably due to under-insulinisation of the liver.
In non-diabetic individuals, portal insulin is at least twice as high as the systemic
insulin concentration ( 506 ). The post-receptor resistance to insulin which is present
in IDDM patients ( 507 ), and the lack of pulsatility of exogenous insulin delivery in
contrast to the approximately 10 minute episodic secretion of insulin in normal man,
may also contribute to hyperinsulinaemia.
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In addition, the absorption rate of both short and delayed-acting insulin is highly
unsatisfactory. After subcutaneous injection of short-acting insulin into the diabetic
patient, the plasma free insulin concentration rises slowly to a broad plateau level
approximately 40-120 minutes after injection, after which the insulin gradually falls to
baseline levels some 6 hours after injection. This slow absorption may reflect the time
taken for hexameric insulin to dissociate into dimers and monomers after injection,
the forms in which insulin is absorbed into capillaries ( 508 ). In contrast, after a
mixed meal in non-diabetic individuals, plasma insulin reaches a peak approximately
45 minutes before returning to basal concentrations some 4 hours later. IDDM
patients would therefore be insulin deficient in the first minutes after a meal if insulin
was injected at the start of eating. Thus insulin is now administered approximately
30 minutes prior to a meal in an attempt to match peak plasma free insulin and
glucose concentrations ( 509,510 ). The slow fall to baseline of plasma free insulin
concentrations after injection of short-acting insulin is also problematic and may result
in marked overinsulinisation between meals which carries a consequent risk of
hypoglycaemia.
Delayed-action insulin formulations fail to provide a constant basal supply of insulin,
have different absorbance rates, and plasma free insulin plateaus are observed
3-6 hours after injection ( 511 ). Insulin levels decline approximately 10 hours after
injection, thus delayed-action insulin injected in the early evening does not last
through the night, resulting in insulin deficiency and hyperglycaemia in the few hours
before breakfast. Although increasing the dose of these insulins increases their
duration of action, peak insulin levels are also increased and occur unpredictably
( 512 ). Erratic hypoglycaemia may therefore occur during the night.
104
1.4.1.3. VARIABILITY OF INSULIN ABSORPTION
Species of insulin is of some importance in influencing its absorption, and both
short-and delayed-acting human insulins are absorbed slightly more quickly ( and are
therefore of shorter duration ) than equivalent porcine preparations ( 513,514 ).
For maximum comfort and effect, insulin should be injected into the adipose layer
under the skin. Occasionally patients unintentionally inject insulin intramuscularly
( i.m. ), particularly when injecting perpendicularly rather than obliquely into a lifted
skin-fold. In the thigh, absorption of injected insulin from muscle is approximately
50% higher than from the subcutaneous site ( 515 ). Infections at the injection site
are rare.
The anatomical site of insulin injection also influences absorption rate, and
short-acting insulin is most rapidly absorbed from the abdomen, with intermediate
rates from the arm and a slower rate from the gluteal region ( 516,517 ). For
consistency purposes, injections should be rotated within a given area. This also
prevents lipohypertrophy, i.e. deposition of fatty lumps resulting from repeated
injections of insulin in the same place, which slows insulin absorption ( 518 ). Insulin
absorption is augmented by heat ( 519 ), massage ( 520 ) and exercise (521 ).
1.4.1.4. ALTERNATIVE ROUTES FOR INSULIN DELIVERY
The subcutaneous route for insulin delivery has proved its efficacy and practicality for
self-management by diabetic patients over a long period. However, as discussed
above, several disadvantages exist, thus an alternative route for administration of
insulin, which is less aggressive and more effective, is desirable.
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1.4.1.4.1. The intranasal route
The first attempts to administer drugs into the body through the nasal mucosa were
made in the 1920's ( 522 ). The more recent discovery that surface-active agents such
as bile salts and glycocholate enhance insulin absorption through mucosa ( 523 ) has
led to renewed interest in the intra-nasal route of insulin administration. Intranasal
insulin, when given as a spray, has been shown to lower fasting and postprandial
blood glucose in normal subjects and IDDM patients ( 524 ). Serum levels of insulin
rise within 10-15 minutes. The half-life of insulin in the plasma is short, and the
hypoglycaemic effect only lasts for approximately 30-75 minutes. The insulin level
observed is linearly dose dependent, but unfortunately, bioavailability is low and only
10-30% of the insulin dose is actually absorbed. Possible adverse long-term effects
on the nasal mucosa in the presence of a surfactant that is irritating, if not destructive,
may limit the use of the nasal route for insulin administration. Nasal insulin sprays
might therefore only be used as an adjunct to therapy in diabetic patients treated with
subcutaneously administered insulin, and in IDDM patients on long-acting insulins.
1.4.1.4.2. The gastrointestinal route
Although administration of insulin via the gastrointestinal route would be comfortable
and convenient, the enzymatic digestion of all ingested peptides is a critical factor
which has yet to be overcome.
The absorption of insulin through the mucosa of the mouth is extremely low.
However, when placed directly in the jejunum of animals, insulin is effectively
absorbed through the mucosa ( 525 ). Insulin has also been protected from
degradation by entrapment in positively charged liposome vesicles ( 526,527 )
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although the bioavailability of insulin was only 1-4%, variable and rarely predictable
( 528 ). Attempts have also been made to delay the absorption of orally administered
insulin until in the colon by coating the hormone with polymers that are only
susceptible to digestion by the colonic microbial flora ( 529 ).
Another mode of administration of exogenous insulin which prolongs its action and
thereby improves the efficacy of glycaemic control is the use of sustained-release
implants for insulin delivery.
1.4 2 SUSTAINED RELEASE INSULIN IMPLANTS
A common aspect of all sustained release insulin implants is the presence of a barrier
to delay contact between body fluid and the insulin contained within the implant. This
barrier can take the form of an erodible excipient which dissolves gradually in vivo,
thus releasing the entrapped insulin at a constant basal rate.
One of the first attempts to use sustained release of insulin in the treatment of diabetes
was performed by Davis ( 530 ), who subcutaneously implanted polyacrylamide
admixed with insulin into alloxan-induced diabetic rats. The response of the implants
was found to be influenced by implant porosity, which was dependent upon the
polyacrylamide concentration and the amount of insulin present. Animals bearing
10 mg insulin implants of 40% PAA showed no glycosuria and grew at virtually the
same rate as control rats, until removal 21 days after implantation led to recurrence of
diabetes. More recent advances in this approach of insulin treatment have been
reported by Brown and co-workers, who developed a biocompatible system that
achieved a continuous release of biologically active insulin from small polymer
matrices ( 531 ). Powdered insulin particles were incorporated into an ethylene-vinyl
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acetate copolymer matrix which has previously been shown to be biocompatible in
vivo by this group ( 532 ). The presence of particulate insulin resulted in a matrix of
tortuous channels and constricted pores through which insulin could be released upon
influx of aqueous media. The diffusion of the dissolved insulin through this tortuous
network was driven by the large concentration of insulin within the matrix. The
insulin release kinetics could be enhanced by increasing the powder particle size
( resulting in larger pores ), loading ( resulting in a greater number of pores ),
solubility of insulin, and porosity of the matrix. This group further investigated the
effect of ethylene-vinyl acetate copolymer matrices on STZ-diabetes in the rat ( 533 ).
The 60 mm^ implants designed to release insulin at near constant rates normalised
plasma glucose concentrations and eliminated glycosuria. These parameters were
controlled for up to 105 days by a single implant, and glycated haemoglobin ( HbAj )
values measured 90 days after implantation were reduced compared with values for
the diabetic controls, and were similar to HbA] values observed in normal rats. The
average weight gain of the implant-treated rats was also similar to that of controls,
whereas diabetic controls failed to thrive and developed cataracts one month after the
induction of diabetes. As anticipated, plasma glucose levels began to increase at
approximately the same time as the release rates of insulin from the implants
decreased in vitro.
More recently, Wang ( 534 ) investigated the use of naturally occurring materials to
form the matrix of sustained release insulin implants ( SRII ). Initially, the insulin
release from a cholesterol matrix implant containing differing amounts of insulin was
evaluated in STZ-diabetic rats, and its effect on hyperglycaemia noted. At 3% insulin,
two pieces of quarter-length implants ( approximately 50 mgs each ) caused a slight
short-term decrease in blood glucose levels, although recipients were still
hyperglycaemic. Doubling the insulin content of SRII to 6% normalised and sustained
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blood glucose levels for approximately 10 days. This normalisation was increased to
24 days using 8-10% insulin in the matrix composition. Three successive
subcutaneous insertions of 80 mg pellets containing 10% insulin maintained
normoglycaemia for up to 10 weeks. Increasing the insulin content of the implants to
50% resulted in severe hypoglycaemia when implanted into STZ-diabetic rats.
Additionally, as cholesterol is naturally occurring and found in all animal tissues, no
inflammatory fibrotic response was observed against the implant, thus demonstrating
the suitability of cholesterol as a biocompatible material. However, it should be
noted that the cholesterol implant did not dissipate in the recipient, and was still
present after one year. This is an obvious disadvantage when considering the
insulin-containing cholesterol implant as a potential treatment for the diabetic patient.
Subsequently, Wang replaced the cholesterol excipient with palmitic acid ( 535 ),
which gradually erodes in the rat with a half life of approximately 3 months. These
SRII were used to investigate their reproducibility in insulin delivery and ability to
afford sustained reduction of hyperglycaemia in STZ-diabetic rats. A one-eighth size
piece of pellet containing either 10%, 15%, 20% or 30% insulin by weight was
implanted subcutaneously into the recipient and blood glucose levels measured daily.
Implants with a 10% or 15% insulin content had an unpredictable activity, whereas all
of the implants with a 30% insulin content delivered too high a dose of insulin,
causing fatal hypoglycaemia. The delivery and onset of action of a SRII containing
20% insulin content were both highly reproducible. However, variations in the
service life of these essentially identical implants were larger than anticipated.
Overnight fasting studies showed that diabetic rats implanted with a one-eighth size
piece of implant containing 20% insulin could tolerate the induced hyperglycaemia
without experiencing convulsions.
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Although these alternative methods of insulin administration may be promising, the
classic subcutaneous route of administration is not likely to be substituted in the near
future. However, a serious deficiency in all these current insulin treatments is the
inability to automatically adjust the rate of insulin delivery according to the prevailing
blood glucose concentration. In the non-diabetic individual, the islet cells of the
endocrine pancreas continuously monitor blood levels of several metabolites and
secrete appropriate amounts of insulin to achieve a delicate metabolic balance during
periods of feeding and fasting. In comparison, exogenous insulin therapy is
considerably less sophisticated and through the use of technology, insulin delivery
requires substantial improvement if imitation of the intricate insulin profiles of
non-diabetic subjects is the therapeutic goal for treatment of diabetic patients.
1.4.3. GLUCOSE SENSORS AND CLOSED-LOOP INSULIN DELIVERY
In 1974, a novel insulin delivery system was described that regulated the rate of
insulin delivery in response to measured blood glucose levels ( 536,537 ). This device
quickly attained and maintained normoglycaemia as a direct consequence of its
closed-loop nature and inherent characteristics of negative feedback control ( 538 ).
In addition, blood was sampled every minute, thereby allowing insulin delivery to be
appropriately adjusted on a continual basis. The low basal infusion of insulin could be
combined with appropriately and precisely added insulin at meal-times. This system
clearly promised to reverse diabetes and to normalise blood glucose control with a
precision far greater than that achieved using the most intensive of conventional
insulin treatments ( CIT ). However, because the venous route is used for blood
sampling and insulin delivery, and the apparatus is relatively large and complex, this
system is unsuitable for studies of more than a day or so in duration. Efforts have
therefore turned to miniaturisation of the device and to the development of a blood
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glucose sensor which can be implanted in the body over extended periods of time at a
site not likely to lead to septicaemia and thrombosis, both of which are risks of
intravascular sensing.
1.4.3.1. TYPES OF GLUCOSE SENSOR
Most glucose sensors are enzyme electrodes which use the immobilised enzyme,
glucose oxidase, layered on the surface of the electrode to catalyse the oxidation of
glucose to gluconic acid and hydrogen peroxide. Glucose levels can be measured by
monitoring either the consumption of oxygen or by production of hydrogen peroxide
or hydrogen ions. Amperometric electrodes detect a current change at a set voltage
whereas hydrogen ions may be detected at one of several types of pH electrode.
These are potentiometric ( voltage-measuring ) sensors in which there is an
alogarithmic relationship between analyte ( glucose ) activity and voltage change.
Technical problems of these sensors include significant drift, necessitating frequent
recalibration, difficulties in sealing electrical connections in a liquid environment and
reduced pH due to the buffering capacity of biological fluids.
One variation of the amperometric biosensor is the mediated electrode in which a
small molecular weight redox couple, i.e. the oxidised and reduced forms of a
substance such as ferrocene ferricinium ion, shuttles electrons from glucose oxidase to
the base electrode ( 539,540 ). These sensors are relatively oxygen insensitive
because molecular oxygen is not the final electron acceptor. The technology has been
successfully commercialised as the Exactech Pen ( MediSense, Cambridge, MA ) for
in vitro glucose analysis ( 541 ).
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Fibre optic-based glucose sensors have not reached the stage of in vitro testing but
are attractive in principle because the sensing element is miniature and the fibres are
cheap to manufacture, electrically isolated from the patient, and do not need a
reference electrode. Glucose can be measured by immobilisation of glucose oxidase
and the resultant pH change can be detected by fluorescence quenching ( 542 ) or
colour change of a dye ( 543 ). Oxygen consumption in the glucose oxidase reaction
can be measured with an oxygen sensitive fluorescent dye ( 544 ) and hydrogen
peroxide by the chemiluminescence generated from the reaction of hydrogen peroxide
with an oxalate derivative and surface enhancer ( 545 ).
Long-term glucose sensing in the vascular compartment has generally been avoided,
mainly due to the clinically unacceptable risks of septicaemia, thrombosis and
embolism. However, Armour et al ( 546 ) have successfully operated an
oxygen-detecting type of glucose sensor in the vasculature of dogs for several weeks.
The subcutaneous tissue is a more favourable site for the implantation of a glucose
sensor as it is easily accessible and safe, although some infection or inflammation may
be observed. Furthermore, studies suggest that the glucose concentration in the
subcutaneous interstitial fluid is almost identical to the plasma glucose concentration
( 547 ). The time lag between changes in blood glucose levels during a glucose load
and the generation of a current by the sensor was usually less than 15 minutes when
implanted in the subcutaneous tissue of rats ( 548 ), dogs ( 547,549 ), and humans
( 550 ). This slight delay in subcutaneous changes after rapid increments or
decrements in blood glucose concentration would not negate the clinical usefulness of
this implantation site.
Bindra et al ( 551 ) have developed a miniaturised glucose sensor ( outer diameter,
0.45 mm ) which can be readily implanted in the subcutaneous tissue and replaced
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every 3 or 4 days. This sensor has been extensively evaluated in rats, where it has
been shown to work for up to 10 days ( 548,552 ) and dogs ( 553,554 ). In dogs,
oscillations in current occur after some days, preceding a decline in sensitivity of the
sensor ( 549 ). This failure is accompanied by swelling and exudation at the
implantation site, and since the exudate fluid is of a low glucose concentration it has
been proposed that inflammatory cells may metabolise glucose and contribute to
sensor impairment. The current generated by the sensor was transformed into an
estimation of the concentration of glucose by using the sensitivity coefficient and an
extrapolated background current in the absence of glucose. However, this calibration
was performed on the basis of the retrospective analysis of the changes in blood
glucose and the current generated by the sensor, and for clinical application of the
system, an on-line estimation of glucose is necessary. A method for on-line
calibration using a portable, battery operated, monitor with software which
immediately transforms the measured current into an estimate of glucose
concentration has recently been reported ( 555 ).
Although few studies have looked at the performance of implanted glucose sensors
over several days in human subjects, all enzyme electrodes required replacement after
periods ranging from several hours to days ( 540,556 ). After implantation, output
initially declines but stabilises several minutes to hours later.
Microdialysis which involves sampling of blood or interstitial fluid and analysis by an
ex vivo glucose sensor ( 557,558 ) may reduce problems of bioincompatibility.
Hollow fibres of dialysis membrane are implanted, often subcutaneously, perfused at a
low flow rate with isotonic fluid and the perfusate pumped to a flow-through cell
outside the body that incorporates a glucose sensor. Such devices function well over
one day, but long-term biocompatibility at the fibre/tissue interface and the
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practicability of the device need to be determined. Bolinder et al ( 559 ) employed
microdialysis in a short-term study of diabetic patients, and reported that absolute
glucose concentration could be measured directly. More recently, this group ( 560 )
reported that microdialysis of adipose tissue can be used for continuous long-term
monitoring of glucose concentrations in diabetic patients during ordinary daily life.
Most patients had a reproducible daily glucose profile, and when patients' insulin
therapy was adjusted on the basis of ambulatory glucose monitoring, HbA]c values
decreased by almost 2%, and this decrease lasted for at least 9 months. In this study,
tissue dialysate glucose measurements and data analysis were again retrospective,
although future improvements will include development of on-line glucose analysis.
In spite of considerable progress in technology, long-term in vivo glucose sensing has
not progressed to routine clinical practice. This is largely due to a number of
problems with glucose sensors, including diminished sensitivity in vivo, and
unpredictable drift and bioinstability at the output (561 ). Sensors calibrated initially
in vitro in buffered glucose solutions may suffer a reduction in sensitivity of
approximately 10-80% on implantation ( 539,540 ), necessitating some in vivo
calibration procedure. This impairment of response is usually ascribed to inhibitory
substances in the tissues that interact with the enzyme, base electrode or reaction
products, coating of the sensor with protein or cellular material from the biological
matrix. Covering membranes have not resolved these problems, as they may also be
overgrown or ingrown by body tissue, and eventually simply rejected as foreign.
These devices therefore appear to be more applicable for short-term rather than
long-term monitoring of in vivo glucose concentrations.
In vivo glucose sensing and its inherent problems may soon be superseded by
non-invasive glucose monitoring, which would be highly acceptable to diabetic
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patients. Near-infrared ( NIR) spectroscopy is the most promising approach since, in
the region of 700-1000 nm, radiation passes through several centimetres of tissue.
Specific glucose detection by analysis of NIR absorption peaks has proved difficult
because of the large band due to water, the variable scattering of light in tissues which
alters the optical path length unpredictably, and the overlapping absorption of many
metabolites in this region. However, several groups are now reporting good
correlation between blood glucose and NIR transmission ( 562,563 ). It should be
noted that NIR spectroscopy has not yet been miniaturised to a form that could be
used as a wearable in vivo monitor, and the cost of such a device is likely to be high.
Although NIR spectroscopy resolves the problem of biocompatibility, calibration of
the system requires further study.
1.4.4. CONCLUSION
Substantial evidence implicates the involvement of abnormal blood glucose in the
development of micro- and macroangiopathic complications of IDDM. Normal or
near-normal glucose homeostasis may slow or even halt the progression of these
complications both in experimental animals and in humans, although it is not known
how early in the progression of the disease normal glucose control must be restored to
have an effect. In IDDM, blood glucose control is normally maintained by
subcutaneous insulin administration. However, CIT cannot replace the complex
physiological balance of endogenous insulin released from normal islets which
regulates glucose homeostasis. Even when insulin administration is intensive and
carefully controlled by multiple daily injections, blood glucose concentrations in
patients with diabetes can swing widely outside the normal range. Alternative routes
for insulin administration, including nasal and gastrointestinal routes, are also
problematic and are unlikely to replace the conventional subcutaneous route of insulin
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administration at this time. Sustained release insulin implants release a constant basal
dose of insulin upon implantation into animal models, thereby removing the need for
daily insulin injections. The implants can achieve near-normal blood glucose levels
over a period of several months. The major problem with all the insulin therapies
discussed so far is their inability to respond to changes in blood glucose
concentration, thereby leading to poor metabolic control. Glucose sensors can
measure blood glucose every minute and using this information, insulin delivery could
be adjusted on a minute-to-minute basis, thereby attaining precise blood glucose
control compared with the aforementioned non-responding forms of diabetes
management. However, these closed-loop systems do not function in vivo long-term
mainly due to the unreliability and bioincompatibility of glucose sensors . If suitable
covering membranes for the sensor are discovered that exclude interfering substances
or control coating or encapsulation with proteins and cells, the excellent performance
in vitro may be matched in vivo.
An alternative approach to insulin therapy as treatment for IDDM patients is to
replace the destroyed pancreatic islets, thereby restoring normal metabolic control.
This can be achieved by transplantion of vascularised whole or segmental pancreas or
isolated pancreatic islets.
1.5. PANCREAS TRANSPLANTATION
The first human transplant of a vascularised pancreas was reported in 1967 by Kelly
and co-workers ( 564 ) who showed that the technique was feasible and could restore
blood glucose levels to normal in patients with type I diabetes. After this pioneering
attempt, there was a proliferation of centres offering the procedure, and in the past
116
15 years more than 4000 such operations have been done, nearly 70% of them since
1987.
An important consideration for diabetic patients receiving a pancreas transplant is that
while gaining independence from administration of daily insulin, they become
dependent upon continuous immunosuppressive medication, even in HLA-identical
donor pancreas transplants. Long-term immunosuppression can have multiple toxic
effects, including increased risks of infections and malignant disease. Side effects of
the triple immunosuppression regimen most commonly used to prevent graft rejection
include azathioprine myelosuppression, cyclosporin nephrotoxicity, and steroid
induced gastrointestinal bleeding and perforation. Cyclosporin and steroids also
increase blood pressure and alter the lipid profile, thereby possibly neutralising some
of the cardiovascular benefits of achieving normoglycaemia. A non-uraemic diabetic
patient whose hyperglycaemia is manageable by CIT would therefore be unwise to
ignore these risks simply in the hope of avoiding dependence on insulin injections.
However, if the secondary complications of diabetes were prevented, arrested or even
reversed, then the risks involved in pancreas transplantation may seem more
acceptable.
Three years after a successful pancreas transplant, patients showed no differences in
the severity of their retinopathy compared with those patients having had an
unsuccessful operation ( 565 ). Studies on diabetic neuropathy are more encouraging,
and sensory, motor and autonomic indices have shown benefits from successful
pancreas transplants in contrast to patients with failed grafts or receiving no transplant
( 566 ). Renal function has been reported to deteriorate more rapidly after pancreas
transplantation ( 567 ), probably due to cyclosporin renal toxicity ( 568 ), and seems
to stabilise after the first year or so. Measurements of glomerular structural
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alterations in the native kidneys five years after a pancreas transplantation did not
show a clear benefit in the transplanted groups, compared with those in
non-transplanted patients with controlled IDDM ( 569 ). Moreover, a significant
decline was observed during the study period in transplanted patients, whereas
glomerular filtration rate was virtually unchanged in the comparison group. The
inability of pancreas transplantation to show any amelioration of complications in the
diabetic patient is probably attributable to the fact that transplantation is performed at
a late stage of the disease, when complications are apparently irreversible.
There is growing evidence that kidney transplantation is the preferred treatment in
uraemic diabetic patients rather than long-term dialysis. However, recurrence of
diabetic nephropathy has been observed in the transplanted kidney even as early as
2 years after transplantation in diabetic patients ( 570 ). For these reasons, combined
kidney and pancreas transplantation would be advantageous for the diabetic uraemic
patient, removing dependence on both dialysis and insulin therapy. Since renal
transplant patients are treated with immunosuppressive drugs, further
immunosuppression is unnecessary. The transplanted kidney seems to have a
protective role with regard to the transplanted pancreas, as shown by the International
Pancreas Transplant Registry (571 ), which reports a one year survival rate of 49%
when pancreas was transplanted alone ( n = 92 ), 45% for patients with a previous
kidney transplant ( n = 145 ), and 75% when pancreas and kidney were transplanted
simultaneously ( n = 1360 ). The improved pancreas survival when combined with a
kidney transplant may be due to earlier diagnosis and treatment of rejection.
However, patients with combined transplantation have three times more acute
rejection episodes than those with kidney transplants alone ( 572,573 ), possibly
because pancreas grafts are more immunogenic than kidney grafts.
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Management of the exocrine function of the transplanted pancreas remains a major
problem. Among the different methods proposed, three approaches are commonly
employed : polymer injection ( 574 ), the pancreaticoduodenal technique ( 575 ) and
urinary diversion ( 576 ). Data from the International Pancreas Transplant Registry
(571 ) show a significantly higher survival for bladder drained grafts, although
bladder drainage carries the risks of bladder leakage, bleeding, abcesses, haematuria,
urethral stricture, stone formation and bicarbonate loss.
Thus, considerable morbidity and substantial mortality is still associated with
combined pancreas and kidney transplantation. The 1 year patient survival is 85% for
the combined operation compared with 96% for living related kidney transplant alone
and 93% for cadaveric kidney alone (571 ). The age of the patient is an important
variable : patients under 45 years of age have approximately the same 1 and 2 year
survival rate with combined transplant as with kidney transplant alone, whereas
patients older than 45 years have only 33% survival rate at 1 year after the combined
operation ( 577 ).
The impact of combined transplantation on diabetic complications is difficult to
determine as formal comparison with solo kidney transplantation has not been made.
Landgraf et al ( 578 ) reported an improvement in peripheral neuropathy after
combined transplantation, but similar findings were observed with kidney
transplantation alone, which were not improved by the subsequent addition of a
pancreas graft ( 579 ). Conflicting results have been obtained concerning diabetic
retinopathy : improvements have been reported after the combined operation ( 578 ),
whilst others report comparable visual acuity and retinal appearance in patients who
have had a successful or a failed pancreas transplant ( 565 ). Patients receiving a
pancreas transplant a few years after successful kidney transplantation reportedly
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prevents the development or progression of the earliest of diabetic glomerulopathy
compared with patients who received no subsequent pancreas graft ( 580 ). However,
many diabetic patients receiving kidney transplants alone develop few or no lesions of
diabetic nephropathy in the first 6-14 years after transplantation (581 ).
Thus, successful combined kidney and pancreas transplantation can free the diabetic
patient from daily insulin injections and dietary restrictions. Good metabolic control
is also achieved, with restoration of normal fasting plasma glucose levels, 24-hour
plasma glucose profiles, plasma glucose changes during oral and i.v. glucose tolerance
test ( IVGTT ) ( 582 ), and normalisation of HbAjc and intermediary metabolite
levels ( 583 ). However, these improvements in patients quality of life must be
weighed against the the complications of surgery, side-effects of life-long
immunosuppression, considerably increased morbidity, very high mortality among
older patients and increased cost. Furthermore, the benefits of pancreas
transplantation, alone or combined with a kidney transplant, on long-term diabetic
complications are disappointing, probably because these operations are currently
performed at a late stage in the disease. A vascularised pancreas graft is unlikely to
be considered if early transplantation means transplantation into a patient who is
young, fit and simply inconvenienced by daily insulin injections. At this stage of
IDDM, the associated peri-operative morbidity of pancreas transplantation and the
immunosuppression required could not be justified.
Isolated pancreatic islet transplantation has a number of actual and theoretical
advantages over vascularised pancreas grafts : transplantation of a small volume of
pure islet tissue is a relatively simple and minor procedure, with no exocrine
complications. In addition, pretreatment might reduce islet immunogenicity, and
storage by cryopreservation would allow optimal matching of donor and recipient, as
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well as transplantation of islets from more than one donor into single recipients.
Foetal pancreas transplantation presents similar advantages, and also provides a graft
in which (3-cell replication can occur. However, the use of foetal tissue is associated
with major ethical difficulties.
16 ISLET TRANSPLANTATION IN ANIMAL MODELS OF IDDM
Pancreatic islets have been isolated for many years by a technique described by
Ballinger and Lacy ( 584 ) in which the distended pancreas is chopped into small
pieces, digested with collagenase, and the released islets separated on a density
gradient. Although the preparation of islets is pure, the yield is relatively poor. An
alternative technique for isolating rat pancreatic islets has more recently been
described : the pancreas is distended with collagenase injected via the pancreatic duct
and digested statically at 37°C. Reproducibly high numbers of intact islets are
obtained ( 585,586 ) which maintain biphasic insulin secreting properties in vitro in
response to a glucose stimulus indicating that the islets remain viable after the
isolation procedure.
1.6.1. STZ-DIABETIC MODELS OF IDDM
Early experimental work ( 584 ) looked at the transplantation of isolated pancreatic
islets into the chemically-induced STZ-diabetic rat. A small number ( 400-600 ) of
syngeneic islets implanted i.p. or i.m. resulted in a significant reduction of
hyperglycaemia, polyuria and glycosuria and a normalisation ofweight gain. Excision
of the transplanted islets from the muscle resulted in a return to the fully diabetic
state, and upon histological examination islets were found to be intact but with P-cell
degranulation, probably due to the great demand for insulin in these animals.
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Exogenous insulin given for a period of time after transplantation may lessen the
extreme demand upon the islet graft to secrete insulin and afford the transplanted
islets some degree of protection.
Under normal circumstances, insulin from native pancreatic p-cells is secreted directly
into the portal venous system. Kemp et al ( 587 ) therefore suggested that the
intraportal site may provide a more physiological environment for the transplanted
islets and allow a more effective utilization of secreted hormones than islets implanted
i.p. or subcutaneously. 400-600 islets injected intraportally into the STZ-diabetic rat
also achieved normoglycaemia, normal urine volumes and abolition of glycosuria, and
these parameters were maintained for up to two months after transplantation. Islets
implanted i.p. or i.m. gave similar results to those reported previously ( 584 ). This
data suggests that the site of implantation is an important consideration in islet
transplantation studies. Ideally the site would be safe and permit maximum survival
and function of transplanted islets and maximum effectiveness of secreted hormones.
Many studies followed these initial islet transplantation experiments. Reckard et al
( 588 ) reported that an i.p. injection of 600-1200 syngeneic islets into STZ-diabetic
rats rendered the recipient normoglycaemic for as long as 11 months. However,
insulin response to an IVGTT was sluggish and 25% of test animals returned to a
state of hyperglycaemia 5-6 months after islet transplantation. Similar numbers of
allogeneic islets initially fared as well as the syngeneic grafts but recipients returned to
a state of hyperglycaemia within 12 days of transplantation. In contrast with
syngeneic islets, transplanted allogeneic islets were vulnerable to rejection and could
evoke an immune state characterised by subsequent accelerated rejection of donor
strain skin grafts.
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Islet number is another important factor for successful transplantation. The neonatal
pancreas 2.5-4.5 days before birth reportedly has the highest insulin content, the
largest islet volume percentage, and the lowest exocrine enzyme concentration during
the foetal or postnatal period ( 589,590 ), thus indicating its suitability for
transplantion studies. Islets isolated from 25-35 neonatal rat pancreases were
transplanted i.p. to chemically-induced alloxan-diabetic rats (591 ). Diabetes was
reversed within several days following the islet isograft and normoglycaemia persisted
for more than 5 months. Islets injected into the peritoneal cavity were associated with
the liver, spleen, pancreas and abdominal wall and vascularised grafts consisted of
heavily granulated (3-cells. In alloxan-induced diabetic rats allografted with similar
numbers of dissociated neonatal pancreases, 46% showed a transitory recovery from
their diabetes lasting 3-13 days, before returning to a pretransplant diabetic state.
Again, failure of the transplant was attributed to rejection, and upon removal the graft
showed evidence of degenerating P-cells and lymphoid infiltration indicative of the
rejection process.
The criteria used to assess the effectiveness of islet transplantation in reversing the
diabetic state have so far involved rather gross indices of severe insulin deficiency, i.e.
fasting blood glucose level, degree of polyuria, glycosuria and weight loss.
Pipeleers-Marichal et al ( 592 ) determined the extent to which islet transplantation
could normalise the severely insulin deficient rat. 350-1000 isolated islets injected
intraportally into STZ-diabetic Lewis rats resulted in a normalised fasting plasma
glucose and insulin levels within 24 hours. Polyuria, polydipsia and
hyperglucagonaemia disappeared more gradually over a 2-12 week period, i.e. the
time required for normalisation varied with the severity of the diabetic recipient and
the number of islets transplanted. Long term transplanted islets were shown to
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establish direct contact with surrounding hepatocytes and demonstrated well
granulated a-, (3- and 8- cells.
Gray and Watkins ( 593 ) also confirmed these findings and suggested that the portal
venous site was optimal for reception of transplanted pancreatic islets. Again,
allogeneic islets, even when transplanted across a weak histocompatible barrier, were
shown not to survive for long periods of time unless recipients were
immunosuppressed. Recipients of allogeneic islets after a period of
immunosuppression with ALS became permanently tolerant to the transplanted islets
and to subsequent donor specific skin grafts.
The spleen also possesses a portal venous drainage and, as with the liver, is a highly
vascular organ, ideal for providing an environment for the successful nutrition of
transplanted islet tissue. However, unlike the liver, the spleen is expendible and
therefore allows graft retrieval should irreversible host organ damage ensue.
Finch et al ( 594 ) injected adult rat islets into the splenic pulp of syngeneic and
allogeneic STZ-diabetic recipients. Normal serum glucose levels and 24 hour urine
volumes were restored in a mean of 3.3 days. Syngeneic recipients remained
normoglycaemic for 6 months and splenectomy performed 110-178 days after
transplantation resulted in a prompt return to the diabetic state. In contrast,
allogeneic grafts were rejected in a mean of 5.2 days unless recipients were treated
with a short course of ALS, which resulted in normoglycaemia for at least 4 weeks.
The results using the spleen as the implantation site were not significantly different
from those recorded in comparable groups receiving intraportal allogeneic islets. In
contrast, Reckard et al ( 595 ) found that in order to achieve moderately good control
of glucose homeostasis in the STZ-diabetic rat, twice as many islets were required
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when the spleen was used as the implantation site compared with successful
intraportal transplantation.
A peritoneal-omental pouch constructed by encasing the omentum in a pouch formed
from a strip of the hosts parietal peritoneum was successfully used as an implantation
site for an islet isograft in STZ-diabetic rats ( 596 ). Islets placed in the pouch were
in close apposition to the omental blood supply and normoglycaemia was
subsequently achieved in diabetic recipients. The removal of the islet bearing
peritoneal-omental pouch 6 weeks after transplantation resulted in a prompt return to
the diabetic state in all recipients, and histologically, islet aggregates ( surrounded by
adipose tissue ) were well vascularized and the (3-cells had a normal degree of
granulation.
Brown et al ( 597 ) used another transplantation site, beneath the kidney capsule, for
the implantion of 2-3 foetal syngeneic pancreases in STZ-diabetic Lewis rats. The
experimental diabetes was partially reversed provided that insulin was given for
several days following transplantation to prevent overexhaustion of the islet P-cells
and allow maturation of the graft. However, foetal allogeneic pancreases implanted
under the renal capsule were rapidly rejected, indicating that foetal tissue may not be
less immunogenic than adult pancreatic islets ( 598 ). Shunting the venous drainage
from the transplant site to the liver completely reversed the diabetic state, probably
due to the increased extraction of insulin passing into the liver, indicating the
importance of the hepatic portal circulation in islet transplantation ( 599 ).
Reece-Smith et al ( 600 ) reported that isolated adult syngeneic islets reversed
experimental STZ-diabetes in the Lewis rat when implanted under the kidney capsule.
However, renal subcapsular allografts were rejected with a mean survival time of
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8.4 days. This was comparable to the mean survival time observed for foetal
allografts implanted at this site. Interestingly, survival of intraportal adult islet
allografts was shorter than for islets implanted under the renal capsule, suggesting
that the renal capsule may act as an immunoprivileged transplantation site. This may
be explained with respect to the larger number of fixed elements of the
reticuloendothelial system in the liver, e.g. macrophages, which may play a dominant
role in the rejection of transplanted islets (601 ). Similarly, isolated adult allografts
implanted into the peritoneal cavity, a macrophage-rich site, are also rejected rapidly
( 588 ). Hiller et al ( 602 ) confirmed these findings and reported that isolated islets
transplanted into the portal vein of STZ-diabetic rats showed a progressive
deterioration of function with time. In contrast, islets placed under the kidney capsule
sustained a long-term function, and controlled all clinical signs of diabetes. Recipients
displayed normal growth rate, peripheral serum glucose and insulin levels. However,
their functional reserve was markedly reduced as revealed by diminished glucose
tolerance and reduced insulin-secreting capacity after an IVGTT.
Late graft failure after intraportal islet transplantation in the rodent model is not a rare
occurrence and appears to be strongly related to the site of implantation, as this effect
was not observed in kidney subcapsular islet transplantation. Several reasons have
been suggested to explain this phenomenon. Histological evidence suggests that the
development of fibrosis in the periportal fields of the liver containing the transplanted
islets may impair their blood supply, resulting in progressive loss of islet function.
Islets have to transmigrate intact vessel walls from a branch of the portal vein into the
portal field which may lead to disintegration or destruction. Finally, the portal blood
which directly perfuses the intraportally transplanted islets contains higher
concentrations of glucose than arterial blood perfusing the kidney and therefore islets
transplanted beneath the renal capsule. This may lead to continual stress of the
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intraportal islets and their eventual functional exhaustion. Furthermore, two weeks
after transplantation, the replication of islet cells with a portal venous drainage was
shown to be impaired compared with renal grafts with systemic venous drainage.
Another proposed immunoprivileged site for the transplantation of islets is the
thymus. This organ has been reported to be excluded from routine T lymphocyte
immunological surveillance, and recirculation of mature T lymphocytes back through
the thymic parenchyma is rare. This implicates the existence of a blood-thymus
barrier ( 603 ). Freshly isolated allogeneic rat islets implanted in the thymic lobes of
STZ-diabetic rats survived longer compared with the liver or renal subcapsule as the
site of implantation. Upon treatment of the recipients with a single dose of ALS the
intrathymic grafts survived permanently ( 604 ). Furthermore, a state of
donor-specific unresponsiveness was achieved in recipients carrying long-term
intrathymic islet grafts, as demonstrated by allowing the survival of a second
donor-strain islet allograft transplanted under the contralateral renal capsule. No
additional immunosuppression was required and neither grafts were rejected. In
contrast, third party islets transplanted under the renal capsule were not accepted.
Three weeks after the transplantation, thymectomy did not cause hyperglycaemia.
Under histological examination, islets were abundant, non-infiltrated and contained
well granulated P-cells. A single dose ofALS transiently depleted the peripheral T cell
population to 10% of levels observed in normal rats. Subsequent reconstitution of the
peripheral T cell pool in these animals might require the migration of prothymocytes
to the thymus where maturation in a microenvironment harbouring foreign
alloantigens may induce the selective unresponsiveness observed.
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1.6.1.1. PREVENTION OF ALLOGRAFT REJECTION
Although endocrine tissue is generally less immunogenic than other tissues, islet
allografts are rapidly rejected in rodents, even across minimal histocompatibility
barriers. Three general approaches have been studied to induce islet allograft
tolerance : generalised immunosuppression, immunoalteration of the graft prior to
transplantation and induction of specific immune tolerance.
1.6.1.1.1. Generalised immunosuppression
A variety of immunosuppressive regimens effective in preventing rejection of
vascularized organ allografts in the rodent have been shown to be relatively ineffective
in prolonging allograft survival ( 605 ). Particularly disappointing results were
obtained using the potent immunosuppressive agent CsA. However, Dibelius et al
( 606 ) reported that in a one donor-one recipient model, the mean graft survival of
intraportally transplanted allogeneic islets could be prolonged from 5 to 90 days using
a short term three dose treatment of parenteral CsA. Administration of CsA in this
manner resulted in very high concentrations in the blood. Histologic examination at
150 days post-transplantation revealed intact islets that stained positive for insulin. A
3 day peri-operative course of CsA alone did not prolong islet transplantation across
MHC barriers ( 607 ). However, when combined with a single dose of donor antigen
given the day before transplantation, survival time was prolonged slightly, but
significantly. Three cycles of 3 day CsA courses at intervals of 7 days ( 9 doses in
total ) were found to be effective in delaying rejection of islet allografts. If combined
with donor antigen therapy, the survival of islet allografts was further prolonged, and
50% of recipients were still normoglycaemic 60 days after transplantation. The
combination of donor antigen with a relatively short course of CsA therefore has a
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powerful effect on the prevention of islet allograft rejection. A state of indefinite
donor-specific unresponsiveness was not established using this treatment as shown by
the rejection of donor skin grafts, and a subsequent return to hyperglycaemia.
Toxic effects of CsA on islets have been reported. Daily administration of CsA
(15 mg/kg body weight ) to rats caused impaired glucose tolerance, decreased
( 50% ) pancreatic insulin content, reduced ( 30% ) islet insulin content, and
decreased ( 28% ) pancreatic p-cell volume compared with vehicle-treated control
rats ( 608 ). Helmehen et al ( 609 ) reported similar observations in the rat after a
treatment period of only one week. The pancreatic P-cells are therefore very sensitive
to CsA in vivo, and the toxic effects appear to be P-cell specific, as the glucagon
content of the pancreas was not reduced. In an extensive study, Pipeleers-Marichal et
al ( 610 ) examined the effect of CsA on the survival of rat islet P-cell allografts in
STZ-diabetic rats. A daily oral dose of 5 mg/kg prevented the rejection of freshly
isolated islets relatively uncontaminated with exocrine tissue. However, upon
discontinuation of CsA islets were rapidly rejected unless cultured prior to
transplantation, in order to reduce their immunogenicity. Under these conditions
islets maintained a normalised state for >15 weeks beyond the 5 week drug course,
although this was not the case for shorter periods of treatment. Pure islet P-cell grafts
were found to reverse IDDM in 50% of recipients without treatment ofCsA, although
mononuclear cell infiltration was markedly reduced after CsA administration. In
addition, aggregates ofmixed endocrine islet cells, reported by this group to maintain
a larger insulin reserve and tighter control of basal glucose levels than pure P-cells
( 610 ), were kept virtually infiltration free. Conditions with minimal initial infiltration
were associated with long-term graft survival without the need for continuous
immunosuppression. It was hypothesised that CsA suppressed the mild T lymphocyte
alloreactivity toward the cultured or pure donor islets, thus allowing the generation of
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antigen specific suppressor T lymphocytes. Once developed, these suppressor
T lymphocytes may have induced a state of tolerance toward the graft that persisted
even after cessation of the treatment.
Recently FK506, a neutral macrolide antibiotic extracted from the fungus
Streptomyces tsukubaenis, has been shown to prolong islet allograft survival in the
STZ-diabetic rat ( 611 ). Relatively pure islets were transplanted either beneath the
renal capsule or into the liver via the portal vein of diabetic rats. Recipients were then
treated for 7 days with subcutaneous injections of 0.1-1.0 mg/kg doses of FK506.
The optimal dose of FK506 for the prolongation of rat islet allograft ( mean survival
time of >45.3 days ) was 0.32 mg/kg. Success was only achieved when islets were
transplanted into the liver via the portal vein, and not under the renal capsule.
Histologically, islets from the livers of long-term normoglycaemic animals were intact
and contained well granulated P-cells. Foci of mononuclear cells were only
occasionally observed adjacent to the islet grafts. FK506 has an entirely different
molecular structure to CsA but has the same mode of action, and weight for weight is
ten times more potent than CsA, and less cytotoxic. However, FK506 is also toxic to
islets when used at high doses, but not at the low dose ( 0.32 mg/kg ) used in this
study to prolong islet allograft .
1.6.1.1.2. Immunoalteration
In 1957, Snell ( 612 ) suggested that passenger leukocytes within transplanted organs
may be responsible for the initiation of immune rejection, because of their mobility.
Such cells could carry graft antigen along lymphatics to the regional lymph nodes
where the response to foreign antigen is initiated. However, antigen on the surface of
dead cells is relatively weak immunogenically ( 613 ) leading to the notion that
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alloantigen is only highly immunogenic when presented on the surface of active APC.
If treatment of the graft prior to transplantation removes active APC, immunogenicity
will be reduced. Snell's hypothesis has been further extended : class II MHC antigen
expressed on certain mesothelial cells within islets may induce rejection, whereas the
endocrine epithelial cells lacking class II antigen are not immunogenic. Dendritic cells
within the interstitium, monocytes, and to some extent endothelial cells are class II
positive, and these cells are assumed to be the specialised leucocyte population
primarily responsible for the induction of the immune response against an allograft.
A number ofways of pretreating islets with the aim of reducing their immunogenicity
have been demonstrated in rodent models, which generally involve destruction or
alteration of passenger lymphoid cells without affecting the islet endocrine cells.
Lafferty et al ( 614 ) prevented rejection of thyroid allografts in mice by culturing the
donor thyroid in almost pure oxygen atmosphere for 3 weeks pretransplantation. The
high oxygen tension destroys passenger lymphoid cells in the donor thyroid, thus
hampering antigen presentation and preventing rejection. However, individual rat
islets cultured under these conditions only survived 3-4 days, unless clusters or
aggregates of approximately 50-150 islets were formed. These islet aggregates, after
culture for 7-10 days in 95% oxygen, successfully reversed the STZ-diabetes when
transplanted across a MHC barrier as defined by normoglycaemia and aglycosuria
(615).
It has been reported that human lymphocytes maintained at 22°C survive and
consequently lose their ability to stimulate an MLR in vitro ( 616 ), suggesting that
low temperature culture altered or depleted passenger lymphoid cells. Lacy et al
( 617 ) found that in vitro culture of isolated rat islets for 7 days at 24°C prior to
transplantation into STZ-diabetic rats immunosuppressed with a single injection of
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ALS resulted in islet allograft survival of 100 days, even when islets were transplanted
across a MHC barrier. Both the period of low temperature culture and the temporary
immunosuppression of the recipient were necessary for graft survival, as neither alone
prevented rejection. Subsequently, Tze and Tai ( 618 ) reported that low temperature
culture alone ( 26°C ) for 7 days significantly prolonged the functioning of rat islet
allografts when transplanted into non-immunosuppressed STZ-diabetic animals. Islets
cultured at higher temperatures ( 32°C or 37°C ) failed to prolong islet survival.
Both groups reported that successfully transplanted allografts maintained their
antigenicity, i.e. islets were still capable of being recognised as foreign, as an i.v.
injection of donor strain peritoneal exudate cells or splenocytes ( both a rich source of
class II positive cells) induced the rejection of the established allograft.
Another successful approach used in the alteration or depletion of APC is irradiation
of donor islets with ultraviolet ( UV ) light. Lewis rat islets subjected to a dose of
900 J/m^ did not exhibit any alteration in their endocrine function, and when
transplanted into non-immunosuppressed syngeneic rats, 73% of recipients showed a
marked prolongation of survival (>80 days ) ( 619 ). Lau et al ( 620 ) also observed
that irradiated rat islets remained hormonally functional and had prolonged allograft
survival when transplanted across a relatively weak histocompatibility barrier into a
non-immunosuppressed recipient. The islets were reported to contain numerous,
although apparently non-functional, intra-islet class II positive passenger leucocytes.
This treatment did not prevent rejection when irradiated WF rat islets were
transplanted into Lewis recipients, i.e. across a stronger histocompatibility barrier.
For strong allogeneic combinations, UV-irradiation in conjunction with a 3 day course
of CsA (15 mg/kg ) was necessary to markedly prolong survival ( 18 days) of
transplanted allogeneic islets. If the CsA concentration was increased to 30 mg/kg,
the combined treatment allowed 100% islet allograft survival for >120 days
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demonstrating the effectiveness and synergism between pre-transplant UV-irradiation
of the islet allograft and pretransplant immunosuppression of the recipient with CsA in
inducing prolonged islet allograft survival in high responder recipients. Singular use
of either modality was shown to be ineffective ( 605 ).
As mentioned earlier, dendritic cells are thought to be one of the specialised passenger
leucocyte populations and elimination of these cells using a specific dendritic cell
moAb and complement before transplantation has been achieved with isolated mouse
islets ( 621 ). However, other laboratories have reported no success using this
technique ( 622,623 ) raising the possibility that treatment does not always suceed in
eliminating all MHC class II positive cells and/or that MHC class II negative cells may
also contribute to the immunogenicity of the graft. Unfortunately, a specific dendritic
cell moAb for rat is not available.
Dendritic cells express class II MHC antigens and using the same principle, anti-class
II antibodies with complement have been used in the pre-treatment of rat islets with a
varying degree of success. Reece-Smith et al ( 622 ) pre-treated isolated adult rat
islets with moAb against class II antigens and complement in conjunction with ALS
before their implantation beneath the renal capsule of allogeneic recipients. Treatment
only resulted in a slight increase in survival of the islet allografts when compared with
controls. This lack of success may be attributed to using antibodies that did not fix
complement. Flesch et al ( 624 ) used a secondary antibody in conjunction with
anti-class II antigen moAb and complement to circumvent this problem. Despite an
evident reduction in class II antigen bearing cells within the treated islets,
prolongation of graft acceptance after islet allotransplantation across an MHC barrier
into STZ-diabetic recipients was not observed. Complete class II antigen depletion
within pancreatic islets has also been unsuccessful in prolonging allograft acceptance
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( 623 ), suggesting other factors may also be involved in allograft rejection.
Terasaka et al ( 625 ) found that pre-treatment of donor islets with specific antibodies
to class II rat antigens did not prevent their rejection when transplanted into
STZ-diabetic Lewis recipients unless used in conjunction with a 3 day course of
CsA.
1.6.1.1.3. Induction of tolerance
Evidence from several groups suggest that a state of specific immune tolerance can be
induced in recipient rodents bearing an established islet allograft. Transplants of
untreated islets from a third party donor into tolerant rats were rapidly rejected,
whereas transplants of fresh islets from the original donor strain were retained. The
preculture of islets and the immunosuppression of recipients was not necessary,
although this treatment was essential for the acceptance of the first pancreatic islet
transplant ( 626 ). UV-irradiated donor spleen cells ( 615 ) or blood lymphocytes
( 627 ) could also induce a state of specific immunological tolerance. This
pre-immunisation of recipients with class II positive cells allowed the prolonged
acceptance and function ofuntreated islet allografts.
Allogeneic islets were also permanently accepted when transplanted under the renal
capsule of adult rats bearing long-term allogeneic kidneys of the same donor strain as
the islets, without any further immunosuppression ( 628 ). Acceptance of the kidney
allograft was induced by a 14 day course of CsA, and 100 days later the recipients
were made diabetic with a single dose of STZ. Third party islets transplanted under
the renal capsule were rapidly rejected. Similar results were obtained by Gray et al
( 629 ) who implanted islets either beneath the kidney capsule or into the portal vein
of tolerant STZ-diabetic rats. In both cases, 80% of the recipients showed prolonged
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graft survival ( >100 days ). Thus, once a recipient has accepted a renal allograft
under the influence of CsA treatment it will permanently accept an islet allograft of
the same donor strain as the kidney, and this effect is not influenced by the site of islet
implantation.
Another approach to the specific induction of tolerance was investigated by Liebel et
al ( 630 ). This group inoculated STZ-diabetic WF rats with minced portions of
Lewis rat pancreas initially at a concentration of a millionth of the estimated weight of
the whole gland and finishing using a thousandth of the weight. This treatment was
given for one year and had no effect on the diabetic state of the recipients as judged
by their continued insulin requirement. Transplantation of 500-800 Lewis islets by
injection into the portal vein resulted in the reversal of diabetes in 70% of the rats, and
these rats remained normoglycaemic until they were killed after 6 months.
Histological studies showed the presence of many well granulated islets within the
lumen of portal vessels. No regeneration of P-cells in the native pancreas was
observed, proving normoglycaemia was due to the implanted islets. Controls were
not inoculated with minced pancreas and rejected the allogeneic islets rapidly.
In summary, syngeneic islets transplanted into the STZ-diabetic rat allows the
prolonged, if not permanent, survival of the graft at several implantation sites.
However, the consistent rejection of islet allografts transplanted into antigenically
different diabetic hosts, even across minor histocompatibility barriers, is well
established. Decreasing the immunogenicity of the islets by deletion of intra-islet class
II MHC expressing passenger leukocytes, i.e. dendritic cells and macrophages, has
prevented the rejection of allogeneic tissue and achieved permanent survival of islets
in allogeneic hosts. Although chemically-induced diabetic hosts are useful models for
the study of immunogenetic and metabolic aspects of islet transplantation, the fact
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that IDDM is a disease with an autoimmune pathogenesis necessitates the evaluation
of islet transplantation in an animal model with spontaneously occurring diabetes,
which has an aetiology more comparable to human diabetes.
1.6.2. THE BB RAT
Early transplantation studies showed that MHC-compatible WF islet allografts
transplanted intraportally to the spontaneously diabetic BB rat were rapidly destroyed
unless the recipients received continuous immunosuppression with ALS (631 ).
Survival was indefinite and histologically the majority of intrahepatic islets contained
viable P-cells. Animals normoglycaemic for 6 months after islet transplantation
returned to a hyperglycaemic state soon after ALS therapy ceased. Histological
evidence of islet rejection was observed, indicating that immunosuppression was
necessary to prevent islet allograft destruction. Furthermore, in several long-term
islet allograft recipients, both the intrahepatic and native pancreatic islets contained
viable P-cells suggesting that ALS therapy not only prevented the rejection of
transplanted islets but could also alter the autoimmune response directed against the
native pancreas. Like et al ( 632 ) found that the injection of rabbit antiserum to rat
lymphocytes reversed hyperglycaemia in 36% ofBB rats and prevented diabetes onset
in prediabetic DP-BB rats. Timely immunosuppression could therefore prevent
diabetes in BB rats with sufficient remaining P-cells. However, abnormal glucose
tolerance and focal islet lesions indicate that ALS does not completely protect these
animals against the cell mediated autoimmune process.
Subsequent experiments investigated the survival time of WF and DR-BB rat islet
allografts transplanted intraportally into spontaneously diabetic BB rats or into
long-term normoglycaemic DP-BB littermates rendered chemically diabetic by
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injection of STZ ( 633 ). The immune destruction of islet allografts was rapid in
spontaneously diabetic recipients, whereas in 60% of their non-autoimmune
STZ-diabetic littermates, grafts survived for up to 300 days before rejection was
observed. This data suggests that the autoimmune process responsible for the
destruction of native pancreatic islets in the BB rat could also participate in the
destruction of transplanted islets. In order to distinguish between autoimmune
recurrence of diabetes and rejection in the above studies, rejection had to be
precluded. As syngeneic islet transplantation is not possible in the BB rat, DP-BB
rats were rendered tolerant to WF histocompatible antigens by inoculation of bone
marrow cells at birth, as evidenced by the permanent acceptance of WF skin
allografts, and monitored for the development of diabetes. Littermates that did not
spontaneously develop diabetes were rendered diabetic by the injection of STZ. WF
islet allografts transplanted into tolerant chemically-induced diabetic rats restored
permanent normoglycaemia. In contrast, there was a uniform recurrence of
hyperglycaemia in the tolerant spontaneously diabetic BB recipients after
transplantation ofWF islets, which could not result from rejection. This data strongly
indicates that recurrent autoimmunity leads to the infiltration of transplanted
pancreatic islets by mononuclear cells, resulting in the eventual destruction of (3-cells.
An analogous response was later observed in human IDDM where recurrent insulitis
selectively destroyed islet P-cells following a segmental pancreatic isograft exchanged
between identical twins discordant for diabetes ( 6 ).
As the autoimmune response in BB rats is thought to be both initiated by and directed
towards the native pancreatic P-cells, DP-BB rats tolerant to WF antigens were used
to determine if autoimmunity resulted from an intrinsic islet defect or a defect in the
immunoregulatory system ofBB rats ( 634 ). The development of diabetes in DP-BB
rats was found to correlate highly with the degree of lymphopenia ( 635 ), and
137
tolerant BB rats predicted to develop diabetes were treated with STZ during the
prediabetic period in order to destroy their native P-cells. Transplantation of a WF
islet allograft did not prevent onset of disease despite the replacement of native P-cells
with non-diabetes prone islets. Furthermore, diabetes onset occurred at approximately
the same time as that expected of unmanipulated DP-BB rats. This data indicates
that anti-P-cell autoimmunity is not the result of an intrinsic islet defect but to a defect
elsewhere, such as the immune system of the BB rat.
Evidence points to a T lymphocyte mediated destruction of pancreatic P-cells in the
BB rat and antigen recognition by T lymphocytes has been demonstrated to be
MHC-restricted, requiring antigen to be associated with self MHC molecules in vitro
( 636 ). Indeed, early experiments by Naji et al ( 637,638 ) found that
MHC-incompatible islet allografts transplanted into diabetic BB rats made tolerant to
donor antigens at birth were permanently accepted, providing evidence that this
hypothesis may indeed be the case. It was therefore suggested that the autoimmune
process destroying native islet P-cells might not be able to destroy islets of a different
MHC haplotype.
Woehrle et al ( 639 ) confirmed that freshly isolated islets transplanted into the liver
via the portal vein of the spontaneously diabetic BB rat were destroyed whether the
islets were MHC compatible or not. Preculture of islets for 14 days at 24°C in
conjunction with a single dose of ALS at the time of transplantation was necessary to
allow permanent survival ofMHC-incompatible but not MHC-compatible islet grafts.
This demonstrated that the autoimmune rejection of transplanted islets could be
avoided by tissue culture if the recipient and donor differed at the MHC locus. In the
case of MHC-compatible islet allografts, factors other than recurrent autoimmunity
may contribute to islet destruction since in vitro cultured MHC-compatible islets were
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also destroyed when transplanted into chemically-induced ( non-autoimmune )
diabetic BB recipients. APC depletion was only successful in preventing allograft
rejection if donor recipients were disparate at the MHC locus. This has been verified
by transplanting other endocrine tissues such as thyroid and parathyroid tissue
( 640,641 ). It has been proposed that when MHC-compatible APC-depleted grafts
were transplanted to hosts, the recipients APC population was able to effectively
present graft antigens to appropriately restricted T lymphocytes, thereby initiating a
rejection response ( 642 ). Antigen(s) from an APC-depleted MHC-incompatible
graft when processed by host APC have the capacity to stimulate T lymphocytes
specific for graft antigen(s) only in the context of self MHC. However, the same
antigenic determinants present on the islet allografts are expressed in the context of
the donor foreign MHC and hence are not recognised or destroyed by effector cells.
It should be noted that after the development of diabetes in the BB rat such hosts
have already generated and possess primed T lymphocyte effector populations that
developed during the destruction of their native p cells. Logically the restriction in
such hosts is more likely to be at the level of the effector cell-target cell interaction
than at the induction phase of the immunity. Thus, the survival of APC-depleted
MHC-incompatible islets but not MHC-compatible islets in diabetic BB hosts could
be explained by the fact that effector T lymphocytes generated against native islets are
specific for islet antigen(s) in the context of RT1U and hence are not capable of
interacting with and/or damaging non-RTlu expressing islet grafts.
Furthermore, Markmann et al ( 643 ) examined relative vulnerability of
MHC-compatible and -incompatible islet allografts to autoimmune damage after
transplantation to the liver via the portal vein of the diabetic DP-BB rat. Rejection in
these animals was circumvented by either induction of islet donor-specific
immunological tolerance or by pretransplant in vitro culture of islets to deplete
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intra-islet APC. In the first situation, MHC-compatible and -incompatible islet grafts
were equally susceptible to autoimmune damage, reportedly due to increased
peripheral blood NK cell activity. NK cells are cytotoxic to islets in vitro and may
play a role in the non-MHC-restricted diabetogenic response in vivo, therefore both
MHC-restricted and non-MHC-restricted mechanisms are capable of contributing to
anti-P cell autoimmunity and destruction in BB rats. In the latter case
MHC-incompatible grafts were significantly less vulnerable to autoimmunity than
MHC-compatible grafts, suggesting some degree of protection. This protection was
not absolute and varied depending on the donor strain used, pointing to an MHC
discriminating autoimmune process. This conclusion was further supported by the
recent work of Hegre et al ( 644,645 ) who isolated neonatal rat islets using a
non-enzymatic technique. These islets are known to exhibit reduced immunogenicity
when transplanted to allogeneic diabetic BB rats because of an absence ofMHC class
II positive cells. MHC-matched islet grafts were still susceptible to disease recurrence
in contrast to MHC-mismatched grafts, despite the destruction of the P-cell
population of the endogenous pancreas. All MHC-mismatched grafted animals
showed ameliorated conditions and 75% of recipients were restored to a
normoglycaemic state, i.e. recurrence of diabetes was not observed. Possibly the
culture process that rendered the islets allotransplantable in this study also altered the
expression of the islet-specific antigen on the P-cell surface responsible for the
initiation of the autoimmune process. This target antigen may have been present in
animals in a high enough concentration to allow autoimmune damage or destruction
of MHC-matched WF grafts but not in the remaining animals. Conversely, grafted
MHC-mismatched islets may not bear the diabetic antigen in high enough
concentrations to precipitate autoimmune destruction.
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Furthermore, the endocrine components of neonatal islets increase in mass after
transplantation, and if sufficient tissue is initially transplanted, diabetes may eventually
be reversed. Neonatal islet grafts from diabetic BB rats were also found to be larger
than grafts from non-diabetic controls and the increase in mass was attributable
primarily to proliferation rather than hypertrophy. High glucose levels in the diabetic
BB recipient are known to stimulate J3-cell replication in foetal, neonatal and adult
islets ( 646-648 ) and may be the stimulus for enhanced graft growth in this model. A
small immunomodulated neonatal graft may therefore increase 10-fold in mass when
placed in the diabetic environment of the BB rat, thus leading to the amelioration of
the symptoms of diabetes.
Chabot et al ( 649 ) demonstrated that combination ofUVB donor islet treatment and
pretransplant host CsA immunosuppression led to the indefinite survival of
MHC-incompatible islet allografts, thus avoiding the reinitiation of the original
autoimmune process. Woehrle et al ( 639 ) reported that MHC-incompatible islets
precultured for 14 days at 24°C and transplanted intraportally into diabetic BB rats
treated with a single dose of ALS at the time of transplantation survived long-term.
In contrast, survival of treated MHC-compatible islets was similar to that of untreated
MHC-compatible islets, suggesting the autoimmune destruction of transplanted islets
can be avoided by tissue culture alone if the recipient is briefly immunosuppressed and
differs from the donor at the MHC locus.
Two reports contrast the previous studies concluding that destruction of transplanted
islets in the diabetic BB rat is MHC-restricted. Prowse et al ( 650 ) reported that
allotransplantation of cultured MHC-incompatible islet and pituitary tissue under the
renal capsule of diabetic DP-BB rats resulted in tissue specific destruction of grafted
islets but not of pituitary tissue, despite a pretransplant culture period to reduce
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immunogenicity of the islets. Weringer and Like ( 651 ) confirmed that immune
insulitis in the DP-BB rat was not MHC-restricted in a similar study. Both
MHC-compatible and -incompatible islet grafts were destroyed by the disease process
responsible for damage to the animals native islets, as evidenced by recurrent
lymphocytic insulitis in the transplanted grafts. This process was tissue-specific since
islet a- and 5- cells were relatively undamaged. These studies suggest that cultured
islets retain the antigen specificity necessary for autoimmune attack, and effector cells
responsible for induction of insulitis do not have to share the MHC of their target
cells. In addition, P-cells do not need to be antigenically abnormal as a prerequisite
for autoimmune attack and, as class II antigen positive cells were presumably
destroyed on donor islets by tissue culture, donor class II positive cells appear
unnecessary to initiate insulitis in grafted islets of the DP-BB rat.
Reece-Smith et al ( 600 ) demonstrated that the renal capsule is an immunoprivileged
site compared to the liver. Woehrle et al ( 652 ) compared the kidney capsule as a
site for islet transplantation with the liver, via the portal vein, in spontaneously or
STZ-diabetic BB rats. Both sites are highly vascularized and have been shown to
allow good metabolic efficiency of transplanted islets in the STZ-diabetic rat.
MHC-compatible and -incompatible islet allografts were found to survive significantly
longer when the renal capsule, but not the liver via the portal vein, was used as the
site of transplantation without host immunosuppression or islet pretreatment.
Freshly isolated islets transplanted intraportally or under the renal capsule were
rapidly rejected. Pretransplant culture for 12-14 days at 37°C induced a slight
prolongation of allograft survival at these sites. However, culture at 22°C for the
same period significantly delayed and even prevented rejection, but only when islets
were placed under the kidney capsule. Upon nephrectomy of the islet bearing kidney,
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an abundance of well preserved P-cell clusters were observed histologically. In
contrast, rejected islets showed an almost complete destruction of grafted tissue and
demonstrated many mononuclear cells infiltrating and replacing the transplanted islet
tissue. In a more recent study, Woehrle et al ( 653 ) confirmed their previous findings
using non-diabetic DP-BB donor islets transplanted under the renal capsule or
intraportally into spontaneously or STZ-diabetic BB rats, without immunosuppression
or immunomodulation of the donor islets. Earlier studies showed that intracolony BB
rat skin grafts were permanently accepted. Islets transplanted into STZ-diabetic
DP-BB animals survived indefinitely ( >200 days ) irrespective of the transplant site.
Histologically, islets were found to be intact and stained positive for insulin. Islets
also survived long-term when transplanted beneath the renal capsule of spontaneously
diabetic BB rats. In contrast, islets transplanted into the liver, via the portal vein, of
DP-BB rats only maintained normoglycaemia for 6-14 days before returning to a state
of hyperglycaemia. Body weights of animals decreased, and total destruction of islets
was observed due to the recurrence of autoimmune insulitis. Although in agreement
with earlier studies, these results were in direct contrast with the findings of
Prowse et al ( 650 ) and Weringer and Like (651 ), who observed recurrent
autoimmune insulitis after transplantation of both MHC-compatible and -incompatible
islets under the renal capsule of the DP-BB rat. Woehrle et al suggested that several
factors might explain these differences, including incomplete prevention of islet
allograft rejection and transplantation of a number of islets insufficient to maintain
proper metabolic control.
Posselt et al ( 654 ) also looked at the renal capsule and the liver as sites for the
transplantation of islet grafts in the newly diabetic BB rat, and compared the results
with those obtained using the intrathymic site. The survival of the MHC-compatible
and -incompatible islets transplanted under the renal capsule of the DP-BB rat was
143
significantly prolonged ( 65 days ), compared with islets transplanted intraportally
which failed after a mean of 9 days. However, both MHC-compatible
and -incompatible islets were permanently accepted when transplanted to the thymus,
without the need for chronic immunosuppression. In addition, recipients bearing
established Lewis MHC-incompatible intrathymic grafts for >120 days were given
a second Lewis islet transplant intraportally. These recipients remained
normoglycaemic even after the removal of the primary intrathymic graft and the
thymus showed well granulated, non-infiltrated islets. A return to hyperglycaemia
was only observed following the removal of the liver 60-65 days after injection of the
second graft. The results from these studies show that the intrathymic site not only
prevents rejection of transplanted MHC-compatible and -incompatible islets in the
DP-BB rat but also protects the islets from destruction by recurrent anti-P-cell
autoimmune disease. Furthermore, recipients with established intrathymic grafts
failed to destroy subsequent donor strain islets transplanted to extrathymic sites,
suggesting that mechanisms which modify systemic allogeneic and autoimmune
responses are involved. The deletion or functional inactivation of alloreactive clones
followed by the extensive repopulation of the T cell repertoire by newly matured
tolerant T lymphocytes has been proposed.
In a related study, Posselt et al ( 655 ) investigated the effect of intrathymic
inoculation of a small number of MHC-compatible allogeneic islets ( not enough to
reverse adult diabetes ) at birth in the DP-BB rat. Both autoimmune disease and
pancreatic insulitis were prevented. This phenomenon was islet-specific, as evidenced
by a similar incidence of lymphocytic thyroiditis in both islet-treated and control
animals, and was not due to a global impairment in T cell development, as intrathymic
and saline controls had comparable lymphocyte numbers and phenotypic profiles in
peripheral lymph nodes. The pancreas was found to be healthy and contained viable
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islets with no mononuclear cell infiltration. However, thyroid biopsies taken at
thymectomy showed severe lymphocytic infiltration in 50% of recipients. In contrast,
islets grafted under the renal capsule failed to significantly decrease the incidence of
diabetes, despite the persistence of the transplanted islets, demonstrating that islets
have to be inoculated directly into the thymus in order to influence anti-(3-cell
autoimmunity. As the thymus plays an important role in T cell self tolerance induction
( 656 ), intrathymic inoculation of islets in the neonatal period exposes T cell
precursors to P-cell specific autoantigen(s) resulting in the selective deletion or
inactivation of autoreactive clones from the nascent T lymphocyte repertoire. This
effect could be mediated by interactions of thymocytes with implanted islets
expressing the P-cell autoantigen-MHC complex, or with host-derived thymic APC
bearing processed P-cell antigens shed from the islet graft. Alternatively, long-term
residence of islets in the thymus could stimulate the selection of specific regulatory
cells capable of suppressing the anti-islet autoimmune response.
Brayman et al ( 657 ) obtained similar results when uncultured MHC-incompatible
islet allografts were transplanted intrathymically to 4-6 week old ( i.e. prediabetic )
DP-BB rats. No immunosuppression was administered and none of the DP-BB rats
became hyperglycaemic, compared with 100% incidence of diabetes in controls. The
normoglycaemia persisted for >8 months and all rats had a normal IVGTT.
Thymectomy after 241 days did not precipitate hyperglycaemia, confirming that
intrathymic islet allografts preserved native P-cell function at an early age, i.e. before
puberty. Furthermore, thymuses containing an intrathymic islet allograft were twice
the normal size of thymuses of untreated DP-BB rats suggesting an alteration in the
natural progression of thymic atrophy, a known consequence of insulin deficiency.
Both insulin and insulin growth factor I have been reported to restore the weight of
the thymus in diabetic rats towards normal ( 658 ).
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163 INDUCTION OF TOLERANCE USING MONOCLONAL
ANTIBODIES
The essential function of the immune system is to distinguish self from non-self, and
this discrimination is primarily a function of T lymphocytes. Activation of T cells by
self antigens is under stringent control involving both thymic ( 659 ) and peripheral
mechanisms ( 660 ). Failure of these mechanisms to control tolerance to self antigens
may lead to autoimmunity.
Ideally, therapeutic immunosuppression administered over a short-term period would
achieve long-term unresponsiveness to a desired antigen without impairing the host's
response to infectious agents. As discussed earlier, currently available
immunosuppressive drugs are inadequate since they are relatively non-antigen
specific, exhibit limited efficacy, require long-term administration and incur a
sustained risk of infection and undesirable side effects. If it were possible to
re-establish tolerance in an autoimmune disease or to guarantee tolerance to a
transplanted allograft, then it might be possible to dispense with conventional
long-term drug immunosuppression. However, achieving tolerance induction as a
therapeutic goal in autoimmunity or in transplantation requires an understanding of
the development of self-tolerance.
1.6.3.1. T CELL RECOGNITION OF NON-SELF
T cells recognise foreign or non-self antigen as peptide fragments displayed to them in
the clefts of MHC class I and II molecules which are expressed on the surfaces of
certain cells of the body. In addition, T cells that possess unique clonally distributed
receptors respond to these antigens displayed on APC in lymphoid tissue, proliferate
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and differentiate to effector mode. Dendritic cells have the greatest ability to present
antigen and activate T cells as they possess a particular array of cell surface ligands
complementary to an array of adhesion molecules on T cells, and also express MHC
class II in abundance ( 661 ). A further requirement for T cell activation is one of
collaboration or help from other T cells responsive to the same antigens ( 662 ).
T cells, once activated, develop into cells whose differentiated function can be that of
cytokine release, thereby influencing the functions of other cells. B lymphocytes and
pre-cytotoxic T lymphocytes are stimulated to become antibody-producing plasma
cells and cytotoxic T cells respectively, and NK and inflammatory cells are activated.
The microenvironment in which T cells engage their antigen can determine the type of
cytokines secreted, e.g. IL-2 and IFN-y play a prominent role in IDDM.
1.6.3.2. T CELL RECOGNITION OF SELF
The bulk of self tolerance induction occurs within the thymus where immature T cells
with anti-self receptors engage self antigens and undergo clonal deletion as an obligate
process. The ancillary mechanisms that induce tolerance in T cells to peripheral
antigens are less well defined and probably arise through clonal deletion and anergy,
i.e. inactivation but survival of T cells ( 663 ). There are currently four possible
explanations for tolerance induction following recognition of self antigen which are
not mutually exclusive.
a. T cells may still be exquisitely susceptible to tolerance soon after leaving the
thymus.
b. The first T cell to engage peripheral self will do so without any collaboration from
other T cells therefore the encounter cannot be registered. Consequently,
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antigen-reactive T cells could never accumulate in sufficient numbers to mount a
response.
c. Much antigen presentation would occur on non-professional APC that lack critical
ligands present on dendritic cells and macrophages. Antigen seen in this context
might also be tolerance permissive.
d. The context of antigen presentation may also guide the T cell response to be
regulatory, protective or suppressive by directing it towards a commitment to produce
particular cytokines.
1.6.3.3. MONOCLONAL ANTIBODIES TO ACHIEVE THERAPEUTIC
TOLERANCE
MoAb have been investigated as potential immunosuppressants due to the large
number of surface molecules involved in T cell interactions with APC and T cells.
They can be used as agents to kill defined cell types ( depleting ) or to interfere with
the function of a particular receptor ( non-depleting ). As they must be administered
systemically and are potentially immunogenic, moAb are generally administered over a
short-term period only.
There are two strategic approaches based on self-tolerance : the first involves use of
moAb to bring about central, i.e. thymic, tolerance, which requires a two-stage attack.
Initially, peripheral T cells must be inactivated prior to the introduction of a
permanent source of antigen, which can access the thymus and thereby induce
tolerance in subsequently developing T cells. The second strategy involves the
establishment of a form of peripheral tolerance that would be long-lasting, even after
moAb therapy is stopped. Maintenance of tolerance would depend upon antigen
continuing to engage the immune system.
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Perhaps the most potent moAb investigated are those directed against CD4+ and
CD8+ T lymphocytes, targeted because of the central role these T cell subsets play in
the induction of immune responses. CD4 antigen correlates to a subset of mature
helper/inducer T lymphocytes that recognise antigen on APC in the context of class II
gene products. CD4 is also present on the surface ofmost developing rat thymocytes
( 664 ) and on macrophages ( 665 ). The functional role of CD4 appears to be in
enhancing T cell activation by serving as an accessory molecule for the
antigen-specific T cell receptor ( TCR ) ( 666 ). However, it is not yet clear whether
CD4 functions simply as an accessory molecule, which stabilises the interaction
between the TCR and its specific antigen/MHC class II target, or whether CD4 itself
has an active role in signal transduction. CD8 antigen correlates to the
cytotoxic/suppressor T lymphocyte subset that recognise antigen on APC in the
context of class I MHC gene products and is additionally found on rat thymocytes and
NK cells.
Qin et al ( 667 ) reported that peripheral ( post-thymic ) T cell tolerance was achieved
in mice injected with the foreign protein antigen human y-globulin under cover of a
short course of non-depleting anti-CD4 moAb. Tolerance was lost in the absence of
further exposure to antigen as new T cells were exported from the thymus which had
had no contact with the antigen. Tolerance to skin and bone marrow grafts differing
at multiple minor transplantation antigens additionally required anti-CD8 moAb
treatment. Under these circumstances tolerance was permanent, presumably because
the established grafts acted as a continuous source of antigen to reinforce the tolerant
state. In both cases, tolerance was not broken by infusion of unprimed spleen cells.
More recently, conditioning with anti-CD4 and anti-CD8 moAb allowed the
successful transplantation of allogeneic bone marrow in the immunocompetent adult
mouse when donor and recipient were mismatched at multiple minor
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histocompatibility loci or at MHC class I plus minor loci, but not where the mismatch
involved the entire MHC ( 668 ).
Gutstein et al ( 669 ) found that treatment ofmice with moAb to L3T4 ( a cell surface
glycoprotein expressed on mouse T helper/inducer lymphocytes ) blocked both
primary and secondary immune responses, delayed allograft rejection and retarded
autoimmunity. Tolerance was also induced when anti-L3T4 moAb and anti-chicken
ovalbumin moAb, but not anti-T200 ( an antigen expressed on all mononuclear blood
cells ) moAb, were given concurrently, indicating that treatment with moAb to L3T4
may induce tolerance to some but not all antigens. Koike et al ( 670 ) used moAb to
show that the surface phenotypes of >90% of infiltrated cells in pancreases of NOD
mice were Thyl+ and Lytl+ T lymphocytes, including L3T4+ T lymphocyte subsets.
Administration of the L3T4-specific rat anti-mouse IgG2b moAb, GK1.5, to
2-week-old NOD mice twice weekly for 12 weeks prevented the development of
insulitis and diabetes, suggesting an essential role for L3T4+ T lymphocytes in the
pathogenesis of IDDM.
Short courses of anti-CD4 and anti-CD8 moAb were also shown to induce tolerance
to allogeneic skin grafts ( a demanding test of any tolerance protocol) in mice (671 ).
Tolerance could be obtained without T cell depletion across multiple minor antigen
mismatches both in naive and primed animals demonstrating that peripheral T cells
could be tolerised even if they had been activated previously. When donor and
recipient were incompatible across the whole MHC, a combination of depleting
followed by non-depleting antibodies was necessary to achieve tolerance, as neither
treatment alone was successful. This group further demonstrated that mice given a
single short course of anti-CD4 and anti-CD8 moAb became tolerant to
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MHC-incompatible vascularised heart allografts in a donor and organ-specific manner
( 672 ).
Blocking ( non-depleting ) moAb were equally effective demonstrating that T cell
depletion was not obligatory for tolerance induction. Either therapy alone was
sufficient to establish tolerance although anti-CD8 moAb therapy was associated with
poor recipient survival. A second donor-type heart allografted to the neck of
recipients carrying long-term heart allografts ( >120 days ) was also accepted.
However, donor type skin allografted at 100 days was sometimes chronically rejected
and third-party skin grafts mismatched at the MHC were always rejected indicating
that tolerance induction was donor and tissue specific. Madsen et al ( 673 ) also used
subset-specific moAb directed against the L3T4 ( CD4 ) and Lyt-2 ( CD8 )
differentiation antigens in order to evaluate their effects on murine cardiac allograft
rejection in both naive and primed recipients. Treatment with an anti-L3T4 moAb
effectively prolonged the survival of H-2 and non-H-2 mismatched cardiac grafts in
naive but not skin graft-primed recipients. This group had previously shown that
GK1.5 also significantly prolonged cardiac allograft survival in similar murine strain
combinations ( 674 ). In contrast, anti-Lyt-2 treatment had no effect on allograft
survival in naive recipients bearing a cardiac allograft but did delay graft rejection in
recipients primed for donor alloantigens. These data suggest that the L3T4+
( CD4+ ) T cell subset primarily mediates the first-set rejection response to whole
organ allografts, whereas the Lyt-2+ ( CD8+ ) subpopulation plays an important role
in the second-set allograft rejection.
Shizuru et al ( 675 ) investigated the conditions under which allogeneic pancreatic
islets survived when transplanted intraportally into MHC-disparate STZ-diabetic mice.
Islets survived indefinitely in recipients receiving a single i.p. course of GK1.5 moAb
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at the time of islet allograftment. Treatment selectively depleted >90% of L3T4+
T cells long-term, thereby allowing the survival of islets without additional
immunosuppression. However, tolerance was broken and long-term surviving islet
grafts rejected upon i.p. administration of donor-specific spleen cells. These findings
suggest that the T helper/inducer lymphocyte subset, as defined by the expression of
L3T4 molecules, is central to the induction of allograft rejection.
The rat has also been used to investigate induction of tolerance to cardiac grafts using
moAb therapy {616). Treatment of normal rats with anti-CD4 moAb starting on the
day of transplant prevented heart graft rejection across a full MHC haplotype
mismatch. Adequate doses of 0X35 moAb ( a very potent anti-CD4 moAb in vivo )
completely eliminated all peripheral blood CD4+ T cells and induced tissue-specific
tolerance to the transplants, as second ( fresh ) donor heart grafts were retained
indefinitely whilst third party grafts were promptly rejected. However, 0X38
( an anti-CD4 moAb which binds to a different epitope on the CD4 molecule than
OX35 ) was ineffective in inducing unresponsiveness to neonatal cardiac tissue
transplanted into MHC-mismatched congenic rat strains, despite eliminating all
peripheral CD4+ T cells. Herbert and Roser also report that an intact thymus is
necessary for the development of a population of suppressor T cells in anti-CD4
moAb-treated animals which are responsible for the induction of tolerance. However,
skin grafting to high-responder recipients required CsA treatment in addition to
administration of anti-CD4 antibodies for tolerance induction. Previously, these
authors used a quantitative assay for heart graft rejection to show that the first set
rejection of a full MHC haplotype-mismatched graft depends exclusively on CD4+ T
cells in the rat. In contrast, the accelerated rejection of second-set grafts in
specifically immune recipients depends exclusively on CD8+ T cells ( 677 ).
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Shizuru et al ( 678 ) also used 0X38 moAb to prolong the survival of heterotopic
vascularised rat heart allografts transplanted across MHC barriers in the rat. Using
fluorescence-activated cell sorter ( FACS ) analysis, administration of a maximal
depleting level of 0X38 moAb was shown to selectively deplete 80-95% of CD4+ T
cells from peripheral blood of treated rats, whereas Herbert and Roser ( 676,677 )
reported complete depletion of CD4+ T cells using this moAb. Additionally, animals
given moAb doses corresponding to maximal depletion did not make a humoral
response against the administered immunoglobulin, whereas those treated with less
than maximally depleting amounts made a dose-dependent humoral immune response
against the mouse anti-rat moAb. Another potentially undesirable consequence of
anti-CD4 therapy might be elimination of immunologic memory, thus rendering a
treated recipient vulnerable to a wide range of previously encountered common
immunogens. However, rats allowed to reject a primary heart allograft still rejected a
secondary heart graft transplanted under the cover of 0X38 treatment, indicating that
memory responses to alloantigen persisted in rats receiving anti-CD4 therapy. More
interestingly, and again in contrast to the findings of Herbert and Roser ( 676,677 ),
0X38 moAb, when given prior to transplantation of heterotopic abdominal heart
allografts, promoted long-term survival of the grafts. Furthermore, these rats
accepted second donor-strain hearts, but not third party heart grafts, transplanted into
the femoral space without further treatment. This anti-CD4-induced unresponsiveness
persisted for at least 90 days following surgical removal of the heart allografts and
retransplantation of a second donor-matched heart. Untreated rats rejected their heart
allografts within 14 days following transplantation. These results show that transient,
pretransplant 0X38 moAb therapy induced specific, long-lasting unresponsiveness to
fully MHC-mismatched cardiac allografts in rats without additional
immunosuppression. Preliminary data from this laboratory showed similar results
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using the 0X35 moAb in an identical pretransplant treatment regimen as that
described for 0X38.
Seydel et al ( 679 ) also studied the effects of anti-CD4 moAb treatment on the
survival of allogeneic islet allografts transplanted to STZ-diabetic rats. 0X38 when
given as a 4-day treatment regimen caused depletion of >80% ofCD4+ T cells from
peripheral blood. Three days after initiation of 0X38 immunotherapy, rats received
an allogeneic pancreatic islets graft via the portal vein. The transplanted islets
returned the OX38-treated recipients to a normoglycaemic state which was
maintained indefinitely in the absence of further immunosuppression. Elimination of
CD4+ T cells at the time of transplant was followed by repopulation ofCD4+ T cells
from thymic precursors that were incapable of inducing allospecific responses against
the transplanted tissue. In contrast, treatment of recipient rats with 0X8 moAb,
which recognises the cytotoxic/suppressor T lymphocyte ( CD8+ ) subset, induced
only a slight prolongation of graft survival ( approximately 30 days ) despite efficient
depletion ( >80% ) of peripheral blood CD8+ T lymphocytes. Furthermore,
long-term islet survival following pretransplant 0X38 therapy could be abrogated by
coincident treatment of recipient rats with depleting levels of 0X8 moAb, indicating
the necessity for a regulatory CD8+ T cell to induce and/or maintain anti-CD4
mediated islet survival in the STZ-diabetic rat.
Roza et al ( 680 ) looked at the effect of several different moAb specific for rat T cell
subsets on heterotopic cardiac transplantation in the rat across combined MHC and
non-MHC ( minor ) differences. Administration of 0X19 moAb, which recognises
thymocytes and all T cells ( CD5+ ), at the time of transplantation and on alternate
days thereafter until rejection, significantly prolonged allograft survival when
compared with allografts transplanted into unmodified recipients. Administration of
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W3/25 moAb prolonged allograft survival only slightly. W3/25 moAb recognises
most rat thymocytes, macrophages and the helper/inducer T lymphocyte ( CD4+ )
subset, and competes with 0X38 ( 665 ) for binding to rat CD4, suggesting that these
two antibodies recognise the same epitope, or determinants in the same region of the
CD4 molecule. Administration of 0X8 moAb had no effect on allograft survival. In
contrast, administration of 0X8 markedly prolonged allograft survival across
non-MHC ( minor ) differences, whereas W3/25 moAb administration had no effect.
The relationship between graft survival and depletion of targeted T cell subsets, as
assessed by FACS analysis, was variable. 0X8 moAb administration resulted in a
marked reduction of 0X8+ cells, but no prolongation of graft survival across
combined MHC and non-MHC differences was observed. In contrast, indefinite graft
survival was achieved across isolated non-MHC differences. 0X19 moAb
administration prolonged graft survival, and significant numbers of 0X19+ cells were
present at rejection. Administration of W3/25 moAb prolonged allograft survival
across combined MHC and non-MHC differences despite failing to significantly
reduce the W3/25+ cell population, which suggests that W3/25 moAb binds to its
target cell without subsequent clearing, i.e. W3/25 is a non-depleting moAb.
In contrast, Claesson et al ( 681 ) failed to prolong the survival of anastomotic rat
heart grafts in a semi-allogeneic system using W3/25 moAb treatment. This
discrepancy may be due to differences in the strain of animals used, the degree of
antigenic disparity, or variation in the dose and potency of W3/25 moAb used.
Furthermore, treatment with the anti-CD8 moAb, 0X8, immediately after
transplantation of an allografted heart significantly prolonged the mean graft survival.
When given prior to transplantation, graft survival was further prolonged,
demonstrating that a selective impairment of the cytotoxic/suppressor T cell
population in vivo could prolong organ allograft survival.
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W3/25 and 0X8 moAb were also used to prevent autoimmune recurrence in islets
allotransplanted intraportally into spontaneously diabetic BB rats made tolerant to
donor-specific islets ( 682 ). MoAb treatment was administered pretransplant and
continued until recurrence of hyperglycaemia was observed or to the end of study at
100 days. None of the OX8-treated islet graft recipients exhibited recurrent diabetes,
which strongly implicates the involvement of OX8-bearing cells in the diabetogenic
immune response. However, as both NK cells and cytotoxic/suppressor T cells
express CD8 it is unclear which specific cell type participates in islet destruction, and
contribution of each of these cell types to the autoimmune response requires further
study. In contrast, all diabetic BB rats treated with W3/25 moAb exhibited recurrent
hyperglycaemia within 47 days of transplantation. This group reported partial
effectiveness of W3/25 in eliminating helper/inducer T lymphocytes from the
peripheral blood and from lymphoid organs, and did not exclude the possibility of
helper/inducer T lymphocyte participation in anti-fl-cell autoimmunity.
It should be noted that W3/25 was effective in reversing the disease course of the
autoimmune diseases experimental allergic encephalomyelitis ( EAE ) ( 683,684 ) and
neuritis ( EAN ) ( 685 ). EAE is induced in rat by injection of purified myelin basic
protein. W3/25 has previously been shown to inhibit MLR in vitro by acting on
responder cells without killing them ( 686 ), and prevent in vitro activation of cells
that mediate the transfer ofEAE from sensitised donors to naive recipients ( 687 ). In
order to determine ifW3/25 moAb could inhibit the in vivo immune response to EAE,
a single i.p. or i.v. dose ( l-2mg ) ofW3/25 was injected into animals 12-13 days after
disease induction. Treated animals recovered from EAE within 2 days, whereas
control animals exhibited signs of EAE for a minimum of 4 days. W3/25 had no
perceptible effect on the number ofW3/25+ T cells in the peripheral blood indicating
that its inhibitory effect is not mediated by simple clearing or coating of responding
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cells with immunoglobulin since 0X19 moAb ( which reacts with all T cells including
W3/25+ T cells ) treatment given under the same regimen failed to affect the time
course ofEAE. It was noted that W3/25 moAb took 24 hours to terminate EAE and
may therefore have interfered with T cell activation at an early stage. In support of
this hypothesis, injection of W3/25 moAb did not prevent EAE development in rats
given in vitro stimulated sensitised lymphocytes. In addition, Waldor et al ( 684 )
determined the importance of immunoglobulin isotype in successfully treating EAE by
using IgGl, IgG2a or IgG2b W3/25 moAb. Although all isotypes had identical
binding capacities for rat CD4+ T cells, IgGl and IgG2a W3/25 moAb were
superior to the IgG2b isotype in the treatment of EAE, demonstrating that
immunoglobulin isotype does play a role in the treatment of this autoimmune disease.
In agreement with previous findings, none of the W3/25 isotypes substantially
depleted CD4+ target cells in vivo.
For the induction of EAN, rats were injected with peripheral nerve myelin and
Freunds adjuvant. Subsequent 0X8 moAb treatment completely eliminated CD8+ T
cells from peripheral blood and lymphoid organs and exaggerated the disease
symptoms, suggesting that cytotoxic T lymphocytes only play a minor role as effector
cells in EAN and have a suppressive function. However, additional mechanisms that
downregulate neuritogenic immune reactions must exist in this model since, even in
the maximally 0X8-treated group, the clinical symptoms of EAN disappeared
spontaneously a few days after onset. In contrast W3/13 ( pan T cell reactive ) moAb
completely prevented the onset of disease, even though treatment only caused a
partial elimination of its target cells. In addition, injection of W3/13, but not 0X8,
moAb led to a diminished responsiveness of spleen cells from treated rats to
allogeneic stimulation in vitro, whereas 0X8 injection caused a complete elimination
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of the in vitro cytotoxic response to allogeneic cells in the MLR-activated spleen cell
population.
Finally, Like et al ( 688 ) reported that treatment ofDP-BB rats with 0X8 or 0X19
moAb achieved stable reductions of splenic and peripheral blood NK and
T helper/inducer cells respectively, and in addition protected against diabetes. In
contrast, none of the anti-CD4 moAb ( 0X35, 0X38 and W3/25 ) tested depleted the
CD4+ T cell population in the BB rat or had a significant effect on the course of the
disease. This group therefore concluded that it is the subsets of rat lymphocytes that
express CD8 and CD5 surface antigens which participate in DP-BB pancreatic P-cell
autoimmune destruction.
The conflicting results reported by different groups with respect to success of
tolerance induction have been attributed to several factors, including differences in rat
strain combinations used, animal housing conditions, intrinsic differences in moAb
structure, and differences in antibody preparation, dose and treatment regimens.
1.6.4. EFFECT OF ISLET TRANSPLANTATION ON DIABETIC
COMPLICATIONS IN ANIMAL MODELS OF IDDM
Chemically-induced STZ-diabetes in the rat induces secondary complications of
kidney, eye and nervous system similar to the changes observed in the human.
Transplantation of a sufficient number of isolated islets from isogenic donors inhibited
or reversed these lesions. After 2-3 months, STZ-diabetic rats begin to develop renal
lesions with severe morphological changes, including enlargement of the mesangial
space, thickening of the capillary wall, vacuolisation of the tubular epithelial cells,
protein casts, and deposition of immunoglobulins in the glomeruli. Following the i.p.
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transplantation of pancreatic homogenates containing a high number of islets to the
STZ-diabetic rat, Mauer et al ( 689 ) observed the inhibition and reversal of early
lesions within the kidney glomeruli. In subsequent studies, islet transplants were
found to decrease mesangial thickening in diabetic rats, but no effect on basement
membrane thickening in the glomeruli of these animals was observed ( 690 ). Federlin
and Bretzel ( 691 ) reported similar morphological changes after the intraportal
transplantation of 600 pure islets. A decrease in circulating basement membrane
antigens and the normalisation of the increased activity concentrations of
glucosyltransferase ( an enzyme involved in basement membrane synthesis ) were also
observed in the kidney. However, the degree of reversal of diabetic lesions after islet
transplantation was lower in animals with a longer duration of diabetes, suggesting
that an early period of reversibility exists which should not be exceeded.
The retinal capillaries of the eye are leaky in STZ-diabetic rats. Early diabetic vessel
changes consist of an altered fluorescein-blood barrier and increased accumulation of
i.v.-administered dye into the vitreous and the anterior chamber of the eye 10 days
after induction of diabetes. Krupin et al ( 692 ) used ocular fluorophotometry to
demonstrate that leakage returned to normal baseline values when insulin levels were
normalised 13 days after the transplantation of islet isografts. Intraportal or
intracerebral pancreatic islet allografts completely prevented the characteristic
basement membrane thickening in retinal capillaries of the STZ-diabetic rat during a
400-day post-transplantational study ( 693 ). In another long-term study,
alloxan-diabetic rats transplanted with a whole pancreas were killed at intervals of
1-2 years and kidney and eye pathology compared with age-matched diabetic control
rats. Lesions were fewer and less severe in pancreas-transplanted rats than in diabetic
control rats, and differences between the lesions in the two groups were highly
significant at 20-24 months ( 694 ).
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Studies of the articular cartilage of diabetic rats revealed a significant increase in the
activities of enzymes engaged in the synthesis and degradation of
mucopolysaccharides ( 695 ). Transplants of islets into the diabetic recipients
reversed the increased enzyme activities to normal values.
Abnormalities in the function of the autonomic nervous system may be manifested by
cardiovascular, genitourinary, sudomotor and alimentary dysfunction ( 696 ).
Schmidt et al ( 697 ) reported autonomic neuropathy involving the colon wall and the
ileal mesenteric nerves in chronic STZ-diabetic rats. Ultrastructural studies of the
mesenteric nerves revealed a distinct morphological alteration, apparently reflecting
aberrant or frustrated axonal regeneration. Transplantation of pancreatic islets
6 months after induction of diabetes, by which time mesenteric axonopathy was well
developed, quickly re-established normoglycaemia. Within 3 months, resolution of
the axonal neuropathy was almost complete. Lacy ( 698 ) observed the dilatation of
the colon ( megacolon ) after 4-5 months of STZ-diabetes, most probably due to
autonomic diabetic neuropathy. Megacolon could be prevented by the transplantation
of isogenic islets one month after induction of disease.
Due to the nephrotoxic effects of STZ used to induce diabetes, the effect of early islet
transplantation on the prevention of nephropathy is better investigated in the
spontaneously diabetic BB rat ( 207 ). 1000-1200 non-diabetic DP-BB rat islets were
transplanted under the renal capsule of DP-BB rats 1-3 weeks after diabetes onset.
At 9 months of age, the islet-bearing kidney was removed from the diabetic recipient
and examined for glomerular mesangial deposits and vacuolization of epithelial cells.
The amount of mesangial deposits increased slightly with age in the non-diabetic
DP-BB rat and no Armanni cells were visible. In contrast, the mesangial deposits
were doubled in the diabetic DP-BB rat receiving no islet graft, and >60% expressed
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Armanni cells to a high degree. After islet transplantation these parameters decreased
to levels observed in the non-diabetic rat. In addition, body weight, blood glucose
and HbAj values were also similar to non-diabetic control animals.
Islet cell transplantation in the abdominal testis of the BBAVor male rat normalised
fasting glucose and HbA] in 56% of rats for a period of at least 6 months. Improved
metabolic control was associated with normal total urinary protein, sural nerve
morphometry, and sexual function ( 699 ).
1.6.5. HUMAN ISLET TRANSPLANTATION
1.6.5.1. HUMAN ISLET ISOLATION
Gray et al ( 700 ) first described the successful isolation of islets from the human
pancreas in 1984. Prewarmed collagenase was injected via the pancreatic duct to
distend and dissociate the pancreas into a cell suspension from which islets could then
be purified. However, the collagenase digestion step was difficult to control and
produced variable results, thus leading to an automated method for human islet
isolation as described by Ricordi et al ( 701 ). This method involves the distension of
the pancreas with collagenase followed by its placement into a digestion chamber
through which medium recirculates at 39°C. The chamber is then gently shaken until
islets appear, at which point the temperature of the circulating medium is reduced to
15°C and the effluent collected at 4°C. Thus, released islets are immediately
removed from the collagenase solution, thereby preventing overdigestion. Islets are
then purified by density gradient centrifugation using Ficoll ( 702 ) or BSA ( 703 )
and can be kept in tissue culture for up to two months. 2000-3000 islets/g of tissue
with purities of 60-80% have been reported ( 701,703,704 ).
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1.6.5.2. TRANSPLANTATION STUDIES
Recurrent insulitis and (3-cell destruction have been observed in segmental pancreas
grafts transplanted from non-diabetic to diabetic identical twins ( 14 ). This recurrent
autoimmune destruction and subsequent return of IDDM was prevented by an
immunosuppressive protocol similar to that given to patients undergoing pancreas or
kidney allografting ( 705 ). By 1983, 159 islet tissue allografts had been reported to
the International Pancreas Transplant Registry, but none of the patients had achieved
insulin independence that could be attributed to the grafts alone ( 706 ). No
documented transplantation of purified adult human pancreatic islets was given, and
graft preparation techniques, immunosuppressive protocols and transplantation sites
were highly varied. Potential sites for islet transplantation include the renal
subcapsular space, the spleen and intraportal injection into the liver. All of the
successful human islet transplants recently reported have used the intraportal site.
The first report describing short-term insulin independence after islet transplantation
came from Scharp et al ( 702 ). This transplant failed after 20 days probably due to
rejection. Since then, Alejandro et al ( 707 ) have performed five islet transplantations
in four CsA-immunosuppressed ABO-compatible patients with type I IDDM. Islets
were isolated by a double collagenase injection technique and purified using volume
reduction of the dispersed tissue by centrifiiging at slow speeds. Grafts of 5-6 ml,
comprising 20-40% islets, were pretreated in four instances with anti-class II moAb
and percutaneously transplanted into the portal vein. This report shows that donor
islets can be safely engrafted in the liver of patients without the need for general
anaesthesia. One patient received a combined kidney/islet transplant from the same
donor, while all the other patients receiving an islet transplant had established renal
allografts. After islet grafting, three patients demonstrated normal basal plasma
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C-peptide levels for several weeks following, but not before, islet transplantation.
However, there was only a blunted response to a mixed-meal challenge. One patient,
who received an islet transplant on two occasions, showed subnormal C-peptide levels
for 18-26 weeks post-transplant. All patients continued to require exogenous insulin
treatment after islet transplantation.
Several factors may have contributed to the failure of this series of islet transplants.
Islets were isolated from cadaver donor pancreases at least 6 hours after excision, and
delay in islet isolation from the time of pancreas removal has recently been shown to
be detrimental to islet viability ( 708,709 ). In addition, the islet grafts may have been
insufficiently pure ( 20-40% ) using the volume reduction technique. Finally,
therapeutic levels ofCsA were inconsistently achieved.
Since 1990, there have been several encouraging reports of sustained islet graft
function after transplantation into diabetic patients ( 702,710,711 ). These successful
transplants include two diabetic patients that became insulin independent after islet
transplantation, one for more than 6 months ( 711 ). All reports describe islet
isolation from human cadaver pancreases by some form of ductal collagenase injection
and Ficoll density gradient purification.
Warnock et al ( 710 ) transplanted 260 000 purified allogeneic islets isolated from two
pancreases into the portal vein of two IDDM patients synchronously with a kidney
from the same donor. Immunosuppression was induced with antilymphoblast
globulin, azathioprine and prednisolone; cyclosporin was only introduced 8 days after
islet transplantation. Islet cell secretory responses were observed for up to 10 weeks
after transplantation, with C-peptide levels rising from negligible levels before
transplantation, to half the minimum level that has been found after successful
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vascularised pancreas transplantation. Although graft function sufficient to allow
withdrawal from insulin was not achieved, this report provides evidence for a
sustained P-cell secretory response after combined islet/kidney allotransplantation in
an IDDM patient.
Scharp et al ( 702 ) reported the first IDDM patient, with an established kidney
transplant on basal cyclosporin immunosuppression, who was able to eliminate the
requirement for insulin after human islet transplantation. Approximately 800 000
islets were successfully isolated from 1.4 cadaver pancreases that were 95% pure and
contained 121 U of insulin. After 7 days of 24°C culture, the islets were transplanted
into the portal vein under local anaesthesia, followed by 7 days of antilymphoblast
globulin administration and maintenance of the cyclosporin. Blood glucose was kept
under strict control via i.v. insulin for 10 days post-transplantation, after which insulin
therapy was stopped. The average 24-hour blood glucose level remained
<8.3 mmol/1 and the C-peptide values, although initially rising slower, exceeded the
normal range after an oral glucose load. Twenty-five days after islet transplantation
exogenous insulin therapy was reinstated possibly due to a marked stress response ( a
family death ) or a rejection of part of the transplanted islets. Interestingly, some of
the islets were cryopreserved for a time prior to transplantation using
dimethysulphoxide as cryoprotectant. Tissue recovery after thawing is approximately
80%, and advantages of this storage include detailed matching of tissue, banking and
transport of tissue between centres, and pooling of tissue from multiple donors.
Under unusual circumstances, Tzakis et al ( 711 ) described nine patients who became
diabetic after upper abdominal exenteration and liver transplantation for extensive
tumours, and were subsequently given islet grafts obtained from one or two
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pancreases. At the time of publication, the longest survivor required neither
parenteral alimentation nor insulin, more than 6 months after transplantation.
Two important factors are likely to have contributed to these successes. Firstly, the
mass of islet tissue transplanted exceeds that previously reported, and islet grafts were
obtained from two pancreases in the majority of cases. Although the longest survivor
in the report from Tzakis et al received an islet graft obtained from only one pancreas,
the endocrine volume was relatively high (711 ). Secondly, in the latter two reports,
islets were transplanted under conditions that made the rejection of islet tissue less
likely. Evidence suggests that an islet allograft may be less immunogenic in the
presence of a renal allograft or when combined with a liver allograft from the same
donor strain ( 712 ). This last circumstance accords with the report from Tzakis et al,
in that 8 of 9 patients received at least some islets obtained from the pancreas of the
liver donor (711 ).
Thus, islet transplantation may have the potential of restoring normal or nearly-normal
glucose homeostasis in the IDDM patient. In comparison with vascularised pancreas
transplantation, this treatment could be applied early in the course of diabetes when
diabetic micro and macroangiopathy may still be modified. Steady progress has been
made in the techniques of islet isolation, and improvements continue to be made
( 701,704 ), bringing the goal of successful clinical islet transplantation closer.
However, immunological problems such as rejection and autoimmune destruction of
the islet graft necessitate the need for more effective immunomodulation protocols for
human islets, such that diabetic patients do not face a lifetime on
immunosuppressants. A potential method of circumventing this latter problem
involves immunoisolation of the islets in a bioartificial pancreas.
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17 THE BIOARTIFICIAL PANCREAS
The ultimate goal of islet transplantation is to treat diabetic patients without
generalised immunosuppression and early enough in the course of IDDM to prevent
or retard the development of complications associated with the disease. The
bioartificial pancreas offers a distinct advantage in this respect. The principle of this
system involves immunoisolation of non-syngeneic islet tissue, thereby allowing their
transplantation into non-immunosuppressed recipients. Immunoisolation systems have
been conceived that separate islets from the host by an artificial membrane that is
permeable to low molecular weight substances such as glucose, insulin, electrolytes,
oxygen and bioactive secretory products, but not to immunoglobulins and other
inflammatory cells ( 713,714 ). Additionally, these systems offer a solution to the
problem of human islet procurement by permitting the use of xenogeneic islets
isolated from animal pancreases.
1.7.1. TYPES OF BIOARTIFICIAL PANCREAS
Extravascular systems include islets placed inside diffusion chambers, sealed hollow
fibres or microcapsules, all of which may be implanted inside the peritoneal cavity of
the recipient. In vascular devices, the islets can be distributed in a closed
compartment surrounding a semipermeable membrane, and the device implanted as a
shunt in the vascular system. All devices must fulfil certain requirements including the
ability of the system to respond to a glucose load by increasing insulin production,
thereby correcting diabetes, and the efficiency of the membrane to provide
immunoprotection for the islets, so that they survive and remain functional in vivo. In
addition, when considering human implantation of a bioartificial pancreas, size, safety
and biocompatibility are important limiting factors.
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1.7.1.1. DIFFUSION CHAMBERS
Diffusion chambers consist of a ring separating two pieces ofMillipore filter, forming
a chamber in which islets are placed. Early studies by Gates and Lazarus ( 715 )
investigated the use of this system, seeded with rabbit neonatal pancreas, to reverse
diabetes after implantation into STZ-diabetic rats. Blood glucose, plasma insulin and
oral glucose tolerance were all normalised. Upon their removal 6 weeks after
implantation, all animals returned to a state of hyperglycaemia, and the neonatal
pancreatic tissue from within the recovered chambers was shown to secrete insulin,
glucagon and pancreatic polypeptide in vitro. More recently, Ohgawara et al ( 716 )
reported that allogeneic islets encapsulated within a Millipore chamber, consisting of
two nucleopore membranes of pore size 0.6 pm sealed with an O-ring, normalised
plasma glucose for up to 3 months after implantation into STZ-diabetic mice.
This approach was reassessed in studies investigating the in vitro kinetics of glucose
and insulin release from chambers using different membrane materials ( 717 ). The
diffusion of insulin from chambers of different chemical composition, but similar pore
size, differed considerably. In contrast, variation of membrane composition appeared
to have little effect on the diffusion of glucose, which was much faster than that of
insulin due to the difference in their molecular size. Pore size did not appear to
produce significant differences in the rates of insulin or glucose diffusion when
membranes of similar chemical composition were used to construct chambers of
different porosity. Additionally, it was noted that even with the best membranes, the
half-times for transit of glucose into the chambers ( 14 minutes ), and of insulin out
( 54 minutes ) were relatively long, possibly due to the large dead volume inside the
chamber. Thus, although islets transplanted inside diffusion chambers may maintain
an adequate long-term insulin output, they are unlikely to maintain accurate
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minute-by-minute regulation of blood glucose concentration. Indeed, this group
( 718 ) further described that 1100-1400 pancreatic islets enclosed in polycarbonate
diffusion chambers failed to reverse diabetes after i.p. transplantation into syngeneic
STZ-diabetic rats. Upon recovery at the end of the 12 week study, chambers were
found to be overgrown with a fibrous capsule comprising of fibroblasts 10-15 cells
thick. Furthermore, viable islet tissue was not recovered, although this was not solely
due to fibrosis reducing the permeability of the chambers, as viable islets were also
not retrieved from freshly implanted devices. However, Theodorou et al ( 719 )
demonstrated that diffusion chambers were at least effective in preventing contact of
the graft with the inflammatory cells responsible for initiating immune responses, since
1200-1500 allogeneic rat islets encapsulated in polycarbonate membrane in chambers
of 0.45 pm pore size and implanted into STZ-diabetic rats produced no detectable
anti-islet antibodies in the recipients.
More recently, Lanza et al ( 720,721 ) described a series of experiments that use
wider-bore tubular membrane diffusion chambers with an internal diameter of
1.7-4.8 mm. Amicon XM-50 membranes used in these studies had a smooth outer
skin and a nominal cutoff of 50-80 kD. Porcine, canine and bovine islets placed
within these chambers restored normoglycaemia in STZ-diabetic rats for >150 days
without immunosuppression ( 720 ). Only minimal tissue reactivity was observed, and
the external membrane surfaces were generally free of fibrotic overgrowth, exhibiting
only occasional host cell adherence. Encapsulated canine xenografts implanted in
spontaneously diabetic BBAV rats were equally successful, resulting in fasting
normoglycaemia for >1 month in all animals ( 721 ). IVGTT K values, i.e. the decline
in blood glucose levels ( %/min ), improved 10 days after implantation in BBAV rats
and after 1 month in STZ-diabetic rats. Both light and electron microscopy of
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long-term functioning grafts revealed well preserved islets, with hormone-producing
a-, p- and 8- cells.
In conclusion, wider-bore XM membranes have solved many of the early problems
associated with diffusion chambers, including fibrosis, maintaining viability of the
islets within the chamber, abscess formation and adhesion of host cells ( 717,722 ).
Results from preliminary experiments in totally pancreatectomised, severely diabetic
dogs, i.e large animal models more closely resembling human diabetes, indicate that
canine islet implants can provide long-term correction of hyperglycaemia without the
use of immunosuppressive drugs ( 723 ). Insulin independence has been achieved for
>10 weeks in dogs with preimplantation insulin requirements of >38 U/day. Little or
no fibrosis has been observed for periods as long as 30 weeks.
In view of these encouraging results, other unsolved issues that are crucial to the
clinical success of diffusion chambers must be addressed, including membrane
breakage and further improvements in glycaemic control.
Many studies involving diffusion chambers fail because, under stress, chambers can
bend leading to fracture of their membrane walls and subsequent destruction of
encapsulated islet tissue. An acute and/or chronic inflammatory response ensues,
possibly caused by the broken membranes themselves or by the release of islet tissue
from the ruptured chambers. A modest increase in the membrane wall thickness or a
decrease in chamber length will produce a stronger chamber and possibly resolve this
problem.
Lanza et al ( 724 ) observed a 4-fold average increase in insulin secretion over
baseline levels upon perifusion of encapsulated canine islets with high-glucose
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medium, and the insulin concentration in the perifusate increased after a delay of only
7 minutes. This increase in insulin delivery is comparable to the lag time observed
using an artificial pancreas in humans, and will thus avoid overexcursion of
postprandial blood glucose concentration ( 725 ). More recently, wider-bore
chambers were implanted i.p. into pancreatectomised dogs ( 723 ) and the responses
to i.v. and oral glucose determined. A progressive deterioration of blood glucose
control was observed, possibly reflecting membrane chamber breakage or inadequate
secretory capacity secondary to a loss of islet cell viability and/or insulin secretory
function. In addition, all immunoisolated islets lacking intimate vascular access must
be supplied with oxygen and nutrients by diffusion from the nearest blood vessels. In
wider-bore membrane chambers, the problem of cell death or dysfunction as a result
of oxygen and nutrient supply is likely to be more severe.
1.7.1.2. SEALED HOLLOW FIBRES
In this bioartificial pancreas, islet tissue is placed inside semi-permeable hollow fibres,
and the ends sealed prior to implantation. Archer et al ( 726 ) initially evaluated the
efficacy of implanted hollow fibres ( 50 kD ) containing cultured xenogeneic mouse or
inbred isogeneic hamster islets in the reversal of STZ-diabetes in the Chinese hamster.
Both islet types returned recipients to a state of normoglycaemia for 46.8 and
52.3 days in xenografted and isografted animals respectively. A second transplant
using a larger number of islets after the reappearance of the diabetic state also resulted
in long-term normoglycaemia ( 142 and 230 days respectively ), confirming the
absence of immune responsiveness to the xenogeneic tissue. However, a fibrous
envelope was observed around grafts upon recovery, 3-6 months after implantation.
This fibrotic layer is thought to play a critical role in determining the functional
capacity of the graft.
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Altman et al ( 727 ) subsequently reported that permselective tubular Amicon XM-50
hollow fibres ( 1 mm internal diameter ) seeded with human insulinoma fragments
normalised non-fasting plasma glucose and insulin levels in 50% of STZ-diabetic rats
for up to 1 year, when implanted i.p. These animals showed a comparable weight
gain over a 12 month period as control rats. Removal of the hollow fibres led to
recurrence of hyperglycaemia, thus demonstrating that the encapsulated
insulin-secreting tissue was responsible for the long-term correction of diabetes in
these animals. Histological analysis of recovered implants revealed a fibrous tissue
layer surrounding the membranes. However, insulinoma tissue retrieved from fibres
was shown to be functionally active by electron microscopy studies, and in one case,
by perifusion studies after removal of the hollow fibre at 6 weeks. In addition,
cataract development and diabetic glomerulopathy were completely prevented in
successfully grafted animals ( 728 ). This group also reported the positive effect of
implanting a hollow fibre seeded with human islets in NOD mice ( 729 ).
50% of recipients achieved complete and long-term ( >3 months ) correction of
hyperglycaemia. Moreover, splenocytes isolated from normoglycaemic transplanted
NOD mice were able to transfer diabetes upon injection into irradiated non-diabetic
NOD males. This finding suggests that the immune process is still active in these
mice, thus reinforcing the fact that hollow fibres can protect the graft not only against
immune rejection, but also against the diabetogenic autoimmune mechanisms.
Icard et al ( 730 ) extended these studies to diabetic and non-diabetic pigs. The same
type of fibre was observed to elicit an inflammatory pericapsular response when
implanted i.p. or in various other sites, including the area surrounding the splenic vein,
the epiploic chambers in the omentum, the external wall of the stomach and the
abdominal muscles. Implantation sites possessing a portal drainage showed a milder
fibrotic reaction than the other sites studied. The tissue reaction was generally more
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intense, though qualitatively similar to that seen in the rat, except for lymphoid
clusters with giant and pseudoepithelioid cells that were observed only in pigs. The
reaction consisted of several layers ( <50 gm in the peritoneum to >100 pm in the
abdominal muscles ) of fibroblasts and collagen with polymorphonuclear leukocytes,
macrophages, histiocytes and small lymphocytes. The fenestrated outer wall of the
tubular membrane was always infiltrated by collagen, fibroblasts and macrophages.
Despite this intense fibrosis observed in the pig, metabolic success of
immunoprotected grafts was obtained, stressing the importance of the quality of the
grafted tissue.
Zekorn et al ( 731 ) demonstrated the importance of the chemical nature and
molecular cut-off of the hollow fibre membrane with respect to the insulin diffusion
rate. Furthermore, this group ( 732,733 ) failed to correct diabetes in STZ-diabetic
mice and rats on a long-term basis using several different types of hollow fibre for the
macroencapsulation of islets, including Amicon XM-50 which had successfully been
used by Altman et al ( 727 ) to completely reverse the STZ-diabetic state in rats. In
the former studies, a correction of diabetes lasting only 3-4 days was observed. These
different results may have been due to the use of different insulin-producing tissues
seeded in the hollow fibre. Zekorn et al ( 732 ) also described the influence of the
hollow fibre membrane surface on the tissue reaction of the host : membranes with a
cavernous surface induced the formation of a thin fibrotic layer and allowed an inward
spreading of capillaries and tissue into the interspaces of the wall structure, which
might have a beneficial effect on islet survival and function. In contrast, a thicker
fibrotic layer was observed around fibres with a smooth surface ( 734 ). Again, the
protective effect provided by the membrane against the cytotoxic effect on islets of
IL-ip was demonstrated ( 735 ).
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1.7.1.3. MICROENCAPSULATED ISLETS
Another possible approach to avoid rejection in islet transplantation studies is the
microencapsulation of isolated pancreatic islets in a biocompatible and semipermeable
membrane.
Evidence that the membrane provides efficient immunoprotection for the encapsulated
islet tissue was demonstrated by Darquy and Reach ( 736 ) who assessed the
immunoisolation of rat insulinoma RINm5F cells by microencapsulation using a
chromium cytotoxicity test. Significant 51 chromium release was observed when
free ( non-encapsulated ) islets were incubated with complement and either the serum
of a rabbit immunised with RINm5F cells or the sera of two recently diagnosed IDDM
patients. This effect was not observed when islets were encapsulated demonstrating
successful immunoisolation from anti-islet complement-fixing cytotoxic antibodies by
microencapsulation. Soon-Shiong et al ( 737 ) further demonstrated the efficacy of
the microcapsule in protecting target cells against specific cell-mediated destruction
involving cytotoxic T lymphocytes, and non-specific killing by NK cells and NK
cytotoxic factor. Again using the 51 chromium-release assay, significant cell lysis was
observed when pancreatic and tumour cell targets were incubated with free effector
cells, or with NK effector cells co-encapsulated with NK-sensitive target cells via the
release of NK cytotoxic factors. This effect was not observed with encapsulated
effector cells alone.
Lim and Sun ( 738 ) first reported the transplantation of microencapsulated islets into
the peritoneal cavity of chemically-induced diabetic animals to correct the diabetic
state. Basically, isolated rat pancreatic islets were suspended in a sodium alginate
solution and extruded through a needle in contact with an air flow, thus generating
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microcapsules containing islets. Capsules dropped into a calcium chloride solution
causing alginate to gel and form calcium-alginate microbeads. The negatively charged
gel capsules were successively coated with the positively charged amino acid
poly-L-lysine, followed by an outer layer of polyethyleneimine to mask the
bioincompatible poly-L-lysine. Finally, the islets were incubated in sodium citrate
buffer and the unbound alginate within the capsule was liquified by removal of the
calcium ions.
The viability of the islets after microencapsulation was determined in vitro in
perifiision experiments. Insulin secretion from microencapsulated islets was
comparable to free ( unencapsulated ) islets, and upon raising the glucose
concentration from 2.8 to 16.6 mmol/1 there was a biphasic insulin response from
both groups of islets. However, a delayed response in insulin secretion was reported
in the microencapsulated islets, and this was attributed to the time required for the
passage of insulin across the capsular membrane into the medium. The increased
secretion of insulin in response to elevated glucose concentrations clearly
demonstrated that the viability and function of the islets were retained throughout the
process of microencapsulation. Furthermore, microencapsulated islets remained
morphologically and functionally intact, and had a normal degree of P-cell granulation
when cultured for up to 13 weeks at 37°C. Using immunoperoxidase staining the
presence and location of the four pancreatic hormones were also found to be normal
( 738 ).
This group also demonstrated that free islet allografts implanted i.p. into STZ-diabetic
rats only survived for 6-8 days as expected, whereas recipients of microencapsulated
islets were normoglycaemic for almost 3 weeks. The symptoms of diabetes, including
polyuria and polydipsia, were markedly reduced during the normoglycaemic period.
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The failure of the encapsulated islets was attributed to an inflammatory response
induced by the bioincompatibility of polyethyleneimine, and not to allograft rejection.
In two similar studies ( 739,740 ), multiple i.p. transplants of approximately 3000
islets encapsulated in alginate-poly-L-lysine-polyethyleneimine capsules were injected
into STZ-diabetic rats. Initial transplants lowered blood glucose concentrations to
control values, but after 20 days the animals returned to a diabetic state. A second
transplant of microencapsulated islets again lowered the blood glucose to within the
normal range and this pattern was repeated until the animals were killed 90 days after
the initial islet transplants. A control group of STZ-diabetic rats received no
transplants or transplants of empty capsules and had blood glucose levels
>19.4 mmol/1 throughout the study. The body weights of the control STZ-diabetic
rats did not change significantly over the period of study and eye cataracts developed
within 12 weeks of diabetes onset. In contrast, the two animals receiving multiple
islet transplants increased in body weight and remained cataract free. Upon sacrifice,
histological studies revealed that capsular membranes were completely surrounded by
giant cells and fibrous tissue whether they contained islets or not. No intact
microcapsules or viable islets were recovered from the recipients and failure of the
microencapsulated islets was again attributed to the poor biocompatibility of the outer
polyethyleneimine layer.
Subsequently, Sun et al ( 739 ) modified the composition of the microcapsule
membrane by replacing the outer polyethyleneimine coating with a more
biocompatible alginate layer. The thickness of the poly-L-lysine layer was also
increased in order to strengthen the capsule. Untreated STZ-diabetic control rats
given single injections of free islets were normoglycaemic for less than 10 days. In
contrast, a single transplant of 4500 modified islet-containing capsules restored
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normoglycaemia in all recipients within 2 days. This state persisted for up to
10 months, demonstrating the immunoprotective properties of the
alginate-poly-L-lysine-alginate ( APA ) membrane. Good control of diabetes was
observed during the normoglycaemic period, and recipients steadily gained weight,
excreted normal volumes of urine and showed no development of eye cataracts. A
second transplant of 5000 encapsulated islets upon regression to the diabetic state
again reversed diabetes, and 80% of recipients remained normoglycaemic for a
significantly longer period than was observed after the first transplant, demonstrating
that simple allograft rejection was not the cause of graft failure. 50% of free capsules
recovered from the abdominal cavity were found to be intact with surfaces free of cell
attachment, and contained viable islets which secreted low levels of insulin in vitro in
response to a glucose challenge. Remaining capsules also appeared intact but had
fibroblast-like cells several layers thick on their external surfaces. Electron
microscopic studies revealed essentially smooth capsule membranes and the thickness
of the wet wall suggested that the capsule wall was a hydrogel containing 90% water.
Hydrogels are good biocompatible materials which reduce frictional irritation to
surrounding tissues and cause minimal protein interaction with the aqueous biological
environment thereby contributing to their biocompatibility.
The variation observed in the life span of the individual transplants is probably due to
the variable number of functioning P-cells. If layers of fibroblast-like cells build up on
the surface of capsules, the rate of diffusion of nutrients, glucose and insulin across
the capsule membrane would be slowed and death of some islets may result. Upon
transplant failure, the number of surviving P-cells is insufficient to maintain glucose
homeostasis but may prolong the life span of a subsequent transplant by increasing the
total number of functional P-cells.
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Cole et al ( 741 ) looked at the metabolic effects, namely intermediary metabolites,
diurnal blood glucose and HbAj, of allogeneic microencapsulated islets implanted
into the peritoneal cavity of STZ-diabetic Wistar rats. Transplantation of
approximately 3000 microencapsulated islets normalised blood glucose concentrations
for 4 weeks, before a return to hyperglycaemia at 6 weeks. Blood concentrations of
the ketone 3-hydroxybutyrate was also corrected during the 4 weeks of
normoglycaemia, showing that the grafts were effective in reversing ketosis normally
associated with uncontrolled hyperglycaemia in IDDM. Both these metabolic
parameters remained abnormally elevated in control STZ-diabetic animals implanted
with empty microcapsules. No differences in lactate, alanine or glycerol
concentrations were observed between the two groups. HbAj as an indirect measure
of long-term glycaemic control was lower, but not significantly so, in transplanted
animals compared with control diabetic animals, and did not return to normal levels.
A gradual increase in HbAj values was observed in both groups with increasing
duration of poorly controlled diabetes. Transplanted animals also showed a marked
variation in blood glucose over a 24 hour period, with lower values during daylight
hours and nocturnal peaks during the animals normal feeding times. This observed
hyperglycaemia probably reflected poor carbohydrate tolerance as suggested by
Fritschy et al ( 742 ). This group confirmed that normoglycaemia could be achieved
after transplantation of microencapsulated rat islet allografts into STZ-diabetic
recipients for up to 4 months, in the absence of immunosuppressive therapy. Body
weight and weight gain were normalized as was the volume of urine excreted.
However, despite persisting normoglycaemia, the kinetic responses to oral and i.v.
glucose challenge were abnormal. The low insulin increments during glucose
tolerance testing seemed to suggest that the observed non-fasting normoglycaemia
was achieved by a basal release of insulin from the encapsulated islet graft. However,
glycaemic stimulation ofmicroencapsulated islets has previously been shown to result
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in a rapid and significant insulin response when tested in vitro ( 743 ). Other factors
possibly explaining the lack of insulin response by microencapsulated islets to blood
glucose elevation after transplantation include the large size of the microcapsules and
the total volume of the encapsulated islet tissue implanted, and a gradual decrease in
graft viability due to the occurrence of fibrotic overgrowth. Thus, microencapsulated
islets grafts did not achieve normal metabolic homeostasis in the chemically-induced
diabetic rat despite an amelioration of the diabetic state.
The effect of the capsule size on insulin release by microencapsulated rat islets in
response to glucose in vitro was further investigated by Chicheportiche and Reach
( 744 ). APA capsules were found to range from 300-800 pm in diameter and two
groups ( n = 10 ) were used for static incubation studies according to their size.
Large ( 650 pm ) or small ( 350 pm ) microencapsulated islets were cultured in
medium containing either 5.5 mmol/1 glucose ( basal medium ) or 16.5 mmol/1 glucose
and 5.5 mmol/1 theophylline ( stimulatory medium ). The insulin concentration of
basal or stimulatory medium bathing small capsules rose significantly from the fifth
minute onward, whereas the increase in insulin concentration of basal and stimulatory
medium bathing large capsules was not significant. Two hypotheses were suggested
to explain the absence of a significant insulin response to stimulatory glucose
observed in large capsules. Firstly, possibilities for exchange across the microcapsule
membrane decrease as the capsule diameter increases, and secondly, islets contained
in small or large capsules are of similar size and will secrete similar amounts of insulin
in response to glucose. Thus, intracapsular insulin concentration will be much smaller
in large microcapsules, since the secreted insulin will be diluted in a volume
approximately 8-fold larger. As the driving force for insulin diffusion is the difference
in insulin concentration across the membrane, a slower insulin release from the large
microcapsules would be expected. In agreement with this hypothesis is the finding
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that the magnitude of insulin secretion by free islets in response to glucose was, under
similar conditions, 7-fold greater. The volume of the microcapsule has therefore been
shown to be an essential parameter in the kinetics of insulin secretion in response to
glucose by microencapsulated islets.
Fritschy et al ( 743 ) also observed a very poor secretion of insulin by freshly
microencapsulated islets in response to glucose stimulation, and the glucose-induced
insulin secretion of free islets was 10-fold greater. This observation could not be
explained by inadequate permeability of the capsule because insulin release was also
severely reduced when islets were subjected to the encapsulation procedure but
without the membrane-forming poly-L-lysine step. Therefore, islets were tested
in vitro after each step of the encapsulation procedure, as originally described by Lim
and Sun ( 738 ). Insulin release was severely reduced after prolonged suspension of
islets in saline or treatment with citrate. Insulin release improved significantly when
the saline and citrate steps were replaced by calcium-free Krebs-Ringer bicarbonate
buffer and 1 mmol/1 EGTA respectively, both with and without complete
encapsulation. Interestingly, the capsule membrane as such was found to have no
influence on glucose and insulin diffusion, as suggested by Chicheportiche and Reach
( 744 ).
Recently, Zekorn et al ( 745 ) cross-linked alginate with barium cations to produce a
matrix which reportedly was more stable than calcium-alginate ( 746 ). 80% of
STZ-diabetic mice xenotransplanted with 800 barium-alginate encapsulated rat islets
i.p. achieved post-prandial normoglycaemia for the duration of the experiment
( 28 days ). Upon retrieval, barium-alginate beads were surrounded by a thin layer of
fibrotic tissue. Siebers et al ( 747 ) employed these novel barium-alginate capsules to
assess the amount of free and microencapsulated syngeneic islets required to correct
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STZ-diabetes in the rat. 3000 free islets transplanted i.p. failed to normalize
non-fasting blood glucose levels unless the recipient received a second transplant of
3000 islets. In contrast, transplantation of only 1200-1500 islets beneath the kidney
capsule regularly resulted in long term normoglycaemia within 10 days of
transplantation. After graft removal by nephrectomy the diabetic state was
re-established. These findings are in agreement with the work ofWoehrle et al ( 748 )
who described the peritoneal cavity as an inferior transplantation site compared with
the kidney capsule. However, in the rat model the peritoneal cavity is the only
transplantation site that is capable of bearing the volume of microencapsulated islets,
although in terms of nutrition and oxygenation its unsuitability is well recognised
( 749 ). Nonetheless, 3000 encapsulated islets were able to restore long term
normoglycaemia within 10 days of i.p. transplantation in the rat. Empty microbeads
did not alter the diabetic state of recipients. The need for an increased free islet mass
in these transplantation studies may be explained when considering oxygen supply and
cytokine action. Oxygen concentration in the peritoneal cavity is low and free or
microencapsulated islets rely on diffusional transport for their oxygenation which in
turn is dependent on the membrane surface of the capsule, the diffusion distance, and
the diffusion coefficient of the medium. As the barium-alginate gel contains >98%
water, the membrane does not represent a significant barrier for oxygen diffusion
although the diffusion distance is enlarged in the case of the microcapsules. In
addition, the individual microencapsulated islets act as seperate oxygen consuming
units which decreases competition for a deficient substrate and moreover, the contact
surface is enlarged approximately 20-fold. Cytokines released during any
inflammatory process have been shown to be potent inhibitors of islet function and,
depending on the type and concentration, can be cytotoxic to islet cells ( 349-351 ).
Microencapsulation might protect the islets against such attack.
180
The transplantation of microencapsulated islets into spontaneously diabetic BB rats
has been less successful than transplantation into chemically-induced diabetic rats.
Only one group has achieved long-term normoglycaemia following implantation of
microencapsulated islets ( 750 ). Transplantation of 4000-5000 encapsulated islets
i.p. reversed the diabetic state of all recipients within 3 days and normoglycaemia was
maintained for 190 days without immunosuppression. Normal body weight and urine
volumes were maintained during this period and no cataracts were detected in the
transplant recipients. Removal of the capsules in one recipient 67 days after
transplantation resulted in recurrent hyperglycaemia within 2 days. Approximately
90% of the implanted capsules were recovered and of these, 70% were free-floating,
free of cell overgrowth and contained viable islets. The remaining 30% of the
capsules had cell overgrowth on their membranes. A second transplant of
microencapsulated islets was required by some animals after the reappearence of
hyperglycaemia and again a state of normoglycaemia was achieved. Control rats
receiving transplants of free islets were normoglycaemic for less than 2 weeks,
demonstrating that microencapsulation of islets not only protected allografted islets
from graft rejection, but also from autoimmune destruction.
In contrast to this work, Gotfredsen et al ( 751 ) reported that diabetic DP-BB rats
receiving 5000 MHC-compatible DR-BB rat islets encapsulated in an APA membrane
resulted in state of normoglycaemic with a mean duration of only 54 days. Upon
recovery from the peritoneal cavity after graft failure, most capsules were shown to be
covered by a layer of histocytes and occasional foreign body giant cells, surrounded
by concentric layers of myofibroblasts with an abundance of collagen fibres,
suggesting a non-immunological mediated foreign body reaction. Islets within these
capsules were degranulated and vacuolized, although there was no evidence of
lymphocytic invasion of the capsules or infiltration of the islets. Empty capsules
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recovered after 15 and 60 days were also overgrown to a similar extent suggesting
that bioincompatibility of capsular materials is responsible for the inflammatory
response rather than molecules secreted by the islets through the capsule membrane.
As expected, animals receiving an i.p. transplant of 5000 free islets reverted to the
diabetic state after a mean of 17 days.
Cole et al ( 752 ) confirmed these findings and also observed a marked foreign-body
reaction around microcapsules implanted i.p. in both diabetic and non-diabetic DP-BB
rats. In contrast, little or no reaction was observed around capsules recovered from
the STZ-diabetic WF rat. The finding that biocompatibility of APA microcapsules
from the same production run was good in WF rats but poor in BB/E rats suggests
that the inflammatory response observed cannot be attributed to variations in
preparation methods and/or materials used in different laboratories. Implantation
under the kidney capsule, a proposed immunologically privileged site, afforded the
microcapsules no additional protection.
Various biomedical polymers have been shown to activate macrophages involved in
foreign-body reactions which stimulate IL-ip production, a known P-cell toxin
( 753 ). The role of cytokines in the failure of microencapsulated islet grafts in the
BB/E rat has therefore been investigated ( 752 ). Reduced secretion of insulin and
progressive islet cell damage were demonstrated when microencapsulated islets were
incubated with IL-lp in vitro for 9 days, showing that the APA membrane does not
exclude cytokines. It is conceivable that the activation ofmacrophages as part of the
foreign-body response to the capsules leads to the release and subsequent penetration
of IL-ip across the membrane resulting in islet tissue damage and graft failure.
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Wijsman et al ( 754 ) also reported that 5000 allogeneic islets encapsulated in APA
membranes and transplanted i.p. into diabetic BBAV rats resulted in graft failure
within 2 weeks of transplantation in 68% of recipients. Again, graft failure was
associated with a dense pericapsular infiltrate that starved the islets of nutrients and
oxygen, resulting in islet necrosis. Approximately 5% of empty capsules recovered
23 days after transplantation showed a capsular infiltrate, and this increased to 60%
by day 65, strengthening the view that the APA membrane is not biocompatible.
50% of the capsules recovered were free-floating in the peritoneum, the rest were
clumped and adhered to the liver and stomach or surrounded by fibrous sacs
associated with omentum or fat within the peritoneum. Again, the pericapsular
infiltrate was composed of fibroblasts and granulomas with macrophages immediately
adjacent to the membrane, 10-15 cell layers deep. Immunohistologically, islets in
capsules free of infiltrate were found to be morphologically normal, viable and
contained 62% insulin positive cells. Duration of the graft function was reported to
be inversely proportional to the density of the capsular infiltrate. Immunosuppression
of diabetic BB recipients receiving 5000 allogeneic microencapsulated islets with CsA
or dexamethasone both significantly decreased the percentage of capsules surrounded
by infiltrate and the amount of capsular infiltrate ( although no effect on the infiltrate
cell population was reported ). The number and function of viable encapsulated islets
was also increased resulting in the prolonged, but not indefinite, function of the graft
( 754 ). Indomethacin had no effect on graft survival unless used in conjunction with
CsA. Mazaheri et al ( 755 ) reported similar findings, and additionally observed
capsular overgrowth decreased with an increased microcapsule survival. This is in
agreement with the observed increase in pericapsular infiltrate upon implantation of
microcapsules into newly diagnosed diabetic animals, as opposed to recipients with
established diabetes ( >5 months ), which show a less vigorous autoimmune response.
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The stimulus for the pericapsular infiltration ofmicroencapsulated islets implanted i.p.
into the spontaneously diabetic DP-BB rat appears to be the bioincompatibility of the
outer alginate layer. Wijsman et al ( 754 ) in the above study reported that, more
specifically, it was alginate with a high mannuronic acid content that initiated the
reaction, and its removal resulted in a decrease in the pericapsular infiltrate. Clayton
et al ( 756 ) encapsulated rat islets in high mannuronic acid alginate and subsequently
coated these capsules with either poly-L-lysine alone, poly-L-lysine high mannuronic
acid alginate or poly-L-lysine and an outer layer of high guluronic acid alginate. All
capsules responded to an in vitro glucose challenge in a similar manner. Results from
the implantation ofmicroencapsulated islets under the renal capsule of non-diabetic or
diabetic DP-BB rats suggested that infiltration was strain-dependent. The most
severe reaction was observed in diabetic BB rats, and this response was relatively
unaffected by the microcapsule composition. The infiltration reaction to the capsules
was also found to be strain-dependent after i.p. implantation. In addition, the reaction
was most severe at this site and was affected by capsule composition. An outer layer
of poly-L-lysine alone provoked the strongest immune response, and poly-L-lysine
subsequently covered by an outer layer of high mannuronic acid alginate resulted in
the weakest response. The finding that high mannuronic acid alginate capsules
minimise pericapsular fibrosis is in direct contrast to the findings of Wijsman et al
( 754 ). Soon-Shiong et al ( 757 ) transplanted empty capsules composed of alginate
with either high or low mannuronic acid content into the peritoneal cavity of normal
Lewis rats and retrieved them 2-180 days post-transplantation. Low mannuronic acid
alginate capsules were largely free of cellular overgrowth, whereas 90% of high
mannuronic acid capsules were associated with cellular and fibroblast overgrowth
21 days after implantation. Soluble alginate and alginate gels composed of
mannuronic acid blocks have been shown to be potent stimulators of IL-1 and TNF-a
production, whereas incubation of monocytes with alginate made from guluronic acid
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blocks resulted in only a minimal release of cytokines. In addition, Wolters et al
( 758 ) reported that empty capsules prepared from purified alginate of medium
guluronic acid content were completely free of overgrowth when recovered 4 weeks
after implantation in the omentum. Soon-Shiong therefore proposed that commercial
alginate containing high mannuronic acid activates the macrophages involved in
inflammatory responses in vivo, resulting in cytokine production, fibroblast
proliferation and eventual overgrowth of the microcapsule. Subsequently,
Soon-Shiong formulated microcapsules with purified alginate containing high
guluronic acid that had improved biocompatibility ( 757 ), mechanical stability, and
adequate porosity. These microcapsules were shown to reverse diabetes after i.p.
transplantation in the large animal model ( 759 ), with long-term ( up to 2 years ) islet
function after transplantation in spontaneous diabetic dogs even after cessation of all
immunosuppression ( 760 ), suggesting that biocompatible APA microcapsules can be
prepared for use in islet transplantation studies.
Soon-Shiong et al ( 761 ) recently obtained regulatory and institutional approval for
the first human trials using these improved islet-containing microcapsules. Human
islets, isolated by standard collagenase digestion from 8 cadaveric donor pancreases,
were encapsulated and cultured for 22 days prior to transplantation into the peritoneal
space of the patient. The islets were 85% pure and 9957/kg body weight
encapsulated islets were transplanted. The patient had established IDDM ( 30 years ),
and suffered from severe long-term complications. End-stage renal failure resulted in
a living-related kidney transplantation, thus the patient was on low-dose
immunosuppressive maintenance prior to and following transplantation of
encapsulated islets. A supplemental dose of 5000 encapsulated islets/kg was given
6 months after the initial dose of approximately 10 000 islets/kg, as part of a
dose-escalation study.
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At the time of publishing ( 9 month post-transplant ), the patient had no adverse
effects and maintained a stable daily mean blood glucose concentration, even after
discontinuation of exogenous insulin in the ninth month. Basal C-peptide secretion
increased with the drop in exogenous insulin requirements, confirming sustained
insulin secretion from the encapsulated islets. Proinsulin levels during insulin
independence were high, suggesting that 15 000 islets/kg was sub-clinical, and that
islets were being stressed to maintain insulin independence. HbAl values decreased
from 9.3% pre-transplant to 7.6% at 4 months and 7.9% at 9 months. In addition,
lower extremity peripheral neuropathy and axonal nerve function improved
post-transplantation, and the patient reported increased energy, an ability to walk
further, and a general feeling of improved health.
Although immunoprotection of capsules under conditions of low-dose
immunosuppression has been demonstrated, further trials on non-immunosuppressed
patients are needed to determine the immunoprotection of the capsules without
immunosuppression, as well as establish the optimum human i.p. dose of encapsulated
islets required to achieve insulin independence.
The apparent success of encapsulated islets in achieving insulin independence in the
IDDM patient renews concerns about difficulties in obtaining sufficient supplies of
donor human pancreases. In the above study, 8 donor pancreases were required for
the treatment of one patient. Alternative sources of pancreas tissue, i.e. from larger
animals, might have to be considered.
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1.7.1.4. MICROENCAPSULATED ISLET XENOGRAFTS
An extremely attractive feature of immunoisolation of islets by microencapsulation is
the possibility of using xenograft tissue without the need for immunosuppression of
the recipient. Early studies involved the implantation of microencapsulated islets from
a donor into a recipient of a closely related species. O'Shea and Sun ( 762 ) reported
that 1000 rat islets encapsulated in APA membranes and implanted i.p. into
non-immunosuppressed STZ-diabetic mice reversed diabetes within 3 days. Animals
remained normoglycaemic for up to 144 days with a mean xenograft survival of
80 days, and >80% of the xenografts functioned for >50 days. A second xenograft of
1000 encapsulated islets given after the failure of the initial transplant also had a
prolonged survival rate. Survival of rat islet xenografts after encapsulation in
alginate-polyornithine membranes was prolonged in STZ-diabetic mice, with a mean
duration of 39 days. This was significantly greater than for xenotransplanted free
islets which functioned for <14 days. Upon recovery, the polyornithine capsules were
more severely overgrown than the poly-L-lysine capsules, confirming that the former
capsules were less biocompatible. Graft failure could be attributed to gradual cell
death of the islet cells resulting from lack of oxygen and nutrients as the capsules
became overgrown.
Calafiore et al ( 763 ) reported that canine islets encapsulated in
alginate-poly-L-ornithine biomembranes provided a favourable microenvironment for
long-term (120 days ) in vitro culture, with maintenance of (3-cell function and a
retention of normal insulin secretory patterns. Microencapsulated human islets were
also shown to sustain normal insulin secretory kinetics for at least 28 days in
culture. Upon implantation into the peritoneal cavity of STZ-diabetic mice,
canine islet xenografts were rapidly destroyed unless microencapsulated
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in alginate-poly-L-ornithine biomembranes. These microcapsules initially afforded
protection against islet xenograft destruction, and prolonged reversal of
hyperglycaemia in all STZ-diabetic and some NOD mice was observed. However,
microcapsule properties appeared to be variable both within and between various
strains of diabetic mice, and the reversal of diabetes was more frequently observed in
STZ-diabetic, rather than spontaneously diabetic NOD mice. This difference may be
explained by differences in the quality of islet preparations, immunoreactivity of
recipients or severity and reversibility of diabetes. Upon retrieval of microcapsules
from long-term (120 days ) euglycaemic mice, islets were consistently found to
contain no viable p-cells. In contrast, P-cells were shown to be present in the native
pancreas, suggesting that the initial euglycaemia induced by the implanted
encapsulated islets allowed repair or regeneration of islets in the recipients native
pancreas. The loss of islets in vivo within microcapsules could be a result of specific
immune response to islet xenograft antigens, non-specific reaction to putative
mediators of inflammation in the area immediately surrounding the capsules or may
reflect the inability of a large mass of islet cells to remain viable in the special
microenvironment created by the capsule.
More recently, Soon-Shiong et al ( 764 ) showed prolongation of discordant islet
xenograft function in STZ-diabetic rats after microencapsulation. Encapsulated canine
and human islets were implanted i.p. and free islet grafts acted as controls. Low dose
CsA therapy was instituted in both groups, and euglycaemia was maintained for
43-123 and 42-136 days after implantation of encapsulated canine and human islets
respectively. In contrast, free islets achieved euglycaemia for <2 days.
Hamster islets encapsulated in an APA membrane were shown to secrete insulin in
response to secretagogues in short-term in vitro culture and maintain a similar level of
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insulin secretion as observed for free islets for 28 days ( 765 ). No overgrowth of
fibroblastic cells was observed inside the capsule even after 70 days of culture. When
xenotransplanted i.p. to STZ-diabetic rats, 3500 encapsulated hamster islets did not
achieve prolonged normalization of fasting plasma glucose levels of recipients,
although microcapsules recovered from a recipient 27 days after transplantation
showed some islet viability. Free islets were replaced by massive connective tissue
elements and insulin-positive (3-cells were almost undetectable 22 days after
transplantation.
Lum et al ( 766 ) investigated a novel method of encapsulation using an electrostatic
droplet generator to produce APA microcapsules of a significantly reduced size
( 250-350 pm diameter ). The smaller capsules were proposed to increase cell
viability, allow faster cell response to glucose fluctuations and greater mobility, and
reduce the volume of capsules required for transplantation, which is of paticular
importance in microencapsulated islet transplantation experiments using mice as
recipients. In an earlier study, this group reported that rat islets microencapsulated in
much larger capsules ( 700 pm diameter ) restored normoglycaemia in STZ-diabetic
mice for an average of 80 days ( 761 ). In a concurrent study, rat islets encapsulated
in small capsules and transplanted into STZ-diabetic BALB/c mice survived and
secreted insulin in recipients for up to 308 days ( 767 ). This study investigated the
transplant survival of these smaller capsules in the spontaneously diabetic NOD
mouse. In vitro, both free and encapsulated islets showed comparable responses to
glucose challenge in terms of insulin secretion, although the level of secretion from
islets encapsulated in the smaller capsules was approximately 20% lower than that
from free islets. Using these new capsules, 16 spontaneously diabetic NOD mice
received i.p. transplants of 800 encapsulated rat islets. Non-fasting plasma glucose
decreased within 2 days of implantation. At 4 to 5 months post-transplantation only
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two animals were normoglycaemic, and removal of their capsules resulted in a return
to the hyperglycaemic state. Recovered capsules remained physically intact with
enclosed islets clearly visible. Furthermore, perifusion studies showed that recovered
microencapsulated islets still secreted insulin in response to a glucose challenge,
although the amount secreted was lower than that observed for fresh free islets or
freshly encapsulated islets. It is possible that some islet cells, especially in the central
portion, became necrotic, possibly due to lack of nutrients, leading to graft failure in
the majority of recipients. In addition, there may have been a possible gradual
degeneration of some islet cells during long-term function. After a second
transplantation of microencapsulated islets, normoglycaemia was again restored
within 2 days. However, in approximately 30% of recipients, the xenografts
functioned for <3-4 months. Failure was partially attributed to improperly
constructed capsules, i.e. capsules produced using impure compounds or of an
impaired surface smoothness and shape, which could lead to a more severe capsular
overgrowth. In control mice, free rat islets remained functional for <10 days.
It is commonly accepted that the failure of transplanted microencapsulated islets is
related to a cellular reaction, particularly intense in the NOD mouse. Weber et al
( 768 ) attempted to characterize this reaction by xenografting APA microcapsules
containing dog or rat islets i.p. into STZ-diabetic and NOD mice. In addition, the
immunologic reaction to " concordant " and " discordant " donor islets could be
compared. Both microencapsulated dog and rat islets routinely normalized blood
glucose in both types of diabetic mice within 24 hours. However, all grafts were
eventually destroyed, more rapidly so in NOD mice than STZ-diabetic mice, and
microcapsules eliciting an intense cellular reaction contained no viable islets. In
prediabetic NOD mice, implantation of encapsulated dog or rat islets resulted in a
moderate cellular reaction. Interestingly, empty microcapsules elicited no cellular
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reaction in either diabetic or prediabetic NOD mice, suggesting that the reaction was
not directed against the microcapsule itself, but against a secreted product of the
xenogeneic islets within. Treatment of the recipient with GK1.5 moAb significantly
prolonged the survival of both dog and rat microencapsulated islets xenografted to the
NOD mouse. Long-term functioning grafts recovered on days 75-95 demonstrated
viable islets in capsules free of infiltrate. Flow cytometry showed undetectable CD4+
T cells in the peripheral blood of all moAb-treated NOD mice with functioning
xenografts. However, cessation of antibody treatment after 95 days resulted in
eventual graft failure in most recipients receiving microencapsulated rat or dog islets.
These results indicate that the reaction to microencapsulated xenogeneic rat or dog
islets in diabetic NOD mice is helper T cell dependent.
1.7.1.5. VASCULAR DEVICES
This type of implantable bioartificial endocrine pancreas is advantageous over
extravascular devices as continuous blood flow permits quick and direct exchange of
nutrients and oxygen between the hosts circulating blood and the transplanted islets
suspended in the extracapillary space. In addition, it should be possible to access the
cell chamber for the removal and replacement of non-functioning islets once a device
is implanted. Finally, the vascularised artificial pancreas is devised so that the artificial
capillary is enclosed by an outer casing to prevent fibroblast overgrowth on the
extracapillary surface.
Initial investigations by Chick et al ( 769 ) showed that P-cells cultured in Amicon
XM-50 semipermeable hollow fibres, consisting of a thin retentive skin surrounded by
an outer macroporous spongy layer, continued to synthesise, store and release insulin.
Furthermore, insulin release was readily modulated by altering the glucose
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concentration of the perifusion medium circulated through the lumen of the fibres.
However, the use of these small diameter fibres with an internal diameter of <1 mm is
limited because of the problems associated with clotting and/or the need for systemic
anticoagulation. The application of more non-thrombogenic and biocompatible
synthetic materials and larger diameter fibres may enhance the survival of diabetic
animals implanted with artificial vascular devices. However, the kinetics of insulin
release in response to glucose by such a system may be inappropriately slow if the
compartment housing the islets is too large ( 770 ). Alternatively, decreasing the
resistance to flow may decrease the thrombogenic risk, increase flow through the
vascular device and improve kinetics of glucose-stimulated insulin release from islets
seeded in the device (771).
Due to a drop in hydrostatic pressure, the pressure at the inlet of the fibre used in the
vascular device is greater than that in the islet compartment and an ultrafiltration flux
from the blood to the chamber occurs. Similarly, the hydrostatic pressure in the
second half of the fibre is lower than that of the islet chamber, and a backfiltration flux
from the compartment towards the bloodstream is observed ( 772 ). In order to
utilise this flux, a U-shaped bioartificial vascular device should be considered to
overcome the observed time lag in glucose-stimulated insulin release, since the
ultrafiltration-backfiltration flux crosses the islet compartment as a short circuit. The
blood channel surrounds the islet chamber, which consists of two flat membranes, and
blood circulates successively above the first membrane and then in the reverse
direction below the second membrane. Reach et al ( 773 ) introduced isolated islets
into the chamber and perfused the system with Krebs buffer containing high or low
glucose concentrations to determine the insulin release kinetics. For up to 1000 islets,
insulin release in response to glucose was linearly correlated to the number of islets
seeded in the chamber, indicating that insulin did not significantly inhibit its own
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secretion in this system. A significant rise in insulin release was observed after
3 minutes, and a maximal response was observed after 10-20 minutes. When the
glucose concentration was reduced to a sub-stimulatory level, insulin secretion
declined rapidly. The kinetics of this vascular device were therefore much more
satisfactory than those obtained with hollow fibre devices. Finally, during glucose
stimulation, the insulin concentration was found to be 4-fold higher than the
concentration present at the turning point of the blood channel, suggesting that insulin
was transferred into the perfusing medium in part by a countercurrent flux of
ultrafiltrate crossing the membranes.
Araki et al ( 774 ) demonstrated that vascular bioartificial pancreases could release
large quantities of insulin in response to glucose. Capillary devices seeded with
approximately 50 000 canine islets released up to 20 units of insulin per day when
perfused with culture medium containing 16.6 mmol/1 glucose, i.e. approximately
one-third of the daily production of insulin by an adult human pancreas. Initially the
insulin content of the perifiisate during the first 1-2 days of culture was low ( possibly
as a result of P-cell damage during the isolation procedure ), before subsequently
rising after 3-4 weeks and reaching a stable plateau after 7 weeks of perifusion.
Tze et al ( 775 ) seeded a synthetic capillary unit with approximately 1200 allogeneic
rat islets, or 3000 xenogeneic rabbit or human islets and implanted these vascular
devices into STZ-diabetic rats. Approximately 77% of the rats receiving allogeneic
islets only survived for 12-24 hours and the remaining 23% survived 1-11 days. The
diabetic rats receiving implantable devices containing rabbit islets survived for up to
4 days, whereas recipients of human islets seeded in a vascular device survived for
8 days. Immediately following implantation, plasma glucose fell to normoglycaemic
levels, and a corresponding increase in circulating insulin levels was observed in all
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recipient animals. Furthermore, the bioartificial pancreases produced a near-normal
plasma glucose and insulin response to an IVGTT, suggesting the feasibility of
achieving amelioration of diabetes with allogeneic or xenogeneic pancreatic islets
implanted as a bioartificial endocrine pancreas unit.
However, there was still a time lag in the correction of hyperglycaemia in the diabetic
recipients following implantation of the vascular device, probably due to the relatively
thick walled large-bore artificial capillary fibre used in this implantable unit.
Molecular transport depends greatly on the thickness and surface area of the barrier
and volume of the extracapillary space, therefore the delay in achievement of glucose
and insulin equilibrium between the extracapillary space and the host circulation
would result in reactive hypoglycaemia. Units must therefore be constructed with a
larger surface area, reduced extracapillary space and a thinner membrane barrier in
order to decrease the observed time lag.
More recently, an artificial pancreas device utilising a single, coiled, tubular membrane
with an internal diameter of 5-6 mm and a wall thickness of 120-140 gm, has been
investigated ( 776,777 ). An XM-50 membrane is incorporated within an acrylic
housing, and the islet chamber is created in the space between the membrane and the
housing. As the XM-50 membrane cannot be sutured, it is connected to standard
PTFE graft material of the same diameter, which extends beyond the housing, and is
used for anastomosis to the vascular system. The device was seeded with
approximately 260 000 allogeneic canine islets and implanted into pancreatectomised
dogs. In 50% of animals requiring <20 U of exogenous insulin per day pre-implant,
the daily dose of exogenous insulin was significantly reduced or eliminated. However,
even when the implant resulted in fasting normoglycaemia, the response to an oral or
i.v. glucose challenge was abnormal. Increasing the number of islets seeded in the
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vascular device to approximately 320 000 removed the need for exogenous insulin
administration for periods ranging from 1 month to >8 months, demonstrating that
these implants can be used to treat severe diabetes. However, the response to a
glucose challenge remained impaired. Upon removal, histological evaluation of the
vascular devices indicated a substantial loss of islet mass, indicating that islets in the
implanted device may need replacing. Furthermore, there was no evidence of
infiltration by immune cells, suggesting that the membrane was indeed
immunoprotective.
1.7.2. CONCLUSION
As mentioned earlier, the concept of the bioartificial pancreas is extremely attractive
and the different systems have been shown to meet the functional requirements,
including insulin secretion in response to glucose and other secretagogues, long-term
survival in an immunoprotected state, and efficiency of the artificial membrane in
protecting the islets against immune factors. However, many problems have yet to be
solved, the most important one being the biocompatibility of the foreign material used
to form the membrane. An inappropriate immune response of the host can induce a
foreign-body reaction for extravascular devices, or thrombosis of the blood channel in
the case of a vascular system. Only progress in this field will permit the bioartificial
pancreas to be used successfully for the treatment of diabetic patients. Interestingly,
the same obstacle limits the development of glucose sensors. Concerning the
microcapsules formulated in alginate high in guluronic acid by Soon-Shiong, it
remains to be seen whether the same immunoprotectivity of islets by the capsules is
observed in non-immunosuppressed patients.
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18 SOMATIC CELL GENE THERAPY IN 11)DM
1.8.1. INTRODUCTION
Gene therapy is a novel approach to overcoming the problems of insulin delivery to
the diabetic patient. A major problem of pancreatic and islet transplantation as
treatments for IDDM is the immune rejection of transplanted tissue. Even if this
problem can be overcome using immunosuppressive drugs, tissues are still destroyed
by recurrence of the autoimmune process responsible for the destruction of the native
islets. Somatic cell gene therapy could resolve these problems of tissue rejection if
cells were used from the diabetic patient.
The principle of this treatment involves the insertion of a functional gene into the
genome of a target cell such that expression of the introduced gene is expected to
have a therapeutic effect. In the case of IDDM, implanted cells will be genetically
modified to produce insulin.
1.8.2. TARGET CELLS
Human tissues used in somatic cell gene therapy at present include bone marrow, skin
and lymphocytes, all of which can easily be extracted from the body, grown and
manipulated in vitro. Upon subcutaneous reimplantion back into the patient, the
cellular products will be secreted into the systemic circulation ( 778 ). In addition,
cells could be encapsulated in a biocompatible membrane so that they could easily be
removed if any deleterious effects were observed ( 779 ) or if transfected cells die and
need replacing. Many studies have used haemopoietic stem cells in particular, as bone
marrow transplantation is a well established and successful procedure. The gene of
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interest is introduced into totipotent stem cells contained in the bone marrow, and
after autologous reinfusion, these cells have the capacity for self-renewal throughout
the lifetime of the patient. However, to have a sustained effect, the genetic correction
must occur at the level of self-renewing pluripotent stem cells so that there can be
continued production of progeny cells containing the introduced gene. These cells are
difficult to identify and purify and more research is necessary before bone marrow
gene therapy can proceed ( 780 ). Alternatively, differentiated cells can be used in
gene therapy.
1.8.3. METHODS FOR GENE TRANSFER
DNA can be introduced into target cells as a co-precipitate with calcium phosphate
(781 ) or encapsulated within liposomes ( 782 ). Alternatively, target cells can be
made permeable by electroporation ( 783 ), in which a brief electric pulse allows entry
of DNA by way of local areas of reversible membrane breakdown. However, all of
these methods suffer limitations, including damage and/or death of target cells, and
instability and low frequency of integration of DNA. Direct microinjection of DNA
using glass pipettes is more efficient than these aforementioned methods, but is limited
by the number of cells that can be microinjected over a given time and the need to
purify target cell populations.
Retrovirus vectors are more widely used in genetic engineering as they are non-toxic,
have a wide host range and infect cells with high efficiency. The virion binds to cell
surface receptors and the RNA genome is transferred into the cell where it is copied
into DNA by the virus-encoded reverse transcriptase. This DNA copy then integrates
into the host genome.
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The use of retroviruses to transfer genes into mammalian cells carries several
disadvantages and potential risks, including host cell damage by the insertion of the
vector into an essential gene, the activation of a silent proto-oncogene by introduction
ofviral promoter sequences, or the activation of latent viruses encoded by the genome
( 784 ). Improvements in retroviral vector design may eventually solve these
problems.
1.8.4. INSULIN EXPRESSION. BIOSYNTHESIS AND SECRETION
The islet P-cell is exquisitely sensitive to blood glucose levels, and rapidly adjusts
insulin secretion accordingly, thus maintaining normoglycaemia at all times. The
processes by which the p-cell achieves this degree of control are dependent upon
complex, multi-faceted intracellular signalling systems, that are currently impossible to
reproduce in a non-P-cell. However, many studies have attempted to identify the
mechanisms involved in insulin production and secretion in the hope that this
knowledge may be used to produce an alternative genetically-modified
insulin-secreting cell.
The tissue-specific regulation of insulin gene expression is dependent on promoter and
enhancer sequences located upstream of the transcription start site ( 785,786 ).
Recently cDNA sequences of insulin gene regulatory proteins have been determined
( 787-789 ), one of which specifically binds to the most important
transcriptionally-active promoter/enhancer sequence. Welsh et al ( 790 ) reported
that the insulin gene responds to glucose over long periods of time, but until the
glucose response elements within the insulin gene are further characterised, expression
of the insulin gene in transfected cells is best controlled by constitutive viral
promoters.
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The transcription of the insulin gene generates a pre-mRNA which is processed in the
nucleus. The mature preproinsulin mRNA is then transferred to the cytoplasm where
it is translated. This process represents the predominant short-term control of insulin
production in response to blood glucose ( 791 ). Insulin is then synthesised as its
larger precursor preproinsulin, which undergoes post-translational proteolysis during
its transfer through the cellular secretory apparatus ( 792,793 ). The prepeptide is
removed by a signal peptidase located on the luminal surface of the endoplasmic
reticulum. Within the endoplasmic reticulum, proinsulin folds to form the native
disulphide bonds of insulin, and is transferred via a vesicular compartment to the
Golgi apparatus. Proinsulin then leaves the golgi in immature granules which develop
into insulin storage granules ( 794 ), before being processed to insulin by
endopeptidase ( 795 ) and carboxypeptidase ( 796,797 ) action. Fibroblast and
keratinocyte cells have no endogenous prohormone-processing endopeptidases, and
therefore insulin gene transfected cells would secrete proinsulin rather than insulin.
The response of the P-cell to glucose is dependent on glucose metabolism within the
cell rather than the transport of glucose into the cell, which is not a rate-limiting step.
Evidence suggests that the enzyme glucokinase, which is involved in the first step in
glucose metabolism, serves as a glucosensor linking the metabolism of glucose to the
electrical and ionic changes associated with the secretory response of the P-cell. Both
the P-cell transporter ( Glut 2 ) ( 798 ) and glucokinase ( 799 ) have been cloned and
sequenced.
1.8.5. PRELIMINARY STUDIES
Although it may be impossible to engineer these complex control mechanisms in a
surrogate cell, it might be constructive to evaluate the clinical usefulness of what can
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be achieved with gene therapy. In a preliminary experiment, Selden et al ( 800 )
implanted a clonal fibroblast cell line expressing the human preproinsulin gene into
diabetic mice. A transient fall in blood glucose levels, which paralleled an increase in
insulin levels, was observed. Furthermore, 24 days after transplantation of the
transfected cells, normoglycaemia was restored in these animals. It should be noted
that the level of expression of the preproinsulin cDNA depends on the strength of the
promoter located upstream of the cDNA. Since there is no regulated secretory
pathway present in these cells (801 ), the expressed product will be secreted from the
cell as it is produced, at a level determined by the number of cells transplanted.
Proinsulin is approximately 8% as active as insulin in maintaining blood glucose
control in diabetic patients ( 802 ), and acts by suppressing glucose output from the
liver, with little stimulation of glucose disposal ( 803 ). The basic transfected cell
could therefore be improved by introducing a gene encoding a processing
endopeptidase along with the preproinsulin cDNA, so that proinsulin can be cleaved
to the more active insulin.
More recently, Stewart et al ( 804,805 ) transfected pituitary AtT20 cells by calcium
phosphate co-precipitation with cDNA encoding human preproinsulin. This gene is
driven by the zinc-sensitive metallothionein-1 promoter which generates an
approximately 17-fold increase in insulin levels in response to zinc ions ( 806 ). The
transfected clone, AtT20MtIns-1.4, constitutively released insulin at a rate of
approximately 4 ng/10^ cells/24 hours when cultured in medium containing 10 mmol/1
glucose, and >80% was shown to be human insulin by high pressure liquid
chromatography. However, increasing the glucose concentration of the medium did
not lead to a consequent increase in insulin secretion from these cells. In initial
studies ( 804 ), 2 x 10^ transfected cells were implanted i.p. into athymic nude mice,
and the release of insulin in vivo was evaluated using a specific human C-peptide
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assay. Human C-peptide was detected in recipient plasma after implantation, but
3 weeks after induction of diabetes with STZ, these mice became severely
hyperglycaemic, despite C-peptide concentrations of approximately 0.1 pmol/ml.
These findings indicate that a greater number of cloned cells are necessary to prevent
hyperglycaemia. In a subsequent study ( 803 ), 5 x lO^ AtT20MtIns-1.4 cells were
implanted either i.p. or subcutaneously into STZ-diabetic immunocompetent nude
( nu/nu ) mice. Plasma human C-peptide concentrations of >0.1 pmol/ml were
achieved within one day. These concentrations declined rapidly after subcutaneous
implantation, but more slowly after i.p. implantation. Addition of zinc sulphate
( 500 mg/1 ) to drinking water immediately and significantly increased human
C-peptide to >10 and >17 pmol/ml in subcutaneously and i.p. implanted mice
respectively. The response was only maintained in the latter group. Despite these
circulating levels of insulin, plasma glucose was not consistently lowered by the
implants, reflecting insulin resistance in this model. Upon removal of the
AtT20MtIns-1.4 cells on day 30, the subcutaneous implants were found to be larger
but almost entirely necrotic when compared with the i.p. implants, further
demonstrating that this peritoneal cavity favours the functional performance of
genetically engineered insulin secreting pituitary cells.
In conclusion, advances have been made towards using genetic and cellular
engineering as a potential treatment for diabetes. Indeed, somatic cells capable of
in vivo insulin secretion have been constructed. However, the secretion of insulin is
low ( insufficient to reverse STZ-diabetes in mice ) and more importantly, not
regulated by glucose. The implant therefore produces a continual background
secretion of insulin at a level determined by the number of cells implanted. Regulation
of insulin secretion in response to glucose is undoubtedly the most difficult problem to
overcome, and will probably never be engineered into a surrogate cell. It is more
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feasible to envisage the use of genetically manipulated insulin-secreting cells in
conjunction with insulin injections to attain normal blood glucose control in the
diabetic patient, with resultant effects on the complications arising from
hyperglycaemia.
19 OVERALL CONCLUSIONS
Human IDDM is a heterogenous and multifactorial disorder. Genetic factors play a
major role in disease susceptibility and interact with environmental factors to
precipitate the disorder. Animal models of diabetes, although unable to fully replicate
all aspects of the human condition, have proved invaluable in elucidating the sequence
of events leading to the onset of IDDM. The BB rat more accurately reflects human
EDDM as it spontaneously develops diabetes, and although this model shares many
similar characteristics with the NOD mouse, there is no sex difference in the
propensity to develop diabetes in the BB rat. For these reasons, the BB rat is the
animal model of diabetes used in the studies described in this thesis. Despite
improved understanding of the pathogenesis of the disease, no safe and effective
method of preventing diabetes is currently available. Prevention studies have been
hindered by the need to identify factor(s) initiating onset of IDDM. In addition, a
method that accurately predicts diabetes-susceptible individuals in the general
population is still not available. For these reasons, many groups have concentrated
their efforts on searching for improved methods of insulin delivery. CIT achieves
poor metabolic control, and close-to-normal blood glucose values are not achieved,
leading to severe long-term microvascular complications including morphological
changes in the eyes, kidneys and nerves. Sustained release insulin implants achieve
near-normal blood glucose concentrations but cannot respond to daily fluctuations in
blood glucose. In contrast, glucose sensors respond to changes in blood glucose
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concentrations but do not function in vivo long-term due to their unreliability and
bioincompatibility. An alternative approach to daily exogenous insulin administration
as a treatment of IDDM is replacement of pancreatic islets destroyed by the
autoimmune process. Transplantation of isolated islets has several advantages
compared with vascularised pancreas grafts, although this procedure is not
problem-free. Islets transplanted into an autoimmune model of IDDM are rapidly
destroyed by recurrence of the autoimmune process. Immunosuppression,
immunoalteration and induction of tolerance are three possible ways to circumvent
these problems. Alternatively, bioartificial pancreases isolate islets from the hosts
immune system by an artificial membrane, and include extravascular and vascular
systems. Failure of these systems is generally due to bioincompatibility of the foreign
material used to form the membrane. Somatic cell gene therapy might resolve the
problems of tissue rejection and recurrent autoimmunity if target cells taken from the
diabetic patient are used for the insertion of the insulin gene. However, the inability
to regulate insulin secretion in these cells in response to glucose stimulation is an
obstacle that will be extremely difficult to overcome in the genetically engineered
surrogate cell. Thus, all the aforementioned systems designed to improve the delivery
of insulin to the diabetic patient are not currently problem-free. Only progress
towards resolving these problems will permit these systems to be successfully used in
the clinical treatment of IDDM.
The studies described in this thesis comprise three novel approaches to improved
insulin treatment of human IDDM using the insulin-dependent BB/E rat as an animal
model of spontaneous autoimmune diabetes.
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( i) Comparison of effect of treatment with daily single subcutaneous injections of
insulin, i.e. CIT, and SRII on metabolic control and feeding patterns in BB/E and
STZ-diabetic rats and comparison with non-diabetic rats.
( ii ) Comparison of insulin secretory response of freshly isolated free islets and free
and microencapsulated islets, cultured for different periods of time, using a perifusion
system to determine whether a recovery culture period is necessary for optimal
function ofAPA microencapsulated rat islets.
( iii) Determination of effect of short-term anti-CD4 and anti-CD8 moAb therapy on
intraportal islet allograft survival in well-established diabetic BB/E rats.
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CHAPTER 2
ACHIEVING AND ASSESSING METABOLIC CONTROL IN RATS
WITH SPONTANEOUS INSULIN-DEPENDENT AUTOIMMUNE AND
STREPTOZOTOCIN-INDUCED DIABETES : COMPARISON OF
METABOLIC CONTROL AND FEEDING PATTERNS IN NON-DIABETIC
AND DIABETIC RATS TREATED CONVENTIONALLY WITH




The use of animal models for the study of the development of IDDM not only
depends on the availability of an animal displaying a diabetic syndrome similar to
human IDDM, but also on accurate methods of assessing glycaemic control. In
addition, a means of achieving and maintaining various levels of metabolic control for
prolonged periods are mandatory for studies involving the development of diabetic
microangiopathy. Limited information is available on daily blood glucose profiles of
diabetic BB rats treated by CIT, despite the importance of ensuring that a random
blood sample taken for blood glucose determination is representative. Animals that
are normoglycaemic several hours following a single injection of insulin may later
return to a hyperglycaemic state, since insulin action does not continue throughout the
day. This observation may be relevant to analysis of experimental data involving
" normoglycaemic " BB rats.
In this study, the effects ofCIT and SRII on metabolic control and feeding patterns in
spontaneously diabetic BB/E and STZ-diabetic rats were compared with non-diabetic
rats. Plasma glucose concentrations and food intake were measured every 2 hours for
24 hours and HbAj values were determined. In addition, tissue concentrations of the
principal metabolites of the polyol pathway were determined in STZ-diabetic rats at
the end of study.
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2.2. MATERIALS AND METHODS
2.2.1. ANIMALS
2.2.1.1. The BB/E rat
The Edinburgh colony of inbred spontaneously diabetic, insulin-dependent BB rats
( designated BB/E ) was established in 1982 from animals donated by Dr. Pierre
Thibert at the Animal Resources Division in Canada, Ottawa and is therefore derived
from the original BB colony. The BB/E colony consists of two sublines of animals
created by selective breeding. The DP mainline was established by selecting breeding
pairs from high incidence litters, where at least 55% of the litter would develop
diabetes. The incidence of diabetes in the DP-BB/E line is 50-60% with a mean age
at onset of diabetes of 96 days. The DR subline was derived by selecting rats from
litters of low incidence ( <30% ). If any of the mating pairs subsequently developed
diabetes at any stage, they and their progeny were killed. The incidence of diabetes
amongst the DR-BB/E rats is zero.
BB/E rats are maintained in rooms with independent heating and ventilation from the
rest of the Biomedical Research Facility. Ventilation involves two sets of filters to
produce 100% fresh air ( 21 + 2°C, 50% humidity ). Animals are kept in an
automatic light cycle of 12 hours light/dark. Animals are allowed free access to food
( SDS rat and mouse no.l Expanded Diet, Special Diet Services, Witham, UK ) and
water. All animals are weighed twice weekly to monitor for diabetes onset and
indicate control of diabetes in rats receiving insulin. Diagnosis of diabetes is based on
a continuous decrease in body weight and confirmed by the presence of glycosuria
and hyperglycaemia. Glycosuria is detected using Multistix ( Ames Division, Miles
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Laboratories Ltd., Slough, UK ) and values of >14 mmol/1 are regarded as a positive
result. Blood glucose is measured following tail vein sampling using ExacTech blood
glucose test strips ( MediSense Britain Ltd., Birmingham, UK ) in conjunction with an
ExacTech blood glucose sensor. Readings of > 18 mmol/1 are regarded as indicative
of diabetes onset. Following diagnosis, BB/E rats are maintained on single daily
subcutaneous injections of Ultralente MC insulin ( 40 I.U./ml ) ( Novo Nordisk,
Copenhagen, Denmark ) administered between 0900-1000 hours. The dose of insulin
is adjusted for individual animals according to regular measurements of body weight
and the degree of glycosuria.
2.2.1.2. The normal Wistar albino rat
Normal Wistar albino rats were bred and maintained in the Biomedical Research
Facility, University of Edinburgh. Diabetes was chemically-induced in these animals
by a single i.v. injection of 65 mg/kg streptozotocin ( Sigma Chemical Co. Ltd.,
Poole, Dorset, UK ) administered in citrate buffer, pH 4.5 (2.1 g citric acid [ BDH
Chemicals Ltd., Poole, Dorset, UK ], 20 ml 1 M NaOH made up to 100 ml with
sterile distilled water ) into the tail. Diabetes was confirmed by subsequent blood
glucose concentrations of >18 mmol/1, weight loss and glycosuria.
2.2.2. INSULIN TREATMENT
2.2.2.1. Conventional insulin therapy
BB/E rats were initially maintained on a single daily subcutaneous injection of
2.4 - 4.0 I.U. of insulin. CIT ceased upon implantation of Linplant SRII
( Mollegaard, Skensved, Denmark)
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2.2.2.2. Sustained release insulin implants
SRII are made by high pressure compression of a powder admixture of 17% bovine
insulin and 83% recrystallised palmitic acid. Entrapped insulin is gradually released
from the implant ( 7 mm long with a diameter of 2 mm ) by slow surface erosion in
vivo. For this reason, even when the implant is broken into smaller pieces, there is
little change in the insulin release rate, although less insulin will be released per day.
The insulin release rate from a single SRII is approximately 2 units/day for ar least
40 days. The dosage varies with age of the animal and severity of its diabetes. The
recommended dosage for an adult BB rat with mild to severe diabetes is 1 or 2
implants. If given an optimal implant dose, glycosuria and ketonuria are absent in the
recipient since a set basal dose of insulin is continuously released during the day. In
contrast, glycosuria and ketonuria are difficult to prevent using CIT since the action
of the injected insulin does not last throughout the day.
2.2.2.2.1. Insertion of sustained release insulin implants
Recommended sites of subcutaneous insertion of an SRII include upper abdominal
and dorsal skin and neck region. Animals receiving an implant were anaesthetised
with halothane and the site of injection shaved and cleaned with Betadine antiseptic
solution ( Napp Laboratories, Cambridge, UK ). The skin was pinched and pierced
with a 16G needle and a 12G trocar ( Mollegaard ) was pushed through the skin
orifice created following brief immersion in 2% Betadine solution. The implant was
briefly immersed in 2% Betadine solution prior to insertion into the proximal end of
the trocar and the implant was pushed to the distal end with an obturator until it
exited the trocar. The skin was pinched over the inserted implant and the trocar
withdrawn. The orifice required no suturing or clips for closure. Progressive erosion
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of the SRII starts immediately following implantation, and the effect of the released
insulin on blood glucose level can be detected in less than 1 hour.
Since preliminary experiments indicated that diabetic BB/E rats implanted with 2 SRII
died of hypoglycaemia ( blood glucose concentration <2 mmol/1), rats were implanted
with a single SRII in the majority of subsequent studies.
2.2.3. EXPERIMENTAL PROTOCOL
2.2.3.1. Metabolic control in BB/E rats
Four groups of BB/E rats were studied : ( 1 ) non-diabetic BB/E rats ( n = 13 )
comprising both DR-BB/E ( n = 9 ) and DP-BB/E ( n = 4 ) rats; ( 2 ) diabetic
DP-BB/E rats treated by CIT (n=19);(3) diabetic DP-BB/E rats treated by a
single SRII implanted subcutaneously in the sternal region ( n = 13 ) and ( 4 ) diabetic
DP-BB/E rats initially treated by a half-sized piece of SRII, i.e. 3.5 mm long and
2 mm diameter, implanted subcutaneously in the back neck region with the
subsequent implantation of 0-4 quarter-size pieces, i.e 1.8 mm long and 2 mm
diameter ( mean SRII = 1%, range = V2-V/2 ), so as to maintain normoglycaemia
( n = 6 ). The mean ( ± SEM ) duration of diabetes prior to implantation of SRII was
137 + 11 days. Blood glucose concentration and body weight were measured
three-times each week after SRII implantation ( daily for group 4 ). Urine samples
were also monitored for the presence of glucose and ketones. All diabetic BB/E rats
were subjected to a 24 hour plasma glucose analysis 7 days before substituting CIT
with SRII and again 27 days after implantation of SRII to assess the variation in
24 hour glycaemic control. Plasma glucose concentrations of non-diabetic rats were
also determined over a 24 hour period. Blood samples were collected for plasma
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glucose estimations every 2 hours from 0800 to 0800 the following day. The initial
blood sample taken at 0800 was also used to determine UbAj.
2.2.3.2. Metabolic control in STZ-diabetic rats
Four groups of rats were studied : ( 1 ) normal Wistar rats (n = 4);(2) untreated
STZ-diabetic Wistar rats (n = 6);(3) STZ-diabetic Wistar rats treated by CIT
( n = 15 ) and ( 4 ) STZ-diabetic Wistar rats treated by a single SRII implanted
subcutaneously in the sternal region ( n = 10 ). Untreated STZ-diabetic rats were
diabetic for 8 days prior to determination of 24 hour plasma glucose concentrations
and treated STZ-diabetic rats were diabetic for 12 ± 1 days before starting CIT or
SRII. 24 hour plasma glucose profiles were assessed 28 ± 1 days later.
2.2.3.3. Feeding study
Food intake was measured every 2 hours over a 24 hour period in the following
7 groups of rats : ( 1 ) non-diabetic Wistar rats (n = 4);(2) non-diabetic BB/E rats
( n = 13 ) comprising both DR-BB/E ( n = 9 ) and DP-BB/E ( n = 4 ) rats;
( 3 ) diabetic DP-BB/E rats treated by CIT (n = 6);(4) diabetic DP-BB/E rats
treated by variable amounts of SRII ( mean = VA, range V2-V/2 ) implanted
subcutaneously in the back neck region (n = 6);(5) untreated STZ-diabetic Wistar
rats (n = 6);(6) STZ-diabetic Wistar rats treated by CIT ( n = 15 ) and
( 7 ) STZ-diabetic Wistar rats treated by a single SRII implanted subcutaneously in
the sternal region ( n = 10 ). The rats were given a known weight of food at the start
of the study and the quantity eaten every 2 hours determined. Animals were allowed
free access to food and water.
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2.2.4. GLYCATED HAEMOGLOBIN ANALYSIS
HbA] values were determined by the method described by Tames et al ( 807 ).
Briefly, mixed venous/arterial blood samples ( approximately 100 pi ) were collected
from the tails of non-anaesthetised rats and mixed ( 50 units/ml of blood ) with
preservative-free heparin ( Multiparin, CP Pharmaceuticals Ltd., Wrexham, UK ) on
parafilm strips and transferred to a 1.5 ml Sarstedt tube ( Sarstedt Ltd., Leicester,
UK ). Blood was centrifuged ( 3500 x g, 3 minutes ) and plasma removed for
subsequent glucose estimation using a Beckman Glucose Analyser 2 ( Beckman
Instruments [ UK ] Ltd., High Wycombe, Buckinghamshire, UK ). Red blood cells
were washed three times in 0.9% saline and incubated overnight with an equal volume
of saline at room temperature. The cells were centrifuged and the packed cells
haemolysed by addition of 3 volumes of a 1 : 10 dilution of haemolysing reagent
containing 0.1 % saponin and 0.05% ethylenediaminetetra-acetic acid ( EDTA ) in
distilled water ( Corning Medical and Scientific Ltd., Halstead, UK ). After vortex
mixing for 15 seconds, the cells were centrifuged ( 3500 x g, 5 minutes ) and 1 pi of
the haemolysate containing approximately 40 pg of rat haemoglobin applied to
individual sample wells on citrate agar plates ( Corning ).
Rat haemoglobin variants were seperated by electroendosmosis ( Corning " Glytrac "
electrophoresis system, 1.5 x 17 cm band width ) using 0.1 mmol/1 citrate buffer
( pH 6.3 ) under 60 V for 40 minutes. The percentage of HbAj was determined by
automatic scanning densitometry on a Corning 720 fluorometer/densitometer
equipped with a 420 nm filter.
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2.2.5. TISSUE POLYOL ANALYSIS
Tissue concentrations of sorbitol, fructose, glucose and //rpo-inositol were determined
in nerve, kidney and lens samples of insulin-treated STZ-diabetic rats at the end of
study by capillary gas chromotography of trimethylsilyl ether derivatives ( 808 ) by
Dr R M Lindsay. In brief, a-methylmannoside ( 500 nmol ) was added as internal
standard to approximately 50-100 mg of tissue in polypropylene tubes and boiled for
25 minutes. After cooling, proteins were precipitated by sequential addition of zinc
sulphate ( 200 pi; 5% ) and barium hydroxide ( 200 pi; 5% ). After centrifugation
( 1000 x g, 15 minutes ), the supernatant was transferred to glass tubes and
lyophilised. Samples were derivatised for 24 hours by adding 300 pi Tri-Sil reagent
( Pierce and Warriner [ UK ] Ltd., Chester, UK ) then extracted by adding 2 ml
distilled water and 300 pi cyclohexane. After centrifugation ( 1000 x g, 15 minutes ),
the cyclohexane layer was removed and 1 pi injected into a Hewlett-Packard HP5890
series II gas chromatograph ( Hewlett-Packard Ltd., Cheadle Heath, Cheshire, UK ).
Quantitation was achieved using a Hewlett-Packard HP3396A integrator by
comparison with authentic mixed standards of fructose, glucose, sorbitol
and /nyo-inositol containing a-methylmannoside as internal standard extracted
simultaneously.
2.2.6. STATISTICAL ANALYSIS
All results are presented as mean + standard error of the mean ( SEM ) and were
analysed using unpaired Student's t-test. Regression equations and scatter plots were




Figure 1 shows the 24 hour plasma glucose profiles of CIT-treated diabetic BB/E rats
7 days prior to transfer to SRII treatment and subsequently 27 days later. Mean
plasma glucose concentration of single SRII-treated ( 7.3 ± 0.4 mmol/1,
range = 5.5 - 10.0 mmol/1 ) or variable ( mean = VA ) SRII-treated ( 11.1 ± 0.5
mmol/1, range = 9.1 - 13.1 mmol/1 ) but not CIT-treated ( 8.0 ± 1.4 mmol/1,
range = 2.4 - 18.3 mmol/1 ) diabetic BB/E rats were significantly higher ( p<0.001 )
than non-diabetic rats ( mean = 5.7 ± 0.1 mmol/1, range = 5.2 - 6.2 mmol/1). Diabetic
BB/E rats initially treated with a half-sized piece of SRII and subsequently
quarter-sized pieces ( mean = VA ) were slightly hyperglycaemic and the mean plasma
glucose concentration was significantly higher than that of single SRII-treated BB/E
rats ( p<0.001 ). Mean plasma glucose concentration of CIT-treated BB/E rats was
not significantly different from diabetic BB/E rats treated with a single SRII, but was
significantly lower ( p<0.05 ) than animals treated with variable amounts of SRII.
Diabetic BB/E rats maintained by CIT showed considerable diurnal variation in
plasma glucose levels whereas both SRII treatments reduced these fluctuations. The
service life, i.e. the length of sustained action, of a single SRII was 55 ± 4 days which
was significantly higher ( p<0.001 ) than that of variable amounts of SRII ( 31 ± 4
days ).
Mean HbAj values in diabetic BB/E rats treated with CIT or a single SRII were
identical ( 4.9 ± 0.4% and 4.9 ± 0.2 % respectively ) despite the greater diurnal
variation and higher mean plasma glucose concentration observed in the CIT-treated
group. Mean HbAj of diabetic rats treated with variable amounts of SRII ( 6.2 ±
0.5% ) was significantly higher ( p<0.05 ) than diabetic BB/E rats treated with a
single SRII but not CIT. BB/E rats treated with either a single or variable amounts of
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Figure 1. 24 hour plasma glucose profiles in diabetic BB/E rats
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Plasma glucose concentrations were measured over a 24 hour period in non-diabetic
( o , n=13) and diabetic BB/E rats initially treated by CIT ( ■ , n=19) and subsequently
treated with either a single SRII ( A, n=13) or variable (mean = 11/4, range = 1/2 -
11/2) amounts of SRII ( • , n=6). Non-diabetic rats comprised of both DR-BB/E (n=9)
and DP-BB/E (n=4) rats.
Profiles of CIT-treated rats were performed 7 days prior to transfer to SRII treatment.
Profiles of SRII-treated rats were performed 27 days after inititiation of SRII treatment.
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SRII, but not CIT, had mean HbAj values that were significantly higher ( p<0.05 and
p<0.01 respectively ) than non-diabetic BB/E rats ( 4.2 ± 0.2% ). Mean values of
plasma glucose concentration and HbAj of DP-BB/E and DR-BB/E rats which
comprised the non-diabetic group were not significantly different.
The 24 hour plasma glucose profiles performed on STZ-diabetic rats maintained by
CIT or SRII are shown in Figure 2. The mean plasma glucose concentration
(24.1 ± 1.0 mmol/1, range = 19.3 - 31.4 mmol/1) of untreated STZ-diabetic rats was
significantly higher than CIT-treated ( 8.6 ± 1.3 mmol/1, range = 2.8 - 16.6 mmol/1 )
and SRII-treated ( 6.6 ± 0.4 mmol/1, range = 4.0-9.0 mmol/1) STZ-diabetic rats and
non-diabetic ( 6.0 ±0.1 mmol/1, range = 5.4 - 7.0 mmol/1 ) Wistar rats ( p<0.001 ).
Both CIT and SRII treatment lowered the mean plasma glucose concentration in
STZ-diabetic rats and these values were not significantly different from the mean
plasma glucose concentrations observed in non-diabetic Wistar rats. Treatment of
STZ-diabetic rats with a single SRII reduced the diurnal fluctuations observed in
CIT-treated rats.
CIT- and SRII-treated STZ-diabetic rats had lower HbAj values
( mean = 7.4 ± 1.0% and 6.2 ± 0.6% respectively, p<0.01 ) compared with untreated
STZ-diabetic Wistar rats ( mean = 9.3 ± 0.8% ). CIT- and SRII-treated diabetic rats
both had significantly higher mean HbAj values compared with non-diabetic
( 4.4 ± o.4% ) rats ( p<0.05 ).
Figure 3 shows the correlation between mean plasma glucose concentration and
HbAj in ( a ) spontaneously diabetic BB/E rats and ( b ) STZ-diabetic rats treated
with either CIT or SRII. The correlation between these two parameters
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Figure 2. 24 hour plasma glucose profiles in STZ-diabetic BB/E rats
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Plasma glucose concentrations were measured over a 24 hour period in non-diabetic
(o , n=4) and untreated (■ , n=6), CIT-treated ( A, n=6) and SRII-treated ( • , n=6)
STZ-diabetic rats .
Plasma glucose profile of untreated STZ-diabetic rats was performed 8 days after
confirmation of diabetes. Insulin treatment of diabetic rats was initiated 12±1 days
after confirmation of diabetes and plasma glucose profiles performed 28 days later.
SRII-treated rats received a single SRII.
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Figure 3. Correlation between HbA, and mean plasma glucose
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STZ-diabetic rats were treated with either CIT (n=15) or an single SRII (n=10).
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was significant for spontaneously diabetic BB/E rats ( r = 0.36, p<0.05 ) but not for
STZ-diabetic rats ( r = 0.28 ).
Twenty-four hour feeding profiles in non-diabetic and diabetic BB/E rats maintained
by CIT or variable amounts ( mean = VA ) of SRII are shown in Figure 4.
Non-diabetic rats comprised DP-BB/E and DR-BB/E rats and there was no significant
difference between the amount of food consumed during either the 12 hour light and
dark cycles or the 24 hour period of study between these two groups. Non-diabetic
BB/E rats consumed significantly more food during the dark cycle than the light cycle
( p<0.001 ). Diabetic BB/E rats treated with CIT or SRII did not consume
significantly different amounts of food during the light and dark cycle and ate
significantly more during the light cycle compared with non-diabetic BB/E rats
( p<0.001 ). Food intake of CIT-treated diabetic and non-diabetic rats during the
dark cycle was not significantly different. However, SRII-treated rats ate significantly
less food compared with CIT-treated diabetic and non-diabetic rats ( p<0.05 ). The
total amount of food consumed in a 24 hour period by CIT- and SRII-treated diabetic
BB/E rats was not significantly different, although CIT-treated ( but not
SRII-treated ) animals consumed significantly more food than non-diabetic rats in the
24 hour period of study ( p<0.01 ).
Figure 5 shows the 24 hour feeding profiles in non-diabetic and STZ-diabetic Wistar
rats either untreated or maintained by CIT or a single SRII subcutaneously implanted
in the sternal region. Non-diabetic Wistar rats ate significantly more food during the
dark cycle than the light cycle ( p<0.001 ). Untreated and SRII-treated rats did not
eat significantly different amounts of food during the light and dark cycle and
CIT-treated rats ate significantly more food during the light cycle than the dark cycle
( p<0.01 ). All diabetic animals ( untreated, CIT- and SRII-treated ) ate significantly
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Figure 4. 24 hour feeding profiles in diabetic BB/E rats maintained by
CIT orSRII.
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Food consumption was measured over a 24 hour period in non-diabetic (o , n=13)
and diabetic BB/E rats treated with CIT ( ■ , n=6) and subsequently after 27 days
treatement with variable (mean = 11/4, range 1/2 - 11/2) amounts of SRII (A, n=6).
Non-diabetic rats comprised of both DR-BB/E (n=9) and DP-BB/E (n=4) rats.
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Food consumption was measured over a 24 hour period in non-diabetic (o , n=4)
and untreated (■ , n=6), CIT-treated (A . n=6) and SRII-treated ( • , n=6) STZ-
diabetic rats. SRII-treated rats received a single SRII.
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more during the light cycle compared with non-diabetic rats ( p<0.001 ). Untreated
STZ-diabetic rats consumed significantly larger amounts of food than CIT- and
SRII-treated rats during both the light ( p<0.05 and p<0.01 respectively ) and dark
( p<0.01 ) cycles and also ate significantly more than non-diabetic Wistar rats
( p<0.05 ) during the dark cycle. However, non-diabetic Wistar rats consumed
significantly greater amounts of food than both CIT- and SRII-treated rats during the
dark cycle ( p<0.05 ). There was no significant difference in food consumption of
CIT-treated and SRII-treated rats during either the light or dark cycles. The total
amount of food consumed over the 24 hour period of study by non-diabetic Wistar
rats was significantly less than the food consumed by untreated and CIT-treated ( but
not SRII-treated ) rats ( p<0.01 and p<0.001 respectively ). Untreated STZ-diabetic
rats consumed significantly more food than CIT- and SRII-treated diabetic rats
( p<0.01 ), and CIT-treated rats ate more food than SRII-treated and non-diabetic
rats.
Table 1 compares the food consumption and metabolic control in non-diabetic and
diabetic rats. Non-diabetic BB/E rats consumed significantly more food than
non-diabetic Wistar rats during the light cycle ( p<0.05 ). When the data for
non-diabetic rats was combined and compared with that for all diabetic rats, the latter
group were found to consume significantly more food during the 12 hour dark cycle
and the 24 hour period of study and had significantly higher mean plasma glucose and
HbAj values ( p<0.001 ).
The results of analysis of the principal metabolites of the polyol pathway in sciatic
nerve, kidney and lens samples from CIT- and SRII-treated STZ-diabetic rats are
shown in Table 2. Data obtained from previous studies in the Metabolic Unit for
non-diabetic and untreated STZ-diabetic rats is also presented in Table 2 for
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comparison. Tissue levels of glucose, sorbitol and fructose are significantly increased
and /wyo-inositol concentrations significantly reduced in untreated diabetic rats as
previously reported ( 809 ). Both CIT and SRII treatment normalised tissue
concentrations of these metabolites although the differences between the two insulin
therapies were not significant.
2.4. DISCUSSION
The sustained delivery of insulin by an implant is thought to achieve improved
physiological blood glucose control than CIT. Initially Brown et al ( 533 ) used
non-degradable ethylene-vinyl acetate copolymer matrices to entrap insulin and a
single device controlled plasma glucose concentration for up to 105 days in
STZ-diabetic rats. However, removal of the implant was necessary once the insulin
supply was exhausted. Other problems with long-term use include toxicity and lack
of biocompatibility. Use of natural, non-antigenic materials may resolve these
problems if the insulin delivery is comparable to that of versatile synthetic polymers.
Water insoluble lipids have been studied since they are natural constituents of all
tissues. Cholesterol is a suitable matrix for insulin delivery but the observed poor
biodegradability in vivo, even after one year ( 534 ), is clinically undesirable in IDDM
patients. In a subsequent study of 11 lipids, Wang ( 810 ) reported that palmitic acid
( a long chain fatty acid ) containing 20% insulin had the longest service life ( 37-50
days ) and achieved near-normoglycaemic blood glucose profiles. Palmitic acid
implants were also gradually eroded in vivo with a half-life of approximately 3 months
in the rat and no fibrous overgrowth was observed on these SRII.
In this study, the degree ofmetabolic control achieved in spontaneously diabetic BB/E
and STZ-diabetic rats by different insulin treatment regimens was assessed. For this
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purpose, plasma glucose concentration and HbAj ( determined using the
electrophoretic method described by Tames et al [ 807 ] ) were measured. This
method determines HbAj without interference from either Hb variants or labile
glycated fractions, the importance of which has been described in IDDM patients
( 811 ). Elevated HbAj values have previously been reported in both genetically
diabetic mice ( 812,813 ) and rats ( 807 ) and in mice ( 813 ) and rats ( 814,815 ) with
chemically-induced diabetes. This study also demonstrated increased HbAj values in
diabetic BB/E and STZ-diabetic rats compared with non-diabetic rats. Furthermore,
HbAj values observed in CIT-treated diabetic BB/E rats were significantly lower
( p<0.05 ) than those reported for STZ-diabetic animals as previously reported
(814, 815).
Two different methods of insulin treatment were evaluated in BB/E and STZ-diabetic
rats : CIT and SRII. Both insulin regimens were effective in lowering the raised
plasma glucose levels associated with IDDM. However, two SRII implanted
subcutaneously in the sternal region of two diabetic BB/E rats resulted in fatal
hypoglycaemia after 4 and 20 days. Diabetic BB/E rats initially maintained by half a
single SRII in the back neck region (the site ofCIT administration ) followed by 0-4
quarter-sized pieces ( mean = VA ) were difficult to control and were slightly
hyperglycaemic. This observation was reflected by significantly higher mean plasma
glucose concentration and HbAj compared with BB/E rats maintained on a single
SRII implanted in the sternal region. A single SRII reduced fluctuations in plasma
glucose concentrations ofCIT-treated diabetic BB/E and STZ-diabetic rats during the
24 hour period as reflected by lower values of SEM and range of plasma glucose
concentration in SRII-treated diabetic rats. However, mean plasma glucose
concentration of SRII-treated diabetic rats was higher than non-diabetic animals and
significantly so for BB/E rats. In addition, the sequential implantation of variable
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amounts of SRII to achieve normoglycaemia was less convenient. The service life of
variable amounts of SRII implanted in the back neck region was also significantly
shorter than a single SRII implanted in the sternal area. Several explanations for this
difference include the simultaneous and increased erosion of the multiple pieces of
SRII implanted in the former group due to increased exposure of surface area, and
weakening of the implant pieces following dissection. In this study, implantation site
also appears to play a role in determining the length of service life although no
information is currently available to confirm this preliminary finding.
Although mean HbA] values of CIT- and SRII-treated rats were not significantly
different, only SRII-treatment significantly decreased mean HbA] value compared
with untreated STZ-diabetic rats. Mean HbAj values of CIT- and SRII-treated rats
were significantly higher than non-diabetic rats indicating that neither insulin treatment
achieved long-term normoglycaemia. The mean HbAj value of SRII-treated diabetic
BB/E rats was also significantly higher than non-diabetic rats. There was no
significant relationship between mean plasma glucose concentration and HbAl in
insulin-treated STZ-diabetic rats which is in agreement with a previous report (816 ).
However, the correlation between these two parameters just reached significance for
diabetic BB/E rats in contrast to the results of Tames et al ( 807 ).
Mean HbAj and plasma glucose concentrations of CIT- and SRII-treated diabetic
BB/E rats were not significantly different despite the more pronounced glycaemic
excursions observed in the former group. These apparently conflicting results may be
explained by considering the 24 hour plasma glucose profiles. The considerable
diurnal variation in plasma glucose concentration in CIT-treated spontaneously
diabetic and STZ-diabetic rats meant these animals were only briefly normoglycaemic.
Between approximately 0600 - 1000 hours, CIT-treated rats were hyperglycaemic
227
whereas following administration of insulin at 1000 hours, plasma glucose levels
rapidly decreased to hypoglycaemic levels between 1400 - 2200 hours. This marked
fluctuation in the 24 hour plasma glucose profile has previously been reported in
CIT-treated diabetic rats ( 807 ). The near-normal mean plasma glucose and HbA]
values in spontaneously diabetic and STZ-diabetic rats maintained on CIT indicate
that metabolic control cannot be adequately assessed by either a single random
measurement of plasma glucose concentration or HbA]. For this reason, plasma
glucose concentration should be determined at both 0800 hours ( i.e. pre-CIT ) and
1400 hours when CIT-treated animals are hyperglycaemic and hypoglycaemic
respectively. In contrast, measurement of a single random plasma glucose
concentration or HbAj accurately reflects the metabolic control of diabetic rats
maintained on SRII. Tames et al ( 807 ) reported similar results after studying
long-term glycaemic control achieved in diabetic BB/E rats maintained by continuous
insulin infusion using an osmotic minipump, or CIT. However, in contrast to the
surgical implantation and limited service life ( 14 days ) of osmotic minipumps, SRII
are implanted simply with minimal surgery and no special aftercare, and maintain good
glycaemic control for 55 ± 4 days.
Since SRII cannot respond to varying insulin demands, Wang ( 535 ) determined the
extent of blood glucose fluctuation that might result in dangerous convulsions due to
feeding schedules. Wang observed reasonably stable blood glucose levels of
STZ-diabetic Wistar rats implanted with a single SRII under self-feeding or scheduled
feeding conditions. Animals also tolerated an overnight ( 16 hour ) fast and
hypoglycaemic convulsion was not observed despite blood glucose levels of
approximately 2.5 mmol/1.
228
In this study, diabetic rats ate significantly more food during the 12 hour light cycle
and over the 24 hour period of study compared with non-diabetic rats. This was
primarily due to the fact that diabetic rats fed continuously throughout the 24 hour
day irrespective of glycaemic control and insulin treatment. In contrast, non-diabetic
rats consumed significantly more food during the dark cycle, when these animals are
active, compared with the light cycle. Indeed, non-diabetic BB/E and Wistar rats ate
significantly more food during the dark cycle than SRII-treated diabetic BB/E rats and
CIT- and SRII-treated STZ-diabetic rats respectively. Interestingly, non-diabetic
BB/E rats ate significantly more food than non-diabetic Wistar rats during the light
cycle. Diabetic BB/E rats treated with CIT or SRII ate similar amounts of food
although CIT-treated rats consumed significantly more food during the dark cycle.
Untreated STZ-diabetic rats were most severely hyperglycaemic and hyperphagic.
Insulin treatment with CIT or SRII lowered mean plasma glucose concentrations to
near-normal values, and HbAj values and food consumption decreased accordingly
suggesting that hyperphagia in severely diabetic animals may be reduced but not
normalised by insulin treatment. The feeding patterns observed in BB/E or
STZ-diabetic rats may be explained when considering the role of neuropeptide Y
( NPY ), a potent central appetite stimulant. NPY is a 36 amino acid neurotransmitter
related to pancreatic polypeptide ( 817 ) and found at high concentrations in the
hypothalamus where it is synthesized in neurons in the arcuate nucleus ( ARC )
( 818 ). These neurons, together with specific neurons in the medulla, principally
project to the paraventricular nucleus ( PVN ) and dorsomedial nucleus ( DMN ),
both of which are major appetite-regulating areas within the hypothalamus ( 819 ).
Upon injection into PVN, DMN and other hypothalamic sites, NPY induces
carbohydrate-selective hyperphagia ( 820 ) even at extremely low dosages. Indeed,
the effect is so intense and sustained that repeated administration induces weight gain
and obesity ( 820 ). These findings suggest that NPY plays an important role in
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controlling food intake and body weight in vivo. In fasted rodents, NPY is increased
in the PVN and to a lesser extent in other hypothalamic nuclei ( 821 ) and NPY
mRNA is increased in the ARC ( 822 ). Increased hypothalamic NPY concentrations
have also been reported in insulin-deficient BB/E and STZ-diabetic rats ( 823,824 )
and the increases in STZ-diabetic rats were subsequently localised to specific
hypothalamic regions ( ARC, PVN and DMN ) implicated in metabolic and
neuroendocrine regulation ( 825 ). Increased NPY concentrations, together with
raised NPY mRNA content in the ARC, downregulation ofNPY receptor numbers in
the hypothalamus and enhanced NPY release within the PVN ( 823-827 ) suggest that
synthesis, transport and release ofNPY in the hypothalamus are increased in diabetic
rats. In view of the documented central action of NPY in stimulating appetite, this
peptide is thought to mediate the hyperphagia characteristic of untreated diabetes.
McKibbin et al ( 828 ) reported that insulin deficiency rather than hyperglycaemia was
the major stimulus for elevation of hypothalamic NPY in STZ-diabetic rats and that
hyperglycaemia may exert an inhibitory effect on feeding. Insulin crosses the
blood-brain barrier from the circulation and interacts with insulin receptors on
neurons in the ARC where it acts as a satiety signal, serving to regulate body weight
( 829 ). Indeed, peripheral insulin administration to diabetic rats reduces
hypothalamic NPY to near-basal levels ( 830 ) and normalises food intake ( 828 ).
Furthermore, Schwartz et al ( 831 ) recently reported that insulin may inhibit NPY
gene expression directly. In agreement with these results, reduced hyperphagia was
observed in insulin-treated STZ-diabetic rats as shown previously ( 830, 832 ).
Metabolic control of SRII-treated rats was more stable compared with CIT treatment
and this was reflected by the lower food consumption of these rats. If indeed NPY
mRNA in the ARC responds relatively rapidly to small changes in circulating insulin
as suggested by Marks et al ( 833 ), a consequent decrease in NPY concentration in
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SRII-treated diabetic rats may explain the greater reduction of food consumed by
these animals compared with CIT-treated diabetic rats. However, although insulin
treatment reduced food consumption in diabetic animals, hyperphagia was not
abolished in spontaneously diabetic and STZ-diabetic rats treated by CIT or SRII as
both groups ate significantly more than non-diabetic BB/E and Wistar rats. This
finding is in agreement with Williams et al ( 823 ) who reported that even in
intensively insulin-treated BB/E rats, physiological blood glucose values were not
achieved and central hypothalamic NPY levels were ( as in poorly controlled groups )
significantly higher than in non-diabetic DR-BB/E rats.
This study also investigated the effect of CIT and SRII treatment on polyol pathway
activity in three tissues susceptible to development of diabetic microangiopathy.
Excessive glucose flux through the polyol pathway to produce elevated tissue levels
of sorbitol and fructose and the associated reduction in tissue /wyo-inositol
concentration have been implicated in the pathogenesis of diabetic vascular
complications ( 194, 195 ). CIT and SRII treatments both corrected the characteristic
abnormalities in tissue levels of these metabolites observed in untreated STZ-diabetic
rats. This result contrasts the significantly higher values of mean glucose
concentration and HbAj observed in both groups of insulin-treated STZ-diabetic rats.
One factor which may account fro this difference is the time at which tissues were
sampled since polyol pathway activity closely parallels blood glucose concentration.
Tissue samples were collected between 1100 to 1200 hours when plasma glucose
levels were decreasing following recent insulin administration in CIT-treated rats.
This time point occurs at approximate normoglycaemia in these animals ( 7.0 ± 1.4 )
and would suggest similar correction of tissue polyol pathway metabolism. The
insignificant differences in concentration of the principal polyol pathway metabolites
between CIT- and SRII-treated groups may also be due to the similar plasma glucose
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concentrations at this time point in these two groops. However, sampling of tissues
at other time points may have revealed differences in polyol pathway activity in
CIT- and SRII-treated rats which could be important in the development of diabetic
complications.
In summary, this study demonstrates that a single SRII implanted subcutaneously in
the sternal region can achieve and maintain relative normoglycaemia in spontaneously
diabetic BB/E and STZ-diabetic rats and lower food consumption towards that of
non-diabetic rats. Different degrees of glycaemic control can be achieved by varying
the number of SRII implanted, and the metabolic status of the recipient is accurately
reflected by random assessment of plasma glucose concentration and HbAj thus
providing an alternative to large numbers of plasma glucose determinations. In
addition, the daily plasma glucose fluctuations observed in diabetic rats maintained on
CIT, which may contribute to long-term complications related to the diabetic
condition, are eliminated in SRII-treated rats. Indeed, sorbitol concentrations were
reduced in the sciatic nerve, kidney and lens of STZ-diabetic rats treated with SRII,
although this reduction was not significantly different to the decreases observed in
diabetic rats maintained by CIT.
It will be difficult to estimate the number of SRII required to clinically treat human
IDDM patients using rat body weight and implant size. Further studies with diabetic
animals of larger sizes are necessary to supplement results obtained using rats.
However, SRII do not respond to glucose fluctuations and only provide a sustained
basal daily dosage of insulin. Since insulin demand varies with meal intake and
physical activity, supplemental doses of insulin in addition to the basal dose of insulin
provided by SRII, will be necessary. Wang ( 834 ) recently demonstrated that the
transient hyperglycaemia observed in alloxan-diabetic rabbits maintained on a single
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SRII ( containing 15% insulin ) after drinking sweetened water could be interrupted
by a supplemental bolus of insulin provided by a silicone implant. This second implant
contained compressed insulin, some ofwhich was dissolved when serous fluid entered
the internal volume of the implant through an orifice. When required, sideways
compression of the silicone implant over the abdominal skin fold of the rabbit
delivered the supplemental dose. Further research is required to determine whether
this open-loop arrangement can be modified to a closed-loop system in the IDDM
patient by using SRII in conjunction with an implant with internal modulation
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Microencapsulation of islets of Langerhans in an APA membrane is a potentially
effective method to prevent allograft and xenograft rejection without the need for
immunosuppression. However, the application of the microencapsulation technique
to islet transplantation has had variable success. Although the maintenance of an
adequate insulin response by encapsulated islets is a prerequisite for successful
transplantation, few studies have determined glucose-induced insulin secretion of
APA encapsulated islets. Furthermore, conflicting results have been reported upon
testing the capacity of APA microencapsulated islets to secrete insulin in response to
glucose challenge in vitro. Lim and Sun ( 738 ) and Darquy and Reach ( 736 )
reported that microencapsulated islets responded adequately to glucose stimulation,
whereas Chicheportiche and Reach ( 744 ) and Fritschy et al ( 743 ) observed very
poor glucose-induced insulin response by islets after microencapsulation.
The aim of this study was to investigate the glucose-induced insulin secretory
response ofAPA microencapsulated islets and to determine whether the encapsulation
procedure had any effect on islet function and the effect of a period of culture
post-encapsulation. Microencapsulated islet function was compared with the insulin
secretion of freshly isolated and cultured free islets.
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3.2. MATERIALS AND METHODS.
3.2.1. ANIMALS
3.2.1.1. The normal Wistar albino rat
Normal Wistar rats were bred and maintained in the Biomedical Research Facility,
University of Edinburgh.
3.2.2. ISOLATION OF PANCREATIC ISLETS
Pancreatic islets were isolated from normal male Wistar albino rats ( 200-250 g body
weight ) by two different collagenase digestion methods depending on whether the
islets were to be cultured or used immediately after isolation, i.e. fresh.
3.2.2.1. Isolation of islets for culture
Animals were anaesthetised throughout the procedure using fluothane inhalation
anaesthetic ( Zeneca Ltd., Cheshire, UK ). The abdomen was opened by a midline
incision to expose the pancreas and the pancreatic duct and the distal duct was
clamped off at its point of attachment to the duodenum. The proximal duct was
cannulated with a Portex cannula ( diameter 3FG ) ( Portex Ltd., Hythe, Kent, UK ).
Collagenase type XI ( Sigma ) was diluted to 0.43 mg/ml in Hanks Buffered Salt
Solution ( HBSS ) ( Sigma ) containing 5.5 mmol/1 glucose and supplemented with
0.04% sodium bicarbonate (Imperial Laboratories Ltd., Andover, Hants, UK ), 0.1%
BSA ( Sigma ), 20 mmol/1 Hepes ( Imperial Laboratories Ltd. ), 100 U/ml penicillin,
0.1 mg/ml streptomycin ( Imperial Laboratories Ltd. ) and 7.5 mmol/1 calcium
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chloride ( Sigma ), and placed on ice. The pancreas was inflated by injecting 6 ml of
the collagenase solution through the cannula over a 30 second period. The inflated
pancreas was carefully dissected from the attached gut tissue and placed on ice in a
sterile universal container until sufficient pancreases were obtained. The digestion
reaction was started upon the addition of 5 ml of prewarmed ( 37°C ) supplemented
HBSS ( Ca^+-free ) containing 4% BSA to each pancreas, and continued in a static
water bath at 37°C for exactly 16% minutes. The reaction was stopped by pouring
the digest into 20 ml of cold ( 4°C ) HBSS medium containing 0.1% BSA, and the
suspension was vigourously hand-shaken for 60 seconds. Digests were centrifuged
( 173 x g, 2 minutes ) at 4°C and the supernatants discarded. The tissue pellet was
resuspended in 15 ml of cold HBSS medium and further disaggregated by drawing
and expelling the suspension 7 times in a 20 ml syringe with a sterile 14G steel needle.
The digest was then passed through two sterile 1 mm pore size steel meshes to
remove fat and ductal tissue. The filtrate was centrifuged as before and after
decanting the supernatants, the digests were separated from contaminating exocrine
elements by layering onto a discontinuous dextran gradient.
Dextran T70 ( Pharmacia, Uppsala, Sweden ) was diluted in supplemented HBSS
medium to the following densities : 1.105, 1.095, 1.070 and 1.060 g/ml and used to
create a four-layer density gradient. Gradients were centrifiiged ( 500 x g,
25 minutes ) at 20°C and the islets, once removed from between the first and second
interfaces, were washed in 50 ml of supplemented HBSS, followed by a second wash
in 15 ml of HBSS. Islets were further purified by hand picking under a
stereomicroscope.
Seperated islets were washed twice in 15 ml of HBSS and once in RPMI 1640
medium ( Sigma ) containing 11.1 mmol/1 glucose and supplemented with
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0.2% sodium bicarbonate, 20 mmol/1 Hepes, 2 mmol/1 L-glutamine ( Imperial
Laboratories Ltd. ), 100 U/ml penicillin and 0.1 mg/ml streptomycin. Islets were
cultured free-floating in sterile Falcon tissue culture dishes ( Becton Dickinson,
Cowley, Oxford, UK ) containing 5 ml of RPMI 1640 supplemented with 10%
heat-inactivated foetal calf serum ( FCS ) ( Imperial Laboratories Ltd. ) in a fully
humidified atmosphere of 5% CC>2 at 37°C. Each culture dish contained 400-500
islets, and media was changed 24 hours after islet isolation and every 2 days
thereafter.
3.2.2.2. Isolation of fresh islets
Animals were killed by cervical dislocation and an immediate laparotomy was
performed. The pancreas was located and dissected out as previously described into a
tissue culture dish containing C02-free salt solution with the following ionic
composition : Na+ 141 mmol/1; K+ 5.9 mmol/1; Ca^+ 2.5 mmol/1; Mg2+ 1.2 mmol/1;
PO^" 1.2 mmol/1 and CI" 101 mmol/1 ( BDH ); pH 7.4. The medium was
supplemented with the sodium salts of glutamic, lactic and fumaric acids ( Sigma ) at
a concentration of 5 mmol/1, 0.55% BSA fraction V ( Pentex, Miles Inc. Diagnostics
Division, Illinois, USA ) and 2.8 mmol/1 glucose. After removal of excess fat the
pancreas was inflated with 10 ml of cold ( 4°C ) C02-free salt solution using a 25G
needle ( Microlance, Becton Dickinson, Dublin, Ireland ) and finely minced. The
tissue was washed twice with C02-free salt solution and twice with
bicarbonate-buffered salt solution containing 24.9 mmol/1 HCO"3 ( BDH ) in addition
to the C02-free salt solution, and was continually gassed ( 5% CO2 and 95% O2 )
to maintain pH 7.4, and transferred to a 25 ml conical flask. Collagenase type XI was
diluted to 5 mg/ml in bicarbonate-buffered salt solution and added to the minced
pancreas, and incubated in a shaking water bath at 37°C for 8-9 minutes, with
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vigorous 30 second hand-shaking every minute. Upon completion of the collagenase
incubation, the suspension was transferred to a universal container and washed three
times with C02-free salt solution and three times with bicarbonate-buffered salt
solution. In between washes, the islets were allowed to settle under gravity for
90 seconds before the supernatant was removed. After the last wash, islets were
resuspended in 5 mis of bicarbonate-buffered salt solution and transferred to a
siliconised black tissue culture dish and hand-picked under a dissecting microscope.
Islets, which appeared as free, round or ovoid structures with a greyish-white colour,
were pooled in fresh bicarbonate-buffered salt solution and immediately transferred
to the perifusion apparatus.
3.2.3. MICROENCAPSULATION OF ISLETS
Islets were cultured for 48 hours prior to microencapsulation by a method originally
described by Lim and Sun ( 738 ) and modified by O'Shea et al ( 740 ). Islets were
suspended in a sterile-filtered solution of 1.5% ( w/v ) sodium alginate ( Sigma ) at a
concentration of approximately 2000/ml. The suspension was transferred to a 10 ml
syringe containing a small magnet and connected to the droplet-forming apparatus as
described by Ennis and James ( 835 ). The flow rate of the syringe pump ( Razel
model A-99, Razel Scientific Instruments Inc, Stamford, Conneticut, USA ) was set at
0.66 ml/min and the air flow at approximately 2000 ml/minute. Islet-containing
droplets were extruded through a stainless steel 22G needle surrounded by a purpose
built air jacket and collected in a large tissue culture dish containing 50 ml of
100 mmol/1 calcium chloride ( BDH ). The distance from the tip of the needle to the
surface of the calcium chloride solution was exactly 4 cm, and upon contact with the
calcium chloride solution the islet-containing alginate droplets formed solid beads
which gravitate to the bottom of the tissue culture dish. At the end of the extrusion,
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the gel beads were transferred to a sterile 50 ml Corning centrifuge tube ( Corning
Incorp., New York, USA ) and the supernatant decanted down to 15 ml. The gel
beads were washed three times with sterile 0.9% saline ( Baxter Healthcare Ltd.,
Norfolk, UK ) and the volume reduced to 5 ml. The gel beads were then treated with
30 ml of 0.1% 2-N-( cyclohexamino )-ethane-sulphonic acid ( CHES ) buffer, pH 8.2
( Sigma ) for 3 minutes on a rotator and washed, prior to coating of the beads in
30 ml of 0.05% poly-L-lysine ( molecular weight by viscosity : 21 500; Sigma ) for
10 minutes. Capsules were immediately treated with 30 ml of 0.1% CHES for
3 minutes, washed twice and finally coated in 30 ml of 0.15% sodium alginate
( Sigma ) for 4 minutes. The solid inner core of the capsules was reliquified by
rotation in 10 ml of 55 mmol/1 sodium citrate, pH 7.4 ( Sigma ) for 6 minutes, and
after two final saline washes the microcapsules were incubated in supplemented
RPMI-1640 at 37°C in a fully humidified atmosphere of 5% CO2. Under a low
power stereomicroscope, the microcapsules were approximately 600 pm in diameter,
and possessed a perfectly smooth and spherical outer membrane. Only microcapsules
containing a single islet were used in this study.
3.2.4. PERIFUSION OF ISLETS
The perifiision chambers consisted of a 3.5 cm length of 100 pi Eppendorf pipette tips
( Eppendorf, Hamburg, Germany ), the narrow end of which was occluded with a
piece of sponge on which the islets were placed. Bicarbonate-buffered salt solution
containing either 2.8 mmol/1 ( non-stimulatory) or 16.6 mmol/1 ( stimulatory ) glucose
was continually gassed ( 5% CO2 and 95% O2 ). The glucose concentrations of the
media were checked using Beckman Synchron Clinical System CX3 ( Beckman
Instruments [ UK ] Ltd. ). Non-stimulatory medium was pumped over the islets at a
rate of approximately 1 ml/minute using a multichannel Desaga PLG peristaltic pump.
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This instrument produced a minimal pulsatile flow and hence minimised physical
agitation of the islets. A three-way tap placed between the pump and the media
resevoirs allowed the selection of either non-stimulatory or stimulatory medium.
Silicone tubing with an internal diameter of 0.5 mm connected the perifusion chamber
with both the three-way taps and the LP3 collecting tubes ( Denley Instruments Ltd.,
West Sussex, UK ). The total dead space was approximately 0.5 ml. The perifusion
chambers, media reservoirs and as much of the interconnecting tubing as possible
were immersed in a thermostatically controlled water bath at 37°C.
Twelve chambers could be perifused simultaneously and each channel was loaded
with 30 representative islets selected from a common pool. In this study, islets were
( a ) freshly isolated ( n = 18 channels ), ( b ) cultured for either 4 ( n = 5 channels ),
6, 9 or 13 days ( n = 7 channels each ), or ( c ) encapsulated after 2 days culture and
cultured for a further 2, 4, 7 or 11 days ( n = 7 channels each ). The time interval
between the removal of the pancreas and the administration of the first glucose
stimulus was approximately 2 hours for freshly isolated islets. After loading, all islets
were perifused for a minimum of 30 minutes with non-stimulatory medium. Islets
were then subjected to two consecutive sustained glucose challenges with stimulatory
bicarbonate-buffered medium, seperated by a 20 minute wash with non-stimulatory
medium. Samples of perifusate were collected over 2 minute periods when islets were
perifused with non-stimulatory medium. Upon switching to stimulatory medium,
samples were collected at 1 minute intervals for the initial 10 minutes and over
2 minute intervals thereafter. After perifusion, samples were frozen at -20°C prior to
RIA for insulin content. Islets were washed with non-stimulatory medium followed
by 0.9% saline for a minimum of 30 minutes, and the microcapsules examined under a
light microscope to ensure structural integrity had been maintained throughout
perifusion. The constancy of flow rate in each channel was checked during the course
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of the experiment and any variation in flow rate between channels was accounted for
when insulin secretory rates were calculated.
3.2.5. ANALYTICAL METHODS
3.2.5.1. Total insulin content
Washed islets were removed and suspended in 0.5 ml of distilled water and sonicated
( Sonicator model A180G, Ultrasonics Ltd., Shipley, Yorkshire, UK ) at speed and
tuning setting 5 for 30 seconds ( 40 seconds for encapsulated islets ). The insulin
present in 100 pi of sonicate was extracted overnight in 900 pi of acidified absolute
alcohol ( Hayman Ltd., Witham, Essex, UK ) at 4°C and total insulin content ( TIC )
determined by RIA. Insulin secretion by islets in each channel was standardised for
TIC.
3.2.5.2. Insulin radioimmunoassay
Insulin was assayed by radioimmunoassay using the method described by Ashby and
Speake ( 836 ). 100 pg of lyophilised rat insulin ( Novo Nordisk ) was reconstituted
in 1 ml of distilled water and used to prepare a standard curve. This stock solution
was diluted to 10 ng/ml with buffer B, containing 40 mmol/1 sodium di-hydrogen
orthophosphate ( BDH ), 0.6 mmol/1 thiomersal ( BDH ), 0.5% BSA fraction V,
150 mmol/1 sodium chloride and 25 pl/ml of trasylol ( Bayer, Newbury, Berkshire,
UK ), pH 7.4, and 7 insulin concentrations ( 0.2 - 6 ng/ml) prepared. 100 pi of each
standard and sample were pipetted in triplicate and duplicate respectively into LP3
tubes on ice and 200 pi of anti-porcine insulin guinea pig serum ( Scottish Antibody
Production Unit, Carluke, Lanarkshire, UK ) diluted 1:15 000 in buffer A containing
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40 mmol/1 sodium di-hydrogen orthophosphate, 0.6 mmol/1 thiomersal and 0.5% BSA
fraction V, pH 7.4, added. Tubes were vortexed briefly and incubated for 2 hours at
4°C. After incubation, 100 pi ( 0.125 pCi/ml) of I^5_iabeueci insulin ( Amersham,
Aylesbury, UK ) was added and tubes further incubated for 2 hours at 4°C.
Following the second incubation, 400 pi of charcoal reagent ( 50 mg/ml Norit GSX
charcoal [ BDH ] made up in heat-inactivated filtered horse serum [ Imperial
Laboratories Ltd. ] diluted 1 : 2 with buffer A ) was added, vortexed and allowed to
stand for 10 minutes at room temperature. Following centrifugation ( 1300 x g,
30 minutes ) at 4°C, 400 pi was diluted with 200 pi distilled water and transferred
into duplicate LP3 tubes using a LKB 2075 diluter ( BCL, Lewes, UK ). Samples
were counted for 60 seconds using an NE1600 gamma scintillation counter ( Nuclear
Enterprises, Edinburgh, UK ). Values were expressed as a percentage of total count
( 100 pi sample of 1^ ^^-labelled insulin ) and a standard curve of percentage total
count against insulin concentration ( ng/ml) constructed. Quality control samples of
known insulin concentration were simultaneously analysed.
3.2.6. HISTOLOGY
Microencapsulated islets were fixed in neutral-buffered formalin ( Gurr microscope
materials, BDH; pH 7.2 ) after 7 days of culture. Immunohistochemistry was
performed by Mr Lawrence Brett and sections analysed by Dr M Mclntyre of the
Department of Pathology, Western General Hospital, Edinburgh. Sections
( 4 pm thick ) were stained with haematoxylin and eosin. Further sections were
mounted on poly-L-lysine coated slides and immunostained for insulin and glucagon
using a biotin-Streptavidin alkaline phosphatase conjugate method. Non-specific
staining was blocked with 20% sheep serum in Tris-buffered saline for 10 minutes
prior to incubation of sections in rabbit anti-insulin or rabbit anti-glucagon primary
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antibody ( Euro-path Ltd., Bude, Devon, UK ) diluted 1 : 100 in a solution of 1%
BSA in Tris-buffered saline for 30 minutes. After a Tris-buffered saline wash, primary
antibodies were detected with a biotinylated F(ab)2 antibody fraction ( Boehringer
Mannheim UK, Lewes, Sussex, UK ) diluted 1 : 400 for 30 minutes. Following a
further Tris-buffered saline wash, sections were incubated in Streptavidin/alkaline
phosphatase conjugate ( Boehringer Mannheim UK ) diluted 1 : 1000 for 30 minutes.
After a final Tris-buffered saline wash the alkaline phosphatase label was detected
using New Fuchsin Chromogen ( Dako Ltd., High Wycombe, Buckinghamshire,
UK ). Finally, sections were counterstained with haematoxylin, dehydrated and
mounted in Synthetic Xylene Substitute Mountant ( Life Sciences International,
Basingstoke, Hampshire, UK ). All incubations were performed at room temperature
( approximately 20°C ).
3.2.7. STATISTICAL ANALYSIS
All results are presented as mean ± SEM and were analysed by unpaired Student's
t-test.
3.3. RESULTS
Figure 6 shows the insulin release pattern observed when freshly isolated rat islets
were subjected to two sustained periods of stimulation with perifusion medium
containing 16.7 mmol/1 glucose. Eighteen channels ( 30 islets/channel ) were
perifused. Islets were initially equilibriated in perifusion medium containing a basal
glucose concentration of 2.7 mmol/1. Upon switching to stimulatory glucose, a
vigourous biphasic insulin secretory response was observed with clearly defined first
and second phase insulin secretion. Total insulin secretion ( % of TIC ) expressed as
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Figure 6. Insulin release pattern of freshly isolated rat islets during
perifusion.
Time(mins)
2.7 16.7 2.7 16.7 2.7
Perifusion glucose concentration (mmol/L)
Mean ± SEM
18 channels (30 islets/channel) were perifused.
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area under the curve ( AUC ) or peak first phase first stimulation was 589.0 ± 143.3%
and 23.1 ± 6.0% respectively. Upon removal of stimulatory glucose medium, insulin
release rapidly declined towards basal secretory levels. Following a 20 minute " rest"
period in basal glucose medium, islets were subjected to a second high glucose
stimulation. A more pronounced biphasic response was observed and the insulin
secretion ( % of TIC ) was 699.8 ± 196.2% and 44.7 ± 13.0% when expressed as
AUC or peak first phase second stimulation respectively.
The effect of culture period on insulin release pattern of free ( non-encapsulated ) rat
islets during perifusion is shown in Figure 7. The biphasic insulin secretory profiles
were qualitatively similar to those observed upon perifusion of freshly isolated islets.
However, quantitatively, free cultured islets secreted significantly decreased amounts
of insulin ( % of TIC ) at each culture period studied when compared with freshly
isolated islets, whether insulin secretion was expressed as AUC or peak first phase
following first and second glucose stimulation or as total AUC ( i.e. sum of first
stimulation AUC and second stimulation AUC ). Free islets showed a maximal
secretion of insulin on culture day 6 whether expressed as AUC or peak first phase
following first and second glucose stimulation or as total AUC. Insulin secretion
( % ofTIC ) expressed as AUC following first glucose stimulation decreased after the
optimal culture period and this reached significance ( p<0.05 ) on day 13. Following
a second glucose stimulation, insulin secretion increased significantly from culture day
4 to the optimal culture period on day 6 ( p<0.05 ) after which insulin secretion
decreased and this was significant by day 13 ( p<0.001 ). Insulin secretion on culture
day 13 was significantly lower than insulin secretion on day 4 ( p<0.05 ). Similar
observations were made when considering insulin secretion expressed as total AUC.
Insulin secretion increased significantly from culture day 4 to day 6 ( p<0.05 ) and
decreased thereafter, reaching significance on day 13 ( p<0.01 ). Insulin secretion
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Figure 7. The effect of culture period on insulin release pattern of free







2.7 16.7 2.7 16.7 2.7
Perifusion glucose concentration (mmol/L)
Mean ± SEM
Free islets were cultured for 4 (O , n=5), 6 (■ , n=7), 9 ( A, n=7) or 13 ( • , n=7)
days. Numbers in brackets indicate the number of channels perifused (30
islets/channel).
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expressed as peak first phase increased significantly ( p<0.05 ) from culture day 4 to
day 6 when considering both first and second stimulation. Peak first phase values
decreased after culture day 6 and reached significance on day 9 ( p<0.01 ) and day 13
( p<0.05 ) respectively. A further significant decrease in insulin secretion expressed
as peak first phase following second glucose stimulation was observed from culture
day 9 to day 13 ( p<0.05 ). Furthermore, free islets on culture day 4 and day 6 had
significantly increased peak first phase second stimulation values compared with first
stimulation values ( p<0.05 and p<0.01 respectively).
Figure 8 compares the effect of culture period on insulin release pattern of
encapsulated rat islets during perifiision. Encapsulated islets were cultured for 2, 4, 7
and 11 days and 7 channels (30 islets/channel) were perifiised at each culture period.
Although a slight delay in insulin secretion was observed ( maximum of 2 minutes )
from microencapsulated islets upon high glucose challenge, the biphasic insulin
secretory profiles of encapsulated islets were qualitatively similar to the profiles of
freshly isolated and free cultured islets. Insulin secretion ( % of TIC ) expressed as
AUC or peak first phase following first and second glucose stimulation or as total
AUC was significantly lower than freshly isolated islets at all culture periods.
Encapsulated islets showed optimal insulin secretion on culture day 7 whether
expressed as AUC or peak first phase following first and second glucose stimulation
or as total AUC. On culture day 2, insulin secretion ( % of TIC ) increased
significantly when expressed as AUC or peak first phase following second compared
with first glucose stimulation ( p<0.01 ).
Table 3 compares the insulin secretion ( expressed as AUC or peak first phase
following first and second glucose stimulation or as total AUC ) from freshly isolated
free, cultured free and cultured encapsulated rat islets during perifiision. Insulin
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Figure 8. The effect of culture period on insulin release pattern of











2.7 16.7 2.7 16.7 2.7
Perifusion glucose concentration (mmol/L)
Mean ± SEM
Encapsulated islets were cultured for 2 (o ), 4 (■ ), 7 (A ) or 11 (• ) days.
7 channels (30 islets/channel) were perifused at each culture period studied.
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secretion from free and encapsulated cultured islets was comparable at the 4 culture
periods studied although insulin secretion from free cultured islets was initially greater
than insulin secretion from microencapsulated cultured islets until day 6 ( optimal
culture period for free islets ). Indeed, free islets on culture day 4 and day 6 secreted
significantly more insulin ( p<0.05 ) than encapsulated islets on day 2 and day 4
respectively when considering peak first phase following first high glucose
stimulation. Free islets on culture day 6 also secreted significantly more insulin than
microencapsulated islets on day 4 ( p<0.05 ) when considering insulin secretion as
AUC following first glucose stimulation. After this culture period encapsulated islets
secreted more insulin when considering AUC and peak first phase following second
glucose stimulation and total AUC, although these differences were not significant.
Single rat pancreatic islets encapsulated in APA membranes are shown in Figure 9(a)
following 7 days of culture at 37°C. Microcapsules were then fixed in
neutral-buffered formalin and stained for insulin (b and c) and glucagon (d) as
specified in Materials and Methods. Approximately 50% of islets stained positive for
insulin and 33% for glucagon.
3.4. DISCUSSION
The transplantation of pancreatic islets is the most physiological way to clinically treat
IDDM patients, and microencapsulation of islets has been proposed as an alternative
to lifelong immunosuppression for prevention of graft rejection and recurrent
autoimmune destruction. The prolonged function of allogeneic and xenogeneic islets
encapsulated in APA membranes compared with free islets has been described in
STZ-diabetic rats and mice ( 738,762 ). In contrast, the prolongation of islet function















Figure 9(a). Rat pancreatic islets encapsulated in APA membrane after 7 days of
culture at 37°C in a humidified atmosphere of 5% CO2 Capsule diameter is
approximately 600 pm. x 50 (b) Encapsulated rat islet after 7 days of culture
















Figure 9(c), Encapsulated rat islet after 7 days of culture stained for insulin, x 125.
(d) Encapsulated rat islet after 7 days ofculture stained for glucagon, x 125.
253
and BB rats ( 751,752,755,763,837 ). Capsule failure in all cases was ascribed to
fibrotic overgrowth of the APA capsules. Only one group ( 750 ) has reported
successful engraftment of microencapsulated islets in diabetic BB rats, although
approximately 30% of recovered capsules exhibited cellular overgrowth and some
animals required a secondary transplant to maintain relative normoglycaemia.
An essential prerequisite for successful transplantation of encapsulated islets is the
maintenance of an adequate secretion of insulin in response to a glucose challenge.
Results of in vitro testing of APA microencapsulated islets are conflicting since
adequate insulin secretion has been reported by some groups ( 738, 736 ) but not
others ( 743, 744 ). One explanation for these differences is the time period between
encapsulation of islets and in vitro testing. Lim and Sun ( 738 ) cultured encapsulated
islets for approximately one week prior to perifusion studies, Reach ( 736, 744 )
allowed a recovery period of approximately 18 hours, whereas Fritschy et al ( 743 )
tested the glucose-induced insulin response of microencapsulated islets immediately
after completion of the encapsulation procedure.
The insulin release profiles of APA-microencapsulated rat islets, cultured for different
periods of time, during perifusion studies are reported here and compared with
freshly isolated and cultured free islets. All islets types gave a biphasic pattern of
insulin release in response to a high stimulatory concentration of glucose
( 16.7 mmol/1 ), demonstrating that islets remained functional and viable after
collagenase digestion and isolation, and microencapsulation. Glucose challenge
elicited an immediate insulin response from fresh and cultured free islets whereas a
slight delay ( maximum of 2 minutes ) was observed from microencapsulated islets.
This delay in insulin release from perifused encapsulated islets in response to glucose
has previously been observed by Lim and Sun ( 738 ) and Cole et al ( 752 ).
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However, Lim and Sun observed a 5 minute delay in the response of
microencapsulated islets to a glucose challenge. This extended delay could be due to
a slower flow rate ofmedium through the perifusion apparatus, although the flow rate
used is not stated. Horcher et al ( 838 ) observed a similar delay ( 2 minutes ) upon
challenging islets encapsulated in barium-alginate gel beads to a high glucose
concentration during perifusion. In all cases, the delay was attributed to the time
required for the passage of glucose across the capsule membrane to the islet and the
subsequent release and passage of insulin back across the membrane and into the
perifusion medium. The perifusion technique, in which insulin is continuously
removed by the perifusion flow, minimises this delay and demonstrates that the APA
membrane is permeable to both glucose and insulin.
The biphasic pattern of insulin release upon glucose challenge corresponds to an
initial, transient and rapidly-released pool of insulin which is quickly exhausted
( 839 ) and a second phase in which insulin release is slower and prolonged ( 840 ).
The first phase of insulin release may be crucial for glycaemic control as most IDDM
patients do not show this initial insulin secretion ( 840 ). The secretion of insulin
decreased towards basal levels after returning to a basal concentration of glucose
(2.7 mmol/1 ) demonstrating an adequate downregulation of insulin secretion upon
removal of glucose stimulation. This observation is equally important as an adequate
response to increasing glucose concentrations if immunoisolated islets are to provide
minute-to-minute regulation of blood glucose levels in vivo. Following a 20 minute
" rest " period with basal glucose, islets were subjected to a second high glucose
challenge. An increased first and second phase of insulin secretion was observed for
all islet types. The observation that exposure of pancreatic islets to a stimulatory
concentration of glucose has a priming effect on the P-cell, such that subsequent
glucose challenge results in an enhanced secretion of insulin, is well established
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( 841-844 ). However, the mechanism by which priming is induced is unknown.
Physiologically, islet P-cells adapt to increased demands for insulin following
prolonged exposure to elevated glucose concentrations by stimulating insulin
biosynthesis ( 845 ) and P-cell replication ( 846 ) thereby promoting the capacity of
the P-cell to secrete insulin and correct hyperglycaemia in vivo. The insulin response
is therefore dependent on immediate and previous exposure to glucose. Furthermore,
Grill et al ( 844 ) demonstrated this priming effect after only 5 minutes exposure of
isolated rat pancreas to stimulatory ( 27.7 mmol/1 ) glucose followed by a 5 minute
rest period in a perifusion study. This suggests that glucose acts through mechanisms
devoid of any appreciable time lag for their expression. It is therefore unlikely that
priming is caused by an effect on insulin synthesis or P-cell replication, which involve
lag periods of hours ( 847,848 ) or days ( 849 ) respectively before initial stimulation
of these two processes increases the pancreatic content of insulin and the secretory
capacity of the P-cell. The immediate stimulatory signal in the P-cell elicited by
glucose exposure may alternatively involve realignment of insulin-containing secretory
granules to positions more favourable for exocytosis, a reported secondary action to
the effect of glucose on the microtubular-microfilamentous system of the cell ( 849 ).
Translocation of insulin granules from the interior of the P-cell to its periphery upon
repeated glucose stimulation will allow easier release compared with granules located
further away from the site of exocytosis. This process is dependent on the presence
of calcium ions ( Ca^+ ). However, controversy exists with regard to the role of
Ca^+ in glucose priming. Grill et al ( 850 ) reported that omission of Ca^"1" from the
perifusion medium during the first exposure of islets to glucose failed to prevent the
induction of priming, and subsequent responses to glucose were enhanced. In a
conflicting report, Ashby and Shifting ( 851 ) stated that omission of Ca^+ during the
first glucose challenge prevented the induction of priming in islets. More recently,
Chalmers et al ( 842 ) also found that priming of islets with high glucose
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concentration was only observed if Ca2+ were present in the perifusion medium. If
Ca2+ were absent during the first exposure to high glucose, no enhancement of
insulin release to a subsequent glucose challenge was observed. Furthermore, priming
also appears to be dependent on glucose metabolism, as perifusion of islets with
medium containing mannoheptulose in addition to glucose blocked priming, and
D-galactose had no priming ability ( 850 ). In contrast, priming was induced by
glyceraldehyde ( 850 ), suggesting that priming may involve Ca2+-dependent
enzymes, as well as Ca2+-dependent processes such as microtubule polymerisation.
Alternatively, Grill et al ( 844 ) suggested that glucose could induce priming by
promoting the availability of energy in the p-cell. Insulin secretion is an
energy-dependent process ( 852,853 ), therefore an energised state of the P-cell could
promote insulin secretion. Indeed, ATP levels in pancreatic islets were found to be
elevated following priming with high glucose in a perifusion system.
Although the insulin secretion profiles were qualitatively similar for each islet type,
the actual amount of insulin secreted by the islets was quantitatively different. The
glucose-induced insulin secretion from freshly isolated islets was significantly higher
than that secreted from free and encapsulated cultured islets whether the data was
expressed as AUC or peak first phase following first and second glucose stimulation
or as total AUC. This observation has previously been reported in static culture
( 854,855 ) and perifusion systems ( 856 ). Gingerich et al ( 856 ) observed that after
24 hours of culture, glucose-stimulated insulin secretion had fallen to approximately
37% of freshly isolated islets. During the subsequent 4 days of culture, insulin
secretion remained constant at 20-25% of that of freshly isolated islets. Indeed, in
this study, optimal secretion of insulin from free islets ( culture day 6 ) in response to
a glucose challenge was 21-26% of that secreted by freshly isolated islets when
expressed as AUC following first and second glucose stimulation or as total AUC.
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The decrease in insulin release observed by Gingerich et al ( 856 ) was not due to loss
of islets from the perifusion chamber since counting experiments showed that at least
90% of the islets originally placed in the perifusion system remained after 3 days of
culture. Loss in insulin secretory rate with increased periods of culture may be caused
by a loss of functional P-cells within islets. However, this possibility was not studied
in detail by this group. An alternative explanation for the observed decrease in the
insulin secreted by cultured islets was proposed by Gingerich et al ( 856 ). The
presence of the hormone somatostatin, secreted by the islet 8-cells, is thought to
modulate the release of islet hormones ( 857 ). The secretion of insulin from freshly
isolated islets appears relatively unaffected by the inhibitory effect of exogenous
somatostatin ( 856,858 ). This initial lack of inhibition by exogenous somatostatin
may indicate that endogenous somatostatin may also be unable to regulate insulin
secretion in the usual manner, thereby explaining the greater basal and stimulated
insulin secretion observed in freshly isolated islets. The inhibitory effect of
somatostatin on insulin secretion returned after culture of the same islets for 24 hours
when both basal and stimulatory insulin secretory responses decreased. The later
inhibitory mechanism of somatostatin is unknown and a recovery period to allow
repair and regeneration of cellular components that were adversely affected during the
isolation procedure appears necessary.
Insulin secretion from free and encapsulated cultured islets in response to a high
glucose challenge was similar when compared at the four culture periods studied.
Lum et al ( 766 ), Cole et al ( 752 ) and Lim and Sun ( 738 ) also reported
comparable insulin secretion from free and encapsulated islets in response to high and
low glucose concentrations in perifusion studies after overnight, 24 - 48 hours and
approximately 1 week culture respectively. Lim and Moss ( 859 ) also showed that
the amounts of insulin released from free and microencapsulated islets by a
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combination of high glucose and theophylline were comparable in perifusion studies.
However, after 24 days of culture, perifusion of free islets showed a high level of
baseline insulin release and an abnormal stimulation-response pattern. In contrast,
microencapsulated islets produced a reasonably low level of baseline insulin release
and a typical biphasic stimulation-response pattern. Abundant and continued cell
proliferation was evident in all encapsulated islets and viable P-cells were observed
upon staining with haematoxylin and eosin and with aldehyde-fuchsin.
Microencapsulated islets continued to respond to glucose stimulation during an 8
week period. In contrast, free islets showed signs of degeneration, including
progressive P-cell degranulation at the end of 3 weeks.
These observations have been confirmed in long-term static incubation studies ( 860 )
although the normal biphasic pattern of glucose-induced insulin secretion cannot be
evaluated using this technique. Free cultured rat islets initially secreted significantly
more insulin into the medium than encapsulated cultured islets on day 1. On day 3
this difference was no longer significant. By day 10 a significantly higher insulin
concentration was detected in the medium bathing the encapsulated islets. In this
study, secretion of insulin from microencapsulated islets upon high glucose challenge
was optimal after a recovery culture period of 7 days whereas insulin secretion from
free cultured islets was optimal on culture day 6 and decreased thereafter. This
decrease in insulin secretion from free cultured islets may be due to the disintegration,
i.e. detachment, of P-cells as observed by Leung et al ( 860 ) after 2-3 weeks of
culture at 37°C. Throughout the remaining 8 week incubation period, encapsulated
islets consistently secreted more insulin than free islets. Indeed, Lim and Sun ( 738 )
observed a normal degree of P-cell granulation in microencapsulated islets cultured
for as long as 13 weeks. Cole et al ( 752 ) observed that static insulin release from
encapsulated rat islets decreased to 35% following 6 weeks culture. Although a
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greater reduction was observed from free islets after approximately 18 days,
significance was not achieved until week 6.
In contrast, Chicheportiche and Reach ( 744 ) and Fritschy et al ( 743 ) reported poor,
sometimes absent, insulin response to a glucose challenge using encapsulated islets.
Chicheportiche and Reach concluded that the insulin secretory response correlated
with the volume of the microcapsule since small ( 350 pm ) capsules responded
rapidly to glucose stimulation in a static incubation whereas no response was
observed with larger capsules ( 650 pm ). Diffusion across the microcapsule
membrane is known to decrease as the capsule diameter increases and is dependent on
the difference in insulin concentrations across the membrane in static incubations.
Since islets contained in large and small capsules secrete the same amount of insulin in
response to glucose stimulation, intracapsular insulin concentration will be
considerably lower in large capsules due to their larger volume. This may explain the
slower insulin release from larger capsules. In vivo, Lum et al ( 766 ) observed
prolonged reversal of the diabetic state in NOD mice after transplantation of rat islets
encapsulated in smaller ( 250-350 pm ) APA microcapsules. Advantages of these
smaller capsules in vivo include increased islet viability since oxygen and nutrients are
more accessible to the cell across the reduced dead space of the capsule. This also
enables faster P-cell response to glucose fluctuations in the recipient, an important
consideration for clinical application of microencapsulated islets in IDDM patients.
Kinetic modelling of glucose homeostasis in man indicates that the lag time of
increased insulin delivery in response to a glucose load by an artificial pancreas must
be shorter than 15 minutes to avoid overexcursion of postprandial blood glucose
levels (861 ). Further advantages of using smaller capsules in transplantation studies
include a reduced graft volume and greater mobility of capsules, which may lessen the
chance of mechanical damage after implantation. Reduced tissue irritation may
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consequently decrease cell overgrowth on capsule surfaces thus prolonging the
survival ofmicroencapsulated islet grafts in vivo.
However, Fritschy et al ( 743 ) reported that the presence of the microcapsule could
not explain the decreased insulin secretion by encapsulated islets since the response
was similarly decreased when islets were encapsulated without the final
membrane-forming step. Instead, this group observed a severely reduced insulin
release after prolonged suspension of islets in saline or treatment with citrate during
the encapsulation procedure, possibly as a result of damage to the islet secretory
system. Replacement with Ca^+-free Krebs-Ringer bicarbonate buffer and 1 mmol/1
EGTA respectively improved insulin release significantly. Levesque et al ( 862 ) also
reported that decreased glucose-induced insulin secretion from freshly
microencapsulated islets compared with free islets could not be explained by the
presence of the microcapsule since this decrease was also observed using
microencapsulated islets that had been mechanically freed from their capsules prior to
in vitro testing. This group investigated static insulin and glucagon secretion from
microencapsulated islets in response to long-term exposure to glucose. Glucagon
secretion was examined as glucagon-secreting a-cells are located in the periphery of
islets and are thus more susceptible to damage during encapsulation than other islet
cells. Glucose-induced insulin secretion was significantly reduced from islets 48 hours
after microencapsulation compared to free cultured islets. In contrast, secretion of
glucagon was similar in the two groups of islets. Differences in insulin diffusion
properties of the capsule membrane were eliminated since islets mechanically freed
from their capsules also exhibited reduced insulin, but normal glucagon, secretion in
response to high glucose stimulation. These findings further demonstrate the
permeability of the APA microcapsule to small molecules such as insulin, glucagon
and glucose. Analysis of islets immediately after encapsulation demonstrated
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significant reductions in both insulin and glucagon content, possibly due to damage
during the encapsulation procedure or by significant stimulation of secretion of both
hormones by one of the reactant solutions used to create the microcapsule. Further
reductions in the insulin and glucagon contents of both free and encapsulated islets
were observed over a 5 day culture period, although the loss of both hormones from
microencapsulated islets was less than that from free cultured islets. The insulin
content of microencapsulated islets remained significantly lower than free islets
thereby accounting for the lower secretion of insulin observed in encapsulated islets.
However, islet glucagon content became identical in free and microencapsulated islets
during the 5 day culture period. Thus, although microencapsulation induced an
immediate loss of islet insulin and glucagon content, the microcapsules seemed
beneficial over long-term culture by diminishing further hormone loss, as observed
with free cultured islets, by preventing islet disintegration.
In this study, insulin secretion from free and encapsulated islets upon glucose
challenge were comparable after defined periods of culture. Thus, although islets may
initially show a poor, sometimes absent, glucose-stimulated insulin response following
microencapsulation ( either as a result of islet damage by certain reactants used to
create the capsule or by significant reductions in the insulin content of islets following
microencapsulation ), a period of culture ( optimal after 7 days ) allowed recovery of
insulin-secreting function. This suggests that the deleterious effect of the
encapsulation procedure, as originally described by Lim and Sun ( 738 ), is at least
partially reversible. The recovery period may allow time for repair and regeneration
of cellular components of the islet affected by the encapsulation procedure. This
observation is particularly important for clinical transplantation of microencapsulated
pancreatic islets.
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Microencapsulation of pancreatic islets in APA membranes also provides a favourable
microenvironment for long-term in vitro maintenance of P-cell function compared
with free cultured islets. A normal degree of P-cell granulation in microencapsulated
islets is observed during long-term culture whereas free islets show signs of
degeneration and progressive P-cell degranulation. This suggests microencapsulated
islets may be clinically advantageous compared with free islets for islet transplantation
in the diabetic patient. However, several problems remain to be solved before
microencapsulated islet transplantation becomes a realistic option for treatment of
IDDM. These problems include modification of the composition and purification of
alginate to improve capsule strength and biocompatibility respectively, and
determination of microcapsule diameter, graft volume and transplantation site for
optimal function of microencapsulated islets. The recent report by Soon-Shiong et al
( 761 ) describing insulin-independence in an immunosuppressed IDDM patient after
encapsulated human islet transplantation is encouraging although further trials to
determine the optimal dose of encapsulated islets necessary to achieve
insulin-independence in non-immunosuppressed patients are required.
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CHAPTER 4
PREVENTION OF RECURRENT DIABETES IN SPONTANEOUSLY
DIABETIC, INSULIN-DEPENDENT AUTOIMMUNE BB/E RATS AFTER




The potential of isolated pancreatic islet transplantation as a treatment and possible
cure of IDDM is evident. In contrast to exogenous insulin therapy, islet
transplantation restores physiological control of glucose homeostasis and may also
prevent the secondary long-term complications and morbidity associated with IDDM.
However, two immune responses jeopardise the success of islet transplantation in
subjects with IDDM : allograft rejection and recurrence of the P-cell-specific
autoimmune process responsible for primary disease onset. T lymphocytes are the
principal effectors of all immune responses and must therefore be " controlled " to
ensure successful transplantation of an islet allograft.
Conventional immunosuppression, including CsA, comprimises the entire immune
system, involves long-term administration, exhibits limited efficacy and risks infection
and drug toxicity. The alternative approach involving immunoisolation of islets has
failed due to the bioincompatibility of materials used to form the protective
membranes. An improved and more sophisticated approach to immunosuppression is
clearly necessary. Ideally, immunosuppression would control the T lymphocytes
specifically responsible for initiation of the immune response without affecting the
remainder of the immune system. A major advantage of moAb therapy is specificity
for target antigens. Indeed, since collaboration between T cells and several other cell
types is essential for function of the immune system, interruption of these
collaborative events should result in therapeutic immunosuppression. The ability to
induce specific immunological unresponsiveness in the adult would have major
implications for both tissue grafting and treatment of autoimmune diseases. CD4+
and CD8+ T lymphocytes have been targeted by depleting and non-depleting moAb
because of the central role of these cells in the induction and maintenance of immune
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responses. However, studies in the rat utilising anti-CD4 and anti-CD8
immunotherapy to prevent allograft rejection have reported variable results. In this
\
study, the effect of short-term administration of depleting or non-depleting moAb
specific for the helper ( CD4+ ) or cytotoxic/suppressor ( CD8+ ) T lymphocyte
subsets on survival of islets transplanted intraportally in the spontaneously diabetic,
insulin-dependent autoimmune BB/E rat was investigated.
4.2. MATERIALS AND METHODS
4.2.1. ANIMALS
4.2.1.1. The BB/E rat
The BB/E rat has been previously described in this thesis. The mean age at onset of
diabetes was 108 + 3 days and the mean duration of diabetes at the start of treatment
was 117 + 3 days in this study.
4.2.1.2. The Wistar and Wistar Han albino rat
At the time of this study, breeding and use of normal Wistar rats had been replaced by
outbred Wistar Han ( WH ) rats in the Biomedical Research Facility. RTl-serotyping
ofWH rats indicated that the gene frequencies for the d, u, I and c haplotypes were
50%, 30%, 15% and 5% respectively. The supply ofWH rats was supplemented by
normal Wistar rats supplied by Harlan Olac Ltd., Bicester, Oxon, UK. No
RTl-serotyping was available on these outbred rats.
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4.2.1.3. The Balb/c mouse
Female Balb/c mice were bred and maintained in the Biomedical Research Facility and
used for the raising of ascites at 6-8 weeks of age.
4.2.2. HYBRIDOMA CELL LINES
The three hybridoma cell lines used ( Table 4 ) were obtained from the European
Collection of Animal Cell Cultures ( ECACC ), Division ofPHLS Centre for Applied
Microbiology and Research ( Salisbury, Wiltshire, UK ) and were grown in culture or
as ascites.
4.2.2.1. Culture of hybridoma cell lines
Hybridomas were received frozen in solid CO2 and were thawed in 0.5 ml
supplemented RPMI-1640 prewarmed to 37°C. Each cell line was transferred to a
sterile 50 ml Corning centrifuge tube, washed and harvested by centrifugation
( 75 x g, 5 minutes ) at 20°C. Cells were resuspended in supplemented RPMI 1640
and cultured in 25 cm^ Falcon tissue culture flasks ( Becton Dickinson ) in a
humidified atmosphere of 5% CO2 at 37°C. All cells were maintained at a
concentration of approximately 5 x 10^ cells/ml. The growth of the W3/25
moAb-secreting hybridoma cell line in supplemented RPMI 1640 medium was poor
and was significantly improved in Iscoves Modified Dulbecco's medium containing 25
mmol/1 glucose ( Sigma ) supplemented with 0.3% sodium bicarbonate, 0.1% BSA,
25 mmol/1 Hepes, 4 mmol/1 L-glutamine, 100 U/ml penicillin and 0.1 mg/ml
streptomycin.
267
Table 4 : Characteristics ofmoAb used
MoAb ECACC clone Isotype Specificity Reference
W3/25 84112002 IgGl CD4 : thymocytes, 863
( non- helper T cells and
depleting) macrophages
0X8 84112009 IgGl CD8 : thymocytes, 864
( depleting) cytotoxic/suppressor
T cells and NK cells
0X38 88051303 IgG2a CD4 : thymocytes, 665
( depleting ) helper T cells and
macrophages
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4.2.2.2. Determination of viability and concentration of cells
Viability and concentration of cells were checked daily using 1 volume of cell
suspension mixed with 1 volume of a 10 pl/ml solution of acridine orange ( Sigma )
and ethidium bromide ( Sigma ). The cells were placed in a haemocytometer
( Hawksley Cristalite, Hawksley, UK ) and viewed through a mercury lamp
fluorescent microscope ( Leitz, Wetzlar, Germany ) using UV and visible illumination
simultaneously. Viable cells took up acridine orange and appeared green, whereas
dead cells took up ethidium bromide and appeared orange.
4.2.2.3. Collection ofmonoclonal antibodies
Antibodies were collected daily by centrifugation ( 2500 x g, 10 minutes ) of cells at
20°C. The pelleted hybridoma cells were resuspended to the appropriate
concentration in fresh supplemented RPMI 1640 and returned to culture, whilst the
immunoglobulin present in the supernatant was precipitated using saturated
( 0.9 g/ml ) ammonium sulphate ( SAS ), pH 7.4 ( Sigma ). SAS was added slowly
and with stirring to the supernatant until 40% saturation was achieved. Following
overnight incubation at 4°C, precipitate was recovered by centrifugation
( 2500 x g, 30 minutes ), washed twice and resuspended in two volumes of 40% SAS
and stored at 4°C.
4.2.2.4. Raising of ascites
Ascites were raised in female Balb/c mice in addition to growing of hybridomas in
culture. Mice were primed with 0.8 ml of pristane ( 2, 6, 10, 14-tetramethyl-
pentadecane ) ( Sigma ) 7 days prior to intraperitoneal injection of 2 - 5 x 10^
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hybridoma cells in 0.5 ml of sterile phosphate-buffered saline ( PBS; 140 mmol/1
sodium chloride; 8 mmol/1 di-sodium hydrogen orthophosphate; 2.7 mmol/1 potassium
chloride and 1.5 mmol/1 potassium dihydrogen orthophosphate; BDH ). Ascites were
drained 14 days after immunisation and again after killing of the animal by inserting a
19G needle into the peritoneal cavity and draining the fluid into a sterile universal
container under gravity. The solution was centrifuged ( 300 x g, 20 minutes ) at
20°C and the supernatant washed three times to remove the pristane layer, prior to
the precipitation of immunoglobulins in 40% SAS.
4.2.2.5. Determination of protein ( antibody ) concentration
The protein ( antibody ) concentration of each precipitate after centrifugation and
resolubilisation in sterile PBS was determined regularly by spectrophotometry ( Pye
Unicam PU8610 UV/VIS kinetics spectrophotometer, Pye Unicam Ltd., Cambridge,
UK ) based on an absorbance of 0.69 for a 1 mg/ml protein solution at 280 nm using
PBS as a zero blank. After a sufficient quantity of each antibody had been generated,
the precipitates were purified and concentrated by ultrafiltration.
4.2.2.6 Ultrafiltration ofmonoclonal antibodies
Precipitates were centrifuged ( 2500 x g, 10 minutes ) at 20°C and the pellets
resolubilised in 50 ml of PBS. Undissolved material was removed by centrifugation
and the supernatants sterile-filtered through Falcon 0.45 pm cellulose acetate
membrane filters ( Becton Dickinson ) prior to transfer to a sterile ultrafiltration
stirred cells ( model 8050, Amicon Ltd., Gloucestershire, UK ). A sterile Diaflo
ultrafiltration filter ( membrane type YM 30; Amicon ) with a 30 000 molecular
weight cut-offwas appropriate for elution of toxic SAS under pressure ( 30 psi) and
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retention of antibody in the stirred cell. Each antibody was washed with 9 volumes of
sterile PBS and slowly concentrated to a final volume of 10 ml. The concentrated
solutions were transferred to sterile 20 ml universal containers ( Sterilin, Bibby
Sterilin Ltd., Staffordshire, UK) and the final protein concentrations determined using
PBS as a zero blank. All antibodies were diluted in sterile PBS to a final
concentration of 10 mg/ml, and 1 ml aliquots were transferred to sterile 5ml glass
vials ( Monoject, Sherwood Medical Industries Ltd., West Sussex, UK ). Samples
were then lyophilised ( ChemLab Freeze-drier, ChemLab Instruments Ltd., London,
UK ) to prevent bacterial and fungal growth during storage at -20°C.
4.2.3. MONOCLONAL ANTIBODY TREATMENT
4.2.3.1. Effect ofmoAb dose in vivo
Established diabetic BB/E rats maintained on CIT were randomly divided into
5 treatment groups : ( 1 ) PBS-treated, i.e. controls (n = 3);(2) W3/25
moAb-treated (n = 3);(3) 0X8 moAb-treated (n = 3);(4) 0X38 moAb-treated
( n = 3 ) and ( 5 ) treated with a combination of0X8 and 0X38 moAb ( n = 3 ). Rats
were bled ( approximately 1 ml ) by tail-tipping prior to subcutaneous injection of a
priming dose ( 10 mg ) of the appropriate moAb on day -3. Blood samples were
collected 60, 120 and 240 minutes and 24 hours (i.e. day -2 ) after injection. Animals
were subsequently injected with daily maintenance doses ( 1 mg ) ofmoAb from days
-2 to day 10. Animals were bled again during moAb treatment on day 0 (the day of
islet transplantation for experimental diabetic BB/E rats ), the last day of treatment
( i.e. day 10 ) 1 week post-moAb treatment and 2 weeks post moAb-treatment at
which time animals were killed. Lymphoid tissues were also collected and processed
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for immunofluorescence analysis. In addition, blood samples were used in Con A
proliferation assays.
4.2.3.2. Experimental protocol
Established diabetic BB/E rats maintained on CIT were randomly divided into
5 treatment groups : ( 1 ) PBS-treated, i.e. controls (n = 8);(2) W3/25
moAb-treated (n = 9);(3) 0X8 moAb-treated (n = 9);(4) 0X38 moAb-treated
( n = 9 ) and ( 5 ) treated with a combination of 0X8 and OX38 moAb ( n = 9 ).
Either 1 mg or 10 mg of each moAb was dissolved in 0.5 ml sterile PBS and injected
subcutaneously in the nape of the neck at the same time every day ( 0930-1100 ). On
day -3, animals were injected with 10 mg of the appropriate moAb and subsequently
with 1 mg for the remaining 13 days of treatment. Diabetic BB/E rats were
maintained on CIT from day -3 until day 0 when half the usual dose of insulin was
administered prior to receiving an intraportal islet graft. After the islet graft the
animals received no further insulin treatment. Peripheral blood samples were taken
pre-moAb treatment ( day -3 ), prior to transplantation of the primary ( 1°) islet graft
( day 0 ), at the end of moAb treatment ( day 10 ), upon failure of the 1° islet graft
and at death, at which time lymphoid tissues were also collected and processed for
immunofluorescence analysis. Animals maintaining a long-term functioning 1° islet
graft were also bled prior to transplantation of a secondary ( 2° ) islet graft under the
kidney capsule. The experimental protocol is summarised in Table 5.
4.2.4. ISOLATION OF PANCREATIC ISLETS
At the time of this study, breeding and use of normal Wistar rats had been replaced by
outbred WH rats in the Biomedical Research Facility. WH rats are anatomically
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Table5.Experimentalprotocolforislet-transplant ddiabetiBB/Er sceivingmoAbtreatment. Tune|1■//■j■//■■//■i (days)-3-201079±4110±4
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immature when compared to weight-matched Wistar rats, thus insulin secretion by
islets isolated from both rat types in response to glucose was evaluated by a static
incubation technique. Wistar rats weighing approximately 250 g ( n = 2 ) and
WH rats weighing approximately 280 g(n-2);315g(n = 2); and 375 g ( n = 2 )
were used for the isolation of islets. The method for the isolation of pancreatic islets
was as previously described except that digests were separated from contaminating
exocrine elements using a four-layer discontinuous BSA gradient ( Advanced Protein
Products, West Midlands, UK ) at the same densities as previously used for the
dextran gradients. BSA is reported to be less toxic to islets than dextran ( 865 ).
4.2.4.1 .Static incubation
For each group of animals, isolated islets were transferred to a sterile 4 well multidish
( Nunclon Delta, Denmark ) ( 20 islets/well ), suspended in 1 ml of glucose-free
RPMI 1640 supplemented media and incubated overnight at 37°C in a humidified
atmosphere of 5% CO2. The supernatants were removed ( approximately 900 jil )
and replaced with an equivalent volume of fresh media containing 11.1 mmol/1
glucose, and islets cultured for a further 2 days. Supernatants were subsequently
removed and stored at -20°C until assay of insulin. Islets were washed three times
with glucose-free RPMI 1640. During each wash, islets were left in the medium and
maintained at room temperature for 10 minutes to remove insulin which may have
accumulated during the previous culture period. After completion of washing,
prewarmed ( 37°C ) RPMI 1640 medium containing 2.5 mmol/1 glucose
( non-stimulatory ) was added to each well and the plate returned to the incubator for
90 minutes. Supernatants were then removed and replaced with RPMI 1640 medium
containing 20 mmol/1 glucose ( stimulatory ) and the plate incubated for 90 minutes.
Islets were washed three times after removal of supernatant and re-incubated in
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non-stimulatory medium for 90 minutes. Supernatants were then removed and islets
were washed three times with 0.9% saline and suspended in 500 pi distilled water
prior to sonication. TIC was assessed as previously described.
4.2.5. ISLET TRANSPLANTATION
4.2.5.1. Intraportal route
A 3 cm long midline abdominal incision was made under fluothane anaesthesia.
Displacement of the large and small bowel to the left side of the animal revealed the
portal vein. Blood supply was restricted by a steel wire placed underneath the portal
vein and allowed to sit across the wound. 1200-1600 pooled islets, cultured for 5-6
days and washed four times in sterile PBS prior to transplantation, were drawn into a
1 ml syringe ( via a 23G needle ) in a minimal volume of PBS and injected slowly into
the portal vein. Care was taken to avoid the introduction of air into the portal system.
Blood was withdrawn into the syringe and re-injected to ensure transfer of any
residual islets. The needle was removed and pressure applied over the venipuncture
for approximately 3 minutes using a cotton bud by which time bleeding had usually
ceased. The steel wire was removed from beneath the portal vein, allowing blood
flow to carry the islets forward into the liver. After returning the bowel to its original
position, the wound was closed with 3/0 braided silk suture ( Mersilk, Ethicon Ltd.,
Edinburgh, UK ) and the outer skin with Michel suture clips ( Northern Hospital
Supplies, Edinburgh, UK ).
After islet transplantation, rats from all groups were observed in metabolic cages and
allowed free access to food and water. Blood glucose concentration was initially
determined daily to assess the immediate function of the islet graft and subsequently
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measured twice weekly upon stabilisation of glycaemic control. Blood glucose level
was assessed between 0930 and 1100 and values during this period were similar to
those determined at peak feeding time ( 2200 ) as determined in Chapter 2 of this
thesis. In addition, body weight was measured and urine samples checked for the
presence of glucose and ketones twice weekly.
Animals maintaining normoglycaemia for 64-91 days ( mean ± SEM : 79 ± 4 days )
post-transplant received a second graft of approximately 500 islets implanted under
the kidney capsule to determine whether induction of tolerance to islet tissue had been
achieved. The islets for both the intraportal and kidney capsule transplants were
isolated from the same donor species and cultured 5-6 days prior to transplantation.
4.2.5.2. Kidney capsule site
Under halothane anaesthesia, rats were shaved over the left loin and a small incision
made after swabbing the area with alcohol. The left kidney was exposed by gentle
traction and a small incision through the kidney capsule ( approximately 2 mm long )
was made at the upper pole of the lateral border of the kidney using a scalpel blade.
The capsule was then raised from the kidney surface by inserting a round-ended
mouth gavage needle. Islets suspended in a minimal volume of PBS were drawn up
into a Portex cannula attached to a 1 ml syringe and transferred slowly into the space
created under the kidney capsule. The kidney was kept moist with saline throughout,
and upon completion of islet transfer, the wound was closed with 3/0 braided silk
suture and the outer skin with Michel suture clips. Animals were killed 31 ± 3 days
later. Untreated insulin-dependent diabetic BB/E rats ( n = 6 ) transplanted with
approximately 500 islets under the kidney capsule alone acted as controls. CIT was
administered as required in order to maintain a degree of normoglycaemia.
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Islet grafts were considered to have failed after 3 consecutive blood glucose
concentrations of >13.1 mmol/1 in conjunction with consistent weight loss and/or the
presence of glycosuria. After absolute graft failure, animals were killed by CO2
asphyxiation, and all lymphoid tissues were removed from animals using standard
surgical techniques. After preparation and determination of cell concentrations, cells
were used for immunofluorescence analysis. Peripheral blood lymphocytes ( PBL )
were also used in an in vitro mitogen stimulation assay.
4.2.6. PREPARATION OF LYMPHOID TISSUE
4.2.6.1. Peripheral blood lymphocytes
Heparinised blood samples collected from the tails of non-anaethetised rats were
transferred to a sterile 1.5 ml Starstedt tube and centrifuged ( 3500 x g, 3 minutes ).
Larger volumes of blood ( 5 ml ) were obtained by cardiac puncture prior to killing
and collected in a sterile 20 ml tube containing heparin. Peripheral blood lymphocytes
were isolated by centrifugation ( 560 x g, 10 minutes ) at 20°C. The buffy coat was
transferred to a sterile 15 ml Corning centrifuge tube and washed with 9 volumes of
sterile PBS supplemented with 0.1% BSA. Contaminating red blood cells were lysed
by addition of 9 volumes of freshly prepared sterile Tris-ammonium chloride solution,
pH 7.2 ( 9 volumes of 160 mmol/1 ammonium chloride mixed with 1 volume of
170 mmol/1 Tris [ hydroxymethyl ] methylamine ) to the pelleted cells for 10 minutes
at room temperature. The procedure was repeated after centrifugation of cells
( 560 x g, 10 minutes ) at 20°C. Cells were washed three times and harvested
between each wash by centrifugation ( 560 x g, 10 minutes ) at 20°C. Cells were




The spleen was processed in FACS-PBS medium ( PBS supplemented with 0.1%
BSA Fraction V, 15 mmol/1 sodium azide [ Sigma ] and 0.5 mmol/1 EDTA [ BDH ] )
by teasing the spleen apart using forceps and a scalpel blade. The disrupted tissue
was homogenised by hand and the resultant cell suspension was lysed of red blood
cells by the same procedure described in the preparation of PBL, with the exception
that FACS-PBS was used for the washing steps.
4.2.6.3. Peripheral and mesenteric lymphocytes and thymocytes
Peripheral and mesenteric lymph nodes ( PLN and MLN respectively ) and thymic
tissue were processed in FACS-PBS by mincing the tissue finely with scissors prior to
gentle homogenisation. The resultant cell suspension was washed once in
FACS-PBS.
4.2.6.4. Peritoneal exudate cells
10 ml of FACS-PBS were injected intraperitoneally prior to opening up the peritoneal
cavity and retrieving the maximum volume of medium containing peritoneal exudate
cells ( PEC ) using a plastic pipette. The cells were washed once in FACS-PBS.
4.2.7. IMMUNOLABELLING OF CELL SURFACE ANTIGENS
Cell surface phenotype was assessed using aliquots of 1 x 10^ cells from processed
tissues. Cells were incubated with 20 pi of conjugated moAb ( see Table 6 ) for
40 minutes at 4°C. All conjugated moAb were pretitrated using 1x10^ lymphocytes
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Table 6 : Conjugated moAb used for immunolabelling.












0X38 see Table 4 Pharmingen, 665 0.01
Mouse anti- 0X19 Thymocytes, Pharmingen,
rat CD5 peripheral










FITC : fluorescein isothiocyanate
*volumes indicated were suspended in 20 pi FACS-PBS medium for staining
0.25 - 1 x 106 cells.
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isolated from peripheral and mesenteric lymph nodes of WH donors to establish
optimal conditions for FACS analysis. Unbound antibody was removed by
washing twice with FACS-PBS and fixed in 300 pi of FACS-PBS and 10% formalin
(2:1) prior to immunofluorescence analysis.
4.2.8. IMMUNOFLUORESCENCE ANALYSIS
Immunofluorescence analysis was performed by Andrew Sanderson at the Department
of Zoology, University of Edinburgh using a Becton Dickinson FACScan ( Becton
Dickinson Immunocytometry Systems, Mountain View, California, USA ) fitted with
an argon-ion laser ( excitation wavelength 488 nm ). During FACS analysis, cells in
suspension pass from a reservoir through a nozzle assembly, become centred in a
cell-free sheath fluid, and pass through a focused laser beam ( 868 ). Light is
scattered by the cells and molecules are excited and fluoresce. Fluorescent light is
collected and focused, and a dichroic reflector directs defined wavelength ranges to
separate photomultiplier detectors which convert light signals to electronic signals.
Where overlap in emission spectra of fluorescent dyes occurred, as for phycoerythrin
( PE ) and fluorescein isothiocyanate ( FITC ) used in this study, it was necessary to
carry out a process of 2-colour compensation to obtain independent dye
measurements. This was accomplished by comparison with standard solutions of each
cells labelled with either PE- or FITC-conjugated antibody alone, and adjusting the
output of samples to zero for the inappropriate dye.
Light scattered by cells is generally collected in the forward-scatter ( FSC ) range of
3°-12°, and in the side-scatter ( SSC ) range of 70°-110°. Light scatter is most
proportionate to cell size at low scatter angles ( i.e. FSC ) whilst at large scatter
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angles (i.e. SSC ) the signals tend to reflect the fine internal structure and granularity
of cells ( 868 ). During data collection ( 10 000 cells ), red cells and dead cells were
routinely gated out according to their low FSC values which tend to be significantly
lower than other cells. During data analysis, non-lymphocyte cells ( including
macrophages and granulocytes ) were gated out according to their large SSC which
is substantially higher than for the lymphocyte population. Data was analysed using
dot plots to determine % lymphocytes and lymphocyte subsets.
4.2.9. MITOGEN STIMULATION ASSAY
Initially, MLR was considered as a standardised method to assess the responsiveness
ofPBL from moAb-treated BB/E rats to foreign islet tissue from donor Wistar or WH
rats. This method was unsuitable due to the highly variable response of BB/E PBL
even before treatment. For this reason, a mitogen ( Con A ) stimulation assay was
chosen to monitor the effectiveness of moAb treatment with time. PBL were
harvested and resuspended in supplemented RPMI 1640, and aliquots ( 2.5 x 10^
cells ) were cultured in 96-well round-bottom microculture plates ( Corning Cell
Wells ) with or without Con A at a final concentration of 2.5 pg/ml. The final sample
volume was 200 pi and samples were analysed in triplicate. The proliferation assays
were incubated at 37°C in a humidified atmosphere of 5% CO2 for 88-96 hours and
pulsed with 1 pCi ^H-thymidine ( specific activity : 5 Ci/mmol, Amersham ) per well
during the final 24 hour period. Cells were collected onto filter mats ( Skatron
Instruments Ltd., Suffolk, UK ) using a semi-automated Combi cell harvester
( Skatron ) and ^H-thymidine incorporation was assessed by liquid scintillation
counting using a 2000CA Tri-Carb liquid scintillation analyser ( Canberra Packard,
Berkshire, UK ). Mean + SEM counts per minute for triplicate cultures were
expressed as a ratio of the Con A-treated and untreated PBL, i.e. a stimulation index.
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4.2.10. HISTOLOGY
Upon termination, livers and pancreases were removed from animals and immediately
fixed in neutral buffered formalin. In long-term surviving rats that received a 2° islet
graft under the kidney capsule, the kidney was also removed and fixed.
Representative sections of tissue were cut ( 4 pm ) and stained as previously
described.
4.2.11. STATISTICAL ANALYSIS
All results are presented as mean ± SEM and were analysed using unpaired Student's
t-test. Differences between islet graft survival in Figure 10 were determined using the
Mantel-Haenszel test.
4.3 RESULTS
4.3.1. Comparison of insulin secretion during static incubation of islets isolated from
Wistar and Wistar Han rats.
Table 7 compares the insulin secretion ( as % of TIC ) from Wistar and WH rat islets
in static incubation. All WH rat islets secreted significantly more insulin in basal
glucose medium over a 48 hour culture period compared with Wistar rat islets
( p<0.01 for 320 g and 370 g and p<0.001 for 280 g WH rat ). Islets isolated from
320 g and 370 g WH rats secreted significantly less ( p<0.05 ) insulin compared with
islets isolated from 280 g WH rats. Following a 90 minute incubation in basal glucose
medium, islets isolated from 280 g and 320 g WH rats secreted significantly more
insulin ( p<0.01 and p<0.05 respectively ) compared with Wistar rat islets. Upon
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replacement with high glucose medium, insulin secretion from Wistar and WH ( 280 g
and 320 g ) rat islets increased significantly ( p<0.001, p<0.001 and p<0.05
respectively ) and insulin secreted by islets isolated from 280 g and 320 g WH rats
was significantly higher ( p<0.05 ) compared with Wistar rat islets. Upon returning to
basal glucose medium, insulin secretion from Wistar ( p<0.05 ) and 280 g and 320 g
WH ( p<0.001 ) rat islets significantly decreased. The insulin secreted by islets
isolated from 280 g WH rats was significantly lower than islets isolated from Wistar
( p<0.05 ), 320 g ( p<0.05 ) and 370 g ( p<0.01 ) WH rats. Consequently, WH rats
weighing between 280 g and 320 g were used for the isolation of islets in this study.
4.3.2. Comparison of the periods of normoglvcaemia following intraportal islet
transplantation in moAb-treated diabetic BB/E rats.
Table 8 shows the periods of normoglycaemia following a primary ( 1° ) intraportal
islet transplant in diabetic BB/E rats receiving depleting or non-depleting anti-CD4 or
depleting anti-CD8 moAb treatment. Animals maintaining a long-term functional
graft (79 ± 4 days ) received a secondary ( 2° ) islet transplant under the kidney
capsule and were killed 31 ± 3 days later. Only one animal receiving a 2° islet graft
was killed after returning to a hyperglycaemic state. Three animals were killed due to
megacolon while still normoglycaemic. The periods of normoglycaemia following
transplantation of 1° islet grafts were significantly greater for OX8, 0X38 ( p<0.05 )
and 0X8/0X38 ( p<0.01 ) moAb-treated rats compared with PBS-treated rats.
Figure 10 shows the percentage of functioning islet grafts ( i.e. grafts maintaining
normoglycaemia ) in diabetic BB/E rats following short-term ( 14 days ) treatment
with depleting or non-depleting anti-CD4 or depleting anti-CD8 moAb. 0X8, 0X38
and 0X8/0X38 moAb-treated diabetic BB/E rats maintained functional islet grafts for
significantly longer than PBS-treated control rats (p<0.001 ). MoAb treatments were
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also compared using the x2 test for rectangular contingency tables after separating
islet-transplanted BB/E rats into three groups ( A, B and C ) determined by the
periods of normoglycaemia following an intraportal islet graft. Group A comprised
animals with an intraportal islet graft that functioned for less than 10 days ( end of
PBS or moAb treatment ) and therefore represented early graft failures. Group B
comprised rats with a 1° islet graft that functioned >10 days ( short-term functioning
grafts ). The diabetic BB/E rats in group C maintained long-term functioning 1° islet
grafts and subsequently received a 2° islet graft under the kidney capsule on day 79 ±
4. The number of islet-transplanted BB/E rats receiving moAb treatment in each
group is given in Table 9. Islet grafts survived for significantly longer in 0X8, 0X38
and 0X8/0X38 moAb-treated diabetic rats compared with islet-transplanted control
rats ( p<0.001 ) and islets transplanted into 0X38 moAb-treated rats survived for
significantly longer than islets transplanted into W3/25 moAb-treated rats ( p<0.05 ).
4.3.3. FACS analysis
Results of FACS analysis of PBL and lymphoid tissues are presented as both
percentages and absolute cell numbers. Lymphocytes were expressed as % of total
cells. Lymphocyte subsets were expressed as % of lymphocytes.
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4.3.3.1. Percentages
4.3.3.1.1. PBL and PBL subsets in PBS-treated or short-term moAb-treated diabetic
BB/E rats.
The % lymphocytes and lymphocyte subsets in PBS-treated ( control ) or short-term
W3/25, 0X8, 0X38 or 0X8/0X38 moAb-treated diabetic BB/E rats are shown in
Tables 10-14 respectively.
The % lymphocytes was significantly decreased 120 ( p<0.001 ) and 240 minutes
( p<0.05 ) and 24 hours ( p<0.01 ) following the priming injection of OX8 moAb
compared with pre-moAb treatment. The % lymphocytes was also significantly
decreased during ( p<0.01 ) and 1 week after the end of moAb treatment ( p<0.05 ).
The % lymphocytes staining for the cytotoxic/suppressor T cell marker, CD8 was
significantly decreased 60 ( p<0.05 ), 120 and 240 minutes and 24 hours after the
priming moAb injection and also during, at and 1 week after the end of moAb
treatment compared with the value before moAb treatment ( p<0.01 ). The %
lymphocytes staining for both CD4 ( helper ) and CD8 T cell markers was
significantly decreased 240 minutes and 24 hours following the priming injection of
0X8 moAb and were completely depleted during moAb treatment compared with
pre-moAb treatment ( p<0.05 ).
The % CD8+ lymphocytes was significantly reduced 120 and 240 minutes and 24
hours following the priming injection of 0X38 moAb compared with the value prior
to moAb treatment ( p<0.05 ). The % of these cells was also significantly reduced
during, at ( p<0.001 ) and 1 week after ( p<0.05 ) the end ofmoAb treatment The %
CD4+ lymphocytes was significantly reduced 24 hours following moAb injection
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Table10.PBLndsu sets(%)inBS-treateddiab ticBB/Er t
LYMPHOCYTESandLYSUBSETS(%)
LymphocytePre-m Ab+60in120i24in+ 4hrDur gmoAbEndofo b1w ek2eeks subset^treatmenttreatmenttr t tpos - oAbpost-moAb (day-3)( -2)day0)(10)(death lymphocytes45.0+2.633.31401.36.76.14 836 02.19 7+5 27 3. CD5+5.70 0+64 30.7.9.3+1 250.6 792+0 IgM+53.79.5346 0+0 61.34.1237.0673 3451.47.8 CD8+12.32.0 0+5.7+38.0+.710 04310.733+528.1 CD4+29.3.378 61 0+45.0 79.726 9334. +1 20.39 CD4+/CD8+7.00 6733.2 14.6 70 95.71.3 3 Mean±SEM fLymphocytesareexpress d%oft talcell .Ly ytesubse sexpres dlymphocyt .
Table11.
PBLandsubsets(%)inhort-t rmW3/25moAb- reateddiabeticBB Er t .
LYMPHOCYTESandLYMPHOSUBSETS(%)
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Table14.PBLndsu sets(%)inshort-termcombine0X8/0X38moAb-trea dd abe icBB/Erats. LYMPHOCYTESandLYMPHOCYTESUBSETS(%) LymphocytePre-m Ab+60in12i+24minhrDuri gmoAbEndof oA1we k2we ks subset^treatmenttreatmenttrea mentpost- oApost-moAb (day-3)(day-2)0)(day10)(death lymphocytes48.3±4.536.77.9.3±25.7±2.0a75. a3 .0± 240 3523.7 6.4a48.±3 CD5+7.3±0.95.72.20.64 3±1.56.3 53.7±05 03.7± 92.0 IgM+36.3±1.91.74.828.0±1 520.7±36.1 446.7±6.134 0±1 550.7±8 145.3±7 CD8+10.0±0.6d6.3.3b3.7 0.71.0±0. C1 C0C0.3±0.32b17.7± 9 CD4+37.3±0.409.32.78.719.2.6b12.0±8.3a21 8b3 .3±4339.± 5 CD4+/CD8+9.3±3.45.74 22±1.0.0.1.3±0 94.35.±1. Mean±SEM fLymphocytesareexpressed%oft talcell .Lymphocytsubs sarexpr sedoflymphocy es. ap<0.05,b0.01andcp<0.comparedwithpre-moAbtreat ent. dp<0.05comparedwithdeath.
compared with the value 60 minutes after injection ( p<0.05 ). The % CD4+/CD8+
lymphocytes was significantly reduced 120 and 240 minutes ( p<0.05 ) and 24 hours
( p<0.01 ) following the priming injection of 0X38 moAb compared with pre-moAb
treatment. During and at the end of moAb treatment, the % of these cells was also
significantly decreased ( p<0.01 and p<0.05 respectively ).
The % lymphocytes was significantly reduced 240 minutes and 24 hours following the
priming injection of 0X8/0X38 moAb and also 1 week post-moAb treatment
compared with the value prior to moAb treatment ( p<0.05 ). The % CD8+ cells was
significantly reduced 60, 120 ( p<0.01 ) and 240 minutes ( p<0.001 ) and 24 hours
( p<0.01 ) following the priming moAb injection compared with pre-moAb treatment.
The % of these cells was also significantly decreased during, at ( p<0.001 ) and 1
week after ( p<0.01 ) the end of moAb treatment. The % CD4+ cells was
significantly reduced 240 minutes ( p<0.001 ) and 24 hours ( p<0.05 ) following the
priming injection of moAb compared with pre-moAb treatment. The % CD4+/CD8+
lymphocytes was significantly reduced 240 minutes ( p<0.01 ) and 24 hours ( p<0.05 )
following the priming injection of 0X8/0X38 moAb and also during moAb treatment
when CD4+/CD8+ lymphocytes were completely depleted compared with the value
prior to moAb treatment ( p<0.01 ).
The absolute effect of each moAb treatment was determined by comparison of the %
lymphocytes and lymphocyte subsets ofPBS-treated and moAb-treated rats.
The % CD8+ lymphocytes was significantly reduced 60, 120, 240 minutes ( p<0.05 )
and 24 hours ( p<0.01 ) following moAb injection, during ( p<0.05 ), at and 1 week
after the end of moAb treatment ( p<0.01 ) in OX8-treated diabetic BB/E rats.
However, upon killing of 0X8 moAb-treated animals 2 weeks post-moAb treatment,
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the % CD8+ T cells were not significantly different compared to pretreatment or to
PBS-treated control rats. The % CD4+/CD8+ lymphocytes was significantly reduced
in diabetic BB/E rats 120 and 240 minutes after the priming injection of 0X8 moAb
( p<0.01 and p<0.05 respectively ) and at the end of treatment ( p<0.05 ).
The % CD8+ T cells was significantly reduced 240 minutes and 24 hours ( p<0.05 )
after moAb treatment was started, during and at the end of moAb treatment
( p<0.01 ) and 1 week post-moAb treatment ( p<0.05 ) in 0X38 moAb-treated rats
compared with PBS-treated rats. At the time of killing there was no significant
different in the % CD8+ T cells compared with PBS-treated rats, although %
lymphocytes was significantly higher in the control group ( p<0.05 ). At the end of
moAb treatment, % CD4+/CD8+ T lymphocytes was significantly reduced in OX38
moAb-treated diabetic BB/E rats ( p<0.05 ).
The % lymphocytes were significantly reduced 240 minutes after the priming injection
of 0X8/0X38 moAb ( p<0.01 ). The % CD8+ T cells was significantly decreased
120 and 240 minutes ( p<0.05 ) and 24 hours after moAb treatment was started and
during, at and 1 week after the end of moAb treatment ( p<0.05 ) compared with
PBS-treated rats. Although the % CD4+ T cells was significantly greater in
0X8/0X38 moAb-treated BB/E rats prior to treatment ( p<0.05 ), the % of these
cells was significantly reduced 240 minutes following moAb injection ( p<0.01 ).
The % CD4+/CD8+ T cells was also significantly lowered in BB/E rats 240 minutes
after priming injection of 0X8/0X38 moAb and at the end of treatment ( p<0.05 )
compared with PBS-treated rats.
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4.3.3.1.2. The effect of PBS treatment or short-term moAb treatment on PBL and
PBL subsets in islet-transplanted diabetic BB/E rats.
The % lymphocytes and lymphocyte subsets in islet-transplanted diabetic BB/E rats
following PBS-treatment or short-term W3/25, 0X8, 0X38 or OX8/OX38 moAb
treatment are shown in Tables 15-19 respectively. Lymphocyte data for diabetic
BB/E rats was analysed after separating experimental animals into 3 groups depending
upon the period of normoglycaemia following 1° islet transplantation on day 0 as
previously described.
Islet-transplanted PBS-treated rats were all group A and had significantly increased %
CD4+ T cells at failure of the 1° islet graft compared with the % of these cells
pretransplant and at death ( p<0.05 ).
The % lymphocytes at the end of moAb treatment in group B was significantly lower
in W3/25 moAb-treated BB/E rats receiving an intraportal islet graft compared with
% lymphocytes pretreatment and pretransplant ( p<0.05 ).
In 0X8 moAb-treated rats, the % CD8+ T cells was significantly decreased ( p<0.05 )
prior to islet transplantation compared with pre-moAb treatment. CD8+ T cells was
significantly lower pretransplant ( p<0.01 ), at the end of moAb treatment and upon
islet graft failure ( p<0.05 ) in group B compared with % CD8+ T cells upon killing,
although there was no significant difference between the % CD8+ T lymphocytes at
the time of death and prior to moAb treatment. The % CD4+ T cells was significantly
increased at failure of the intraportal islet graft compared with values at the end of
treatment and upon killing ( p<0.01 ). Upon combination of groups A, B and C, the
% lymphocytes at the time of islet graft failure was significantly greater than at the
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lymphocytes CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
23.8±5.5 5.8±0.8 46.5±14. 1.8±0.8k 48.0±6. 1.8±0.9'
23.1±4.4 5.8±0.8 47.4±8.4 2.9±1.9e 37.0±3.1 2.6±1.2'
47.7±4.6 4.0±0.6 50.7±4.1 4.0±1.0e 35.0±12.5 6.3±2.8
32.6±4.2 2.8±0.7J 64.5±5.2 12.4±2.0 38.9±2.1 7.1±1 5
Mean±SEM
*DiabeticBB/Eratsweredividedin o3groupsd e minedyhperiodfnormoglycaemiafoll w ngani traportali l tgr ft.GroupA:earlygraftfailures(<10d y).G oupB:short-termfunc ioninggrafts(>10day).G oupC:long-termfu ctioninggraftsreceiving2°isl tgraftunderthkid eycapsule. f Lymphocytesarexpres eda%ftotalc lls.Lymphocyteubsetsrexpr s eda%flym hocytes,tThedataforpre-moAbt atmentndpretransplantfhe1°islgr ftiexpressedto alf rgroupsBandC.
ap<0.05comparedwithpretransplantof2°islgr fti groupC.b p<0.05comparedwithpre-moAbtr tment.
cp<0.01comparedwithfailureof1°isl tg aft(TOTAL).f p<0.05,hp<0.01,dp<0 01comparedwithdeating oupB.8p<0.05,ep<0. 1andp̂<0.001comparedwithdeat(TOTAL).
' p<0.05comparedwithdea .
Jp<0.05comparedwithfailu ef1°isl tg aft.
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CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
Mean±SEM
*DiabeticBB/Eratsweredivid dinto3groupete minebythperiodofnormoglycaemiafoll inganintr p t lisgraft. GroupA:earlygr ftfailures(<10days).roupBsho t-termfuncti ningg afts>10d ys.GroupC:long-termfu cti ni g graftsreceivinga2°islgr tund rthkid yc psule. TLymphocytesareexpress d%oft talcell .Lymphocytesubs tarex r ssedoflymphocytes. +Thedataforpre-moAbtre tmentndpretra spl tfth1°isl tgr tex res eatot lf g upA,BandC. ap<0.05,b<0.01andhp .0comparedwithpretra splantf2°isl tgr tnoupC cp<0.05andf . 1comparedwithde tingroupB d p<0.05,0<0.01and&.comparedwithde t(TOTAL)
1 p<0.05,m .01ande<0.comparedwithpre-moAbtre ent. ' p<0.05comparedwithdeatingroupCJp<0. 01comparedwithpretransplantof2°islgr(TOTAL). k p<0.05comparedwithdeath.np<0.05comparedwitpretr nsplantof1°islgr7.0±1 2 52.7±6 6 0.3±.3e-g 42.7±2.3 2.0±2.0)5.9±0.5 51.0±8 1 0.9±.5e'S 41.6±3 1 0.9±0.4dJ'm
3.8±0.8 47.8±5.0 5.0±1.6° 29.0±9.6 7.3±1
3.4±0.3 59.3±5 9 14.8±2 6 42.8±3.1 11.1±4 5
end of moAb treatment ( p<0.05 ). The % CD8+ T cells was significantly decreased
prior to transplantion of the 1° islet graft ( p<0.01 ), failure of the 1° graft and at the
end of moAb treatment ( p<0.05 ) compared with % CD8+ T cells upon killing.
There was no significant difference in % CD8+ T cells between pre-moAb treatment
and death. The % CD4+ T cells was significantly greater upon failure of the 1° islet
graft compared with cells prior to 1° islet transplantation and killing ( p<0.01 and
p<0.05 respectively ). The % CD4+/CD8+ T cells was significantly greater upon
killing compared with pretransplant of the 1° islet graft ( p<0.05 ).
The % CD5+ T cells was significantly decreased pretransplant of the intraportal graft
in 0X38 moAb-treated diabetic BB/E rats compared with pre-moAb treatment
( p<0.05 ). However, there was no significant difference between the % CD5+ T cells
at failure of the 1° islet graft and the end of moAb treatment when compared with
pre-moAb treatment in group B experimental rats. There was a significant decrease in
the % CD8+ T cells between pre-moAb treatment and the end of moAb treatment
( p<0.05 ), and the % CD8+ T cells upon killing was significantly higher than % of
cells pre-moAb treatment, pretransplant, at failure of the 1° islet graft and the end of
moAb treatment ( p<0.001 ). The % CD4+/CD8+ T cells was also significantly
increased at death compared with pre-moAb treatment ( p<0.05 ), pretransplant
( p< 0.01 ) and failure of the intraportal islet graft ( p<0.05 ). In group C, the %
lymphocytes was significantly increased at the time of the 2° islet graft under the
kidney capsule compared with pre-moAb treatment, pretransplant of the 1° intraportal
islet graft and at the end of moAb treatment ( p<0.05 ). The % CD4+ T cells
significantly increased from the end of moAb treatment to the time of death
( p<0.05 ). For the combined data of groups B and C, % CD5+ T cells at failure of
the 1° islet graft was significantly greater than the % of cells pretransplant and upon
killing ( p<0.01 and p<0.05 respectively ). The % CD8+ T cells was higher at killing
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compared with pre-moAb treatment, pretransplant of both 1° and 2° islet grafts, end
ofmoAb treatment ( p<0.01 ) and failure of the 1° islet graft ( p<0.001 ) in the 0X38
moAb-treated rats. The % CD4+/CD8+ T cells was also significantly higher at death
compared with pre-moAb treatment ( p<0.05 ), pretransplant ( p<0.01 ) and failure of
the 1° graft and at the end of 0X38 moAb treatment ( p<0.05 ).
The % CD8+ and CD4+/CD8+ T cells were both significantly reduced prior to
transplantion of the intraportal islet graft in 0X8/0X38 moAb-treated diabetic BB/E
rats compared with pre-moAb treatment ( p<0.001 ). In group B, % CD8+ T cells
upon killing of the BB/E rat was significantly higher compared with % of cells
pre-moAb treatment ( p< 0.05 ), pretransplant ( p<0.01 ), failure of the 1° islet graft
and at the end of moAb treatment ( p<0.05 ). At these two latter time points, all
CD8+ T cells were completely depleted. The % CD4+/CD8+ cells was significantly
reduced at the end ofmoAb treatment and were completely depleted at failure of the
intraportal islet graft. The % lymphocytes decreased from pre-moAb treatment to the
end of treatment in group C ( p<0.05 ) and was significantly increased at the time of
2° islet grafting under the kidney capsule compared with values prior to moAb
treatment ( p<0.05 ), pretransplant ( p<0.01 ) and end of treatment ( p<0.05 ). The %
CD8+ T cells was significantly decreased at the end of treatment, pretransplant of the
2° islet graft and at death compared with pre-moAb treatment ( p<0.01 ), but not at
the time of failure of the 1° islet graft. The % CD4+/CD8+ T cells was significantly
decreased from pre-moAb treatment to the end of moAb treatment ( p<0.01 ) which
was significantly lower compared with pretransplant of the 2° islet graft under the
kidney capsule and at death ( p<0.01 and p<0.05 respectively ). The % of these cells
was also significantly reduced prior to transplantation of the 1° islet graft compared
with pretransplantation of the 2° islet graft ( p<0.001 ) and at death ( p<0.05 ). Upon
combining the data for groups A B and C, % lymphocytes before moAb treatment
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and pretransplant were significantly higher compared with % lymphocytes at the end
of0X8/0X38 moAb treatment ( p<0.05 ), although this difference was not significant
at death. The % CD8+ T cells was significantly reduced at the time of 1° graft failure
and the end of moAb treatment ( p<0.001 ) but not prior to transplantation of the 2°
islet graft, compared with pre-moAb treatment. However, upon killing, the % CD8+
T cells was significantly higher than at pre-moAb treatment ( p<0.05 ), pretransplant
of the 1° ( p<0.001 ) and 2° ( p<0.01 ) islet grafts, failure of the 1° graft and at the end
of 0X8/0X38 moAb treatment ( p<0.001 ). The % CD4+/CD8+ T cells was
significantly reduced at the end of moAb treatment compared with that pre-moAb
treatment ( p<0.01 ). These cells were significantly higher prior to transplantation of
the 2° islet graft under the kidney capsule compared with pretransplant and failure of
the 1° islet graft and at the end of moAb treatment ( p<0.001 ). Upon killing, the %
CD4+/CD8+ T cells was significantly higher than at pretransplant and the end of
treatment ( p<0.05 ) but was not significantly different compared with the value prior
to moAb treatment.
The % lymphocytes and lymphocyte subsets of PBS-treated diabetic BB/E rats
receiving an intraportal islet graft ( Table 15 ) were compared with islet-transplanted
diabetic rats receiving W3/25, 0X8, 0X38 or 0X8/0X38 moAb treatment ( Tables
16- 19).
Prior to intraportal islet transplantation, both the % lymphocytes and CD8+ T cells
were significantly lower in diabetic rats receiving 0X8 moAb-treatment ( p<0.05 ).
The % CD8+ T cells remained significantly reduced in group B at failure of the 1°
graft and at the end of treatment compared with islet-transplanted rats receiving PBS
treatment ( p<0.001 and p<0.05 respectively ). The % CD4+ T cells was significantly
increased at the time of failure of the 1° islet graft in islet-transplanted diabetic rats
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receiving 0X8 moAb-treatment ( p<0.05 ). Combining the data for the groups A, B
and C confirmed that the % CD8+ T cells was significantly decreased in BB/E rats at
the time of 1° islet graft failure and at the end of 0X8 moAb treatment ( p<0.001 and
p<0.01 respectively).
The % CD8+ T cells was significantly reduced in islet-transplanted diabetic rats
receiving 0X38 moAb-treatment in group B upon failure of the intraportal islet graft
and at the end of moAb treatment compared with PBS-treated rats ( p<0.001 and
p<0.05 respectively ). Upon killing of 0X38 moAb-treated rats in group C, the %
CD8+ and CD4+/CD8+ T cells were significantly reduced ( p<0.05 ).
The % CD8+ and CD4+/CD8+ T cells were both significantly reduced in
islet-transplanted diabetic rats receiving 0X8/0X38 moAb-treatment at pretransplant
compared with PBS-treated rats ( p<0.05 ). The % of both lymphocyte subsets
remained significantly reduced at the time of 1° islet graft failure in Group B
( p<0.001 and p<0.01 respectively ), and with respect to the % CD8+ T cells, at the
end of moAb treatment also ( p<0.01 ). Upon killing, % CD4+/CD8+ T cells was
significantly reduced ( p<0.05 ). In group C, % CD8+ T cells at the end of
OX8/OX38 moAb-treatment was significantly reduced compared with PBS-treated
rats ( p<0.05 ), and were significantly reduced upon failure of the 1° islet graft and at
the end of moAb treatment ( p<0.001 ) upon combining the data from groups A, B
and C.
To determine the effect of islet transplantation on % lymphocytes and lymphocyte
subsets, PBS-treated ( Table 10 ) or W3/25, 0X8, 0X38 or combined 0X8/0X38
moAb-treated diabetic BB/E rats ( Tables 11-14 respectively ) were compared with
the % cells in corresponding islet-transplanted rats receiving PBS-treatment or
310
W3/25, 0X8, 0X38 or combined 0X8/0X38 moAb-treatment ( Tables 16 - 19
respectively ).
At the end of 0X8 moAb treatment in group B, the % cells staining for the B
lymphocyte marker, IgM+ was significantly greater in islet-transplanted rats compared
with rats treated with 0X8 moAb alone ( p<0.05 ). This finding was also observed
when the data for groups A, B and C were combined.
The % IgM+ B cells was significantly greater in islet-transplanted diabetic BB/E rats
receiving 0X38 moAb treatment at death in group C and upon combining the data for
groups A, B and C ( p<0.01 and p<0.05 respectively ).
At the end of 0X8/0X38 moAb treatment, diabetic BB/E rats in group B receiving an
islet graft had significantly increased IgM+ B cells ( p<0.05 ) and % CD4+ T cells
was significantly increased ( p<0.05 ) upon killing of rats in group C compared with
OX8/OX38 moAb-treated rats .
4.3.3.1.3 Lymphocytes and lymphocyte subsets in lymphoid tissues of PBS-treated or
short-term moAb-treated diabetic BB/E rats.
The % lymphocytes and lymphocyte subsets in the lymphoid tissues upon killing the
PBS-treated or W3/25, 0X8, 0X38 or 0X8/0X38 moAb-treated diabetic BB/E rats
are shown in Tables ( 20 - 24 ). MoAb treatment had no effect on the % lymphocytes
or lymphocyte subsets in the lymphoid tissues compared with PBS-treated rats.
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Lymphocytes CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
67.3±5.8 14.7±.2 14.0±9. 2.3±0.3 17.7±.9 1.0±0.0
68.3±7.4 6.7±1 5 37.0±15 6 0.7±0.3 10.3± 1.0±0.0
55.0±3.1 5.3±1 2 52.0±3 2 6.7±1 2 20.3±5.9 4.3±1 5
43.0±7 2 7.0±2.6 30.0±15 6 6.0±2.0 61.7±9.5 9.0±5.5
95.7±0.3 83.0±2 3 1.0±0.0 8.3±0.7 6.7±0.3 81.3±0 9
Mean±SEM.n=3.
t Lymphocytesarexpress d%oft talcell .hocytesubsexpress dlymphocyt s.









CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
13.0±.2 9.3±2.0 2.0±0.0 15.0±.5 2.0±1 2
6.3±0.9 33.3±5.2 1.0±0.0 9.7±1 5 1.0±0.0
3.3±1 54.0±5 7 6.0±0.6 13.0±4.5 6.3±1 5
3.0±1 2 42.0±8 1 2.7±0.3 53.7±18 3 16.3±0 5
80.7±3.5 2.0±1 9.0±2.1 5.3±1 83.0±3.1
Mean±SEM.n=3.
t Lymphocytesareexpress d%oft talcell .phocytesubexlymphocytes.
4.3.3.1.4. The effect of PBS treatment or short-term moAb treatment on
lymphocytes and lymphocyte subsets in lymphoid tissues of islet-transplanted diabetic
BB/E rats.
The % lymphocytes and lymphocyte subsets in the lymphoid tissues of
islet-transplanted diabetic BB/E rats receiving PBS treatment or W3/25, 0X8, 0X38
or 0X8/0X38 moAb treatment are shown in Tables 25 - 29 respectively. MoAb
treatment had no effect on the % lymphocytes or lymphocyte subsets in the lymphoid
tissues compared with PBS-treated rats.
The only finding of significance upon comparing the % lymphocytes and lymphocyte
subsets of the lymphoid tissues ofPBS-treated ( Table 25 ) or W3/25, 0X8, 0X38 or
0X8/0X38 moAb-treated ( Tables 26 - 29 ) diabetic BB/E rats was the reduction in
% CD8+ T cells in the thymus of group B rats receiving 0X8 moAb treatment at
death ( p<0.05 ). However, this reduction was not significant upon combining the
data from groups A, B and C.
To determine the effect of islet transplantation on the % lymphocytes and lymphocyte
subsets in the lymphoid tissues, PBS-treated ( Table 20 ) or W3/25, 0X8, 0X38 or
OX8/OX38 moAb-treated diabetic BB/E rats ( Tables 21-24 respectively ) were
compared with the % cells in corresponding islet-transplanted, PBS-treated
( Table 25 ) or W3/25, 0X8, 0X38 or 0X8/0X38 moAb-treated rats ( Tables
26 - 29 ).
The % CD4+ T cells was significantly higher in PLN and the thymus of PBS-treated
BB/E rats receiving an intraportal graft compared with rats receiving PBS treatment
alone (p<0.05 ).
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Table25.Lymphocytendlymphocytesu se s(%)inl p itissuesofislet-tran plantdiabetiBB/Er trec ivingPBS- r tme t. LYMPHOCYTESANDLYMPHOCYSUBSETS(%) Sub-group* (n)Lymphocyte subset1"PLNMLNSPLEENPECTHYMUS A(8)lymphocytes45.9±4.335.9±8.331.4±6.025.1±9.487.6±1.8 CD5+28.7±4.67.4±14.4±0.820.6±8.273.9±7 6 IgM+26.4±7.849.1±1064.7±519.7±6.65.3±2.6 CD8+3.0±0.32.7±1 25.6±0.910.6±5.5.3±1 5 CD4+22.4±1.11.0±.611.0±2.547.3±9.59.9±0.8 CD4+/CD8+0.3±0.21.4±0.61.9±01.0±55.3±11 9 Mean±SEM *DiabeticBB/Eratsw redivid dinto3groupsdete minebyhperiofnormoglycaemiafoll wingaintr ort lsgraft. GroupA:earlygr ftfailu es(<10days).rBshort-t rmfuncti ningg aft>ysGr upClong-te mfu cti ning graftsreceivinga2°isl ftunderthkid ycapsule. t Lymphocytesareexpressed%oft talcell .Ly tsubse sexpressedlymphocyt .
Table26.heeffectofshort-t rmW3/25m Atreatmentonlymphocytandlymph cysubset(%)inlymphoidtissueof islet-transplanteddiabeticBB/Erat . LYMPHOCYTESANDLYMPHOCYTESUBSETS(%) Sub-group* (n)Lymphocyte subset^PLNMLNSPLEENPEC
THYMUS
A(5)
lymphocytes CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
51.6±9 5 21.2±1.3 11.2±5 3 4.6±0.5 20.8±2 0 0.8±0.4
58.4± 9 8.8±0.6 35.4± 1.6±0.5 13.2±.7 0.6±0.2
50.0±5 5 3.8±0.4 56.6±3 3 4.6±1.5 18.2±.5 2.4±1 0
43.0±6 9 3.6±0.6 43.4±10 0 1.8±0.4 74.8±7 6 7.8±4.1
79.2±10. 57.6±1 .3 10.6±9.4 10.8±2 0 14.6±3 7 52.0±14.
B(3)
lymphocytes58.7±9.4 CD5+ IgM+ CD8+ CD4+ CD4+/CD8H21.3±2 7 27.7±3 4
2.3±0.3 25.7±2 0 0.7±0.3
73.0±2 1 7.3±0.7 53.7±10.4 0.7±0.3 11.7±0.3 0.7±0.3
43.0± 5 6.7±1 5 62.3±5 2 5.3±0.3 20.0±1.0 2.7±1 5
49.7±1.8 3.3±0.7 70.0±9.5 1.0±0.6 65.7±22.5 3.0±3.0









































































*DiabeticBB/Eratsweredivid dinto3g oupsdeterminedbythper odofnormoglycaemiafoll wi ganintrap rtalisgraf . GroupA:earlygr ftfailu es(<10days).GroupBshort-termfuncti ninggraf s>10days).Gro pC:long-te mfu cti ning graftsreceivinga2°islgraund rthekid ycapsul . tLymphocytesareexpressed%oft talcell .Lymphocytsubsetarex r s doflymphocyt .




















































































































































*DiabeticBB/Eratsweredivid dinto3groupsete minedbythperiofnormoglycaemiafoll winganintr ort ls tgr ft. GroupA:earlygr ftfailures(<10days).roupBsho t-t rmfuncti ningg aft>d ysGr upClong-te mfu cti ning graftsreceivinga2°isl ftund rthkidneycapsul . t Lymphocytesareexpress d%oft talcell .Ly tesubse sexpre dlymphocyte .




































































TOTALlymphocytes47.4±.353 28 55.162 .47.22±9 (9) CD5+19.0±3.93 70 314.±65 65 IgM4"33.3±7.5426 756± 039.38.1 29 5 CD8+8.6±3.56 2472.0±1.815 32 CD4+23.9±3.418 25.634 .38.412 9± 8 CD4+/CD8+2.4±0.93 01 79.511.1559±7 8 Mean±SEM *DiabeticBB/Eratsw redivid dinto3groupseterminedbyhperofno moglycaem afoll winganintr t lsg aft. GroupA:earlygraftfailu es(<10days).Bshort-t rmfuncti ningg aft>sGr upClong-termfu cti ning graftsreceivinga2°isl tftunderthkid ycapsule. t Lymphocytesareexpress d%oft talcell .tsubse srexpre dflymphocyte .










































































CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
9.8±5.1 53.8±16 7 2.3±0.5 20.0±3 5 5.0±1 4
16.5±.9 37.0±11 3 2.0±0 6 22.0±3.1 2.8±0.8
7.5±0.3 47.0±8 3 3.3±2.3 14.0±.1 3.5±1 2
36.5±9.2 18.5±8.0 14.0±2 8 43.8±4 3 17.5±
76.8±4 4 3.3±1 1 13.0±.8 16.8±4 4 64.5±3 4
TOTAL (9)
lymphocytes CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
47.9±5 2 16.4±3 6 32.0±11 4 2.9±0.4 20.9±2 3 2.8±1 1
61.7±4 9 14.3±.7 34.7±6.4 3.0±1 4 18.6±2 2.3±0.6
60.4±8.3 6.8±0.5 49.9±6 1 5.1±1 8 14.5±2 9 2.5±0.7
12.0±4 7 21.6±7.1 30.3±7.5 10.8±2 2 50.6±7.0 10.9±4 6
77,3± .4 72.8±9 2.3±0.7 12.1±.3 12.3± 7 60.8±8 9
Mean±SEM
*DiabeticBB/Eratsweredivid dinto3groupdetermin dbythper odofnormoglyc emiafoll inganintr po t lisgraf . GroupA:earlygr ftfailu es(<10days).GroupBshort-termfuncti ningg afts>10days).Gro pC:long-termfu cti ni g graftsreceivinga2°islgrund rthkid yc psul . t Lymphocytesareexpressed%oft talc ll .Lymphocytsubs tarex re s doflymphocyte .
In group B, the % IgM+ B lymphocytes was significantly increased in PLN and PEC
( p<0.05 ), and the % CD4+ T cells was significantly increased in PLN and MLN of
islet-transplanted, W3/25 moAb-treated diabetic BB/E rats ( p<0.05 ). Combining the
data for groups A, B and C, demonstrated that % IgM+ B cells was significantly
increased in PEC ( p<0.01 ), % CD5+ T cells was significantly increased in PLN and
MLN ( p<0.001 ), % CD8+ T cells was significantly increased in PLN ( p<0.01 ) and
% CD4+ T cells was significantly increased in the thymus ( p<0.05 ) of W3/25
moAb-treated rats receiving a 1° islet graft.
The % CD5+ and CD4+ T cells were significantly increased in PLN and the thymus
respectively ( p<0.05 ) of islet-transplanted, 0X8 moAb-treated BB/E rats in group
B. Using the combined data for groups A, B and C, the % CD5+ T cells was
significantly greater in PLN and PEC ( p<0.05 ) and the % CD4+ T cells was
significantly greater in the thymus ( p<0.01 ) of 0X8 moAb-treated rats receiving an
intraportal islet graft.
0X38 moAb-treated diabetic BB/E rats in group B receiving an islet transplant had a
significantly greater % CD5+ T cells ( p<0.05 ) in PLN compared with 0X38
moAb-treated rats. Islet-transplanted diabetic BB/E rats in group C receiving 0X38
moAb treatment had a significantly greater % CD5+ T cells in PEC and IgM+ B cells
in PLN ( p<0.05 ) compared with 0X38 moAb-treated rats and % CD4+ T cells was
significantly greater in the thymus ( p<0.001 ).
In group B islet-transplanted rats receiving 0X8/0X38 moAb treatment, % CD8+ T
cells was significantly increased in PLN and % CD5+ T cells was significantly
increased in PEC ( p<0.05 ) compared with 0X8/0X38 moAb-treated rats. The %
lymphocytes and CD5+ T cells were significantly increased in the spleen ( p<0.05 ) of
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islet-transplanted diabetic BB/E rats receiving 0X8/0X38 moAb-treatment in Group
C, and with respect to the % CD5+ T cells, also in MLN and PEC ( p<0.01 and
p<0.05 respectively ). The % IgM+ B cells was significantly increased in PLN of
islet-transplanted rats receiving 0X8/0X38 moAb-treatment ( p<0.05 ) and % CD8+
T cells was significantly increased in MLN and PEC ( p<0.05 ) compared with
0X8/0X38 moAb-treated rats. The % CD5+ T cells was also significantly increased
in MLN ( p<0.01 ), PEC and spleen ( p<0.05 ) of islet-transplanted, 0X8/0X38
moAb-treated rats upon combining the data for groups A, B and C. The % CD8+ T
cells was significantly increased in PLN and PEC ( p<0.05 and p<0.01 respectively )
and the % CD4+ T cells was significantly increased in MLN and thymus ( p<0.05 )
compared with 0X8/0X38 moAb-treated rats.
4.3.3.2. Absolute cell numbers
4.3.3.2.1. PBL and PBL subsets in PBS-treated or short-term moAb treated diabetic
BB/E rats.
The number of lymphocyte and lymphocyte subsets ( expressed as xlO^ cells/ml
blood ) in diabetic BB/E rats receiving PBS treatment or short-term W3/25, 0X8,
0X38 or 0X8/0X38 moAb treatment are shown in Tables 30 -34 respectively.
CD8+ T cells were significantly reduced 60, 120 ( p<0.05 ) and 240 minutes and 24
hours ( p<0.01 ) following the priming injection of 0X8 moAb and during, at and 1
week after the end of moAb treatment ( p<0.01 ) compared with cell numbers
treatment. CD4+/CD8+ T cells were completely depleted during moAb treatment and
were significantly reduced 1 week post-moAb treatment ( p<0.05 ) compared with
cells pre-moAb treatment.
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Table30.PBLndsu sets(xlO^cells/mlbloo)inBS-treat ddiab ticBB/Er t LYMPHOCYTESandSUBSETS(xlO5cells/mlblood) LymphocytePre-moAb+60in12244hrDur goAbEndofb1week2eeks subsettreatmentreatmenttpo t- oAbpost- oAb (day-3)-2)ay0)10)(de th) lymphocytes14.79+4.201 43350 562 1283.14.81679.34+.74 55 CD5+0.86306123+0.121 4287.0 5615.408 IgM+7.652 543 870 95 166.4 +1 34 70.69+5 140 07 32 1 CD8+1.990 761523583601+0.52. 41. 00 64 52 CD4+4.431 2.34+051+0.777 53682 153 805 706.63 CD4+/CD8+1.150 28500636. 239470.1325 Mean±SEM
Table31.PBLndsubsets(xlO^cells/mlb oo )inshort-termW3/25m Ab- reat ddiab ticBB Er t . LYMPHOCYTESandSUBSETS(xlO5cells/mlbloo ) LymphocytePre-m Ab+60in1224i4hrDur goAbEndof Ab1week2eks subsettreatmentreatmenttr t tpos - oAbpost- oAb (day-3)-2( ay0)d10)(death) lymphocytes15.40+3.24.30+499.55 82.013 770 892.3 +62.2175 1 CD5+0.660281+0.29254.1970. 36. 10 4 IgM+6.63+1.105 40 965.8432981+2 0662.80 40.7 +1 954 91 CD8+1.430 677094.138073+0.51.27043 648 CD4+6.08+1.563 990 64272 058 804 2130 8+99.75574.75+1 3 CD4+/CD8+1.480 366052739410. 52110.+0.9240 Mean±SEM
Table32.PBLndsu sets(xlO^cells/mlblood)inshort-ter0X8m Ab-treateddiabe icBB/Erats. LYMPHOCYTESandLYSUBSETS(xlO5cells/mlblood) LymphocytePrc-m Ab subsettreatment (day-3)+60min12i+24niinhrDuri gmoAbE dofin b1week2eeks
treatmenttr t tpost- oAbpost-moAb
(day-2)(0)10)(death
lymphocytes13.88+.060.+2 63693.59 1498 831.9.87+.414 4+98 53.10 172 CD5+ IgM+ CD8+ CD4+ CD4+/CD8~t0.75+17 6.47+0 72 1.47+0 26 4.82+1. 1 1.02+0 340.48+01 2.87+0 98 0.27±.09a 6.26±2 4 0.71+0.220.49+1 3.44+1. 7 0.32±.12a 3.10+1.20 0.20±080.37+1 2.64+1.44 0.09±.05b 2.20+1.02 0.11+0.040.34+18 2.72+1.83 0.06±.03b 2.80+1.36 0.10+3.47+03 4.75+0 58 0.01±0.01b 3.09+0 22 0a
0.90+14 4.90±0.7 0.04±.04b 6.04+1.25 0.12+
0.30+.15 4.78+1.68 0.06±.03b 3.67+1.44 0.06±.03a
0.24+06 4.26+1.42 0.62+59 3.88+2 02 0.76±69
Mean±SEM
ap<0.05andb 1comparedwithpre-moAbtre t ent.
Table33.PBLndsubsets(xlO^cells/mlb oo)inshort-term0X 8moAb-treateddiabe icBB/Era LYMPHOCYTESandL TESUBSETS(xlO5cells/mlb oo) LymphocytePre-moAb+60in12244hrDu goAbEndof1week2eeks subsettreatmentr t entea tpost- oAbpost-mo b (day-3)2)0)(10)death) lymphocytes11.43+.349 260 62.60+17052 592.93 910 88 3572 CD5+0.85285769414 4.1.8 +0 036+2 IgM+5.340 753 0618202.1 +1 1534.38+62 CD8+1.330 248705815.040.15±0.0 b01.27+.+.13366 CD4+3.500 779424308612 34 59.2 +.5 11 CD4+/CD8+0. 41047236.143±.07b0550.02±0.0 b0.16±0.11b 21. 8 Mean±SEM 3p<0.05andb 1comparedwithre-moAbtre tment.












































































ap<0.05,b<0.01andcp .0 1comparedwithpre-moAbtreat ent.
CD8+ T cells were significantly reduced 240 minutes ( p<0.05 ) and 24 hours
( p<0.01 ) following the priming injection of 0X38 moAb and remained significantly
reduced during ( p<0.01 ) and 1 week after the end of moAb treatment ( p<0.05 )
compared with cell numbers treatment. CD4+/CD8+ T cells were significantly
reduced 120 ( p<0.05 ) and 240 minutes and 24 hours ( p<0.01 ) after the priming
0X38 moAb injection compared with cells pre-moAb treatment. Cell numbers
remained significantly reduced during and at the end ofmoAb treatment ( p<0.01 ).
CD5+ T cells were significantly reduced 120 minutes ( p<0.001 ) and 24 hours
( p<0.01 ) following the priming injection of combined 0X8/0X38 moAb and
remained significantly reduced during ( p<0.001 ), at and 1 and 2 weeks after the end
of moAb treatment ( p<0.01 ) compared with CD5+ T cell numbers pretreatment.
CD8+ T cells were significantly reduced 60, 120 ( p<0.05 ) and 240 minutes
( p<0.01 ) and 24 hours ( p<0.05 ) following the priming injection ofmoAb compared
with cell numbers pretreatment. During moAb treatment, CD8+ T cells were
completely depleted and remained significantly reduced at and 1 week after the end of
moAb treatment ( p<0.01 ). CD4+/CD8+ T cells were completely depleted during
moAb treatment.
Values for PBS-treated rats ( Table 30 ) were compared to those for W3/25, OX8,
0X38 and combined 0X8/0X38 moAb-treated rats ( Tables 31-34 respectively ) to
determine the absolute effect of each moAb on the number of lymphocytes and
lymphocyte subsets.
CD5+ T cells were significantly reduced at the end of moAb treatment in W3/25
moAb-treated rats ( p<0.05 ).
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CD8+ T cells were significantly reduced 60, 120 and 240 minutes and 24 hours after
the priming injection of 0X8 moAb ( p<0.05 ), during ( p<0.05 ) and at the end of
moAb treatment and 1 week post-moAb treatment ( p<0.001 ) in 0X8 moAb-treated
rats. CD4+/CD8+ T cells were significantly reduced 120 and 240 minutes after the
priming 0X8 moAb injection ( p<0.01 ), at the end of moAb treatment ( p<0.01 ) and
1 week post-moAb treatment ( p<0.05 ) compared with PBS-treated rats.
Lymphocyte numbers were significantly reduced in 0X38 moAb-treated rats 120
minutes after the priming injection of moAb and at the end of moAb treatment
( p<0.05 ). CD8+ T cells were significantly reduced 120 minutes and 24 hours after
the priming injection of 0X8 moAb ( p<0.05 ), during ( p<0.05 ) and 1 week after the
end of moAb treatment ( p<0.01 ) compared with PBS-treated rats. CD4+/CD8+ T
lymphocyte numbers were significantly reduced 120 minutes and 24 hours after the
priming injection of 0X38 moAb ( p<0.05 ) and at the end of moAb treatment
(p<0.01 ).
The combination of 0X8/0X38 moAb significantly reduced lymphocyte numbers in
diabetic rats 120 minutes after the priming injection of moAb ( p<0.05 ) and CD5+ T
cells were significantly reduced at the end of moAb treatment ( p<0.01 ). CD8+ T
cells were significantly reduced 120 minutes and 24 hours following the priming
injection of moAb ( p<0.05 ), during ( p<0.05 ) and at the end of moAb treatment
( p<0.001 ) compared with PBS-treated rats. CD4+ T cells were significantly
reduced 240 minutes after the priming injection of 0X8/0X38 moAb ( p<0.05 ).
CD4+/CD8+ T cells were also significantly reduced at this time point and at the end
ofmoAb treatment ( p<0.01 ).
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4.3.3.2.2. The effect of PBS treatment or short-term moAb treatment on PBL and
PBL subsets in islet-transplanted diabetic BB/E rats.
The number of lymphocyte and lymphocyte subsets ( expressed as xlO^ cells/ml
blood ) in islet-transplanted diabetic BB/E rats receiving PBS treatment ( Table 35 )
or short-term W3/25, 0X8, 0X38 or 0X8/0X38 moAb treatment are shown in
Tables 36 - 39 respectively. Lymphocyte and lymphocyte subset data was analysed
after dividing animals into groups A ( early failing islet grafts ), B ( short-term
functioning islet grafts ) and C ( long-term functioning islet grafts ) as previously
described.
All PBS-treated rats were group A. IgM+ B cells were significantly increased at
failure of the islet graft in PBS-treated rats compared with B lymphocyte numbers at
the end ofPBS treatment ( p<0.05 ).
W3/25 moAb-treated rats in group A and B had significantly increased CD5+ T cell
numbers prior to moAb treatment than at death ( p<0.001 and p<0.01 respectively ),
and in group B at the end of moAb treatment ( p<0.01 ). Combining the data for
groups A, B and C also demonstrated that CD5+ T cells were significantly higher
before moAb treatment than at death ( p<0.001 ) and also upon failure of the 1° islet
graft ( p<0.05 ). Lymphocyte numbers were also significantly greater prior to moAb
treatment than at death ( p<0.05 ), and upon failure of the 1° islet graft lymphocytes
were significantly greater compared with the end of W3/25 moAb treatment
( p<0.05 ). At death, CD8+ T cells were significantly greater in W3/25 moAb-treated
rats in group A compared with group B ( p<0.001 ).
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*DiabeticBB/Era sw red videdinto3groupsdetermin dbyhp r ofnormoglycaemiafoll wingi r p rtalsl tgraf . GroupA:earlygraftfailures(<10day).roupBshort-termfunctioningg s>yGClo - rfunc ioning graftsreceiving2°isletraftunderthkidneycapsule. tThedataforpre-moAbtreat entndpr ransplantof1°islgr fexpr ssedt t lf roupsA,BdC. d p<0.05,b0.01andap .0comparedwithpre-moAbtreat ent. cp<0.001comparedwithgroupA.
Table37.heffectofshort-t rm0X8moAbtreatmentnPBLndsubsets(x10^ce l / lbl od)islet-transpla ed diabeticBB/Erats. LYMPHOCYTESANDLYMPHOCYTESUBSE(x105cells/mlblood) Sub-group*LymphocytePrc-moAbPretransplantFailurfE dbP etranspl tDea h




















































































































Table38.heffectofs ort-term0X38moAbtreatm nnPBLndsubs ts(x10^c lls/mlblo d)inislet-transp anted diabeticBB/Erats. LYMPHOCYTESANDLSUBSETS(X105cells/mlblood) Sub-group*LymphocytePre-moAbret ansplantFailurefEndoAbPretransplantD th















































































lymphocytes CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
9.94±2.41 0.54±0.10 5.54±2.80 0.18±.09a 4.60±0 84 0.32±0.10
12.05±3 434.9010 198.70 2.30a>c 0.71±0.19 5.64±1 70 0.55±.4 4.24±0 9 0.40±21.44±0.56 17.10±4.65 5.69±4.32
0.25±0.06b>d 4.74±1.5 1.06±0.4
11.81±6.284.36±2 17 2.37±1 220.68±50
Mean±SEM
*DiabeticBB/Eratsw redivid dinto3groupsete minebythperiofnormoglycaemiafoll winganintr o t lis tgraf . GroupA:earlygr ftfailures(<10days).Bsho t-t rmfuncti ningg afts>d ys).Gr upClong-te mfu cti ning graftsreceivinga2°isl ftunderthkid ycapsule. tThedataforpre-moAbtreat ntndpretransplanft1°isl tg ftexp es edtf g ou sBandC. ap<0.05andb 1comparedwithpre-moAbtreatment. cp<0.05comparedwithretransplantf2°isl tgr t. d p<0.05comparedwithfailuref1°is etgra .
Table39.heffectofshort-termcombined0X8/0X38m Abtre t ntnPBLandsubsets(x1 ^c lls/mlblo d)in islet-transplanteddiabeticBB/Ets. LYMPHOCYTESANDLYMPHOCSUBSETS(X105cells/mlblood) Sub-group*LymphocytePre-m AbretransplantFail reofEndm AbPret ansplantD t























































































































*DiabeticBB/Eratsw redividedinto3groupseterminedbythperioofno moglycaemiafoll w ngintrap r alsl aft. GroupA:earlygr ftfailures(<10days).Bshort-te munctioningr ft>Clong-termfu c i i graftsreceivinga2°isleftunderthkid ycapsule. tThedataforpre-moAbtreat entndpretransplanf1°isl tg aftxpre sedlou sA,BC. ap<0.05,b<0.01ande0.00comparedwithre-moAbtreatment. cp<0.05comparedwithpretransplantf2°isl tgr . dp<0.05andh0.001comparedwithdea(TOTAL) f p<0.05comparedwithdeath.§rfailurf1°is etgra
CD8+ T cells were significantly greater prior to 0X8 moAb treatment compared with
pretransplant of the 1° islet graft ( p<0.05 ). In group B, lymphocytes were
significantly reduced upon killing compared with pre-moAb treatment, pretransplant
( p<0.05 ) and failure of the intraportal islet graft ( p<0.01 ). CD8+ T cells were
significantly higher upon killing of 0X8 moAb-treated rats compared with
pretransplant of the 1° graft ( p<0.05 ). CD4+ T cells were significantly greater at
failure of the 1° islet graft compared with pretransplant, end of moAb treatment
( p<0.05 ) and upon killing ( p<0.01 ). Combining the lymphocyte data for groups A,
B and C demonstrated that numbers were significantly reduced at death compared
with pre-moAb treatment, pretransplant ( p<0.05 ) and failure of the 1° islet graft
( p<0.001 ). CD5+ T cells and IgM+ B cell numbers were both significantly greater
at failure of the 1° islet graft compared with cell numbers at death ( p<0.05 and
p<0.01 respectively ). CD8+ T cells were significantly higher at death than prior to
transplantation of the intraportal islet graft ( p<0.05 ).
CD5+ T cells were significantly reduced prior to transplantation of the 1° graft in
0X38 moAb-treated BB/E rats compared with cell numbers pre-moAb treatment
( p<0.05 ). In group B, lymphocyte and CD5+ T cell numbers were significantly
greater prior to moAb treatment than at death ( p<0.05 ). CD8+ T cells were
significantly reduced at the end of moAb treatment and upon failure of the islet graft
compared with cell numbers pre-moAb treatment ( p<0.05 ). Final CD5+ and CD4+
T cell numbers of 0X38 moAb-treated BB/E rats in group C were significantly
reduced compared with cell numbers prior to moAb treatment ( p<0.01 and p<0.05
respectively ). Combining the lymphocyte and lymphocyte subset values for groups B
and C demonstrated that both lymphocytes and CD5+ T cells were significantly
reduced at death compared with pre-moAb treatment ( p<0.05 and p<0.01
respectively ) and CD5+ T cells were significantly higher at failure of the 1° islet graft
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compared with cell numbers upon killing ( p<0.05 ). Lymphocyte numbers were
significantly higher at the time of transplantation of the 2° islet graft under the kidney
capsule compared with the time of death ( p<0.05 ).
CD8+ and CD4+/CD8+ T cell numbers were significantly lower in OX8/OX38
moAb-treated rats prior to transplantion of the 1° graft than pretransplant ( p<0.05
and p<0.01 respectively ). In group A, both lymphocyte subsets were completely
depleted at the end ofmoAb treatment. In group B, CD8+ T cells were also depleted
at the end of moAb treatment and remained depleted at failure of the islet graft.
CD4+/CD8+ T cells were also depleted at failure of the intraportal islet graft. Both
lymphocyte and CD5+ T cells were significantly reduced prior to islet transplantation
and at death compared with cell numbers pre-moAb treatment ( p<0.001 and p<0.05
respectively ). Lymphocyte numbers were significantly greater at islet graft failure
compared with the final values at death ( p<0.05 ). CD5+ T cells were significantly
reduced at the end of moAb treatment ( p<0.01 ). In group C, CD8+ T cell numbers
were significantly lower at the end of 0X8/0X38 moAb-treatment and upon killing
compared with pre-moAb treatment ( p<0.01 ) and pretransplantation of the 1° islet
graft ( p<0.01 ) respectively. CD4+ T cells were significantly lower at the end of
0X8/0X38 moAb treatment compared with pre-moAb treatment ( p<0.05 ).
CD4+/CD8+ T cells were significantly higher at pre-moAb treatment compared with
the end of moAb treatment ( p<0.05 ) and at the end of treatment compared with
pretransplantion of the 2° islet graft under the kidney capsule ( p<0.05 ). The
combined data for groups A, B and C demonstrated that lymphocytes and CD5+ T
cell numbers were both significantly higher pre-moAb treatment than at the time of
death ( p<0.05 and p<0.01 respectively ). CD5+ T cells were also significantly higher
at the time of 1° graft failure compared with cell numbers upon killing of OX8/OX38
moAb-treated rats ( p<0.05 ). CD8+ T cell numbers were significantly lower at the
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time of 1° graft failure and at the end of moAb treatment compared with cell numbers
pre-moAb treatment ( p<0.01 ). Upon killing, CD8+ T cells were significantly higher
at the time of 1° graft failure and at the end of moAb treatment ( p<0.001 ). CD4+ T
cells were significantly higher at the time of 1° graft failure compared with cell
numbers at death ( p<0.05 ). CD4+/CD8+ T cells were significantly lower at the end
of treatment compared with pre-moAb treatment ( p<0.05 ) but were significantly
higher at death compared with pretransplantion of the 1° islet graft ( p<0.05 ).
The lymphocyte and lymphocyte subset numbers ofPBS-treated BB/E rats receiving a
1° islet graft ( Table 35 ) were compared with islet-transplanted animals receiving
short-term W3/25, 0X8, 0X38 or 0X8/0X38 moAb treatment ( Tables 36 - 39 ).
0X8 moAb-treated diabetic BB/E rats had significantly decreased numbers of
lymphocytes and CD8+ T cells prior to transplantation of a 1° islet graft compared
with PBS-treated rats ( p<0.05 ). In group B and the combined group ofA, B and C,
CD8+ T cells were significantly lower at the time of 1° graft failure ( p<0.05 ).
Prior to transplantation of the 1° islet graft, lymphocytes and CD8+ T cells were
significantly lower in 0X38 moAb-treated BB/E rats ( p<0.05 ). In group B, CD8+ T
cell numbers were significantly lower in 0X38 moAb-treated rats at the time of islet
graft failure and at the end of moAb treatment compared with PBS-treated rats
( p<0.01 and p<0.05 respectively ). Combining the data for groups B and C
demonstrated that CD8+ T cells were significantly reduced in moAb-treated rats at
the time of 1° graft failure ( p<0.01 ).
Lymphocyte and CD8+ T cell numbers in 0X8/0X38 moAb-treated diabetic rats
were significantly reduced prior to transplantation of the 1° graft compared with cell
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numbers pre-moAb treatment ( p<0.05 ). In group B, CD8+ T cells were significantly
lower at islet graft failure and at the end of moAb treatment ( p<0.001 and p<0.05
respectively ). CD4+/CD8+ T cells were significantly lower at the time of islet graft
failure in 0X8/0X38 moAb-treated rats ( p<0.05 ). In group C and the combined
group ofA, B and C, CD8+ T cell numbers were significantly lower in moAb-treated
rats at the end of treatment compared with PBS-treated rats ( p<0.05 ) and also at the
time of 1° graft failure in the combined group ( p<0.01 ).
There was no significant difference between the numbers of lymphocytes and
lymphocyte subsets in islet-transplanted diabetic BB/E rats receiving PBS treatment
( Table 35 ) or short-term W3/25, 0X8, 0X38 or 0X8/0X38 moAb treatment
( Tables 36 - 39 respectively ) when compared with diabetic BB/E rats receiving PBS
( Table 30 ) or the corresponding moAb alone ( Tables 31 - 34 ).
4.3.3.2.3. Lymphocytes and lymphocyte subsets in lymphoid tissues of PBS-treated
or short-term moAb-treated diabetic BB/E rats.
The number of lymphocyte and lymphocyte subsets ( generally expressed as xlO^
cells/g tissue ) in lymphoid tissues of diabetic BB/E rats receiving PBS treatment
( Table 40 ) or short-term W3/25, 0X8, 0X38 or 0X8/0X38 moAb treatment are
shown in Tables 41-44 respectively. Values for PBS-treated rats were compared to
those for W3/25, 0X8, 0X38 or 0X8/0X38 moAb-treated rats to determine the
effect of each moAb had on the numbers of lymphocytes and lymphocyte subsets in
the lymphoid tissue.
Lymphocyte and CD4+ T cell numbers in the spleen of W3/25 moAb-treated rats
were significantly reduced compared with PBS-treated control rats ( p<0.05 ).
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CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
15.32±.74 22.04±9. 1 2.94±0.70 18.87±.99 0.80±0.80
8.70±2.48 119.66±82.09 2.39±0.79 18.43±5. 1 1.67±0.85
4.83±1 04 42.83±4.77 8.40±2.23 12.26±1.19 3.42±2.06
0.46±0.32 5.10±2.63 10.80± 28 12.30±3 63 0
845.26±2 85 10.95± 84 202.96±83 44 60.66±1 05 680.27±124.51
Mean±SEM.=3.
tValuesforPECrexpressed10^/mlvolu .
Table41.Lymphocyt sndlympho tsubse s(xlO^cells/gti su )inlymp idtis eofhort-termW3/25moAb-treatedd abe icBB E rats. LYMPHOCYTESANDLYMPHOCYTESUBSETS(x106cells/gtissue)t LymphocytesubsetPLNMSpleenPECThymus Lymphocytes101.25±6.37223.15±54.2140.18±8.4713.34±3.13
1296.21±207 6
CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
11.02±0.77 12.10±2.98 2.03±0.13 15.59±.0 1.60±0.53
9.33±1.79 101.52±0.32 2.23±0.01 20.86± 0 2.63±0 00
1.67±0.88 15.78±3 0 2.89±0.87 5.48±1 83 1.65±18
0.09±0.05 2.63±1 56 0.50±0.18 4.00±1 41 0.05±0.05
909.18±22 64 55.26±22.9 121.82±36 53 70.92±12.71 1037.43±44.50
Mean±SEM.=3.
tValuesforPECrexpressed10^/mlvol .
Table42.Lymphocyt sndlymph tesu se s(xlO^cells/gti su )inlym itis uesofhort-term0X8moAb-treateddiabetiBB/E rats. LYMPHOCYTESANDLYMPHSUBSETS(x106cells/gtissue)t LymphocytesubsetPLNMSpleenPECThy s Lymphocytes100.53±45.2173.62±0.9347.45±8.21
10.35±.07
885.28±15 .7
CD5+ IgM+ CD8+ CD4+ CD4+/CD8+
8.27±1.11 38.36±29.48 2.11±1 22 14.00±2.56 1.96±21
7.41±0.01 77.17±0.54 0.31±0.31 15.61±0 06 1.61±0.01
1.47±0.86 27.27±5.04 1.52±0.92 5.73±0.82 2.14±1 02
0.26±0.10 2.84±1 2 0.15±0.10 6.73±2.69 0
680.25±118 68 18.38±7 81 77.68±15 8 42.71±13.66 730.80±12 .09
Mean±SEM.=3.
tValuesforPECrexpressedlO^/mlvol .


















































































0X8 moAb-treated BB/E rats had significantly reduced CD5+ T cells in PLN
( p<0.05 ) and CD8+ T cell numbers were significantly reduced in the spleen and PEC
(p<0.05 ).
Lymphocyte and CD4+ T cell numbers were significantly reduced in the spleen of
0X8/0X38 moAb-treated rats compared with PBS-treated control rats ( p<0.05 ).
4.3.3.2.4. The effect of PBS treatment or short-term moAb treatment on
lymphocytes and lymphocyte subsets in lymphoid tissues of islet-transplanted diabetic
BB/E rats.
The number of lymphocyte and lymphocyte subsets ( generally expressed as xlO^
cells/g tissue ) in the lymphoid tissues of islet-transplanted diabetic BB/E rats
receiving PBS treatment ( Table 45 ) or short-term W3/25, 0X8, 0X38 or
0X8/0X38 moAb treatment are shown in Tables 46 - 49 respectively. MoAb
treatments had no significant effect on the numbers of lymphocytes and lymphocyte
subset in the lymphoid tissues when compared with PBS-treated rats.
Numbers of lymphocytes and lymphocyte subsets in the lymphoid tissues of
islet-transplanted diabetic BB/E rats receiving PBS treatment ( Table 45 ) or
short-term W3/25, 0X8, 0X38 or 0X8/0X38 moAb treatment ( Tables 46 - 49
respectively ) were significantly lower than the number of lymphocytes in the
lymphoid tissue of non-islet-transplanted BB/E rats receiving corresponding PBS
( Table 40 ) or short-term W3/25, 0X8, 0X38 or 0X8/0X38 moAb treatment
( Tables 41-44 respectively ) in most cases.
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Table45.Lymphocytendlymphocytsu se s(x10ĉel s/gti su)inly itissueofisle - ransplantdiabetiBB/Et receivingPBS-treatment. LYMPHOCYTESANDLYMPHSUBSETS(X106cells/gtissue)t Sub-group*LymphocytePLN (n)subsetMLNSPLEENPEC
THYMUS
A(8)
lymphocytes29.14±4.953 79 5617.38 430. 70 22221±67 8 CD5 IgM+ CD8+ CD4+ CD4+/CD8+6.88±1 67 7.03±1 99 0.85±0.15 6.81±1 45 0.10±0.054.67±0 96 25.82±7.61 0.67±05 5.59±0.83 0.45±0.171.01±0.58 7.80±3 9 0.84±0.59 3.09±1 14 0.37±0.35
0.12±0.05 0.25±0.12 0.08±0.05 0.54±0.18 0.02±
186.26±62.52 4.52±0.91 16.31±6.84 16.18±5.67 145.72±62.80
*DiabeticBB/Eratsw redivid dinto3groupseterminedbythperioofno moglyca miafoll wingintrap rt lsg ft. GroupA:earlygr ftfailures(<10days).Bsho t-termfunctioninggraft>).rClong-term functioninggraftsreceivia2°isl ftunderthkidn ycapsule. tValuesforPECrexpressed10^/mlvolum .
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TOTALlymphocytes18.30±3 4961 658.3249 013.66.56276.27 .0 (9) CD5+3.41±1 077.2.564 141.790±0.21 3 5359 1 lgM+6.91±2.6724.026 8530.3±9.822.11 077.5±3.04 CD8+0.85±0.1893312.10±0.640 29± .124 .713 2 CD4+4.69±1.1510.623 96.632 0. 0± 8623 8±6.72 CD4+/CD8+0.54±0.251 2946.3±0.30.750182 9±53 41 ♦DiabeticBB/Eratsweredivid dinto3groupsdete minebythper dofnormoglycaemiafoll inganintra or lis tgraf . GroupA:earlygr ftfailu es(<10days).roupBshort-termfuncti ningg afts>10d ys).GroupC:long-t mfu cti ni g graftsreceivinga2°isl tund rthkid eyc psul . t ValuesforPECrexpressed10^/mlvo e.














































































































*DiabeticBB/Era sw red videdinto3groupsdeterminedbyhp r ofnormogly aemiafoll wingintr p rtalsl tg af . GroupA:earlygraftfailures(<10day).roupBsh rt-termfunctioningg afts>dayG upClo - efunc ioning graftsreceiving2°isl traftunderthkidneyc psule. +ValuesforPECareexp ssed10^/mlvolume.
4.3.4. Stimulation indices.
The stimulation indices of PBS-treated or short-term W3/25, 0X8, OX38 or
0X8/0X38 moAb-treated diabetic BB/E rats are shown in Table 50. The indices
prior to moAb treatment were not significantly different during treatment. However,
at the end of moAb treatment all the stimulation indices were lower compared with
values prior to and during moAb treatment although this reduction was only
significant with 0X38 and 0X8/0X38 moAb-treatment ( p<0.05 ). One week
post-moAb treatment, all stimulation indices had increased from the end of treatment
and this reached significance ( p<0.05 ) in 0X8/0X38 moAb-treated rats. Upon
killing two weeks post-moAb treatment, the stimulation indices were not significantly
different from the pre-moAb treatment values. The stimulation indices for
PBS-treated and moAb-treated diabetic BB/E rats were not significantly different at
any time point.
The stimulation indices of islet-transplanted diabetic BB/E rats receiving PBS
treatment or short-term W3/25, 0X8, 0X38 or 0X8/0X38 moAb treatment are
shown in Table 51.
The stimulation indices of PBS-treated control rats were significantly lower upon
failure of the islet graft, end of PBS treatment and death compared with pretreatment
( p<0.01 ) and pretransplant ( p<0.05 ) of the intraportal islet graft.
The stimulation index ofW3/25 moAb-treated BB/E rats significantly decreased prior
to intraportal transplantation of the 1° islet graft compared with pre-moAb treatment
( p<0.01 ) and remained significantly decreased upon failure of the islet graft, at the
end of moAb treatment and death ( p<0.01 ) in group A. Stimulation indices at the
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end of moAb treatment and death in group B were also significantly lower than the
pre-moAb treatment value ( p<0.05 and p<0.01 respectively ). The single W3/25
moAb-treated BB/E rat in group C had a lower stimulation index at the end of moAb
treatment compared with groups B and C.
0X8 moAb-treated BB/E rats had a lower stimulation index prior to transplantation
of the 1° islet graft compared with pre-moAb treatment although this did not reach
significance. The stimulation index was significantly lower at the end of moAb
treatment compared with pre-moAb treatment for rats in group B ( p<0.05 ). The
stimulation index at the end of moAb treatment was highest for the diabetic BB/E rat
in group A and lowest for the single rat in group C. The stimulation index at the time
of failure of the 2° islet graft in this latter group was 19 which was higher than the
value observed in group B upon failure of the 1° islet graft.
The stimulation index of 0X38 moAb-treated diabetic BB/E rats decreased from
pre-moAb treatment to pretransplant of the 1° islet although this did not reach
significance until the end of moAb treatment ( p<0.05 ). The stimulation index
remained significantly decreased after this time point until death ( p<0.05 ). The
stimulation index at failure of the 1° islet graft in group B was not significantly
different from the values at pre-moAb treatment and pretransplant of the intraportal
islet graft.
After treatment with a combination of 0X8/0X38 moAb, diabetic BB/E rats
demonstrated a lower stimulation index than pre-moAb treatment although this
decrease was not significant. The stimulation index upon failure of the 1° islet graft in
group B animals was significantly lower than at pre-moAb treatment and pretransplant
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of the graft. The diabetic BB/E rat in group A had a higher stimulation index at the
end ofmoAb treatment than animals in group B and C.
Upon combining the data for groups A, B and C, the stimulation index prior to
transplantation of the 1° islet graft was found to be significantly lower compared with
the value pre-moAb treatment ( p<0.001 ) and remained significantly lower thereafter
in groups A, B and C ( p<0.001 ). The stimulation index was also significantly lower
at the time of 1° islet graft failure in group A ( p<0.001 ), the end of moAb treatment
in groups A ( p<0.05 ), B ( p<0.01 ) and C ( p<0.05 ) and at the time of death in
groups A ( p<0.001 ) and B ( p<0.05 ) compared with pretransplantation of the 1°
islet graft. At the time of death, the stimulation index of group C was significantly
higher ( p<0.05 ) than the value for group A indicating that the stimulation index
eventually increased with time in recipients maintaining long-term functioning islet
grafts although this value was not significantly different from the stimulation index
prior to transplantation of the 1° islet graft.
4.3.5. Histology
Representative immunohistochemical staining of pancreas, liver and kidney of
diabetic BB/E rats receiving a 1° intraportal islet graft ( and a 2° islet graft under the
kidney capsule in animals maintaining long-term functioning 1° grafts ) are shown in
Figure ll(a)-(h). Figure 11(a) shows the pancreas of an established ( >140 days )
diabetic BB/E rat. Islets are small and widely separated and only a mild chronic
inflammatory cell infiltrate is noted in relation to them. Immunoperoxidase stains for
glucagon are strongly positive and negative for insulin. Light microscopy of the liver
of a BB/E rat upon failure of a short-term functioning intraportal islet graft is shown
in Figure 11(b). There are several foci of moderate to severe fatty changes associated
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Figure 11(a) Islet cells from pancreas of an established ( >140 days ) diabetic BB/E
rat stained for glucagon. No positivity for insulin was observed, x 400. (b) Islet cells
from a short-term functioning intraportal graft 34 days after transplantation into an
established diabetic BB/E rat receiving 0X38 moAb treatment. Insulin positivity was
observed in approximately 50% of islet cells which were surrounded by chronic
inflammatory cells comprising mainly of lymphocytes and macrophages. No glucagon




Figure 11. Islet cells from a long-term functioning intraportal graft 98 days after
transplantation into an established diabetic BB/E rat receiving combined 0X8/0X38
moAb treatment. Insulin positivity was visible (c) and occasional glucagon positivity
was observed (d). x 400.
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Figure 11. Islet cells from a graft 14 days after transplantation under the kidney
capsule of a diabetic BB/E rat receiving no moAb treatment ( control ).
Immunoperoxidase staining for insulin showed faint positivity for insulin (e). Focal
positivity for glucagon was occasionally observed (f). A moderate chronic




Figure 11. Islet cells from a 2° graft under the kidney capsule 34 days after
transplantation into a diabetic BB/E rat maintaining a long-term functioning 1°
intraportal islet graft ( 125 days ) following combined 0X8/0X38 moAb treatment.
Insulin positivity (g) and focal glucagon positivity (h) was observed and there was a
chronic inflammatory cell infiltrate adjacent to islet cells in the perinephric fat. x 400.
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with small numbers of islets. Immunoperoxidase stains for insulin are mildly positive
for insulin and negative for glucagon. A moderate chronic inflammatory cell infiltrate
is observed around the islets. Figure 11(c) shows the liver of a BB/E rat maintaining
a long-term functioning intraportal islet graft. The overall architecture of the liver
was normal and only mild fatty changes were present associated with several clusters
of islets in the portal triads. Only a sparse chronic inflammatory cell infiltrate was
present in relation to the islets and islet cells were strongly positive for insulin and
only occasional positivity for glucagon is observed (d). Diabetic BB/E rats receiving
a single islet graft under the kidney capsule acted as controls to those moAb-treated
rats receiving a 2° islet graft under the kidney capsule. In the former group, diabetic
rats were normoglycaemic for a mean of 3 ± 2 days and the immunohistochemistry of
a representative islet-bearing kidney is shown in Figure 11(e) and (f). A thick layer of
islet cells were seen beneath the kidney capsule and around the capsule was a
moderate chronic inflammatory cell infiltrate. Immunoperoxidase stains for insulin are
only occasionally positive (e) and stains for glucagon are generally negative although
glucagon-positive cell are occasionally observed at the periphery of the islet cell (f).
The islet-bearing kidney of a diabetic BB/E rat maintaining a long-term functioning
islet graft is shown in Figure 11(g) and (h). There was a thin layer of islets under the
kidney capsule and a chronic inflammatory cell infiltrate including foreign body giant
cells, macrophages and basophils was present in the adjacent perinephric fat .
Immunoperoxidase stains for insulin were strongly positive (g) and stains for glucagon
showed focal positivity only (h).
4.4 DISCUSSION
Transplantation of pancreatic islets for the treatment of diabetes mellitus in the
insulin-dependent autoimmune BB rat may fail as a result of two distinct immune
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responses : allograft rejection resulting from histocompatibility differences between
donor and recipient and recurrence of the autoimmune disease responsible for the
initial destruction of the recipients native pancreatic (3-cells. Naji et al ( 869 ) initially
described recurrent autoimmune insulitis in islet-transplanted BB rats that were made
tolerant to donor-specific tissue. This phenomenon was subsequently observed by
Sibley and colleagues ( 14 ) who reported recurrence of diabetes in human recipients
of segmental pancreas isografts transplanted between identical twins discordant for
IDDM.
IDDM in the spontaneously diabetic BB/E rat has a T lymphocyte-dependent
autoimmune aetiology similar to that in human IDDM. Using moAb directed against
specific T lymphocyte subsets directly involved in (3-cell destruction may prevent the
destruction of islets following transplantation into the diabetic BB rat. In this study,
the ability of a short-course of non-depleting ( W3/25 ) or depleting ( 0X38 )
anti-CD4 moAb or depleting anti-CD8 ( 0X8 ) moAb either alone or combined with
OX38 moAb to prevent recurrence of IDDM following intraportal transplantation of
an islet graft was investigated.
The liver was chosen as the site for implantation of the 1° islet graft rather than under
the kidney capsule, which is a proposed immunologically privileged site in the BB rat
( 653 ), since islets transplanted intraportally become revascularised as early as 4 days
after implantation ( 870 ). In contrast, islets implanted under the kidney capsule only
become revascularised 4 weeks after implantation in the rat ( 871 ). Early
revascularisation is essential to ensure an adequate supply of oxygen and nutrients to
transplanted islets and transport of secreted insulin to the bloodstream of the
recipient. Secretion of insulin into the portal vein is also more physiological than
secretion into arterial blood by islets transplanted under the kidney capsule.
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On the day of intraportal islet transplantation a half dose of insulin was administered
to recipient rats to avoid implantation of islets into a hyperglycaemic environment and
immediate stress of islet P-cells. The detrimental effect of hyperglycaemia on
transplanted islets has been reported ( 872 ). After transplantation ( day 0 ), no
further exogenous insulin was given. Blood glucose levels were normalised in
islet-transplanted diabetic BB/E rats one day following transplantation.
This study demonstrated that a short course (14 days ) of treatment with depleting
moAb directed against the CD8 cell surface marker, 0X8 or the CD4 cell surface
marker 0X38, either singly or in combination, significantly prolonged the survival of
MHC-incompatible Wistar or WH islets intraportally transplanted into established
diabetic BB/E rats. Although outbred Wistar and WH rats are MHC-incompatible
with BB/E rats it should be noted that these animals share the RT1U haplotype ( i.e.
MHC class I homology ). The non-depleting moAb W3/25 directed against the CD4
cell surface marker did not significantly prolong islet graft survival when compared
with PBS-treated BB/E rats. Despite the overall poor survival of islets transplanted
to W3/25 moAb-treated rats, a single BB/E rat maintained long-term normoglycaemia
following an intraportal islet graft and subsequently received a 2° islet graft under the
kidney capsule. This animal was still normoglycaemic ( blood glucose concentration
= 4.1 mmol/1 ) when killed 34 days later. Markmann et al ( 682 ) reported a mean
graft survival of 25 ± 16 days following intraportal islet transplantation in W3/25
moAb-treated BB rats made tolerant to donor tissue which compared well with the
mean survival time observed in this study ( 21 ± 13 days ) despite a different
treatment regimen. Markmann injected islet-transplanted rats three-times weekly with
W3/25 moAb throughout the period of study ( 100 days ) and the concentration of
moAb was not determined. MoAb treatments were also compared after separating
islet-transplanted diabetic BB/E rats into three groups ( A, B and C ) determined by
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the periods of normoglycaemia following intraportal islet grafting. The %2 test for
rectangular contingency tables confirmed that islet grafts survived significantly longer
after transplantation to 0X8, 0X38 and 0X8/0X38 moAb-treated diabetic BB/E rats
compared with islet-transplanted control rats. Islets transplanted into 0X38
moAb-treated rats were also shown to survive significantly longer than islets
transplanted into W3/25 moAb-treated rats as evidenced by long-term
normoglycaemia. This observation demonstrates that although W3/25 moAb
competes with 0X38 moAb for binding to the same determinant(s) on rat CD4 cell
surface marker ( 665 ), treatment with a depleting rather than a non-depleting
anti-CD4 moAb significantly improved graft survival. 33% of 0X38 moAb-treated
rats maintained long-term functioning 1° islet grafts and subsequently received 2° islet
grafts under the kidney capsule. All animals remained normoglycaemic. Seydel et al
( 679 ) reported permanent survival ( >115 days ) of islet allografts intraportally
transplanted into STZ-diabetic rats following a brief ( 4 days ) course of 0X38 moAb
treatment. The priming dose ( 5 mg/kg ) was lower than the dose used in this study
( 10 mg ). Seydel also assessed the effect of 0X8 moAb on islet survival after
intraportal transplantation to STZ-diabetic rats. Using the same treatment protocol,
anti-CD8 moAb treatment was shown to prolong the survival of islet allografts only
short-term and all treated animals rejected their grafts within 30 days of
transplantation ( mean = 25 ± 4 days ). The mean islet graft survival observed using
0X8 moAb in this study was comparable ( 27 ± 9 days ) and 89% of treated animals
remained normoglycaemic past the end of 0X8 moAb treatment. However, of these,
88% failed within 2 weeks of treatment ending. Only a single 0X8 moAb-treated
BB/E rat maintained a long-term functioning intraportal islet graft and was borderline
hyperglycaemic ( blood glucose concentration = 12.2 mmol/1) prior to transplantation
of a 2° islet graft under the kidney capsule. Blood glucose concentration was initially
normalised but a hyperglycaemic state was observed 9 days after implantation of the
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2° islet graft, suggesting 500 islets transplanted to this site were insufficient to achieve
long-term normoglycaemia. In contrast, Markmann and colleagues ( 682 ) reported
that all 0X8 moAb-treated BB rats remained normoglycaemic for >100 days
following intraportal transplantation of approximately 1500 WF islets. Neonatal
tolerance to donor-specific tissues was induced prior to islet transplantation in these
animals and BB rats were treated three-times weekly with OX8 moAb until
termination at 100 days post-transplantation. In this study, the majority of islet-
transplanted rats only returned to a hyperglycaemic state after completion of OX8
moAb treatment suggesting that continued treatment may have further increased
survival of islet grafts similar to the results ofMarkmann et al ( 682 ).
Treatment of islet-transplanted BB/E rats with a combination of 0X8 and 0X38
moAb was the most successful treatment and 44% of rats maintained long-term
functioning grafts as evidenced by persistent normoglycaemia. However, this result
was not significantly different from either of the moAb treatments alone. In contrast,
Seydel et al ( 679 ) reported that the combination of 0X8 and 0X38 moAb abrogated
the protective effect of anti-CD4-mediated islet allograft survival in the rat and
suggested this finding demonstrated the need of a regulator CD8+ cell in the survival
of intraportally transplanted islets in diabetic rats receiving 0X38 moAb treatment.
In each group of 0X8, 0X38 or combined 0X8/0X38 moAb-treated BB/E rats, one
animal was killed whilst still normoglycaemic due to megacolon, an incidence of 7%
in the 44 rats studied. This incidence was approximately 5-fold greater than the
incidence of megacolon in the diabetic BB/E rat colony recently reported ( 873 ).
BB/E rats were in a similar age range in both studies although the larger numbers
studied by Meehan and colleagues may give a better representation of megacolon
incidence in this colony. Since idiopathic megacolon in the BB rat involves an
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inflammatory process including T lymphocytes and macrophages leading to both
muscle and nerve destruction in the bowel wall, it would seem likely that anti-CD4
and anti-CD8 moAb treatment would decrease the incidence ofmegacolon rather than
exacerbate the condition.
To determine the effect of moAb treatment on lymphocytes and lymphocyte subset
numbers, FACS analysis was performed on PBL and lymphoid tissues. The
non-depleting nature of W3/25 moAb observed in this study is in agreement with
several previous reports ( 239,683,684 ). However, despite the absence ofCD4+ cell
depletion, 4 animals maintained functioning intraportal islet grafts beyond the end of
treatment and 1 animal which received a 2° graft under the kidney capsule was still
normoglycaemic at death ( 122 days after 1° islet transplantation ). Interestingly,
although CD4+ cell numbers were not significantly decreased in PBL, this single
animal ( group C ) had the lowest CD4+ cell numbers in all lymphoid tissues which
may have contributed to the prolonged islet survival observed. It should be noted that
despite the observation that W3/25 does not significantly deplete CD4+ cells, this
moAb was effective in reversing the disease course of another animal model of
autoimmune disease, experimental allergic encephalomyelitis ( 683,684 ).
Administration of W3/25 moAb also prolonged heart allograft survival across
combined MHC and non-MHC barriers in the rat in the absence of marked clearance
of CD4+ cells in PBL ( 680 ). This was in contrast to the findings of Claesson et al
( 681 ) who failed to prolong the survival of anastomotic heart grafts in a
semiallogeneic system with a single injection ofW3/25 moAb. This discrepancy may
be due to strain differences in the rats used, the degree of antigenic disparity or
variation in dose and potency ofmoAb. These findings, including those of the present
study suggest that the ( limited ) inhibitory effect of W3/25 moAb on graft survival
may be attributed to interference with activation, either by blockage of T cell receptor
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binding to its target cells or by blocking an essential CD4-mediated activation signal,
without clearing. Alternatively, it has been suggested by Bank et al ( 874 ) that
anti-CD4 antibodies themselves transmit a negative signal and depletion ofCD4+ cells
may not be an essential requirement for induced unresponsiveness.
Administration of depleting 0X8 moAb caused an immediate ( within 60 minutes )
and often complete depletion of CD8+ cells in PBL and was accompanied by a
significant reduction in CD4+/CD8+ cells. The small population of double-stained
cells are thought to be immature thymic precursors which mature into CD4+ or CD8+
T cells. The contribution of these cells to islet graft survival ( if any ) in BB rats is
unknown but may serve to lower the pool of CD4+ and CD8+ T cell precursors in
PBL. At death there was no depletion of CD8+ or CD4+/CD8+ T cells in any of the
lymphoid tissues and this observation may be time-related since two weeks after the
end of 0X8 moAb treatment, CD8+ and CD4+/CD8+ lymphocytes were not
significantly lower in PBL than the values prior to moAb treatment indicating
repopulation of both cell types. Interestingly, it was in this period of time that the
majority ( 78% ) of intraportal islet grafts failed in 0X8 moAb-treated BB/E rats.
This study implicates the involvement of a CD8+-bearing cell in islet graft destruction
in this animal model. 0X8 moAb treatment caused sufficient reduction ( complete
depletion in some cases ) of the CD8+ cell population to allow survival of islet
allografts. However, repopulation of these cells was observed post-moAb treatment
in PBL from thymic precursors with subsequent failure of all but one islet graft and
suggesting the role of these cells in the induction of an immune response against
transplanted tissue in the BB/E rat. The lymphocytes and lymphocyte subsets profile
of the single rat maintaining a long-term islet graft was not significantly different from
rats with early graft failures or short-term functioning grafts. However, the role of
CD8+ cells to mediate allograft rejection remains controversial. Both CD8+ and
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CD4+ T cells are required for the development of IDDM in NOD mice ( 414, 415,
875 ), although CD8+ T cells appear to facilitate the initiation of disease rather than
act as immunological effector cells. However, using a moAb depletion protocol
effective in preventing transfer of diabetes ( a process requiring both CD4+ and CD8+
T cells ), Wang et al ( 876 ) examined the T cell requirement for recurrence of IDDM
upon grafting syngeneic NOD mouse islets to spontaneously diabetic NOD mice.
Recurrence of disease was shown to be a CD4+ ( but not CD8+ ) T cell-dependent
process. Depletion of the CD4+ T cell subset facilitated graft survival and islets
continued to function in the absence of circulating CD4+ T cells. Depletion of CD8+
T cells which was effective in blocking the initiation of disease in NOD mice had no
effect on disease recurrence following grafting of islet tissue which became heavily
infiltrated by inflammatory cells and became non-functional. FACS analysis
demonstrated large numbers ofCD4+ T cells in the damaged tissue following CD8+ T
cell depletion ( 876 ). Similarly, protection against development of diabetes in the
spontaneously diabetic BB/Wor rat by three-times weekly injections of tissue culture
supernatant containing 0X8 moAb demonstrates the role of CD8+ cells in pancreatic
islet p-cell destruction ( 239 ). However, CD8 cell surface antigen is also expressed
on the surface of NK cells and since virtually all CD8+ cells in the BB rat are
considered to be NK cells ( 309 ) and that NK cells lyse islets in vitro ( 877 ), it is
possible that islet destruction is mediated by NK and/or CD8+ T cells. Indeed, Like
et al ( 239 ) reported that NK cell numbers and activity were elevated in untreated
DP-BB rats compared with DR-BB rats and 0X8 moAb injections depleted NK cell
activity. Jacobson et al ( 878 ) reported prevention of recurrent diabetes in BB rats
following treatment of islet recipients with anti-asialo-GMl. Administration of this
polyclonal Ab which binds the glucolipid asialo-GMl present on NK cells effectively
prevented autoimmune destruction of transplanted WF islets in diabetic BB rats. It
should be noted that anti-asialo-GMl is not a specific marker for NK cells since it is
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also found to be expressed on activated peritoneal macrophages, thymocytes and
cytotoxic T lymphocytes. However, markedly reduced NK cell activity in
anti-asialo-GMl-treated rats and an absence of significant alterations in the relative
percentages ofT lymphocyte subsets suggests protection of intraportal islet grafts was
achieved through the effect of anti-asialo-GMl on NK cells. These results and the
finding that CD8+ cells were localised at the site of the insulitis lesion in DP-BB rats
suggest that NK cells contribute to the mechanism of P-cell destruction in the initial
destruction of the native pancreas and recurrent destruction of a transplanted islet
graft. Both these studies ( 239,878 ) demonstrated success in preventing P-cell
destruction using long-term treatment regimens ( 0X8 moAb and anti-asialo-GMl
respectively ). It is not known whether complete islet graft survival would have been
observed if islet-transplanted BB/E rats had received extended 0X8 moAb treatment.
Reduction of CD4+ T cell numbers in PBL or lymphoid tissues of diabetic BB/E rats
by treatment with 0X38 moAb was infrequent and inconsistent. Although >80%
depletion of CD4+ T cells has been described in peripheral blood of non-BB rats
using a lower dose and shorter course of 0X38 moAb treatment ( 678,679 ), Like et
al ( 239 ) also failed to show depletion ofCD4+ T cells in the spleens ofBB/Wor rats
after three-times weekly injections of 0X38 moAb for up to 14 weeks although the
dose of moAb used was not specified and peripheral blood was not analysed. This
study did not observe a significant reduction in the frequency of IDDM in 0X38
moAb-treated BB/Wor rats. Indeed, in the current study all animals remained
normoglycaemic throughout the moAb treatment period afterwhich 67% BB/E rats
returned to a hyperglycaemic state. The remaining 33% of 0X38 moAb-treated rats
maintaining long-term functioning grafts received a 2° islet graft under the kidney
capsule and remained normoglycaemic at death. An increased and/or extended dose
of 0X38 moAb may have caused significant reduction in CD4+ T cells and provided
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greater protection of the islet grafts against destruction. Seydel et al ( 679 ) observed
significant reductions in CD4+ T cell numbers and consequent permanent survival of
intraportally transplanted islets in STZ-diabetic rats receiving short-term 0X38 moAb
treatment. This is in agreement with the earlier observation that in NOD mice
recurrence of islet destruction results from CD4+ T cell-dependent inflammatory
tissue damage activated in and around the islet tissue.
Treatment with 0X38 moAb significantly decreased the CD8+ and CD4+/CD8+ cell
populations particularly for rats treated with 0X38 moAb alone compared with 0X38
moAb-treated BB/E rats receiving an intraportal islet graft. In this group CD8+ T
cells were only significantly reduced in animals with short-term but not long-term
functioning 1° islet grafts suggesting that depletion of CD8+ cells did not result in
additional protection in this group of 0X38 moAb-treated rats. The finding that
0X38 moAb significantly depletes CD8+ lymphocytes suggests a degree of
cross-reactivity with these cells although this observation has not been previously
documented. However, the percentage of 0X38 moAb-treated rats maintaining
long-term functioning grafts ( 33% ) was greater than observed in OX8 moAb-treated
animals ( 11% ). Again, no significant difference in lymphocyte and lymphocyte
subset numbers in the peripheral blood and lymphoid tissues was observed between
0X38 moAb-treated rats with short and long-term functioning grafts. This study
suggests that 0X38 moAb may bind to its appropriate target cells without depleting
and thereby prolong graft survival by preventing antigen-induced T cell activation.
However, the non-depleting anti-CD4 moAb W3/25 binds to the same epitope as
defined by the 0X38 moAb which suggests that if 0X38 did function by binding to
target cells without clearing then similar results should have been observed for both
antibodies. This was not the case since 56% of W3/25 moAb-treated rats failed
before the end of treatment compared with none in the 0X38 moAb-treated group.
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However, the different isotypes of these moAb (IgGl and IgG2a respectively ) may
explain the variation in potency observed. Other studies have suggested that
macrophages, which also express the CD4+ cell surface marker and are therefore
possible targets of 0X38 moAb, may play a role in islet destruction. Oschilewski et al
( 344 ) demonstrated that administration of silica to young ( i.e. prediabetic ) BB rats
almost completely prevented the development of IDDM. Silica is highly specific in its
action against macrophages and protection is a direct consequence of macrophage
depletion or modification. Additionally, a single dose of silica resulted in the
indefinite survival of intraportally transplanted islet allografts in 44% STZ-diabetic
rats. It should be noted that intraportally injected islets are highly accessible to
macrophage surveillance and destruction in the liver ( 879 ). These findings indicate
the important role of macrophages in the pathogenesis of IDDM both initial and
recurrent islet destruction in the rat.
Combined 0X8/0X38 moAb treatment significantly reduced both CD4+ and
CD4+/CD8+ lymphocytes and this was often accompanied by a significant reduction
in lymphocytes and/or CD5+ cells. Occasionally a significant decrease in CD4+ T
cells was observed although this was not a consistent finding. There was no
significant difference in lymphocyte and lymphocyte subset numbers in PBL and
lymphoid tissues of 0X8/0X38 moAb-treated BB/E rats after separation into groups
A, B and C. Using the combined treatment, 44% of diabetic BB/E rats maintained a
long-term functioning islet graft and remained normoglycaemic following a 2° islet
graft under the kidney capsule. Interestingly, 11% of 0X8 moAb-treated and 33% of
OX38 moAb-treated animals maintained long-term functioning islets which may
suggest an additive effect upon combining these moAb. This result was in direct
contrast to the report by Seydel et al ( 679 ) who observed that successful induction
of long-term survival of an islet graft using 0X38 moAb treatment was abrogated by
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the coincident treatment of STZ-diabetic rats with depleting 0X8 moAb. Seydel and
colleagues concluded that a regulator CD8+ cell was necessary in the induction of
anti-CD4-mediated survival of transplanted islets in this rat model. Factors such as
differences in the rat strains used, intrinsic differences in moAb structure as well as
differences in moAb preparation, dose and treatment regimens may contribute to the
discrepancy in results.
Intraportal islet transplantation alone had no significant effect on lymphocyte and
lymphocyte subset numbers in PBL or lymphoid tissues in any of the moAb-treated
diabetic BB/E rats which confirmed the findings of Kuttler et al ( 880 ) who reported
no correlation between changes in lymphocyte subsets and pancreatic (3-cell
destruction.
Stimulation indices were used in conjunction with FACS analysis to assess the
proliferative ability of PBL isolated from moAb-treated diabetic BB/E rats to the T
cell mitogen, Con A. Values of stimulation indices pre-moAb treatment demonstrate
a significant response ofPBL from these rats to Con A in agreement with Varey et al
( 212 ) who reported normal proliferative responses of diabetic BB/E rats to Con A
and lipopolysaccharide. In contrast, Jackson et al ( 308 ) observed that Con A
responsiveness was absent in the peripheral blood and splenic lymphocytes ofBB rats
which correlated directly to the absence of CD4+ T cells, confirming the importance
of these cells in mitogen stimulation. Indeed, CD4+ T cell numbers were not reduced
in the thymus of BB rats and thymic lymphocytes showed a significant increase in the
^H-thymidine uptake when stimulated by Con A. Prud'Homme et al ( 881 ) also
described a poor response in splenic lymphocytes of BB rat to T cell mitogens which
was attributed to suppressor macrophages. These findings suggest that the ability of
certain lymphocytes to significantly respond to Con A may be specific to the
386
Edinburgh colony of BB rats. In non-islet-transplanted BB/E rats, treatment with
PBS or W3/25 or 0X8 moAb had no significant effect on stimulation indices ofPBL.
In contrast, the stimulation indices of 0X38 and 0X8/0X38 moAb treated rats were
significantly reduced during moAb treatment compared with values at the end of
treatment although values 1 week post-moAb treatment were not significantly
different from values pretreatment. Conversely, in islet-transplanted diabetic BB/E
rats all moAb treatments caused a significant and persistent decrease in stimulation
indices ofPBL until death. Values were higher in group C rats (i.e. rats maintaining
long-term functioning intraportal islet grafts ) confirming that the immunosuppressive
effect of moAb decreased with time. Only W3/25 moAb treatment which has been
shown to inhibit T cell activation in vitro ( 686 ) significantly decreased the
stimulation index of PBL prior to transplantation of 1° islet grafts compared with
pre-moAb treatment. The stimulation indices confirm the FACS analysis since there
was no significant difference in stimulation indices values between groups A, B and C.
However, PBL of animals with a short-term functioning islet graft usually had a
higher stimulation index than those with a long-term functioning graft suggesting that
graft failure is accompanied by a return of the proliferative ability of PBL in BB/E
rats. PBS treatment ( control) also significantly reduced the stimulation indices after
transplantation of an islet graft and values remained significantly lower than
pretreatment values at death. This observation may involve the immunosuppressive
effect of hyperglycaemia in BB rats as reported by Hahn et al ( 882 ). The decrease in
stimulation index of PBS-treated BB/E rats does not reach significance compared
with the value prior to PBS injections until failure of the islet graft, i.e. upon a return
to a hyperglycaemic state. Hahn and colleagues reported that delayed rejection of
allografted skin in hyperglycaemic BB rats compared with normoglycaemic BB rats
was accompanied by an altered subset distribution and reactivity of PBL. In this
study, islet graft failure in PBS-treated control rats could have an immunosuppressive
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effect on PBL and hence reduce stimulation index values. Hyperglycaemia may also
contribute to suppression of PBL and hence reduction of stimulation indices in
short-term functioning grafts.
Histological examination of native pancreases of established diabetic BB/E rats used
in this study confirmed that destruction of islets was P-cell specific since a-cells
remained intact and were strongly positive for glucagon. In PBS-treated control rats,
all intraportal islet grafts failed within 6 days of transplantation despite the marked T
cell lymphopenia associated with a reduction of CD4+ cells and almost complete
depletion of CD8+ cells in BB rats. Intraportal islets were chronically infiltrated by
inflammatory cells, showed degenerative changes and were faintly positive or negative
for insulin. Interestingly, all islet cells were negative for glucagon which suggested
islets were being destroyed by allograft rejection rather than by recurrence of P-cell
specific autoimmune destruction. This finding is in agreement with the hypothesis
that MHC-incompatible islets are not destroyed following transplantation to the BB
rat but contrast the findings of Weringer and Like ( 651 ) and Prowse et al ( 423 )
who reported that the autoimmune destruction of grafted P-cells in the BB/W rats
was not confined to cultured islets of MHC-compatible donors but also occurred in
grafted cells ofMHC-incompatible donors. Glucagon-secreting a-cells may also have
been damaged by collagenase digestion during the isolation of islets ( since these cells
are located at the periphery of the islet cell ) or as a result of ischaemia during the
7 day culture period at 37°C prior to transplantation, both of which would contribute
to the lack of glucagon-containing cells. A similar phenomenon was noted in
islet-transplanted BB/E rats receiving moAb treatment irrespective of the length of
survival of intraportal islet grafts, again suggesting allograft rejection rather than
recurrent autoimmune destruction of islets despite the presence of the RT1U
haplotype which the autoimmune response and subsequent P-cell damage
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characteristic of the BB rat are reported to be dependent ( 338,645 ). However,
glucagon-staining was occasionally observed but never in the absence of
insulin-containing (3-cells. Millard et al ( 883 ) reported similar findings following
successful allografting of islets in rats with subsequent long-term survival.
Islet (3-cells, but not glucagon-containing a-cells, were identified suggesting this
observation is not BB rat specific or a result of depleting or non-depleting moAb
treatment. It is possible that a-cells ( which constitute approximately 15% of the islet
cells ) are initially destroyed by allograft rejection due to their peripheral location in
the islet or due to a greater sensitivity to immune rejection.
Intraportally-injected islets were found in the portal triads of all recipient livers upon
examination and those from animals in group A were generally disaggregated and islet
fragments were surrounded by a chronic inflammatory infiltrate comprising
lymphocytes and macrophages. In group B, intraportal islets showed faint positivity
for insulin but were rarely positive for glucagon-staining. Any glucagon positivity
was generally associated with macrophages demonstrating engulfment of
glucagon-containing islet fragments by these cells. This observation provides further
evidence that absence of glucagon-containing a-cells may be due to early destruction
by allograft rejection. In contrast, islets taken from animals in group C were only
associated with a mild infiltrate in liver sections and were strongly positive for insulin
but only positive for glucagon in infiltrating macrophages. Although a mild immune
reaction was observed around islets in these animals, this infiltrate was not sufficient
to cause destruction of islets. However, 2° islet grafts transplanted under the kidney
capsule were not similarly protected and a heavy chronic inflammatory cell infiltrate
was observed in and around islets which was similar in severity to that observed in
islet grafts transplanted under the kidney capsule of diabetic BB/E rats receiving no
moAb treatment. These results do not support the hypothesis that the kidney capsule
389
of diabetic BB rats is an immunologically privileged site with respect to protection of
transplanted islet grafts ( 652 ).
Culture for 7 days at 37°C did not protect islets from allograft rejection as evidenced
by rapid graft destruction following transplantation to PBS-treated rats. Low
temperature culture ( 26°C ) of donor rat islets has been reported to markedly prolong
islet allograft survival when transplanted into STZ-diabetic rats ( 618 ) which may
reflect impaired antigen presentation in the recipient due to depletion or alteration of
putative passenger lymphoid cells within donor islets. However, Woehrle et al ( 652 )
reported that culture of Lewis rat islets at 22°C failed to prolong allograft survival
after intraportal transplantation into diabetic BB rats. Culture in 95% oxygen and UV
irradiation also immunomodulate donor islets in the same way. Both Markmann et al
( 682 ) and Jacobson et al ( 878 ) induced neonatal tolerance to donor islet tissue
prior to transplantation in the BB rat to prevent the possibility of allograft rejection.
In this study the immunosuppressive potentials of both depleting and non-depleting
anti-CD4 and depleting anti-CD8 moAb to promote intraportal islet graft survival
were assessed. Treatment with a depleting anti-CD4 moAb ( 0X38 ) either alone or
in combination with a depleting anti-CD8 moAb ( 0X8 ) was most effective at
prolonging islet graft function. FACS analysis of lymphocytes and lymphocyte
subsets in PBL and lymphoid tissues of islet-transplanted rats receiving moAb
treatment did not reveal any consistent finding which could explain the survival of
certain islet grafts but not others. However, it should be noted that analysis of
lymphocytes and lymphocyte subsets in peripheral blood or lymphoid tissues may not
accurately reflect events taking place within transplanted islet grafts. Similar
observations were made upon analysis of stimulation indices. Histological
examination of intraportal islet grafts showed evidence of allograft rejection but
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recurrence of autoimmune destruction was absent. The immune infiltrate was
observed within islets and was more severe in short-term functioning grafts compared
with the mild infiltrate observed around islets of long-term functioning grafts.
Selective immunosuppression of the recipient of an islet allograft may therefore be a
viable option when considering treatment of human IDDM. However, promising
moAb therapies need to be developed in large animal models before being considered
for clinical application. Strategies to prolong renal allograft survival in the dog using
anti-CD4 and anti-CD8 have recently been evaluated ( 884 ). MoAb therapy had to
be stopped prematurely (10 days ) following adverse reactions associated with the
recipient developing an antibody response against the foreign ( rat ) therapeutic
moAb. In contrast, anti-CD4 moAb at maximal cell-depleting doses suppressed the
immune response against itself in a rat model ( 678 ). Despite stopping therapy
prematurely, blood levels of anti-CD4 and anti-CD8 moAb indicated that saturating
doses were achieved. Neither moAb alone significantly prolonged allograft survival
and renal grafts were rejected after 7 days. However, combined anti-CD4 and
anti-CD8 moAb resulted in good graft function for a median of 14 days even though
the reduction in CD4+ cells in the peripheral blood was only approximately 50%.
Since only a fraction of the normal T cell population is required to initiate immune
rejection of an allograft ( 676 ), the action of the anti-CD4 moAb was thought to
involve coating of the target T cell population. In contrast, anti-CD8 moAb caused
>90% depletion of CD8+ T cells from the peripheral blood. Although allograft
survival was prolonged in the above study, a more extensive graft prolongation is
necessary for the development of specific immunosuppression therapies. A similar
protocol using a mouse anti-human CD4 moAb, OKT4A in cynomolgus monkeys
prolonged allograft survival to a median of 23 days compared with rejection by day 11
in untreated control monkeys ( 885 ). A single high dose ( 10 mg/kg ) ofOKT4A on
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the day of transplantation also resulted in prolonged renal allograft survival in
monkeys further illustrating the therapeutic efficacy of CD4. The beneficial effect
observed when anti-CD4 moAb was combined with conventional immunosuppression
in the primate has also been described ( 886 ). A mixture of depleting and
non-depleting anti-CD4 moAb ( OKT4 and OKT4A ) was tested for its
immunosuppressive potential in rhesus monkeys receiving a kidney allograft in
combination with low dose azathioprine and prednisolone to mimic the clinical
situation. Administration for 21 days, starting 2 days before transplantation of the
kidney graft prolonged graft survival from 13 days in animals receiving azathioprine
and prednisolone alone to 39 days. These studies demonstrate that at this time,
immunosuppression of an allograft in large animal models using moAb is difficult to
achieve. Although long-term acceptance of grafted tissues in humans in the absence
of current and continued immunosuppression and its related side effects is the goal of
moAb therapy, additional immunosuppressive drug therapy may still be required until





Three possible new approaches to the treatment of human IDDM using the
spontaneously diabetic, insulin-dependent BB/E rat as a model for the human disorder
have been studied. Although the BB rat is an invaluable model for human EDDM,
ultimately promising therapies need to be developed in larger animal models prior to
consideration for clinical application.
SRII have been shown to successfully normalise the diurnal variation in plasma
glucose concentrations observed in CIT-treated diabetic BB/E and STZ-diabetic rats
and parameters of metabolic control ( i.e. random plasma glucose concentration and
HbAj ) are accurately reflected in such animals. The impaired control observed with
CIT treatment may contribute to the long-term complications and morbidity
associated with IDDM. Despite the improved glycaemic regulation achieved by SRII
the resulting reduction in tissue concentration of the principal metabolites of the
polyol pathway was similar in both SRII- and CIT-treated STZ-diabetic rats. The
prospects for the clinical treatment of IDDM using SRII are encouraging, although a
dual implant scheme may be necessary. The observed success of SRII in the
maintenance of glucose homeostasis in the BB/E rat model was related to the finding
that these animals ate throughout the 24 hour period and therefore a constant basal
release of insulin was sufficient to maintain normoglycaemia. In human diabetic
subjects, insulin demands vary with meal intake and physical activity and supplemental
doses of insulin in addition to the basal dose of insulin provided by long-acting SRII
will be necessary. For the open-loop arrangement, this pre-prandial insulin bolus may
be supplied by an implantable osmotic pump or injections. Similarly, implants with
internal modulation capability can be used as the required component in a closed-loop
system to provide the additional doses of insulin required to counter post-prandial
hyperglycaemia.
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Encapsulation of pancreatic islets in semipemeable APA membranes has been used as
a method of protecting islets from immune destruction in transplantation studies.
Insulin secretion by microencapsulated islets was optimal after 7 days culture and
diminished thereafter, suggesting a precisely timed recovery culture period prior to
implantation is important to ensure optimal function of encapsulated islet grafts.
However, upon implantation into spontaneously diabetic animals, early capsule failure
was observed. Failure was ascribed to fibrotic overgrowth around the capsule surface
activated by the incompatibility of reagents used to construct the membrane. This
pericapsular infiltrate resulted in necrosis of islets due to lack of oxygen and nutrients
and possible release of p-cell toxic cytokines from components of the immune
response which are not excluded by the capsule membrane. Immunosuppressive
agents such as CsA reduce the amount of capsular infiltrate and clinically, the only
successful report describing insulin-independence after microencapsulated islet
transplantation has been in an immunosuppressed IDDM patient. Although
encouraging, further trials to determine the optimal dose of encapsulated islets
necessary to achieve long-term insulin-independence in non-immunosuppressed
patients are required.
Rejection and/or autoimmune destruction of transplanted islets may also be prevented
using depleting and non-depleting moAb specific for the T cells responsible for
immune destruction. Successful protection and prolongation of survival of intraportal
islet grafts in the BB/E rat was observed with a depleting anti-CD4 moAb ( 0X38 )
either alone or in combination with a depleting anti-CD8 moAb ( 0X8 ). All islet
grafts showed a degree of inflammatory cell infiltrate, the intensity of which was
reflected by the period and degree of normoglycaemia observed in the recipient.
Short-term functioning islet grafts were heavily infiltrated and showed weak or no
positivity for insulin whereas only a mild infiltrate was observed around islets of
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long-term functioning grafts and these were strongly positive for insulin. Secondary
islet grafts transplanted under the kidney capsule of BB/E rats maintaining long-term
functioning intraportal grafts were not afforded similar protection and islets were
heavily infiltrated, demonstrating treatment had not initiated long-term
unresponsiveness to donor-specific islets. Although similar reports of prolonged
tissue allograft survival using moAb therapy are well documented in rodents, studies
with larger animal models including dog and monkey have had limited success.
Adverse reactions associated with an antibody response against the foreign
therapeutic moAb are observed in the recipient demonstrating the need to render such
moAb invisible to the immune systems of large animal models and humans. Antibody
engineering to humanise therapeutic antibody has reduced the risk of immunogenicity
despite the lack of preclinical information available on therapeutic moAb. However,
attempts to simulate the rodent data using anti-CD4 and anti-CD8 moAb therapy have
not been successful. The anti-CD3 moAb, OKT3 has been most widely used and is
effective in reversal of acute rejection episodes both as an initial treatment and for
patients unresponsive to high-dose steroid therapy. There has also been interest in
targeting activated T cells as these cells must include the antigen-reactive cohort.
IL-2R is an obvious choice of target, but limited clinical studies using prophylactic
IL-2R moAb have given mixed results. Initial observations in large animal models and
humans suggest that although it is too early to make a compelling case for moAb
therapy for the prevention of of allograft destruction, it is possible that moAb could
be combined synergistically with additional currently used immunosuppressive drug
therapies.
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5 1 OVERALL CONCLUSION
Several factors have recently underlined the urgent need for a better treatment for
IDDM. These include (1) the high incidence of severe vascular disease seen in
patients maintained on conventional insulin replacement therapy, (2) an increased
incidence of IDDM in Northern Europe and America, (3) the continuing high foetal
loss rate in women with IDDM, (4) the conclusive evidence provided by the DCCT
not only that the long-term complications of diabetes results from the far from normal
metabolic regulation seen in most patients maintained on conventional insulin
replacement therapy, but also that the complications can be prevented by good
metabolic control, and (5) that the inherent limitations of conventional insulin therapy
means that achievement of good control is often accompanied by an increased
incidence of serious hypoglycaemic episodes and imposes unrealistic demands on
patients by the need for multiple daily injections of insulin, dietary measures and
self-measurement of capillary blood glucose concentration.
The availability of valid animal models for human IDDM along with recent advances
in key areas such as genetic engineering, induction of peripheral tolerance to
autoantigens, understanding of the mechanisms underlying P-cell destruction and of
the factors regulating growth and differentiation of islet cells make it possible to
pursue new approaches to more effective management of patients with IDDM.
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